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The interactions between immunoglobulin E (IgE) and its receptors, FcεRI and
CD23, regulate a number of important processes in allergic disorders. The Fc
fragment of IgE, which binds the receptors, has a high degree of conformational
plasticity and can be allosterically modulated. A comprehensive understanding of
IgE-Fc dynamics and allosteric modulation could provide insights that enable the
development of novel therapeutics for asthma and allergy.
Using UCB’s Core Antibody Discovery Process we screened the immune reper-
toire of rabbits immunized against IgE-Fc for antibodies that bind IgE-Fc and
affect the IgE-Fc/CD23 interaction. Surface plasmon resonance (SPR) was used
to identify a subset of antibodies that elicit their effect on IgE-Fc-receptor binding
allosterically. Kinetic and thermodynamic interaction studies of these antibodies
are helping to elucidate the mechanisms of allostery in IgE-Fc. Allosteric commu-
nication in IgE-Fc has previously only been demonstrated between two sites within
the same domain; here we show for the first time that allostery in IgE-Fc can occur
across different domains over long distances. We suggest that allostery in IgE-Fc
is not binary in character; certain domain orientations cannot always be attributed
to inhibition of receptor binding. Rather, we advocate an ensemble treatment of
allostery, in which allosteric phenomena are due to the intrinsic dynamic properties
of the IgE-Fc protein. X-ray crystallographic structures of transiently populated
conformations of IgE-Fc trapped by anti-IgE antibodies will provide insights into
the energy landscape of IgE-Fc and the importance of IgE-Fc dynamics in receptor
engagement.
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1.1 IgE in allergy and asthma
The immune system responds to pathogenic invasions through the coordinated ac-
tion of cellular and molecular defence systems. The antibody response is a molec-
ular defence system that plays a crucial role in the fight against infection. B cells
undergo heavy chain class switching to become plasma cells dedicated to the pro-
duction of a specific antibody isotype: IgG, IgE, IgA, IgM or IgD. The different
antibody isotypes can specifically stimulate a range of cellular activities vital in the
immune response, including the killing of infected cells, lysis of the pathogen’s cells
and inflammation [1]. Antibodies trigger these responses through interactions with
their cognate receptors that are expressed on the surfaces of the effector cells. The
cellular distribution of the various antibody receptors, and the specificity and affin-
ity of the different antibody isotype/receptor interactions contribute to the range
of different response mechanism that occur upon the encounter of distinct anti-
gens [2]. Different antibody isotype responses are associated with different types
of immune responses to infection. Evidence suggests that IgE evolved to help fight
parasitic infections [3], however it is better known for the central role that it plays
in allergic disease through interactions with its two principle receptors, FcεRI and
CD23 [4].
Allergies occur when the body’s immune system mounts a response against an
otherwise innocuous foreign antigen (an allergen). A majority of allergens are pro-
teins or glycoproteins from sources as diverse as animal danders, pollen, dust mite
feces, venoms and foods [1]. The number of people suffering from allergic diseases
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worldwide has reached epidemic proportions: one in three people have at least one
allergy and approximately half of all school-aged children in the developed world
are sensitised to at least one allergen [5]. The global economic burden of asthma
has been estimated to be greater than that of tuberculosis and HIV combined [6],
and is likely to increase as the young population reaches adulthood, and as ambient
temperatures and air pollution rise [5].
Anti-histamines and immunotherapy are often effective treatments for mild al-
lergic diseases such as allergic rhinitis [5]. More severe forms of allergic disease,
such as allergic asthma and atopic dermatitis, are often treated with drugs that
suppress the immune system and can have serious side effects such as glucose and
gastrointestinal intolerance, hypertension and increased susceptibility to infections
[7]. It has also been reported that 5 - 10 % of asthmatics are unresponsive to usual
immunosuppressant treatment [8]. Furthermore, the number of people suffering
from food allergies, for which there are no approved therapeutics, is increasing at
an alarming rate [9]. It is hoped that alternative and superior therapeutics for
allergy and asthma will better treat the growing number of allergic patients, as
well as the sufferers that are unresponsive to the current therapies.
There are ongoing efforts to find ways of specifically targeting cells and molecules
involved in the allergic response, including mast cells [10] and various cytokines [11].
Recently, the US Food and Drug Administration (FDA) approved two monoclonal
antibodies that target the proallergic cytokine, interlukin-5 (IL-5), for the treat-
ment of persistent eosinophilic allergic asthma: reslizumab (CINQAIR R©, Teva)
and mepolizumab (Nucala R©, GSK). Since most allergic responses to allergens are
mediated by IgE, IgE is also highly regarded as an important therapeutic target.
1.1.1 The role of IgE/receptor interactions in allergy and
asthma
In 1966 IgE was identified as the component in the sera of allergic individuals capa-
ble of transferring immediate hypersensitivity to the skin of normally un-reactive
persons [12]. IgE antibodies are produced and secreted by B cells that have un-
dergone heavy-chain class switching from IgM to IgE plasma cells [1]. The serum
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levels of IgE are very low compared to other antibody classes [13], and IgE exists
predominantly in mucosal tissues as part of an IgE-FcεRI complex on the surface
of mast cells and basophils [14]. As for other antibody isotypes, IgE antibodies
are composed of two identical heavy and light chains [1]. The IgE molecule has
two antigen/allergen-specific fragment antigen-binding regions (Fabs) and a single
fragment crystalizable (Fc) region (Figure 1.1). The interaction between IgE-Fc
and its canonical cell-surface receptors, FcεRI and CD23, are important in many










Figure 1.1: Schematic representations of IgE and its receptors. IgE has
a typical antibody architecture; it is composed of two identical heavy and light
chains. The two Fab regions bind to specific epitopes on antigens, or in the case
of allergic disease, allergens. The Fc region binds the receptors, FcεRI and CD23,
and through these interactions, IgE elicits its effector functions. The extracellular
domains of the alpha chain of FcεRI bind IgE-Fc, whereas the C-type lectin head
domains of CD23 contain the IgE-Fc binding activity. Cleavage of membrane
trimeric CD23 by the der p1 protease results in the release of single soluble CD23
head domains (derCD23).
FcεRI is expressed on the surface of mast cells and basophils as an αβγ2
tetramer and on a variety of human antigen presenting cells (APCs) as an αγ2
trimer (Figure 1.1). FcεRI binds to IgE-Fc via the extracellular domains of the α
chain (sFcεRIα), whereas the β and γ chains are involved in signal transduction
[14, 15].
CD23 is expressed as trimer on the surface of B cells, epithelial cells and a range
of inflammatory cells types [16]. Three C-type lectin domain heads are tethered to
the surface of the cell via an α-helical coiled-coil stalk [17] (Figure 1.1). The IgE-Fc
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binding activity is located in C-type lectin head domains, but does not recognise
carbohydrate [18]. Carbohydrate is, however, involved in the binding of CD23
to CD21, an interaction that links the IgE-antibody system to the complement
pathway [16]. The stalk of trimeric membrane CD23 (mCD23) can be cleaved in
various places by a range of endogenous and exogenous proteases, resulting in the
release of soluble CD23 (sCD23) with different stalk lengths and oligomeric states
[19]. Der p1 is a protease found in house dust mite feces, which cleaves human
mCD23, releasing single soluble head domains (derCD23) (Figure 1.1) [20].
The IgE/FcεRI interaction is crucial in the sensitisation of individuals to aller-
gens and in triggering the initial allergic response. Both IgE/FcεRI and IgE/CD23
interactions are also involved in processes that propagate and exacerbate allergic
reactions (Figure 1.2) [4].
Immediate hypersensitivity
Mast cells and basophils of sensitised individuals are primed with allergen-specific
IgE through interactions with FcεRI on their surfaces. Since mast cells and ba-
sophils exist primarily in mucosal tissues, FcεRI-bound IgE is one of the first
immunological molecules an allergen may encounter [4]. Cross-linking of FcεRI-
bound IgE-Fc on the surface of mast cells results in downstream signalling that
triggers mast cell activation and the consequential release of a diverse set of pro-
inflammatory cytokines and lipid mediators (Figure 1.2 (1)) [21]. Within minutes,
this ‘early phase’ of the allergic reaction causes vasodilation and increased vascular
permeability, and results in either localised or systemic reactions. Some of the me-
diators that are released during the ‘early phase’ of the allergic reaction initiate the
‘late phase’ of an allergic response, which peaks around 6 – 9 hours after allergen
exposure. The ‘late phase’ involves the recruitment and activation of T helper 2
(TH2) cells, eosinophils and other inflammatory cell-types to the affected site, as





Both FcεRI and CD23 have important roles in allergen presentation to T cells,
which drive the immune response to allergen. FcεRI is expressed by a variety
of APCs that patrol the body’s surface in search of foreign antigens. The APCs
process and present allergens that have been captured by IgE/FcεRI complexes on
their surfaces to T helper cells, which increase the activity of other immune cells
and propagates the allergic response [22].
Antigen-activated B cells express CD23 on their surface and present allergen
to T cells in a process known as facilitated antigen presentation (FAP). IgE/CD23
complexes on the surface of antigen-activated B cells act as allergen receptors.
Allergen-IgE-CD23 complexes are internalised and processed by the antigen-activated
B cells, and the resulting peptides are displayed on their cell surfaces for T cell
recognition by MHC class II proteins (Figure 1.2 (2)) [23, 22, 24, 25]. FAP allows
antigen-activated B cells to concurrently process and present unrelated antigens and
allergens to cognate T cells, and is thought to be responsible for the phenomenon
of epitope spreading [4]. Epitope spreading is when an antibody response for one
epitope leads to the production of antibodies specific for another epitope on the
same antigen, or a different antigen, and may contribute to the ‘Atopic March’,
whereby individuals become sensitized to an increasing number of allergens [26].
IgE-mediated cytotoxicity
Eosinophils, monocytes and macrophages are amongst the cells are that recruited to
the site of allergic inflammation [21]. Once activated, these cells express CD23 and
FcεRI on their surfaces [27]. The capture of allergen:IgE complexes by receptors on
the surfaces of these cells triggers the lysis of target cells and phagocytosis of cell
fragments [28]. Although beneficial in the fight against a parasitic infection, the
release of cytotoxic mediators by these cells can result in damage to surrounding
tissues, and in the context of allergy and asthma contributes to the inflammation
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Figure 1.2: IgE/receptor interactions are important in the initiation and
propagation of allergic disease. IgE, secreted by IgE-switched B cells, binds
to FcεRI on the surface of mast cells and sensitises them to the allergen to which
they are specific. (1) Cross-linking of FcεRI-bound IgE on the surface of mast
cells activates the mast cells and triggers their degranulation. The release of pro-
inflammatory mediators causes an allergic response. Secreted IgE also binds to
IgE-receptors expressed on the surface of antigen presenting cells, and CD23 on
B cells. Allergen-IgE complexes on the surface of APCs, such as dendritic cells,
are processed and presented to TH2 cells (2). The allergen activated TH2 cells
subsequently produce and secrete type 2 cytokines such as IL-4, which help to
recruit and maintain the TH2 cell population and are also required for heavy chain
class switching to IgE, thereby increasing the local IgE concentration. Eosinophils
are recruited to the site of allergen encounter by the mediators and cytokines
released from activated TH2 cells and from mast cell degranulation. Allergen-IgE
complexes bind to IgE-receptors on the surface of eosinophils, resulting in the
release of inflammatory messengers and molecules that lyse cells. CD23 on the
surface of epithelial cells binds allergen-IgE complexes and transports them across
the epithelia of the gut, nose and lungs into the mucosa (4) where they can bind
the effector cells, and exacerbate the allergic reaction. The resulting inflammation




The epithelial cells of the respiratory tract [29], intestine [30] and nasal passages
[31] constitutively express CD23. Through interactions with IgE, CD23 on the
surfaces of epithelial cells can facilitate the apical to basal transcytosis of allergen-
IgE complexes into the mucosa (Figure 1.2 (4)) [32, 33, 29]. Once in the mucosa,
it has been suggested that the IgE-allergen complexes are capable of binding and
activating immune cells, for example it has been proposed that the IgE-allergen
complexes can bind FcεRI on the surface of mast cells where they can trigger the
acute phase of an allergic response [33, 29]. Similarly, the IgE-allergen complexes
may bind FcεRI on the surface of dendritic cells, ultimately resulting in the acti-
vation of IgE class switching in local B cells. Inflammation occurs as a result of an
allergic response, and damages the epithelium, which in turn allows more allergen
into the mucosa and intensifies the allergic reaction [4]. CD23-mediated transcyto-
sis is therefore thought to play important roles in the initiation and exacerbation of
allergic disease, and may also partly explain why allergic reactions occur so quickly
after allergen challenge (Figure 1.2).
CD23-mediated IgE homoeostasis
CD23 is regarded as a natural regulator of IgE synthesis but the exact mechanisms
through which it acts to control levels of IgE are not fully understood [4]. The
different states of CD23 appear to have differential effects on IgE homoeostasis.
Numerous studies have demonstrated that soluble oligomeric CD23 acts to increase
IgE synthesis [34, 35, 36, 37], whereas soluble monomeric CD23 has been shown to
decrease levels of IgE synthesis [35, 36, 37]. The interaction between CD23 and the
complement receptor, CD21, expressed on the surface of B cells, was shown to be
necessary for the positive effect of soluble trimeric CD23 on IgE synthesis [34]. The
formation of large signalling platforms that lower the B cell activation threshold
are generated by the cross-linking of CD21 and IgM on the surface of B cells by the
complement component C3 [38]. CD23 can bind IgE and CD21 simultaneously [39],
and it has been proposed that trimeric sCD23 could act in an analogous way to C3,
and cross-link CD21 and IgE on the surface of B cells, resulting in the formation
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of a signalling platform that promotes B cell proliferation and differentiation [36]
(Figure 1.3). Monomeric sCD23, which binds IgE with a 2:1 stochiometry, would be
unable to form these extended arrays, and it is suggested that their negative effect
on IgE synthesis is a result of competition with trimeric sCD23 for IgE [36]. There
is also evidence from several studies in mice suggesting that stabilising mCD23 is
associated with a reduction in IgE synthesis [40, 41, 42, 43, 25, 44]. It has been
proposed that a negative signal for B cell proliferation and differentiation could
be delivered by the co-ligation of IgE and mCD23 by IgE-allergen complexes [4]
(Figure 1.3).
Evidence for and against specific models of CD23-mediated IgE homoeostasis is
relatively sparse and there is a lack of substantiating structural data. Nevertheless,
the importance of the CD23/IgE interaction in IgE synthesis is undisputed and
because of the role that IgE plays in allergic disease, CD23 is considered a potential
therapeutic target. Antibodies that bind the head domain of CD23 have indeed
been shown in vitro [45, 46, 47, 48], in animals [49, 50, 51] and in humans [52] to
reduce IgE production.
1.1.2 Targeting IgE/receptor interactions in the treatment
of allergy and asthma
Since the IgE/receptor interactions play a major role in the initiation and propaga-
tion of allergic disease, modulating these interactions may provide a way of treating
allergic disease. Inhibition of these interactions is, in fact, a proven therapeutic
strategy: in 2003 Omalizumab (Xolair R©, Novartis), which blocks IgE/receptor in-
teractions, became the first anti-IgE monoclonal antibody (mAb) to be approved
by the FDA for the treatment of severe and persistent allergic asthma [53], and
in 2014 Xolair was also licensed for the treatment of chronic idiopathic uticaria.
Xolair works principally by reducing the serum levels of free IgE by as much as
97 % [54], and also by down-regulating the expression of FcεRI on the surface of
mast cells, basophils [55, 56, 57] and dendritic cells [58]. The depletion of free IgE
and the reduction FcεRI expression both contribute to reduced levels of IgE/FcεRI
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Figure 1.3: The mechanisms of CD23-mediated IgE homoeostasis. The
exact mechanisms of IgE regulation by CD23 in humans are disputed. (a) One
popular model suggests that cross-linking of membrane IgE and CD21 expressed on
the surface of B cells, by soluble CD23, results in the up-regulation of IgE synthesis.
IgE synthesis is thought to be suppressed by the cross-linking of membrane IgE
and membrane CD23 on the surface of B cells by a IgE-allergen complex. (b)
Large networks, formed through the co-ligation of IgE (green) and CD21 (yellow)
by soluble, trimeric CD23 (red) may act as signalling platforms for the survival
and differentiation of IgE-B cells. Adapted from Gould and Sutton, 2008 [4].
vents IgE-mediated activation of these cells and thereby limits immediate type I
hypersensitivity reactions and antigen presentation [54].
Clinical trials of an anti-CD23 mAb, lumiliximab, also showed promise: lumilix-
imab improved patient outcomes by reducing the levels of serum IgE and inhibiting
allergen-specific T cell responses as a result of limiting antigen-presentation [59].
Further development of lumiliximab however, was discontinued after the merger of
the companies involved in its discovery [60].
Therapeutic mAbs, like Xolair and lumiliximab, are the fastest growing class
of therapeutic molecules [61]. mAbs can be produced with high specificity and
high affinity for an almost infinite number of targets, without requiring structural
rationalisation. However, biologics like mAbs are generally more delicate than small
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molecules and are sensitive to heat, light, agitation and contamination [62]. In the
past, manufacturing large quantities of pure and active monoclonal antibodies has
been a very costly process [63], but a rapid increase in demand of therapeutic mAbs
has driven efforts to increase production and improve purification. The resulting
increase in titers has led to a significant reduction in production costs, which in
the future may become a relatively small proportion of the sales price [64].
Another major consideration of any therapy is immunogenicity- where the ther-
apeutic entity elicits an immune response and results in the production of anti-drug
antibodies (ADAs) and/or the initiation of pro-inflammatory cytokines [65]. Im-
munogenicity can affect the efficacy of the drug, for example ADAs may increase its
clearance thereby reducing its plasma half-life. ADAs may also bind and neutralise
the drug’s pharmacological activity. Immunogenicity can also alter a drug’s safety,
for example a therapeutic agent may initiate IgE-hypsensitivity reactions or ‘cy-
tokine storms’ [65]. Immunogenicity arises because the immune system recognises
the therapeutic agent as ‘non-self’. The larger size and greater chemical complexity
of mAbs, compared to small molecules, in general renders them more immunogenic
[66]. All therapeutic mAbs in clinical use have shown signs of immunogenicity
[67]. Because of the safety risks associated with immunogenicity, Xolair has to be
administered in a healthcare setting under the supervision of a healthcare profes-
sional trained to manage life-threatening anaphylaxis. Fortunately Xolair-related
anaphylaxis is uncommon and has been seen in less than 0.1 % of patients [68].
Small molecule therapeutics are generally considered less expensive to manu-
facture than mAbs and can be administered orally, however, because of their small
size they are generally poor protein-protein interaction (PPI) inhibitors. Typically
small molecules bind deep cavities on proteins (∼300–500 A2) [69], whereas PPI
surfaces are usually flat and large (∼ 1,000–2,000 A2 per side) [70]. Generating
small molecule PPI inhibitors that target the interactions between IgE and its re-
ceptors would be very challenging, but could be a valuable alternative treatment
for sufferers of severe and persistent allergic diseases.
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1.2 The structural and biophysical basis of the
IgE/receptor interactions
1.2.1 The structure and dynamics of IgE
IgE binds to its receptors via its Fc region, which is composed of two identical
chains, each comprised of three C-domains: Cε2, Cε3 and Cε4. Cε3 and Cε4 have
homologous sequences and similar structures to the equivalent domains in the Fc
region of IgG, however, IgG has flexible linkers in place of the Cε2 domains of IgE
[4] (Figure 1.4).
Crystal structures of IgE-Fc show that the Cε2 domains fold back upon the Cε3
domains in an asymmetric manner [71, 72] (Figure 1.5), such that the Cε2 domain
pair interacts with the Cε3 and Cε4 domains of the chain it folds back onto.
Solution studies using fluorescence resonance energy transfer (FRET) [73, 74, 75]
and X-ray and neutron scattering [76] also allude to a bent IgE structure that is


























































Figure 1.4: A schematic representation of IgG and IgE. IgE shares a common
architecture with IgG. The Fc regions of both IgG and IgE are composed of two
identical heavy chains. The Cγ2 and Cγ3 domains of IgG-Fc are homologous to
the Cε3 and Cε4 domains of IgE, respectively. The two chains of IgE-Fc each have
an additional C-domain (Cε2) compared to IgG, which instead has a flexible linker
joining the Fc region to the Fabs. Inter-chain disulphide bonds form in both IgG
and IgE (lines) and both molecules contain multiple glycosylation sites (circles).
Despite forming a more compact structure than IgG in solution, IgE displays
a large degree of conformational flexibility. Different crystal forms of the Cε3-Cε4
sub-fragment of IgE-Fc (IgE-Fc(3-4)) show that the molecule can exist in a range
of ‘open’ and ‘closed’ structures, in which a rigid-body motion of the Cε3 domains




































Figure 1.5: The crystal structures of IgE-Fc suggest that IgE-Fc is asym-
metric and bent. The crystal structures of IgE-Fc show that it exists in a con-
formation in which the Cε2 domains fold back over onto one side of the molecule
[71, 72]. The crystal structure of IgE-Fc (PDB: 2WQR [72]) is shown here in
surface representation.
one another (Figure 1.6) [77].
The Cε3 domains, to which IgE receptors bind, are also intrinsically dynamic
and in isolation they have a molten globule character [78, 79]. The Cε3 domain
is unlike any other immunoglobulin domain in regards to its loose hydrophobic
packing and low thermostability, which are responsible for the relatively low melting
temperature of IgE compared to other classes of antibody [80].
Studies investigating various IgE-Fc/ligand interactions have further demon-
strated the extraordinary conformational diversity of IgE-Fc. The crystal structure
of IgE-Fc bound to an anti-IgE Fab (aεFab1) revealed a conformation of IgE-Fc
in which the Cε2 domain pair is unbent, and IgE-Fc exists in an almost entirely
extended and symmetric state [81] (Figure 1.7).
Saturating concentrations of aεFab1 were shown to inhibit the FRET signal
between donor and acceptor fluorophores in the N and C-termini of IgE-Fc, in-
dicating that aεFab1 stabilises an extended conformation of IgE-Fc in solution.
Isothermal titration calorimetry (ITC) and stopped-flow kinetics suggested that
aεFab1 selects for an extended conformation of IgE-Fc that is already present in a
pre-existing equilibrium of IgE-Fc states [81]. A free-energy landscape of IgE-Fc,
produced from molecular dynamics simulations, also suggested that IgE-Fc exists
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Figure 1.6: IgE-Fc(3-4) exists in a range of open and closed conformations.
Wurzburg et al. solved X-ray structures of IgE-Fc(3-4) from different crystal forms
[77]. An overlay, in which the IgE-Fc(3-4) chains were a aligned on Cε4 domain
residues (441-541), shows that the Cε3 domains move as a rigid-body upon the Cε4
domains, adopting a range of ‘open’ and ‘closed’ conformations. (Figure adapted
from Wurzburg et al. [77].)
in a range of extended conformations along an ‘unbending pathway’ (Figure 1.8).
The energy difference between the apo-bent conformation and the fully extended
state was approximated to be 20 kJ mol-1 (8 kBT), meaning that although fully
extended states of IgE-Fc may be rarely populated, the Cε2 domain pair can ‘flip’
from one side of the molecule to the other [81].
Recently, the structure of IgE-Fc bound to a mutant Xolair Fab (Xolair Fab
mutant 3) was determined in our laboratory, and shows the Cε2 domains in a
partially extended conformation [82] (Figure 1.7). Determining other intermediates
along the ‘unbending pathway’ and alternative states of this dynamic molecule will
help to understand the structure and dynamics of IgE-Fc in the context of its
conformational ensemble.
1.2.2 The IgE/FcεRI interaction
The interaction between IgE and FcεRI has an unusually high affinity compared to
other immunoglobulin/receptor interactions [14]. Kinetic studies performed using
surface plasmon resonance (SPR) show that the high affinity of the interaction
is largely the consequence of an exceptionally slow off-rate [83, 84]. The slow
dissociation of IgE from FcεRI on the surface of mast cells and basophils accounts
for the long half life of IgE in mucosal tissue, and consequently the the long-term
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Figure 1.7: IgE-Fc can adopt extended and partially extended conforma-
tions. Crystal structures of free IgE-Fc suggest it exists predominately in a bent
asymmetric conformation. The crystal structure of IgE-Fc when it is bound to
Xolair Fab mutant 3 [82] shows the Cε2 domains adopt partially extended con-
formations. The crystal structure of IgE-Fc bound to aεFab1 (PDB: 4J4P [81])
demonstrates that IgE-Fc can adopt an almost fully extended, symmetric confor-
mation. All three crystal structures of IgE-Fc are shown in surface representation,
with the two identical chains in different shades of blue.
sensitisation of these cells and the immediacy of the allergic reaction upon allergen
exposure [85]. The off-rate of the interaction sFcεRIα and a subfragment of IgE-
Fc lacking the Cε2 domains (IgE-Fc(3-4)) has a significantly increased off-rate
compared to IgE-Fc or whole IgE, suggesting that the Cε2 domains of IgE-Fc play
an important role in stabilising the IgE/receptor interaction [83].
Several crystal structures of IgE-Fc and IgE-Fc(3-4) bound to sFcεRIα have
been solved [86, 87, 72] and allow an atomic description of this high affinity interac-
tion. The α2 domain, and a linker between the α1 and α2 domains of FcεRI, bind
to two Cε3 subsites on IgE-Fc that are non-identical but overlapping (Figure 1.9).
The largely hydrophobic interaction surface runs across both Cε3 domains of IgE-
Fc, close to the Cε3-Cε2 linker. Two salt-bridges and three hydrogen bonds form
between sFcεRIα and Cε3 residues in subsite 1, and packing interactions form be-
tween a proline of IgE-Fc sandwiched between two sFcεRIα tryptophan residues in
subsite 2. There are no specific contacts between at sFcεRIα and the Cε2 domains
[72]. Thermodynamic data demonstrate that the binding of FcεRI to IgE-Fc(3-4)
is enthalpically driven, whereas the IgE-Fc/FcεRI interaction is entropically driven
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Figure 1.8: A molecular dynamics simulation of IgE-Fc extension. A
multiple-walker metadynamics simulation was performed to look at the unbend-
ing and twisting of the Cε2 domain pair in IgE-Fc. These two collective variables
were extracted from preliminary unbiased and biased simulations through principle
component analysis. The final multiple-walker simulation provided a full-atomic
description of IgE-Fc, starting from the bent structure (1O0V), and converged af-
ter 3755 ns using Gaussians of height 4 kJ/mol added every 4 ps (for more detail
see [81]). (a) The free-energy surface diagram generated from the metadynamics
simulation suggests that IgE-Fc exists predominantly in a bent conformation but
that it may also transiently populate extended states (collective motion 1: IgE-Fc
bending/extension, collective motion 2: Cε2 domain pair twisting in relation to
(Cε3-Cε4)2). A dotted line between energy minima shows a suggested ‘unbending’
pathway. A cross marks the position of the aεFab1-bound IgE-Fc structure in the
energy surface, which deviates from the proposed pathway due to a twisting of the
Cε2 domain pair, presumably stabilised by aεFab binding. Models for the con-
formations of IgE-Fc that exist in the minima along the ‘unbending pathway’ are
shown in (b), and a sketch of the suggested pathway is illustrated in (c). (Figure
taken from Drinkwater et al. [81].)
[83].
The crystal structures demonstrate that conformational flexibility of IgE-Fc
is important in how it interacts with sFcεRIα. The binding of sFcεRIα to IgE-
Fc results in considerable conformational changes in IgE-Fc, although there are
almost no observable rearrangements in the structure of FcεRIα as a result of
the interaction [86, 87, 72]. The Cε2 domains fold back even further onto the
Cε3 and Cε4 domains than in the apo-IgE crystal structures [72], and evidence
from intramolecular FRET data suggests that this more compact shape is also
adopted upon binding sFcεRIα in solution [74, 75]. Furthermore, to accommodate
the simultaneous engagement of sFcεRIα with both subsites on IgE-Fc, both Cε3
domains adopt ‘open’ conformations in which they are further from one another
than in the apo-IgE structures (Figure 1.10). The crystal structures also suggest
that conformational changes in the FcεRI binding loops occur in order to correctly














Figure 1.9: The interaction between IgE-Fc and sFcεRIα. The crystal struc-
ture of sFcεRIα bound to IgE-Fc (PDB: 2YZQ [72]) shows sFcεRIα binds to IgE-Fc
with a 1:1 stochiometry. sFcεRIα contacts both Cε3 domains of IgE-Fc, forming
two different interaction subsites. A network of hydrogen bonds and salt bridges
form at subsite 1, whereas stacking interactions between an IgE-Fc proline, sand-
wiched between two sFcεRIα tryptophan residues, stabilise the interaction at the
subsite 2.
The crystal structures of free IgE-Fc show that one of the Cε3 domains already
exists the in the ‘open’ conformation required for FcεRI binding. It has been
proposed that the Cε2 domains of IgE, which are absent in IgG, stabilise the
flexible Cε3 domains, thereby reducing the entropic penalty that occurs as a result
of FcεRI binding [83, 72].
1.2.3 The IgE/CD23 interaction
A single chain of CD23 binds IgE with a KD of 10
-7 - 10-6 M, [88, 39, 89, 90] but
because CD23 exists as a trimer on the surface of cells, avidity increases the affinity
of the interaction such that its binding affinity is roughly comparable to that of
the IgE/FcεRI interaction [91, 92, 36, 90]. The structure of IgE-Fc(3-4) bound
to recombinant derCD23 confirms previous reports that two CD23 head domains
bind one molecule of IgE [88]. In the context of trimeric CD23, two head domains

























FcεRIα:IgE-Fc IgE-Fc derCD23:IgE-Fc(3-4) (2:1) 
Figure 1.10: sFcεRIα binds to an open conformation of IgE-Fc whereas
derCD23 binds a closed state. The crystal structure of sFcεRIα bound to IgE-
Fc (PDB: 2YZQ [72]) shows sFcεRIα binds to IgE-Fc in which both Cε3 domains
are in an ‘open’ conformation. For clarity only the Cε3 (blue) and Cε4 (white)
domains are shown in the surface representation. In the crystal structure of IgE-Fc
(PDB: 2WQR [72]), one Cε3 domain is in an ‘open’ conformation and the other is
in a ‘closed’ conformation. Again, for clarity only the Cε3 (blue) and Cε4 (white)
domains are shown in the surface representation. The crystal structure of IgE-
Fc(3-4) bound to two molecules of derCD23 (PDB: 4EZM [18]) shows both Cε3
domains adopt ‘closed’ conformations.
IgE since simultaneous engagement would require a very significant ‘unzipping’ of
the CD23 stalk [88, 85]. Two head domains from two different CD23 molecules
could, however, simultaneously engage one molecule of IgE, further adding to the
avidity of the interaction [85].
Each CD23 head domain binds a separate chain of IgE-Fc(3-4) at symmetrically
equivalent binding sites (Figure 1.11). Both crystallography [18, 93] and nuclear
magnetic resonance (NMR) [89] have confirmed the location and composition of the
CD23 binding sites, which primarily involve the Cε3 domains, although the Cε3-
Cε4 domain linkers and the Cε4 domains do make some smaller contributions to the
interaction. The interaction interface is mainly hydrophilic and a network of salt
bridges and hydrogen bonds form between IgE-Fc and flexible loops of the CD23
molecule (Figure 1.11.b) [18, 93]. CD23 belongs to the C-type lectin superfamily:
a family of calcium-dependent carbohydrate-binding proteins, however calcium is
not essential for binding of CD23 to human IgE [39, 93] and the interaction is
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independent of carbohydrate [94]. Although not essential for the interaction, the
presence of calcium increases the affinity of the interaction by about 30 fold (at 37
◦C) [93]. The crystal structure of the IgE-Fc(3-4):derCD23 (2:1) complex in the
presence of Ca2+ shows that it binds to a loop that is partially disordered in the
absence of Ca2+. The stabilisation of the loop by Ca2+ permits the formation of
two additional hydrogen bonds between this loop and IgE-Fc, and accounts for the









Figure 1.11: The crystal structure of the derCD23:IgE-Fc(3-4) 2:1 com-
plex (PDB: 4EZM [18]). (a) Two molecules of derCD23 bind one molecule of
IgE. Each binding site is comprised predominantly of residues from loops in the
CD23 head domain and residues from the Cε3 domain. (b) A network of salt
bridges (black dotted lines) and hydrogen bonds (green dashed lines) form at the
interaction interface.
Conformational dynamics also play a key role in the interaction between IgE
and CD23. Unlike sFcεRIα, the CD23 head domain has a degree of plasticity:
structures of the CD23 head domain demonstrate that the loops involved in binding
IgE are dynamic [85], and as illustrated by the stabilising effect of calcium on
one of these loops, their plasticity is important for the interaction. Similarly, the
conformational variability of IgE-Fc is a crucial aspect of the IgE/CD23 interaction.
The Cε3 domains in the IgE-Fc(3-4):derCD23 (2:1) crystal structures are closer to
one another than in the apo IgE-Fc and IgE-Fc(3-4) structures [18, 93]. The various
derCD23-bound IgE-Fc(3-4) structures all adopt relatively ‘closed’ conformations
compared to apo-IgE-Fc (Figure 1.10), however, the Cε3-Cε4 interdomain angles
vary, indicating that even when complexed to derCD23, the Cε3 domains still retain
a degree of conformational flexibility [18, 93].
Recently, the crystal structure of full-length IgE-Fc in complex with a single
35
Chapter 1. Introduction
derCD23 head was solved (Figure 1.12). This structure has not yet been published
but it shows that the binding interface is very similar to those described in the
crystal structure of IgE-Fc(3-4) bound to derCD23. IgE-Fc remains asymmetrically
bent in the presence of the derCD23 molecule, but the Cε2 domains are slightly
more extended than in the apo-structures. The Cε2 domains fold over onto the
chain that is bound to derCD23 and consequently make a close approach to the
receptor molecule. Nevertheless, the Cε2 domain pair does not appear to make
significant specific interactions with derCD23, and only a single hydrogen bond
forms between derCD23 and the Cε2 domain of the same chain to which it is
bound. As anticipated, the Cε3 domain to which the derCD23 molecule is bound
is in a ‘closed’ conformation, but the unbound Cε3 domain adopts a more ‘open’
conformation [95]. It is possible that this asymmetry is responsible for a difference
observed in the affinity of the binding interaction of the first and second CD23
molecules to IgE-Fc (KD1 = 1.2 µM, KD2 = 14.4 µM) as determined by isothermal
calorimetry (ITC) [95]. The binding of CD23 to the more ‘open’ Cε3 domain of IgE-
Fc may be responsible for the observed lower affinity component of the interaction,
but further research is required to support this hypothesis: at present we are still







Figure 1.12: The crystal structure of the derCD23:IgE-Fc 1:1 complex
[95]. derCD23 binds an asymmetrically bent conformation of IgE-Fc. derCD23
binds a ‘closed’ Cε3 domain, but the other Cε3 domain adopts a more ‘open’




1.3 Allosteric regulation of IgE-Fc interactions
Allostery is the process in which a perturbation by an effector at one site of a
biological macromolecule results in a functional change at a distal site, through
alterations in conformation and/or dynamics. Allostery has a fundamental role in
the regulation of many biological processes, including cell signalling, metabolism
and gene regulation [96, 97]. Because allostery is integral to many aspects of
biology, its disregulation can result in disease, however allostery can also can be
harnessed in the development of therapeutics [98]. Allosteric effectors are diverse:
they can be biological molecules such as proteins, lipids and nucleic acids that bind
to the allosteric macromolecule, covalent modifications such as phosphorylation
and point mutations, and even structural disturbances as a result of changes in the
physical environment, for example irradiation and light exposure [98]. It has been
suggested that all dynamic proteins are allosteric [99]. IgE-Fc is a highly dynamic
protein capable of large scale conformational movements (Section 1.2.1) and it has
been shown that IgE-Fc-receptor interactions can be allosterically modulated.
1.3.1 Reciprocal allosteric inhibition of IgE-receptor
binding
FcεRI and CD23 are unable to bind IgE simultaneously [100, 101]. The mutual
inhibition of the two IgE receptors may have evolved to prevent the cross-linking
of FcεRI-bound IgE-Fc on the surface of mast cells and basophils by CD23, which
would result in systemic anaphylaxis [4]. Before the receptor binding sites had been
mapped, it was suggested that their mutual inhibition was a result of steric overlap
[4]. It is now evident, however, that their respective binding sites are spatially dis-
tinct and are located at opposite ends of the Cε3 domains [18]. Consequently the
two receptors must be allosteric inhibitors of one another, and comparisons of the
structures of IgE-Fc bound to FcεRI and IgE-Fc(3-4) bound to CD23 suggest that
the rigid-body motion of the Cε3 domains upon the Cε4 domains plays an impor-
tant role in the allosteric mechanism [18]. In the ‘open’ structure of IgE-Fc that is
adopted when bound to sFcεRIα, the CD23 binding sites are partly inaccessible,
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and in the ‘closed’ derCD23-bound state, the two FcεRI subsites are incorrectly
coordinated for binding (Figure 1.13) [18]. Given the intrinsic flexibility of the
Cε3 domain, it is is also possible that conformational changes within the receptor-
binding domain itself may contribute towards the mutual allosteric exclusion of






Figure 1.13: The structural basis for the allosteric and mutual incom-
patibility of IgE-Fc receptor binding. Steric clashes (orange) would prevent
sFcεRIα binding the ‘closed’ derCD23-bound IgE-Fc(3-4) (PDB: 4EZM). Steric
clashes (green) would also prevent derCD23 binding the ‘open’ sFcεRIα-bound
IgE-Fc(3-4) (PDB: 1F6A). (Figure taken from Dhaliwal et al., 2012, [18].)
1.3.2 Allosteric enhancement of the IgE/FcεRI interaction
by the Cε2 domain pair
Crystal structures of apo-IgE-Fc(3-4) show that the molecule can adopt a range
of ‘open’ and ‘closed’ conformations [77], whereas the crystal structures of apo
IgE-Fc show that the presence of the Cε2 domains limits this dynamism: one
of the Cε3 domains adopts an ‘open’ conformation whereas the other adopts a
‘closed’ conformation [86, 72]. The Cε3 domains in the crystal structures of both
sFcεRIα:IgE-Fc(3-4) and sFcεRIα:IgE-Fc show that the two Cε3 domains adopt
‘open’ conformations [71, 72]. It has therefore been suggested that the presence of
the Cε2 domain pair acts to limit the entropic penalty that is incurred upon binding
of FcεRI, which requires both Cε2 domains to adopt ‘open’ conformations [72].
This is supported by thermodynamic data, which suggest that the sFcεRIα/IgE-Fc
interaction is entropically driven and has around a 20 fold slower off-rate than the
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enthalpically driven interaction between sFcεRIα and IgE-Fc(3-4) [83, 72]. Because
the Cε2 domain pair of IgE is not directly involved in the interaction between IgE-
Fc and FcεRI, but functions to increase the affinity of the interaction, the domain
pair can be thought of as an allosteric enhancer of the IgE/FcεRI interaction.
Whereas reciprocal allosteric inhibition of receptor binding is thought principally
to be the result of conformational changes, here the allosteric mechanism appears
to be largely driven by changes in dynamics.
1.3.3 Allosteric inhibition of the IgE/FcεRI interaction by
aεFab1
The anti-IgE Fab fragment, aεFab1, was produced by phage display technology
in an effort to find Fabs that block FcεRI binding. aεFab1 binds IgE-Fc with
a 2:1 stochiometry (KD1 = 76 nM, KD2 = 1.5 µM), each aεFab1 molecule binds
predominantly to a single IgE-Fc chain, and each binding interface is centred on the
Cε3 domain (Figure 1.14.a) [81]. As described earlier, the crystal structure of the
aεFab1:IgE-Fc (2:1) complex demonstrated that IgE-Fc is capable of undergoing
a remarkable conformational change (Section 1.2.1). In the structure, the Cε2
domains have extended from the asymmetrically bent conformation (observed for
apo-IgE-Fc) so that there is a complete loss of contacts between the Cε2 domain
pair and the Cε3-Cε4 domains. ITC analysis indicated that both aεFab1 binding
sites on IgE-Fc are occupied in solution and intermolecular FRET studies indicated
that the binding of both aεFab1 molecules also results in an extended conformation
in solution [81]. Moreover, the Cε3 domains in the crystal structure of the complex
are both in ‘open’ conformations and even further apart from each other than in
the crystal structures of IgE-Fc bound to sFcεRIα. The Cε4 domains, however,
appear unchanged.
aεFab1 acts as an allosteric inhibitor of IgE/FcεRI interaction: the conforma-
tional changes associated with the binding of the Fab are incompatible with the
binding of the receptor. The extension of the Cε2 domain pair is accompanied by
a significant shift in the linker region that joins the Cε2 and Cε3 domains (Figure














Figure 1.14: aεFab1 allosterically inhibits the IgE/FcεRI interaction. (a)
The crystal structure of IgE-Fc (blue) bound to two molecules of aεFab1 (white)
in surface representation (PDB: 4J4P [81]). aεFab1 binds to an extended con-
formation of IgE-Fc, in which the newly adopted position of the Cε2 domains
blocks binding of FcεRI. (b) The crystal structure of the IgE-Fc:sFcεRIα complex
(PDB: 2Y7Q, [72]) was aligned to the crystal structure of the aεFab1 complex
upon the Cε4 domain pair, and shows that sFcεRIα (purple representation) over-
laps with the Cε2 domains of aεFab1-bound IgE-Fc (white cartoon representation).
Cε2 domain extension also causes conformational changes in the Cε2-Cε3 linker
region (white dashed box) of IgE-Fc, which shifts key residues involved in the IgE-
Fc/sFcεRIα interaction. (c) R344 is positioned in the linker region of IgE-Fc and
forms salt bridges (black dotted lines) with E132 of sFcεRIα (purple) in the IgE-
Fc:sFcεRIα complex (Fc of this complex in blue). In aεFab1:bound IgE-Fc (white)
R344 is significantly shifted such that it can no longer form salt-bridges with E132.
Furthermore, P426 (blue), is packed between two tryptophans of FcεRI in the IgE-
Fc:sFcεRIα complex, but a shift in the position of P426 in aεFab1-bound IgE-Fc
(white) prevents these stabilising interactions.
linker region, and accordingly when binding aεFab1, this salt-bridge cannot form.
Additionally, the proline residue involved in the stacking interactions at subsite
2 of the IgE-Fc/FcεRI interaction interface (Figure 1.9) is shifted by 6 Å upon
the binding of aεFab1 (Figure 1.14.c). Even if these perturbations were not suffi-
cient to prevent the binding of FcεRI, the extended Cε2 domain pair blocks the
FcεRI binding site, and the further opening of the Cε3 domains prevents optimal
engagement of both subsites on IgE-Fc by FcεRI (Figure 1.14.b) [81]. Presumably
the ‘open’ conformation of aεFab1-bound IgE-Fc would prevent binding of CD23,




1.3.4 Allosteric inhibition of the IgE/FcεRI interaction by
Xolair
The clinical benefits of Xolair in the treatment of asthma are well recognised and
have been attributed to its ability to inhibit the interactions between IgE-Fc and
its receptors [53, 102, 103]. In particular, Xolair is thought to function by binding
to IgE in the serum and preventing it from binding to FcεRI on the surface of mast
cells and basophils [104, 105]. It has been shown that Xolair binds to IgE with a 2:1
stochiometry and through a combination of peptide inhibition and molecular mod-
eling its binding site has been mapped to the Cε3 domains of IgE, which also bind
the receptors [106, 105]. Difficulties in crystallisation of the the IgE-Fc:Xolair Fab
complex have lead to a delay in our structural understanding of Xolair’s mechanism
of action [107]. Very recently, two crystal structures of different IgE-Fc:Xolair Fab
complexes have been solved (Figure 1.15). One structure is of Xolair Fab bound
to a constrained IgE-Fc(3-4) construct held in a ‘closed’ conformation with lim-
ited Cε3 conformational freedom [108], the other is of a mutant Xolair Fab (called
Xolair Fab mutant 3, containing three non-CDR mutations, designed to disrupt
Fab-only crystal packing) bound to IgE-Fc [82].
The Xolair:IgE-Fc binding interface is similar in both crystal structures, and
partly agrees with the previously determined binding site mapping data [106]. One
molecule of Xolair binds to a single Cε3 domain and its binding site is centred
between the FcεRI and CD23 binding sites [108]. Comparisons of the crystal
structures with the structures of IgE-Fc(3-4):derCD23 complexes show that the
Xolair and CD23 binding sites coincide and there is also substantial steric overlap
(Figure 1.15).
Whereas the data clearly suggests that Xolair acts as an orthosteric inhibitor of
the IgE/CD23 interaction, there is some ambiguity about how Xolair inhibits FcεRI
binding. In both Xolair complexes, the Xolair binding site does not encroach upon
the FcεRI binding site and as such Xolair does not inhibit binding of the receptor
to IgE-Fc by engaging the same residues. Pennington et al. suggest that the
binding of Xolair has no substantial effect on the conformation of the residues at
the FcεRI binding site, and instead suggest that FcεRI cannot bind Xolair-bound
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Figure 1.15: Crystal structures of Xolair Fab:IgE-Fc complexes demon-
strate that Xolair binds to a site in the Cε3 domain that is between
the two receptor binding sites. Xolair sterically blocks CD23 binding
but the Xolair binding site does not overlap with the FcεRI binding
site. (a) The crystal structure of Xolair Fab bound to a constrained IgE-Fc(3-4)
construct held in ‘closed’ state (PDB: 5HYS [108]). (b) The crystal structure of
Xolair Fab Mutant 3 bound to IgE-Fc with a 2:1 stochiometry [82]. The crystal
structure of IgE-Fc(3-4):derCD23 (PDB: 4EZM [18]) and the crystal structure of
IgE-Fc:sFcεRIα (PDB: 2Y7Q, [72]) were aligned by the Cε4 domains to the Xo-
lair Fab complex structures. The resulting placement of the derCD23 (green) and
sFcεRIα (purple) are shown in surface representations.
IgE-Fc because of atomic overlap [108]. Davies et al., however, suggest that Xolair
acts allosterically to prevent the binding of FcεRI to IgE-Fc [82].
The structure produced by Davies et al. is of a Xolair Fab construct binding to
full length, unconstrained IgE-Fc, and consequently can report on conformational
changes that may occur in the whole of IgE-Fc upon Xolair binding. The crystal
structure demonstrates that Xolair Fab mutant 3 (aεFabXol3) binds to a partially
extended conformation of IgE-Fc, with its Cε3 domains further apart from each
other than in any structure of IgE-Fc published to date. In this extremely ‘open’
conformation FcεRI would be unable to simultaneously coordinate both subsites
required for binding to IgE-Fc (Figure 1.16) [82].
Time resolved fluorescent resonance energy transfer (TR-FRET) studies showed
that both the apparent affinity (given by KD) and the number of available binding
site (given by Bmax) for the interaction between IgE-Fc and sFcεRIα were reduced
in the presence of increasing concentrations of aεFabXol3. Whereas a reduction
in the apparent affinity can be the result of orthosteric or allosteric inhibition, a
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Figure 1.16: aεFabXol3 allosterically disrupts the interaction between IgE-
Fc and FcεRIα (a) The crystal structure of the IgE-Fc:aεFabXol3 complex [82]
indicates that when IgE-Fc binds aεFabXol3 it adopts a very ‘open’ conformation
(grey cartoon representation). sFcεRIα (purple surface representation) binds a
conformation of IgE-Fc in which the Cε3 domains are closer together (blue cartoon
representation). In the more ‘open’ aεFabXol3-bound structure, subsites 1 and 2
are too far apart for simultaneous engagement by FcεRI. The structure of IgE-Fc
in complex with sFcεRI (PDB: 2Y7Q [72]) was superposed onto the aεFabXol3-
bound structure upon the Cε4 domains. (b) A substantial displacement of Pro426
in the aεFabXol3-bound structure moves the residue out from between two sFcεRIα
tryptophans that usually provide stabilising contacts at subsite 2.
Although the crystal structure of IgE-Fc bound to aεFabXol3 does not provide
evidence that the Xolair construct acts sterically to block FcεRI binding, it does
not rule it out. Consequently Davies et al. suggest that although it is possible that
Xolair acts as a steric inhibitor of interaction between IgE-Fc and FcεRI, Xolair
elicits its effect on the interaction predominately through allosteric processes.
1.3.5 Accelerated dissociation of IgE-Fc:FcεRI complexes
In 2012 Kim et al. published a paper demonstrating that a designed ankyrin repeat
protein (DARPin E2 79) not only inhibited binding of free IgE to FcεRI but also
actively disrupted pre-formed IgE:FcεRI complexes in vitro [109]. Later it was
shown that DARPin E2 79 could also accelerate the dissociation of IgE:receptor
complexes on the surface of human allergic effector cells both ex vivo and in vivo
[110]. Furthermore, it has been shown that Xolair can also facilitate dissociation of
FcεRI-bound IgE, although only at very high concentrations that are substantially
greater than therapeutic doses [110]. SPR experiments performed by Davies et
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al. demonstrated that aεFabXol3 can accelerate the dissociation of IgE-Fc from
sFcεRIα, immobilised on a SPR sensor surface, with greater efficiency than ei-
ther full-length Xolair antibody or Xolair Fab [82]. The group also showed that
the occupation of both Xolair binding sites is required for mediating accelerated
dissociation.
Because IgE-Fc binds FcεRI on the surface of mast cells and basophils with
unusually high affinity, and because of the exceptionally slow off-rate of the inter-
action [14, 15], mast cells in allergic individuals are almost always sensitised, and
cross-linking of IgE on their surface instantly triggers immediate hypersensitiviy
allergic reactions [4]. Consequently, understanding mechanisms that cause accel-
erated dissociation of IgE:FcεRIα complexes could provide exciting insights into a
new therapeutic approach that reduces the lifetime of IgE:FcεRI complexes on the
surface of cells that mediate allergic disease.
The mechanisms by which Xolair and DARPin E2 79 mediate the accelerated
dissociation of IgE/FcεRI complexes have been studied using structural and ki-
netic data from SPR experiments [109, 110, 108, 82]. The structure of DARPin
E2 79 bound to a constrained IgE-Fc(3-4) construct locked in the ‘closed’ confor-
mation showed the DARPin bound to IgE-Fc with a 2:1 stochiometry and that
each DARPin bound a separate Cε3 domain [109]. The two DARPin molecules
bind to non-equivalent binding sites on Cε3; one DARPin molecule is distant from
FcεRI binding site, whereas the other molecule is thought to partially overlap with
FcεRI. Although the crystal structure indicated little about the mechanism of
DARPin E2 79-mediated accelerated dissociation, a study of the binding kinetics
suggested that it occurred through the molecular process of facilitated dissociation
[109].
Facilitated dissociation is the consequence of competition between the effector
and the ligand for attachment points within a ligand binding site, which become
partially exposed during the natural complex dissociation process [109]. Based on
the complex of Xolair Fab bound to a constrained IgE-Fc(3-4) construct, Penning-
ton et al. suggest that Xolair also accelerates the dissociation of IgE-Fc:FcεRI
complexes through the process of facilitated dissociation [108]. They propose that
the lower disruptive capacity of Xolair compared to DARPin E2 79 is the result
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of a larger degree of spatial-overlap with IgE-bound FcεRI, which would reduce
Xolair’s ability to access attachment points during the dissociation process [108].
SPR studies demonstrate that aεFabXol3 can bind IgE-Fc:FcεRIα complexes
with almost the same affinity that it binds uncomplexed IgE-Fc, but that only 10
% of the aεFabXol3 binding sites are available on the IgE-Fc:sFcεRIα complex.
Consequently, Davies et al. suggest that Xolair-mediated accelerated dissociation
of IgE:FcεRI complexes occurs via allosteric processes [82].
1.4 The ensemble model allostery
Historically two main models have been used to describe allosteric processes, the
sequential model (KNF model) posited by Koshland Némethy and Filmer, and the
concerted model (MWC model) put forward by Monod, Wyman and Changeux
[111]. Both models interpret allostery in terms of conformational changes that oc-
cur between two functional states (‘T’ and ‘R’) of a macromolecule upon binding of
an allosteric modulator, and initially described these changes in oligomeric proteins.
The MWC model proposed that the binding of an allosteric modulator to a macro-
molecule shifts the pre-existing equilibrium of the ‘T’ and ‘R’ states in such a way
that the symmetry of the oligomer is conserved [112]. The KNF model, however
suggested that the binding of an allosteric effector induces conformational changes
in the macromolecule between ‘T’ and ‘R’ states (Figure 1.17) [113]. Both models
allow for a description of positive cooperativity - where the binding of ligand to a
macromolecule increases the affinity of further ligand binding sites, but only the
KNF model allows for a description of negative cooperativity - where the binding
of a ligand to a macromolcule decreases the affinity of further ligand binding sites.
This difference lies in the fact that the MWC model insists that conformational
changes of subunits are concerted: if ligand binds and stabilises the ‘R’ state of a
protein, each subunit (and therefore each binding site) must be in the ‘R’ state.
Both the MWC and KNF these models have been used to describe allosteric
systems [114] and were initially proposed to describe the cooperative binding of
oxygen to haemoglobin [112, 113]. The landmark X-ray crystallographic studies
of deoxy-haemoglobin (‘T’ state) and oxy-haemoglobin (‘R’ state) by Perutz led
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Figure 1.17: The concerted and sequential models of allostery. These models
propose that in an allosteric oligomer, made of symmetrically related subunits, the
subunits exist in equilibrium between tensed ‘T’ states and relaxed ‘R’ states.
A substrate can bind both ‘T’ and ‘R’ states, but has different affinities for the
distinct conformations. In this example the substrate has a greater affinity for the
‘R’ state. The binding of an effector shifts the equilibrium either one way or the
other, depending on whether it acts an inhibitor or enhancer of substrate binding.
Here, it is the substrate itself that acts as an enhancer of further substrate binding.
In the concerted model, the symmetry of the oligomer must be maintained and
consequently a change in conformation is simultaneously conferred to symmetrically
related subunits [112]. In the sequential model, the subunits are not connected to
the same extent, instead changes in conformation of the different subunits occur
sequentially through an induced fit [113].
to the first structural description of allostery in the context of the MWC model
(Figure 1.18) [115], which for decades remained the paradigm for studying allostery.
In 1992, however, two papers were published that questioned the legitimacy of a
two-state structure-based description of allostery in haemoglobin. Silva and co-
workers published the structure of an alternative ‘R’ state structure of haemoglobin,
showing that the molecule is capable of existing in more than two-states [116].
Additionally, Colombo et al. published thermodynamic data that suggested the
the ‘T’ to ‘R’ state transition must be accompanied by the preferential binding of
60 water molecules to the ‘R’ state, which could not be determined from the crystal
structure [117].
Recent advances in techniques that probe protein structural dynamics and ther-
modynamics such as NMR, have cast further doubt on the ability of two-state
structural-based models to accurately describe allostery [111]. It is now well es-
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Figure 1.18: The MWC/Perutz model for the cooperative transition from
‘T’ state to ‘R’ state haemoglobin. Tetrameric haemoglobin can be considered
as a dimer of αβ dimers. Each subunit has their own heme group (grey boxes).
Perutz suggested that the salt bridges between positively charged residues (blue
circles) and negatively charged residues (red circles) hold haemoglobin in the ‘T’
conformation. The binding of oxygen (purple diamonds) is accompanied by a 15◦
turn in one dimer relative to the other, which releases the salt bridges, resulting in
the ‘R’ conformation [115]. Perutz hypothesised that ‘T’ state has a lower affinity
for oxygen compared to the ‘R’ state because of strain in the heme moity [115].
Even decades after Perutz proposed this model, however, no structural feature
has actually been identified that has sufficient energy to account for the observed
level of oxygen binding cooperativity [118], and it has been demonstrated that
thermodynamic appreciation of the whole system is necessary: without additional
solvation of the ‘R’ state it is unlikely it would even exist [117].
respond to their environment and are capable of undergoing conformational re-
arrangements on a variety of scales [119, 120, 121, 122]. Since protein structure
and function are tightly coupled, it is reasonable to assume that allosteric pro-
cesses in dynamic molecules may not be described completely by the differences
between only one main ‘T’ state and one main ‘R’ state [123]. Furthermore, there
are reports of allostery occurring in macromolecules without an obvious change
in structure, where allostery is instead manifested through changes in entropy
[124, 125, 126, 111]. This form of ‘dynamic allostery’ was first proposed by Cooper
and Dryden in 1984 and suggests that changes in the frequency and amplitudes of
thermal fluctuations that occur upon binding of an allosteric effector can result in
either a positive or negative contribution to the entropy of ligand binding [127].
Over the years various other models have been used to describe allostery includ-
ing those that use statistical and thermodynamic approaches [128]. In recent years
there has been a revolution in the way we approach allostery: a new uniting model
was proposed which, unlike previous models, encompasses thermodynamics, the
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dynamic behaviour of proteins, and structural considerations in the context of al-
lostery. The ensemble model of allostery, as it has come to be named, is also able to
explain how the same allosteric modulator may have different, or even completely
opposing, effects under distinct sets of conditions [123].
1.4.1 The ensemble model of allostery
Proteins are dynamic and exist as conformational ensembles that include the many
different states that a protein may adopt, including the native state, folding inter-
mediates, numerous active functional states and different inactive functional states
[120, 121, 129]. Depending on the intrinsic dynamics of a protein, these different
conformations may be very closely linked or they may be relatively diverse in their
form [98]. The different conformations of a protein have distinct energies and are
described by the protein’s free-energy landscape under a certain set of conditions
[129]. The free-energy landscape of a protein is dependent on its inherent physio-
chemical properties in its environment [98]. The energy minima in a free-energy
landscape represent the possible conformations that a protein can adopt, the depth
of a minimum represents the stability of that conformer and the breadth represents
the entropic spread of that state [129]. The populations of the different conforma-
tions are distributed according to statistical thermodynamics, such that the lowest
energy conformations are the most occupied. A protein’s function is not simply
described by the most populated state, but is the collective and weighted outcome
of the conformational ensemble [98].
Moving between the different conformations requires ‘climbing’ over the energy
barrier between the different states, and how long a protein spends in a certain con-
formation depends upon the height of the energy barrier. Changes in the environ-
ment of a protein can cause a change in the free-energy landscape and results in the
redistribution of conformational populations. In the ensemble model of allostery,
allosteric modulators acting at a site distal to the functional site of a protein, act
to change the functionality of the protein not by creating new conformations, but
by stabilising certain conformations and thereby redistributing the populations of
the conformational ensemble (Figure 1.19). For example, a protein may adopt a
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number of conformations that are functionally ‘on’ and others that are ‘off’. In the
absence of an allosteric inhibitor, the weighting of the conformations favours those
in the ‘on’ state, resulting in a functional activity. The binding of an allosteric
inhibitor, however may stabilise certain conformers but not others, reshaping the
energy landscape in such a way that the ‘off’ states become more populated and
the protein’s functionality decreases. The level of reduction in protein function is
dependent upon the relative stabilisation of ‘off’ states to ‘on’ states in the pres-
ence of the allosteric inhibitor, and consequently the effects of allosteric modulators
can be subtler than the binary switch provided by orthosteric inhibitors. Further-
more, the relative stabilisation of different states by allosteric effectors depends
upon the initial distribution of molecules in the free energy landscape, which can
be distinct under different environmental conditions. Accordingly, under different
sets of conditions (e.g. temperature, pH, presence of other effectors) the effects of
allosteric modulators can be altered, allowing the fine-tuning of regulatory systems
[123, 130, 98, 111].
Figure 1.19: A schematic representation of the ensemble model of al-
lostery. Proteins are dynamic and exist as an ensemble of conformations. The
free energy diagrams here represent the different energies of the distinct conforma-
tions of a protein (a) before and (b) after binding of an allosteric inhibitor. The
protein has an effector subunit that binds the inhibitor and a functional subunit at
a distal site. Both subunits can exist in active and inactive conformations. Binding
of the inhibitor to active effector subunits stabilises certain conformations (arrows).
The resulting shift in the free-energy landscape leads to an increase in the popula-
tion of inactive functional subunits. Consequently, the overall effect of the shift is
negative in terms of the functionality of the protein.
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The ensemble model has been useful in understanding allostery in various
different systems including those where multiple conformations are involved in
the allosteric process, and in those where conformational changes are mediated
through dynamic fluctuations rather than conformational perturbations [130]. The
allosteric cooperation of ligand binding to cAMP-dependent protein kinase (cAPK)
is a good example of the former. cAMP catalyses the phosphorylation of various
proteins, consequently altering their specific cellular activities. In order to catal-
yse phosphoryl transfer cAPK must first bind adenosine and its peptide substrate.
The binding of adenosine to cAPK results in a 3 - 4 fold increase in the affinity
in the interaction of cAPK with its substrate, and similarly the binding to protein
substrate to cAPK increases the affinity of adenosine/cAPK interaction [125].
X-ray crystallography has revealed that cAPK exists in at least three distinct
conformations that differ in the relation of the large and small lobes of the protein
[131, 132]. An ‘open conformation’ refers to apo-cAPK, the ‘intermediate con-
formation’ refers to cAPK bound to either adenosine or peptide substrate, and
the ‘closed conformation’ is bound to both adenosine and substrate (Figure 1.20)
[131, 133, 132, 134]. According to the ensemble model of allostery, free cAPK
largely populates the ‘open conformation’, but binding of adenosine (or peptide
substrate) to apo-cAPK causes a shift in the free energy landscape that favours
the population of the ‘intermediate conformation’. The ‘intermediate conforma-
tion’ has a higher affinity for peptide substrate (or adenosine) than the ‘open
conformation’. The subsequent binding of the peptide substrate (or adenosine)
stabilise the ‘closed conformation’ and consequently results in a redistribution of
the cAPK population, such that the enzymatically active ‘closed conformation’ is
the most populated state (Figure 1.20) [135, 98]. Although the conformational
changes observed in the crystal structures are clearly important in understanding
the cooperative binding of its two ligands, NMR and molecular dynamic simula-
tions indicate that entropic changes that occur on binding peptide or adenosine
also contribute to the observed cooperativity in cAPK [125].
When a ligand binds to a protein it affects both its thermodynamic and dynamic
properties [98]. Changes in the amplitude and frequency of protein motions affect
the entropic spread of a conformational minimum, and thereby changes the width of
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Figure 1.20: An ensemble description of the allosteric cooperatively of
substrate binding to cyclic to cAMP-dependent protein kinase (cAPK).
cAPK exists as an ‘open conformation’ (apo structure, PDB: 1J3H [134]), an ‘in-
termediate conformation’ (adenosine-bound (adenosine-5’-monophosphate), PDB:
1BKX [132]) and a ‘closed’ conformation (adenosine (adenoside-5’-triphosphate)
and peptide-bound, PDB: 1ATP [131]). The binding of adenosine to cAPK causes
a population shift in the free energy landscape in favour of the intermediate confor-
mation, which has a greater affinity for peptide substrate. The binding of peptide
substrate stabilises the ‘closed’ conformation required for phosphoryl transfer ac-
tivity [98].
the free energy basin without affecting its position (Figure 1.21) [136]. The binding
of cyclic adenosine monophosphate (cAMP) to catabolite activator protein (CAP)
is negatively cooperative, and it was the first allosteric process to be explained
almost entirely in terms of changes in entropy. CAP is a homodimeric transcription
factor composed of a DNA binding domain and a substrate binding domain. The
substrate binding domain binds to two molecules of cAMP, and the binding of the
two cAMP is negatively cooperative. The crystal structures of the substrate binding
domain in the apo state (CAPN), the singly liganded state (cAMP1-CAPN) and the
doubly-bound state (cAMP2-CAPN) indicate that the binding of the first molecule
of cAMP has no significant effect on the binding-site of the second cAMP molecule.
NMR analysis of backbone dynamics, however, suggests that the binding of the first
ligand increases the dynamics of the protein, and thermodynamic analysis using
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ITC indicates the negative cooperatively is entropically driven. It is proposed
that the binding of the first cAMP molecule increases entropy of CAPN, thereby
increasing the entropic penalty incurred upon binding of the second cAMP molecule
[124]. Molecular dynamic simulations have also provided data supporting the role
of entropy in the negative cooperativity of cAMP binding in CAP, however, the
simulations also suggested that side chain movements at the cAMP binding pocket
and the protomer-protomer interface also contribute to the mechanism of negative
allostery [137]. Since this initial demonstration of dynamic allostery many other
examples of entropically driven allostery have been described [138, 125, 126, 111,
139], including the allosteric enhancement of the IgE-Fc/FcεRI interaction by the








Figure 1.21: A change in entropy upon binding a ligand alters the width
of the free-energy basin without affecting its position. The conformation
of a protein under given conditions is represented as a minimum in a free-energy
landscape. The depth of the minimum corresponds to its free-energy and there-
fore its stability, whereas its width indicates the level of conformational spread (or
entropy). If binding of a ligand to a particular conformation of a protein (blue
minimum) decreases the amplitude and frequency of its thermal fluctuations then
the entropic spread of the conformation reduces (purple dotted arrows), and con-
sequently the width of the energy minimum decreases, but not its position (green
minimum).
1.4.2 The ensemble model of allostery and IgE
As described in Section 1.2.1, IgE-Fc is a dynamic molecule: it can ‘open’ and
‘close’, and ‘bend’ and ‘extend’ to varying degrees, and IgE-Fc’s conformational
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flexibility has a considerable impact on how it interacts with its receptors (Sec-
tion 1.2). Additionally, binding of various anti-IgE proteins distal to the receptor
binding sites have been shown to stabilise certain conformers of IgE with altered
affinities for FcεRI and CD23 (Section 1.3). In this way, the allosteric regulation of
IgE-receptor interactions fits inside the framework of an ensemble model of allostery
- it is consistent with a model whereby allosteric modulation is the consequence
of perturbing the distribution of IgE ensemble states, in which ‘open’ and ‘closed’,
and ‘bent’ and ‘extended’ conformations are the extremes. Accordingly, if we are to
gain a deeper understanding of the allosteric regulation of IgE-receptor binding it
will be necessary to achieve a wider appreciation of the conformations that IgE-Fc
can adopt, the energy barriers between them, and their relative receptor affinities
under well-defined conditions.
Because NMR spectroscopy can provide information about the structure, dy-
namics and thermodynamics of a protein at atomic detail, it has played a ma-
jor role in understanding conformational ensembles or proteins and the dynamic
changes coupled to allostery [140, 111, 141]. Relaxation dispersion techniques can
describe conformational heterogeneity and transitions between different conforma-
tional states, and residual dipolar couplings and magnetization transfer techniques
can be used to characterise dynamic processes on a range of timescales [141]. NMR
spectroscopy could therefore provide a wealth of information about the ensem-
ble nature of IgE-Fc and the dynamic changes that occur upon binding allosteric
modulators. Significant amounts of isotopically-labeled protein are required to
investigate protein dynamics using NMR spectroscropy. IgE-Fc is produced in
mammalian or insect cell-lines that allow correct disulphide bond formation and
glycosylation [142]. Isotopic labelling, however, is usually performed in a bacterial
or cell-free system [143], and to date there have been no reports of the successful
generation of functional IgE-Fc in either system. Production of isotopically-labeled
IgE-Fc is a major hurdle in the investigation of the structural and dynamic prop-
erties of IgE-Fc using NMR spectroscopy, and currently no NMR data has been
published for IgE-Fc.
Multi-dimensional NMR experiments are most commonly performed on pro-
teins that have been uniformly labelled with 15N and 13C. Uniform labeling in
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large proteins can generate very complex NMR signals. Signal complexity can be
be reduced by labeling only certain amino acids, which then act as site-specific
probes. Site-specific labeling has been useful in investigating ligand interactions
and conformational changes of relatively large proteins by NMR and could be a
further option for NMR studies of IgE-Fc (75 kDa) [144].
Generally, X-ray crystallography produces a static structure of a protein that is
an average of its dynamic, heterogeneous ensemble within a crystal. Consequently,
X-ray crystallography provides a snapshot representation of the most populated
state under certain conditions, which for the most part cannot be deconvoluted
to determine ensemble properties of a protein [145]. It is possible, however, to
trap transiently populated conformations of a protein through ligand stabilisation:
an extended, open conformation of IgE-Fc was trapped, for example, by aεFab1.
Using this approach it may be possible to gain a greater understanding of IgE-
Fc’s conformational ensemble. As demonstrated in the studies of aεFab1 [81] and
aεFabXol3 [82], crystal structures of anti-IgE Fab:IgE-Fc complexes, in combina-
tion with solution-based binding studies, can help understand allosteric regulation
of IgE-Fc/receptor interactions.
1.5 Rationale
The dynamic behaviour of IgE-Fc’s conformational ensemble is instrumental in the
IgE/receptor interactions (Section 1.2), which are fundamental to the mechanisms
of allergic disease (Section 1.1.1). Understanding the conformational versatility
of IgE-Fc is therefore crucial to understanding its immunological role. IgE-Fc
has evolved a dynamic structure that, through allostery, allows it to separate the
functionality of its two different receptors (Section 1.3.5), and to bind its FcεRI
receptor with an affinity unparallelled by any other antibody/receptor interaction
(Section 1.2.2). By learning about the dynamic conformational ensemble of IgE-Fc
we can understand more about IgE’s function in immunology, as well as how we can
exploit it in the design of therapeutics that target the IgE/receptor interactions.
Allosteric drugs have several main advantages over orthosteric drugs that target
the functional site of the protein. One such advantage is their specificity: allosteric
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modulators do not bind to the the functional sites of proteins, which are generally
more conserved than other parts of the protein, and are usually highly conserved
in proteins of the same family [98]. Moreover, because allosteric drugs work by
shifting the distribution of equilibrium conformations, their binding can simulta-
neously effect multiple functionalities, and in the case of inhibitors, they allow
modulation of function rather than only providing total elimination of function
[98]. Allosteric inhibitors are also an interesting and exciting proposition in the
design of small molecules that target protein-protein interactions PPIs. Because of
their size, small molecule inhibitors are poorly equipped to disrupt the large surface
interfaces of PPIs sterically (Section 1.1.2), the size of an allosteric molecule, how-
ever, does not affect its ability to inhibit PPIs allosterically. Understanding more
about allosteric sites and mechanisms of IgE could therefore provide insights use-
ful in the development of novel therapeutics for asthma and allergy. Furthermore,
the accelerated dissociation of IgE/FcεRI complexes (Section 1.3.5), indicates that
modulators can destabilise the very tight interaction between IgE and FcεRI on
the surface of effector cells, which is responsible for long-term sensitization to al-
lergen and the immediacy of allergic interactions (Section 1.2.2). Accelerating the
dissociation of IgE/FcεRI complexes could be a new way to target allergic disease
therapeutically, and understanding the potentially allosteric mechanisms of this
process is therefore of great interest.
It is only in recent years that we have started to uncover the extent of IgE-
Fc’s conformational dynamism, and only in the very recent past have we learnt
that IgE-Fc can adopt extended conformations (Section 1.2.1). Much remains to
be learnt about the conformational ensemble of IgE-Fc and how it relates to the
functions of IgE. Rigid-body domain movements in IgE-Fc have been shown to
result in a range of ‘open’, ‘closed’, ‘bent’ and ‘extended’ conformations that have
different affinities for FcεRI and CD23 (Section 1.2). There is also some suggestion
that intradomain movements within the intrinsically dynamic Cε3 domain may also
contribute towards changes in receptor-binding (Section 1.2.2). The conformational
ensemble of IgE-Fc is likely to include numerous other IgE-Fc conformers that,
when increasingly populated, affect receptor binding activity. Other conformations
of IgE-Fc may be ‘open’ or ‘extended’ to varying degrees, or they could indicate
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the existence of different rigid-body motions that have not yet been described
in IgE. Additionally, a greater description of the conformational ensemble could
uncover dynamic processes on a smaller scale, such as backbone and side-chain
dynamics that affect IgE/receptor interactions. In addition to understanding more
about the conformational ensemble itself, questions remain about how to target it
allosterically: how can we stabilise conformations in order to modulate a certain
receptor-binding functionality?
When significant amounts of a isotopically-labeled IgE-Fc have been produced,
NMR spectroscopy will reveal much about the conformational ensemble of IgE-
Fc and its dynamic properties. Until then, there is still a lot that can be learnt
through molecular dynamic simulations and X-ray crystallography. The crystal
structure of aεFab1-bound IgE-Fc revealed an unexpected IgE-Fc conformation
and revealed a novel strategy of allosteric inhibition of IgE/receptor interaction
(Section 1.3.3). Based upon the success of the aεFab1 project, King’s and UCB
are working in collaboration to generate a whole panel of aεFabs that trap IgE-
Fc in a variety of transiently populated conformations. We will use UCB’s new
antibody discovery platform [146, 147, 148] to screen the immune repertoires of
rabbits immunised against IgE in order to find antibodies that bind to IgE-Fc
and thereby affect IgE/receptor interactions. This project will involve screening
for antibodies that affect the IgE-Fc/CD23 interaction. Through the biophysical
and structural characterisation of the aεFab/IgE-Fc interactions we hope to learn
more about the different conformations that IgE-Fc can adopt, how they relate to
different receptor-binding activities and accordingly gain a greater comprehension
of allostery in IgE-Fc.
Herein we describe the discovery and biophysical characterisation of antibodies
selected for their ability to alter the CD23/IgE interaction. Using SPR and cell-
binding assays we investigated how the selected aεFabs affect the binding of CD23
to IgE, and determine if they work allosterically. Ultimately, with structural data,
we aim to understand the mechanisms through which the selected aεFabs modu-
late CD23 binding. By linking structure and function in the context of IgE-Fc’s
conformational ensemble we hope to provide insights into new ways of allosterically
targeting the IgE-receptor interactions for the development of novel therapeutics
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 140 mM NaCl, 2.7 mM KCl, 1.5 mM 
KH2PO4, 8 mM Na2HPO4, pH 7.4 	

SDS-PAGE resolving gel 
buffer	

1500 mM Tris-HCl, pH 8.8, 0.4 % SDS	

SDS running buffer (10 x)	
 30 g/L Tris-HCl, pH 8.3,	

144 g/L glycine, 10 g/L SDS	

SDS-PAGE stacking gel 
buffer	

500 mM Tris-HCl, pH 6.8, 0.4 % SDS	





 20 g/L tryptone, 5 g/L yeast extract, 	

5 g/L NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4  	

SPR running buffer	
 10 mM HEPES, 150 mM NaCl pH 7.4, 
0.005 % surfactant P20, 4 mM CaCl2	

Tris-acetate-EDTA	
 1 x TAE 	






 25 mM Tris, 125 mM NaCl, 	

4 mM CaCl2 pH 7.4	

Table 2.1: A list of buffers frequently used for the purposes of this thesis.
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 Davies et 
al., 2017	

Table 2.2: A list of recombinant proteins used for the purposes of this
thesis. All proteins were generously donated by UCB, except those denoted by *
that were produced as part of the project, those denoted by ** which were kindly
donated by Seema Mayank, and those denoted *** which were kindly donated by
Virginia Casablancas Antras.
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2.2 General deoxyribonucleic acid (DNA) analy-
sis and manipulation techniques
2.2.1 Spectroscopic quantitation of DNA
Absorbance readings at 260 nm were used to estimate DNA concentrations, taking
0.020 (µg/ml)-1 cm-1 to be the the average extinction coefficient for double-stranded
DNA. A260/A280 nm and A260/A230 nm ratios were used to estimate the level
of DNA purity in terms of protein and organic compounds respectively, with a
tolerance of ∼ 1.8 and 2.0-2.2 for A260/A280 nm and A260/A230 nm ratios, re-
spectively.
2.2.2 Agarose gel electrophoresis of DNA
Agarose gel electrophoresis was used to separate DNA fragments on the basis of
their size. To make a gel, agarose (Bioline) was added to 1 x TAE buffer to a final
concentration of 1 % and dissolved by heating. After cooling, 0.5 µg/ml ethidium
bromide (Sigma-Aldrich) was added and the mixture was poured into a gel tray
with a plastic comb. Once set, the gel was placed in an electrophoresis tank and
submerged in 1 x TAE. 5-50 µl of samples were pre-mixed with Gel Loading Dye,
Blue (6X) (New England Biolabs). The comb was removed and the samples were
placed in the wells alongside a molecular weight marker. A voltage of 100 V was
applied across the gel until the DNA fragments were sufficiently separated. DNA
bands were visualised under UV illumination. In order to recover DNA, bands were
excised from the gel under UV illumination and purified from the agarose using
the Qiagen gel extraction kit, according to manufacturers instructions.
2.2.3 Heat-shock transformation of E. coli
Plasmid DNA was introduced into E. coli using the heat-shock method. 45 µl of
frozen chemically competent E. coli were gently thawed on ice. 1 µl of 100 µg/ml
DNA solution was added to the thawed cells, mixed gently and incubated on ice
for 20 minutes. The cells were immersed in a water bath at 42 ◦C for 45 seconds
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and subsequently returned to the ice for 2 minutes before the addition of 250 µl
of pre-warmed Super Optimal broth with catabolite repression (SOC) media (New
England Biolabs). The cells were incubated at 37 ◦C with orbital agitation at 225
rpm for 1 hr before plating onto selective LB agar and overnight incubation at 37
◦C.
2.3 General protein analysis techniques
2.3.1 Spectroscopic determination of protein concentration
Protein concentrations were determined using spectrophotometry. Absorption of
UV/visible light was measured from 200-700 nm. Absorbance measurements at
280 nm (from tryptophan and tyrosine residues, and disulphide bonds) were used
to derive protein concentrations using the Beer-Lambert law (Equation 2.1). The
extinction coefficients of different proteins were determined by the number of of
tyrosines, tryptophans and cysteine residues in the amino acid sequence using
(Equation 2.2). Protein concentrations in mg/ml were calculated through mul-
tiplication of the protein concentration (M) by molecular weight (Da). A list of
relevant protein extinction coefficients and molecular weights are given in Table
2.2.
A280 = ε280cl (2.1)
A280 = absorption at 280 nm, ε280 = extinction coefficient (M
-1 cm-1)
c = protein concentration (M) l = path length of sample (cm)
ε280 = 5690nw + 1280ny + 120nc (2.2)
ε280 = absorption at 280 nm (M
-1 cm-1) nw = number of tryptophans
ny = number of tyrosines nc = number of cysteines
2.3.2 SDS-PAGE analysis
Electrophoresis was used to assess the presence and purity of protein in a sample.
Gels were cast according to the recipe in Table 2.3. Samples were prepared in
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2x Laemmli sample buffer (BioRad), with or without 5% β-mecaptoethanol as
appropriate. Samples were heated at 95 ◦C for 3 minutes . For protein samples,
5 – 10 µg of protein in 20 µL was loaded into each well alongside appropriate
molecular weight markers. The gel was placed in a tank containing SDS running
buffer and a voltage of 120 V was applied to the gel until the dye reached the
bottom of the plate. Gels were stained in Instant Blue (Generon) for 1 hr or until
protein bands were clearly visible and then excess dye was removed by washing
with distilled water.
Resolving gel (15%) Stacking gel
Resolving gel buffer (ml) 2.5 1.25
30 % acrylamide (ml) 5 1
Water (ml) 2.36 3.18
10 % APS (ml) 0.075 0.050
TEMED (ml) 0.011 0.025
Table 2.3: SDS-PAGE gel recipe. APS is ammonium persulphate, TEMED is
tetramethylethylenediamine.
2.4 derCD23 production and purification
2.4.1 DNA and vectors
The Swiss-Prot accession code for the human low affinity IgE-Fc receptor is P06734.
The derCD23 construct comprises the amino acids Ser156 to Glu298 of P066734.
The derCD23 construct was previously cloned into the pET5a expression vector
[149]. The pET5a expression vector is under the control of the T7 bacteriophage
promoter, and the T7 RNA polymerase is under control of the lacUV5 promoter.
The lacUV5 promoter can be induced using β-D-1- thiogalactopyranoside (IPTG).
The pET5a vector also encodes a gene for ampicillin resistance, which allows pos-
itive selection of transformed host cells.
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2.4.2 Transformation
Frozen chemically competent BL21(DE3) (New England Biolabs) E. coli were
transformed with derCD23 plasmid DNA using the heat-shock (Section 2.2.3) and
plated onto LB agar plates supplemented with ampicillin (Melfords Laboratories)
(25 µg/ml). 5 ml over-night cultures were set up from single ampicillin-resistant
conlonies in LB broth supplemented with ampicillin (100 µg/ml). DNA from the
cultures was extracted using the QIAprep Spin Miniprep Kit (Qiagen) and se-
quenced using primers specific for the T7 promoter.
2.4.3 Bacterial expression
A 5 ml culture was set up from a single derCD23-transformed ampicillin-resistant
BL21 (DE3) colony, in LB brother supplemented with ampicilln (100 µg/ml). The
culture was used to inoculate 50 ml of LB supplemented with 100 µg/ml ampicillin.
This starter culture was incubated at 37 ◦C, with orbital agitation at 180 rpm over-
night. Over-night culture was added to 500 ml of LB supplemented with 100 µg/ml
ampicillin at a volume sufficient to give an absorbance of approximately 0.1 at 600
nm. The culture was incubated at 37 ◦C, with orbital agitation at 225 rpm in a 2
L baffled conical flask. Expression of derCD23 was induced when the absorbance
of the culture at 600 nm reached 0.7 through the addition of IPTG (Sigma) to a
final concentration of 1 mM. After induction, the culture was left to incubate at at
37 ◦C, with orbital agitation at 225 rpm for a further 3 hours. The cultures were
spun at 4,000 xg for 30 minutes in order to harvest the cells. The cell pellet was
then re-suspended in 40 ml of PBS pH 7.4 and stored at -20 ◦C.
2.4.4 Purification of insoluble inclusion bodies
The cell pellets were thawed on ice and were passed through a cell disrupter (20
PSI) twice at 4 ◦C to release their contents. To purify the inclusion bodies, the
disrupted cells were centrifuged at 15,500 xg for 20 min at 4 ◦C and the pellets
were re-suspended in 30 ml 25 mM Tris, 1% Triton-X, pH 7.5. This was repeated
five more times but after the last centrifugation, the pellet was re-suspended in 5
ml 20 mM Tris, 6 M guanidinium hydrochloride, pH 7.5 and left rotating overnight
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at 4 ◦C to solubilise the protein. The solution was spun at 36,000 xg for 1 hour
to remove the insoluble contaminants. The supernatant containing the solubilised
derCD23 was stored at -20 ◦C.
2.4.5 Protein refolding
Dithiothreitol (DTT) was added to thawed solubilised derCD23 to a final concen-
tration of 1 mM and left to stand for 10 minutes at 4 ◦C. The protein solution
was slowly diluted ten-fold into ice-cold refolding buffer, at 0.15 ml/min with rapid
stirring and then left stirring at 4 ◦C overnight. NaCl was added from a 5 M stock
solution to the solution to a final concentration of 50 mM and then left stirring at 4
◦C for a further 2 hrs. The refolding solution was diafiltrated with a 10- fold excess
of 25 mM Tris, pH 7.5 at 4 ◦C with a 5 kDa molecular weight cut-off (MWCO)
membrane.
2.4.6 Heparin-sepharose chromatography
A HiPrep Heparin 5 ml column (GE Healthcare) was pre-equilibrated with 10
column volumes (CVs) of 25 mM Tris, pH 7.5. The refolded derCD23 was filtered
through a 0.45 µm filter (Sartorius) and loaded at 2 ml/min onto the column. The
column was then washed with 10 CVs of 25 mM Tris, pH 7.5 at 5 ml/min to remove
non-specifically bound protein. After achieving a stable absorbance at 280 nm, the
flow rate was dropped to 0.75 ml/min. A gradient elution from 0 % to 40 % 25
mM Tris, 1 M NaCl, pH 7.5 was performed over 90 ml, collecting 3.5 ml fractions.
Folded derCD23 was the dominant peak and eluted at around 20 % elution buffer.
Following elution, the column was washed with 10 CVs of 25 mM Tris, 1 M NaCl,
pH 7.5, 10 CVs of 25 mM Tris pH 7.5, and 10 CVs of 20 % ethanol.
2.4.7 Size exclusion chromatography
A HiLoad 16/600 Superdex 75 PG column (GE Healthcare) was equilibrated with
200 ml 500 mM arginine, 25 mM Tris, 125 mM NaCl, 4 mM CaCl2, pH 7.5 at 0.75
ml/min. The selected fractions from the heparin column elution were concentrated
to 5 ml using a 3 kDa MWCO centrifugal concentrator at 4 ◦C and 6,000 xg. The
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derCD23 protein solution was loaded onto the column at 0.75 ml/min and eluted
over 140 ml minutes at 0.75 ml/min. Fractions of monomeric derCD23 were pooled
and concentrated using a 3 kDa MWCO VivaspinTM centrifugal concentrator (Sar-
torius) at 4 ◦C and 6,000 xg. The purified derCD23 was then buffer exchanged
into Tris buffered saline (TBS) pH 7.4 using a 3.5 kDa Slide-A-LyzerTM cassette
(Thermo Fisher Scientific) as per the manufacturer’s instructions.
2.4.8 Positive electrospray mass spectrometry
Positive electrospray mass spectrometry (MS) was conducted on the purified derCD23
to ascertain the exact molecular mass of the protein. Protein sample, at 0.1 mg/ml,
was dialysed into a solution of distilled and filtered water, 10 % acetonitrile and
0.1 % formic acid prior to MS analysis. The protein sample was injected at 40
µl/min directly into a Bruker MaXis ultrahigh-resolution electrospray ionisation
quadropole time-of-flight mass spectrometer. The multiple charge states were de-
convoluted into the most probable single mass using the manufacturer’s maximum
entropy algorithm (Bruker Daltonics).
2.4.9 One dimensional 1H NMR spectroscopy
One dimensional (1D) 1H NMR spectroscopy was used to determine if the purified
derCD23 was folded. The spectrum was recorded on 200 µM purified derCD23 in
TBS with 5 % D2O at proton frequencies of 500 megahertz (MHz). 64 scans were
taken at a temperature of 35 ◦C.
2.5 Anti-IgE antibody discovery
UCB’s core antibody disovery process was used to identify antibodies that bind to
IgE-Fc and affect the IgE/CD23 interaction. The process is a single B cell process
that involves:
a) immunisation
b) culturing of B cells from the immunised subject
c) screening of B cell supernatnats for ‘hit’ antibodies with desired characteristics
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d) isolation of the variable region genes of ‘hit’ antibodies from single B cells
e) cloning of the variable region genes into suitable antibody/Fab constructs for
expression
f) expression and purification of antibody/Fab proteins
2.5.1 IgE-Fc immunuzisations
Three New Zealand White rabbits were immunised subcutaneously with 500 µg
of purified IgE-Fc (N265Q, N371Q). The IgE-Fc was emulsified in a 1:1 volume
of complete Freund’s adjuvant (CFA). Booster injections were made at 21-day in-
tervals using incomplete Freund’s adjuvant (IFA). Peripheral blood (10 % bleed)
was taken from the ears of the rabbits 14 days after the second booster injection.
Rabbit immunisations were performed in accordance with the provisions of the An-
imals (Scientific Procedures) Act 1986 and were approved by UCB’s ethical review
process and conducted under project licence 30/2981. The blood was diluted in the
same volume of sterile PBS and then layered onto 15 ml of Mammal Lympholyte
(Cedarlane Laboratories Ltd., CL5120) in a 50 ml Falcon tube. The sample was
centrifuged at 1500 xg for 15 minutes. The white lymphocyte layer was carefully
transferred into a new 50 ml Falcon tube. The cells were washed in PBS using
centrifugation at cells at 800 xg for 10 minutes. The cells were frozen in 10 %
dimethyl sulfoxide (DMSO) in (fetal calf serum) FCS at -80 ◦C. (Work performed
by Victoria O’ Dowd of UCB).
2.5.2 UCB’s core antibody discovery platform
The automated system is composed of three linked class II safety cabinets. The B
cell cultures were set up on the first safety cabinet using Thermo Combi Multidrop
dispensers. The dispensers added the lymphocytes in growth medium to barcoded
96-well culture plates at 37 ◦C. The barcodes were registered and uploaded onto
a tracking system. The plates were then placed into Liconic STX 500 incubators.
Plates were moved within the cabinet by a Mitsubishi robotic arm.
The B cell culture plates were screened in the second safety cabinet. Each plate
was sequentially moved into the second cabinet and its lid removed by another
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Mitsubishi robotic arm. An Agilent Bravo liquid-handing robot then transferred
10 µl of each cell culture supernatant to 384-well assay plates. Multidrop Combi
dispensers were then used to add the assay reagents to the assay plates and were
then incubated for 1 hour and run in the TTP Labtech Mirrorball plate reader.
The Mitsubishi arm then transferred the cell culture plates to an STX 500 holding
incubator where they were held until required for hit picking.
A text file of positive hits generated in the screen was supplied to a Beckman
Biomek NXP in the third cabinet. The Biomek NXP picked off the positive super-
natants from the B cell culture plates and put them into barcoded master plates.
The masterplates were then returned to the incubator for collection.
The hardware and scheduling was controlled by Overload software via PAA’s
Harmony graphical interface.
2.5.3 B cell culture
The peripheral blood lymphocytes were slowly thawed and washed in PBS using
centrifugation at 800 xg. The cells were then mixed with EL4 feeder cells (40,000
cells per well) and a T-cell conditioned media. The details of the T-cell condi-
tioned media are protected by UCB but uses RPMI media as a basis (Gibco R©, Life
Technologies) containing 8.7 % FBS (Sigma-Aldrich), 1.7 % HEPES buffer, 1.7 %
L-glutamine, 0.86 % penicillin/streptomycin solution, 0.17 % normacin and 0.09 %
β-mercaptoethanol.
200 µl of culture was dispensed into each well at density a of ∼5,000 cell per
well. At this empirically-derived lymphocyte density, the target-binding antibodies
within a positive supernatant, will generally have come from a single B cell clone.
The lymphocytes were incubated for seven days during which time the B cells
expanded and secreted high enough antibody titres into the media for antigen-
binding screening.
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2.5.4 The primary fluorescence-based homogeneous
screening assay
The cell culture supernatants were screened for IgE-Fc binding using a homoge-
neous binding assay. 10 µm superavidin polystyrene beads (Bangs Laboratories)
were coated with biotinylated IgE-Fc. 0.5 µg of biotinylated IgE-Fc was used to
coat enough beads for the 384-well-plate and were left to incubate at room tem-
perature for 1 hour. The coated beads were washed three times in PBS and 1
% BSA using centrifugation. Each well of each 384-well assay plate contained 10
µl of beads coated in biotinylated IgE-Fc, 10 µl of B cell supernatant and 10 µl
Alexa Fluor 488-conjugated goat anti-rabbit IgG Fcγ-specific reagent (Jackson Im-
munoResearch). The final dilution of the conjugated antibody was 1 in 5,000 and
all dilutions were made in PBS and 1 % BSA. The plates were then left to incubate
for 1 hour in the dark before fluorescence readings were taken on the Mirrorball
cytometer.
2.5.5 Hit-picking
The primary screening data from the homogeneous fluorescence-based assay were
analyzed in Spotfire DecisionSite (TIBCO) and used to generate a list of positive
wells. ‘Hits’ were identified as those supernatants that gave a fluorescence reading
over 100. The supernatants from the top 800 readings were then transferred into
96-well masterplates, which were then used for secondary screening. The B cells
cultures were then cryo-preserved and stored at -80 ◦C.
2.5.6 The secondary fluorescence-based screening assay
The ‘hit’ cell culture supernatants were screened for modulation of CD23 binding to
IgE-Fc using the homogeneous binding assay. Superavidin beads were coated with
biotinylated IgE-Fc as previously described, except washes were performed in 10
mM HEPES , 1 % BSA and 5 mM CaCl2 (Section 2.4). Each well of each 384-well
assay plate contained 10 µl of coated beads, 10 µl of B cell diluted supernatant and
10 µl of Alexa Fluor 488-labeled derCD23 at 1 µg/ml. The B cell supernatants
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were diluted 1 in 5 as assay design experiments showed some component of the
culture media quenched fluorescence. All dilutions were made in 10 mM HEPES,
1 % BSA, 5 mM CaCl2. 32 ‘baseline’ control wells were set up per a 384-well assay
plate that contained the same components except that supernatant had not been
identified as ‘hits’ in the primary screen. The ‘baseline’ supernatant came from a
different rabbit immunisation and cell-culture. The plates were left to incubate in
the dark for 1 hour and then the fluorescence readings were taken on the Mirrorball
cytometer. As a negative control the same screens were carried out but without
coating the beads with biotinylated IgE-Fc.
2.5.7 Foci-picking
The primary and secondary homogeneous assays identified the wells containing
the B cells of interest. These wells contained both the B cells of interest and
other B cells that were not IgE-Fc-specific. Foci picking is a novel technique that
was used to identify and isolate the IgE-Fc-specific B cells. The B cell culture
plates were removed from storage at -80 ◦C and gently thawed on ice. The B
cell cultures of interest were washed using centrifugation in cell culture media
(Gibco R©, Life Technologies) containing 8.7 % FBS, 1.7 % HEPES buffer, 1.7 %
L-glutamine, 0.86 % penicillin/streptomycin solution, 0.17 % normacin and 0.09 %
β-mercaptoethanol. The B cells were re-suspended at a final density of 1.6 x 106
cells/ ml in cell culture media.
For each culture well, 15 µl of 3.99 µm superavidin magnetic beads (New Eng-
land Biolabs) were coated with 0.5 µg biotinylated IgE-Fc and incubated for 1 hour
at room temperature. The coated-beads were washed three times in 120 µl culture
media using a magnetic rack.
Goat F(ab)2 anti-rabbit Fcγ fragment-specific fluorescein isothiocyanate (FITC)
conjugate (Jackson Immunoresearch) was diluted 1:300 in cell culture media and
was mixed with the washed B cells and the IgE-Fc coated beads in a 1:1:2 ratio
respectively. The mixture was then spotted onto walled-glass slides coated with
Sigmacote (Sigma-Aldrich) and then covered in mineral oil to prevent evaporation.
The slides were then incubated at 37 ◦C for 1 hour. Following incubation the slides
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were inspected for the formation of fluorescent foci using an Olympus IX70 mi-
croscope. Using an Eppendorf NK TransferMan micromanipulator, IgE-Fc-specific
antibody-expressing single B cells were isolated and individual B cells were placed
into 0.2 ml PCR tubes and put on dry ice immediately and stored at -80 ◦C. 6-12
IgE-Fc-specific B cells were picked from each well and placed in individual PCR
tubes to try and guarantee the correct antibody was isolated.
2.5.8 Reverse transcription PCR (RT-PCR)
RT-PCR was used to recover and amplify the cognate antibody genes from the
isolated B cells. RT-PCR was performed on three foci for each ‘hit’ B cell culture
to increase the chances of successful recovery of the variable region genes. The
reverse transcription reactions were performed in a sterile environment using a
class II safety cabinet. Superscript III reverse transcriptase (Invitrogen) primed
with oligo (dT) was added to the PCR tubes containing the individual B cells.
The B cells were kept on dry ice and moved onto a cold block to add the RT-PCR
constituents to prevent non-buffered thawing and subsequent RNA degradation.
The tubes were then placed in a PCR block and were incubated for 1 hour at 50
◦C, and then 10 minutes at 70 ◦C to inactive the Superscript enzyme.
2.5.9 Transcriptionally active PCR (TAP)
A series of PCRs were performed to clone the variable region genes into a suitable
construct for transient mammalian expression. PCR reactions, one for the VH
genes and one for the Vκ genes were performed separately. The PCR primers were
designed by UCB and their sequences cannot be disclosed. KOD DNA polymerase
(EMD Millipore) was used for all reactions.
Both VH and Vκ primary PCR reactions were performed using two 5’ primers
that annealed to the end of the leader sequence and two 3’ primers that annealed
to the CH1 region (VH) or the Cκ (Vκ). The cDNA from the RT reactions was
used as the DNA template in both cases.
The secondary Vκ PCR reactions were performed using a single 5’ primer that
annealed to a small ‘tail ‘at the 5’ end of the primary PCR product, and a set
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of two reverse primers that annealed to J the region. The secondary Vκ PCR
reactions were performed using the same 5’ ‘tail’ primer and a set of three reverse
primers that annealed to the J region of the primary PCR product. The secondary
PCR reactions introduced restriction sites to facilitate later cloning steps and also
introduced at the 5’ end a region of ∼ 25 base pairs that overlap with a human
cytomegalovirus (HCMV) promoter fragment. The secondary PCRs also added a
small heavy/kappa chain constant region fragment overlap to the 3’ end.
The tertiary PCRs combined the variable region DNA with a HCMV promoter
fragment and constant region fragment containing a poly-adenylation sequence.
This was then amplified to produce linear transcriptionally active PCR (TAP)
products - one for the VH genes and for the Vκ genes.
2.5.10 Cloning of variable region genes
The secondary PCR products were run on a 1 % agarose gel and then isolated using
the QIAquick Gel Extraction Kit (Qiagen). The isolated VH PCR products were
then digested with HindIII/Xho I restriction enzymes, and the isolated Vκ PCR
products were digested with HindIII/BsiW restriction enzymes. The digested DNA
was then gel purified and ligated, using T4 ligase (Promega), into a UCB in-house
expression vector with a HCMV promoter, rabbit Fab constant region cassette and
poly-adenylation sequence. XL1-Blue chemically competent E. coli (Agilent) were
transformed with the ligated DNA using heatshock and plated onto LB agar plates
supplemented with kanamycin (25 µg/ml). 5 ml over-night cultures were then
set up from single kanamycin-resistant colonies in 2xYT broth supplemented with
kanamycin (25 µg/ml). DNA from the cultures was extracted using the QIAprep
Spin Miniprep Kit (Qiagen) and then sequenced using forward and reverse primers.
2.5.11 Small scale transient expression of anti-IgE antibod-
ies and Fabs Expi293TM expression system
The Expi293TM expression system (Gibco R©, LifeTechnologies) is a transient mam-
malian expression system that uses lipofectamine to deliver exogenous DNA across
the cell membrane of Expi293FTM human embryonic kidney (HEK) cells. The cell
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density of Exp293FTM cell cultures were measured using a haemocytometer and
trypan blue dye exclusion. Transfections were performed according to the manu-
factures instructions. 3 ml cultures were set up for each VH and Vκ cognate pairing
of tertiary full-length antibody TAP products (5 µl of each TAP product). 12 ml
cultures were set up for each VH and Vκ cognate pairing of µl aεFab plasmid DNA
(3 µg of each DNA).
2.5.12 Large-scale transient expression of anti-IgE Fabs us-
ing the electroporation
Cell cultivation
CHOSXE cells [150] were pre-adapted to CD-CHO media (Thermo Fisher Scien-
tific) supplemented with 2 mM GlutaMAXTM (Thermo Fisher Scientific) according
to manufacturers instructions. The cells were maintained in logarithmic growth
phase agitated at 140 rpm on a shaking incubator (Kuhner AG) and cultured at
37 ◦ C supplemented with 8 % CO2.
Electroporation transfection
Prior to transfection, the cell numbers and viability were determined using a
CEDEX cell counter (Innovatis). The cells were then spun at 1,400 rpm in a
centrifuge for 10 minutes. The pelleted cells were re-suspended in sterile Earles
Balance Salt Solution and spun for a further 10 minutes at 1,400 rpm. The pel-
leted cells were re-suspended to the desired cell density of 2 x 108 cells/ml. For
each transfection the Fab vector DNA (1:1 ratio kappa:heavy) was added at final
concentration of 400 µg per 2 x 108 cells/ml. The cells were transfected in 12
aliquots of 800 µl using the in-house electroporation system. The transfected cells
were then transferred directly into 3 L Erlenmyer flasks containing 1L of ProCHO
5 (Lonza) media enriched with GlutaMAXTM (Thermo Fisher Scientific) and a 1 in
500 dilution of an antimitotic (100x). The cells were cultured in a Kuhner shaker
at 140 rpm, 37 ◦C and supplemented with 8 % CO2. After four days 3 mM sodium
butyrate (n-butric acid sodium salt, Sigma B-5887) was added to the culture. 14
days post-transfection the cultures were spun in a centrifuge at 4,000 rpm for 30
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minutes to harvest the supernatant. The supernatant was filtered through a sterile
0.22 µm filter followed by 0.22 µm gamma gold filter and stored at 4 ◦C.
Protein G High Performance Liquid Chromatography (HPLC)
The final Fab expression levels were determined by protein G HPLC. A HiTrap
Protein G HP 1ml column (GE Healthcare) was equilibrated with 20 mM sodium
phosphate 50 mM sodium chloride buffer pH 7.4. As a control, 100, 80, 64, 48, 32,
16, 8, 4 and 2 µl of 1 mg/ml solution of Certolizumab Fab were separately injected
onto the column at a flow rate of 2 ml/min, and eluted in 50 mM glycine-HCl pH
2.7 with column equilibration steps before each injection of control Fab. The peak
areas were plotted as a function of the amount of control Fab. Once the column had
been equilibrated again in 20 mM sodium phosphate, 50 mM sodium chloride, pH
7.4, 100 µl of Fab expression supernantant was injected onto the protein G column
at 2 ml/min and then eluted with 50 mM glycine-HCl pH 2.7. The resulting peak
area was plotted onto the standard graph generated from the control injections to
determine the amount of Fab present in 100 µl of supernatant and accordingly to
estimate the total amount of Fab expressed.
2.5.13 aεFab purification
Supernatant concentration
The supernatants were concentrated using a tangential flow ultrafiltration system
with a 10 kDa membrane to an estimated Fab concentration of greater than 350
mg/L. A concentration greater than 350 mg/L was required for binding to the
Protein G column.
Protein G purification
The aεFabs were purified by Protein G affinity chromatography. aεFab was bound
to a 100 ml Protein G sepharose column (GE Healthcare) (∼ 400 mg total Fab
capacity) in PBS pH 7.4 and eluted in 100 mM glycine-HCl, pH 2.7. 20 ml fractions
were collected and the peak fractions were pooled and neutralized with 1/25th
fraction volume of 2 M Tris-HCl, pH 8.5. The pooled and neutralized fractions
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collected from the Protein G column were concentrated to volumes between 10-18
ml using Amicon Ultra-15 centrifugal filter units (Millipore).
aεFab size exclusion
Each aεFab was further purified by size exclusion chromatography (SEC) on a
Superdex 26/60 S200 column (GE Healthcare) in PBS pH 7.4. The monomeric
peak fractions were pooled and concentrated using Amicon Ultra-15 centrifugal
filter units (Millipore).
aεFab analytical size exclusion
30 µg of the pooled monomeric aεFab SEC peak fractions were run down a TSKgel
G3000SWxl (Tosoh) analytical size exclusion column in 0.05 M Na2HPO4, 0.05
M NaH2PO4, 0.15 M NaCl, pH 6.8, at a rate of 1 ml/min. The area under the
elution peaks was calculated using the manual integration function in the Clarity
chromatography software (DataApex).
aεFab mass spectrometry
Positive electrospray mass spectrometry was conducted on the aεFabs to ascertain
their exact molecular masses. Protein samples, at 0.1 mg/ml, were dialysed into a
solution of distilled and filtered water, 1 % acetic acid prior to MS analysis. Each
protein sample was injected at 40 µ/min directly into a Bruker MaXis ultrahigh-
resolution electrospray ionisation quadropole time-of-flight mass spectrometer. The
multiple charge states were deconvoluted into the most probable single mass using
the manufacturer’s maximum entropy algorithm (Bruker Daltonics).
2.6 Surface plasmon resonance
Surface plasmon resonance (SPR) is a label-free technique that measures bind-
ing events in real-time and enables the determination of equilibrium and kinetic
constants of biomolecular interactions. In SPR experiments, one of the binding
partners is immobilised onto a matrix of non-cross-linked carboxymethylated dex-
tran that is deposited on a metal surface (usually a thin layer of gold), and the other
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is flowed over the immobilised partner. Binding between the immobilised partner
(the ligand) and the partner in the medium (the analyte) is monitored through
changes in the internal reflection of light at the metal-medium interface. SPR was
used extensively in this project to identify anti-IgE Fabs, to characterise the ki-
netics of the interactions between IgE-Fc and different aεFabs, and to determine
the affinity of the interactions. SPR was also used to characterise the binding of
receptors to IgE-Fc in the presence of different anti-IgE Fabs in order to ascertain
their effects on CD23 and FcεRI binding.
2.6.1 The SPR phenomenon
SPR is a phenomenon whereby incident light stimulates the oscillation of electrons
in plasma of metals at a surface interface. The basic principle of SPR is schemat-
ically represented in Figure 2.1. SPR experiments are performed on sensor chips
that have a thin layer of a metal, usually gold, on top. Conducting metals, like gold,
contain free electrons that can oscillate. These oscillations are known as plasma
waves. The sensor chip is placed on top of a prism and polarised light is shone
through the prism onto the gold surface. Some of the light that hits the interface is
reflected and this light has a measurable intensity. At a certain incident angle, the
photons of the polarised light have a momentum that equals that of plasma waves;
some of the energy of the incident light is transferred to the electrons in the gold
film, generating plasma waves at the surface. At this so called ‘resonance angle’
the intensity of the reflected light is at a minimum because some of the incident
photons have been converted to plasmons [151].
As analyte begins to flow over the sensing layer and binds to ligand, the angle
of reflectivity that satisfies the resonance condition will change accordingly.
The resonance angle at which this minimum occurs is sensitive to changes in
the composition of the material close to the gold film (within 300 nm), because
these changes alter the momentum of the plasma waves and therefore SPR no
longer occurs at the same resonance angle. The shift in resonance angle is directly
proportional to the change of mass at the surface and can therefore be used to
monitor binding occurring at the surface, such as protein binding to an immobilised
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Figure 2.1: A schematic representation of the principles of SPR. At a
certain incidence, light reflected from a prism excites plasmons in the gold surface
of an SPR chip. The light is reflected out of the prism and a detector records the
angle at which the plasmon resonance was satisfied, known as the resonance angle.
The intensity of the reflected light is at a minimum at this angle because some of the
incident photons were converted to plasmons. Changes at the surface of the SPR
chip, such as an increase on mass upon ligand binding, alter the conditions required
for plasmon resonance, and as such the resonance angle. In SPR experiments the
change in resonance angle is called the SPR response and is used to measure the
association and dissociation of complexes on the SPR surface.
ligand [151].
2.6.2 The SPR experiment
A typical SPR experiment involves four main steps.
Step 1: generating the ligand and control surfaces
Step 2: establishing a basal SPR angle observed as a stable response baseline
Step 3: injecting analytes and control analytes over the sensor surfaces
Step 4: regenerating the surfaces.
Step 1: generating the ligand and control surfaces
In any SPR experiment the ligands of interest and control ligands must be immo-
bilised to the binding flow-cell surface and the control flow-cell surface, respectively.
Ligands may be directly or indirectly immobilised using a variety of methods, and
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should be done in such a way as to limit any disruption to ligand activity.
It is very important when preparing SPR surfaces to consider the required or
appropriate immobilisation density as this can affect various aspects of the exper-
iment. The immobilisation density should be high enough to achieve a sufficient
signal-to-noise ratio, but not so high that steric overcrowding, avidity effects and
mass-transport effects significantly affect the data.
Steric overcrowding occurs when the initial binding of analyte to ligand physi-
cally occludes other analyte binding sites within the matrix, consequently reducing
association. Reducing ligand density increases the distance between analyte bind-
ing sites on different ligand molecules, reducing potential steric overcrowding.
The intrinsic affinity of an interaction is the affinity between two sites that bind
to each other monovalently. The functional affinity, or avidity, is the total binding
strength resulting from all binding interactions of the interacting molecules. Lig-
and density may affect to what extent an SPR experiment measures intrinsic or
functional affinity. At high enough ligand densities it is possible that a multiva-
lent analyte may simultaneously bind two or more ligands. If the kinetics of the
interaction sites are the same and independent of one another, the first interaction
will depend on the intrinsic affinity of the site. The association of the subsequent
sites is favoured because of the high local concentration of analyte. In general the
dissociation rate will decrease because the dissociation of individual binding sites
will not result in the the dissociation of the whole molecule, and consequently the
possibility of rebinding increases. In cases where the multimeric interaction sites
do not have identical kinetics and/or are dependent, the SPR data may also re-
flect the multiple different binding events and will be less reflective of the intrinsic
affinity. Accordingly, if an experimenter wishes to proceed with an experiment at
a 1:1 ligand:analyte stochiometry, it is necessary to work at ligand densities low
enough to prevent simultaneous engagement of one or more ligand molecules by
analyte. One way to determine a suitable ligand density for investigating monova-
lent interactions is to perform initial experiments with a range of ligand densities
to identify the densities at which the dissociation rate constant is independent of
ligand density.
In SPR experiments, an analyte binds to a ligand on a sensor chip in a two-
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step process. Initially an analyte is transferred from the bulk solution towards the
matrix, and then the analyte-ligand interaction occurs. The first step is known as
mass transfer and is the result of convection and diffusion [152]. Mass transport
limitation occurs when the diffusion of analyte from the bulk solution is slower
than the intrinsic rate of analyte-ligand binding. Mass transport limitation results
in a depletion of analyte at the interaction surface and consequently the kinetic
constants are more reflective of the mass transfer rate than the binding kinetics.
In addition, if the transfer of analyte from the surface to the bulk solution is slower
than the intrinsic rate of analyte-ligand binding, analyte that has dissociated from
ligand is likely to rebind to ligand.
Limiting the amount of ligand at the interaction surface will help to prevent
mass-transport effects as is reduces analyte consumption at the surface and reduces
the number of sites available for re-binding. In addition, high flow rates can be
used to minimize the diffusion distance from the bulk solution to the surface. Mass
transport limitations can be tested by analysing the association and dissociation
rate constants under different buffer flow rates; if the kinetic constants are inde-
pendent of flow rate it is an indication that there is no mass transfer limitation
[153]. Our group has performed experiments (data not shown) in which IgE-Fc was
injected at different rates over SPR surfaces upon which aεFab1 had been immo-
bilised at different densities. The kinetics of the interaction became dependent on
injection rate at immobilisation densities above 10,000 RU of aεFab1, indicating
mass-transport effects occured at densities above 10,000 RU. It is possible to ac-
count for diffusion limited effects in surface plasmon resonance data using a fitting
model that includes descriptors for mass transport kinetics, however it is always
best to try and design the experiment in such a way that mass transport limitation
is minimized [153].
Control surfaces are necessary to measure any non-specific binding and any
background response. The control surface should be made in as similar a way
to the ligand-surface as possible, and should have similar immobilisation densities
[151].
Most pure proteins can be immobilised using a direct covalent immobilisation
method that employs the free carboxymethyl groups on the sensor chip surface.
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Direct coupling techniques include amine, thiol and aldehyde coupling that utilise
lysine, cysteine and carbohydrate groups on glycoproteins, respectively. Direct cou-
pling, however, has several associated problems including heterogeneity in ligand
coupling, reduced ligand activity and difficult regeneration [154].
For the purposes of this project immobilisation was achieved by direct amine
coupling to carboxymethylated sensor chips (CM5 chips, GE Healthcare). The car-
boxymethylated dextran surface of each CM5 chip was activated by a 420 s injection
of 0.1 M N-hydroxysuccinimide (NHS) and 0.4 M 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDC) at a 1:1 ratio in deionised water. The NHS/EDC solution
reacts with free carboxyl-groups present on the chip and results in the generation
of reactive succinimide esters that can react with surface exposed lysine residues
of proteins, immobilising them on the surface. To immobilise the proteins, they
were injected over the NHS/EDC activated surface at a concentration of 10 µg/ml
in 10 mM sodium acetate pH 5.0 in 60-300 s pulses, until the desired level of im-
mobilisation was achieved. Any remaining active carboxymethylated groups were
blocked by 1 M ethanolamine, pH 8.5, which was injected over the chip for 600
s. Reference cells were prepared using the same procedure, except that buffer was
injected over the surface in place of protein. All immobilisations were performed
at 25 ◦C with a flow rate of 20 µl/min.
Ligands were also immobilised indirectly via capture of a covalently-coupled
molecule, and details are reported in the relevant results sections. This approach
requires that the covalently-coupled molecule recognises an epitope or tag on the
ligand and binding does not significantly affect the ligand activity of interest. This
approach avoids ligand heterogeneity since each molecule is bound to the covalently-
immobilised molecule in the same way. Furthermore, regeneration is usually pos-
sible; using appropriate buffers the captured ligand or ligand/analyte complex can
be selectively dissociated, leaving the covalently-bound ligand immobilised on the
surface.
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Step 2 and 3: establishing a basal SPR angle and injecting analytes and
control analytes over the sensor surfaces
During an SPR experiment, changes in resonance angle as a result of changes at the
surface of the gold surface are plotted in real-time as a change in response versus
time in a sensorgram (Figure 2.2). At the start of an SPR experiment the running
buffer is injected over the surface of the sensor chip until a stable baseline response
in all flow cells is observed. The baseline response corresponds to the starting
SPR angle. The analyte is subsequently injected in SPR sample buffer over ligand
and control flow-cells at a continuous rate. The SPR phenomenon is sensitive to
changes in mass at the surface and binding of the analyte to the immobilised ligand
increases the mass at the surface and is reflected by an increase in SPR signal as
explained above. The amount of complex present is directly related to the SPR
response. The maximum response (Bmax) is the maximum binding capacity of the
ligand (L) for analyte (A), and occurs when all available analyte binding sites have
been saturated. Bmax therefore depends on both the ligand density, determined
from its immobilisation response, the relative masses of the ligand and analyte,
and the stochiometry of the interaction, according to Equation 2.3. Equation 2.3
can be used to derive the theoretical Bmax but the actual Bmax can be determined
experimentally. Differences between the theoretical and experimental Bmax values





Where Bmax is the maximum capacity of the ligand, MWA is the molecular weight
of the analyte, MWL is the molecular weight of the ligand, RL is the
immobilisation response of the ligand, and VL is the stochiometry of the ligand to
analyte.
As analyte begins to flow over the sensing layer and binds to substrate, the angle
of reflectivity that satisfies the resonance condition will change accordingly until it
reaches saturation and all the binding sites have been occupied. The dissociation
of analyte from the substrate causes the angle of the detector to return back to
baseline once all the analyte has been completely removed. Changes in background
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Figure 2.2: A schematic representation of an SPR sensorgram. During a
typical SPR experiment, SPR running buffer is injected over immobilised ligand
on the sensor surface to establish a robust baseline initial SPR angle and thereby a
baseline ‘response’. During the analyte injection, the analyte binds to immobilised
ligand, and the change in mass causes the angle of incidence that satisfies the
resonance condition to change, and is plotted as a change in response. The angle
continues to change until there is no net change in the formation of complex, and
during this steady-state the response does not alter. Buffer is injected over the
surface when the analyte injection stops, and the analyte dissociates from the
ligand. The dissociation of analyte causes the resonance angle to return back
towards the initial resonance angle, and consequently the SPR response returns
back towards baseline. Sometimes the natural dissociation of the analyte from
the ligand may take a long time and it is necessary to treat the surface with
regeneration solutions that remove the analyte from the ligand and return the
response to baseline.
response will also occur if there is a difference in the refractive indices of the running
and sample buffers. The background response is therefore measured by injecting
the analyte over a reference flow cell, which is treated identically as the sample
surface, but without the immmobilised ligand. The reference response is then
subtracted from the response recorded on the ligand flow-cell, in order to obtain
the actual binding response. One resonance unit (RU) represents the binding of
approximately 1 pg protein/mm2 [154].
If the injection of analyte is long enough, the system will reach a steady state,
during which time there is no net change in the amount of complex that is formed,
and accordingly the response does not alter. During the dissociation phase the
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analyte injection stops and instead SPR running buffer is injected over the sensor
surface. Consequently, the analyte concentration is reduced to nothing and the
complexes will dissociate. The resulting complex decay is observed as a decrease
in SPR signal with time [154].
For the purposes of this project, all samples were prepared in filtered SPR
running buffer (10 mM HEPES , 150 mM NaCl pH 7.4, 0.005 % surfactant P20, 4
mM CaCl2). In order to establish a steady baseline, each experiment began with
three initial start-up cycles consisting of buffer injections only. Negative control
samples (containing buffer only) and positive controls (containing molecules known
to bind to the ligand with a certain profile) were also injected in cycles before
and after the test sample cycles. Unless otherwise stated, serially-diluted analyte
samples were injected over the ligand and experiments were run in duplicate. All
injections were performed between 10 - 20 µl/min, depending on the availability
of sample, and all experiments were run in SPR buffer at 25 ◦. The concentrations
of analyte injections, the length of analyte injections and the dissociation times
varied between experiments, and are detailed separately in each respective section.
Step 4: regenerating the surfaces
To reuse the sensor chip before each new injection of analyte, the analyte from the
previous injection must be completely removed but the ligand must stay in-tact on
the surface. The intrinsic dissociation rate of the interaction may be slow and as
such it may take a long time before the ligand is free, in such cases it is necessary
to interrupt the interaction to regenerate the surface. The conditions required for
regeneration are dependent upon the nature of the interaction between the ligand
and the analyte, and need to be such that the analyte is effectively removed but
that the ligand is not irreversibly damaged. In many cases, low pH buffers, such
as 10 mM glycine pH 1.5 - 2.5, successfully regenerate SPR surfaces. At low pH
most proteins partly unfold and become positively charged, and consequently it is
thought that regeneration is achieved at low pH because the ligand and analyte
repel each other. It is important, however, to only use the minimum acidic con-
ditions required for regeneration so as to prevent irreversible ligand damage [155].
The regeneration conditions varied between experiments and are detailed in the
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corresponding results sections.
2.6.3 Performing kinetic experiments using SPR
SPR can be used to determine the affinity of an interaction using either steady-
state experiments or kinetic experiments. A steady-state experiment generates an
equilibrium dissociation constant (KD) by determining the extent of a reaction as
a function of the concentration of one of the reactants [151]. A kinetic experiment,
however, measures the rates of the forward and reverse reactions as a function of the
concentration of one of the reactants, which can be used to derive the forward and






Where KD is the dissociation constant with molar units (M), and describes the
apparent affinity of the interaction. koff is the dissociation rate constant with
units s-1, and describes the stability of the complex in terms of the fraction of
complexes that dissociate per second. kon is the association rate constant of the
interaction with units M-1s-1, and describes the rate of complex formation.
First order kinetic experiments
Because SPR measurements are in real-time, the shape of the curve during asso-
ciation and dissociation can be used to determine the association and dissociation
rate constants, kon and koff, respectively.
Consider the interaction between an immobilised ligand (L) and an analyte (A),





The rate at which the ligand and analyte associate to form complex is given by:
[L] ×[A]× kon
Once the complex has formed, it will dissociate at a rate equal to:
83
Chapter 2. Materials and methods
[LA] ×koff
During the association phase of an SPR experiment the analyte is injected over
the ligand, the analyte binds to the ligand and then dissociates from the ligand.
The rate of the increase of the concentration of complex ([LA]) is therefore given




= ([L][A]kon)− ([LA]koff ) (2.5)
The concentration of ligand at any time ([L]t) is described by
[L]t = [L]t=0 − [LA]t (2.6)
Therefore, equation 2.5 can be re-written:
d[LA]
dt
= (([L]t=0 − [LA]t)[A]kon)− ([LA]koff ) (2.7)
In SPR, complex formation is measured in real time as the response (R) and
because analyte is added in large excess to ligand, the change in concentration
of free analyte upon association with ligand is assumed to be negligible. The
concentration of the free ligand is equivalent to the maximum binding response
(Bmax) minus the response at that time (Rt). This can be substituted into the
above equation, and rearranged to give the Equation 2.8.
dR
dt
= ((Bmax −Rt)[A]kon)− (Rtkoff ) (2.8)
The one-to-one differential rate equation (Equation 2.8) cannot be used to fit the
association curve for a one-to-one interaction. Instead the integral of this equation
provides an integrated rate equation that can be used to fit the non-linear associ-
ation phases of SPR sensorgrams for first order kinetics. First order interactions
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Where R0 is the response at t = 0.
During the dissociation phase of an SPR experiment the analyte dissociates




= −koff [LA] (2.10)
And since the concentration of complex is measured in SPR as the response




As with the association, it is easier to fit the experimental dissociation phase
with an integrated rate equation. For the purposes of this project the dissociation
phase was fitted using the following first order integrated rate equation:
R = R0e
−koff (t−t0) +Rt→∞ (2.12)
Where R0 is the response at t = 0 and represents the amount of bound complex to
be dissociated over time (t), and Rt→∞ represents the response after infinite time.
Higher order kinetic experiments
Not all data fit first order reaction kinetics and there are alternative kinetic models
that can be applied to the measured data. First order reactions give sensorgrams
with simple single exponential association and dissociation curves. In some cases,
however, the sensorgrams may have biphasic character: that is they may have
two components, a faster and a slower component. Biphasic character may be
an indication of mass transport limitation, which occurs when the binding rate
of an analyte is faster than its diffusion rate to the SPR surface. To avoid mass
transport limitation effects the kinetic SPR experiments performed in this project
used low ligand densities (<500 RU) and relatively fast flow rates (15 - 20 µl/min).
Biphasic character can also indicate that an interaction has two components, for
example a ligand may have two non-equivalent analyte binding sites, or the binding
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of analyte to ligand may have fast and a slow component. For the purposes of this
project, biphasic curves were fit using a double exponential integrated dissociation
rate equation (Equation 2.13) and a double exponential integrated association rate
equation (Equation 2.14) in Origin software (OriginLab).
R = (R10e
−k1off (t−t0) +R1t→∞) + (R20e
−k2off (t−t0) +R2t→∞) (2.13)












Where 1 and 2 represent the two different components of the interaction.
In instances where a third component was observed in the binding curves, a











Where 1, 2 and 3 represent the three different components of the dissociation.
2.6.4 Performing steady-state experiments using SPR
If the dissociation rate of an interaction is high, the association and dissociation
phases may be difficult to fit and therefore it may not be possible to determine the
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association and dissociation rate constants [151]. In such cases, steady-state exper-
iments may provide an alternative way to determine the dissociation constant of
an interaction. During the steady-state of a SPR experiment the response remains
steady (Req) because the net rate complex formation is zero. The dissociation
constant can be determined by measuring the concentration of free interactants
([L] and [A]) and complex ([LA]) during equilibrium (Equation 2.16). It should be
noted, however, that the steady-state is not strictly at equilibrium because analyte








Where KD is the dissociation constant, koff is the dissociation rate constant, kon is
the association rate constant of the interaction, and [L], [A] and [LA] are the
concentrations of ligand, analyte and complex, respectively.
The steady-state response (Req) is directly proportional to the concentration
of complex at equilibrium, and if analyte is in large excess of ligand (as in the
experiments performed in this study), the concentration of analyte is assumed
to be the concentration of analyte injected [155]. The concentration of the free
ligand is equivalent to the maximum binding response (Bmax) minus the equilibrium
response (Req). This can be substituted into Equation 2.16, and rearranged to give
Equation 2.17. Equation 2.17 may be used to determine the Bmax and KD of
the one-to-one interaction between ligand and analyte, by fitting the steady-state
response as a function of analyte concentration. For the purposes of this project,






Where Req is the steady state response, and is directly proportional to the
concentration of complex. Bmax is the maximum binding capacity, and is directly
proportional to the maximum amount of complex that can form. [A] is the
concentration of free analyte and KD is the dissociation constant.
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2.6.5 Using KD and Bmax to characterise interactions
Interactions can be characterised using KD and Bmax values, and one or both of
these values change in the presence of a modulator. An inhibitor for example,
may increase the KD and/or decrease the Bmax of an interaction. The dissociation
constant (KD) of an interaction equals the concentration of free analyte (derCD23)
at which half of the total ligand molecules (complexed IgE-Fc) are associated with
analyte (derCD23). An increase in the KD of the IgE-Fc/derCD23 interaction,
when IgE-Fc is pre-bound to aεFab would, in these experiments, suggest that
more derCD23 is required for half saturation because the apparent affinity of the
interaction has been reduced. An aεFab may act allosterically or sterically to
reduce the affinity of the interaction, either by inducing conformational changes
that affect the CD23 binding site, or by sterically preventing optimal coordination
of the binding site, respectively.
If there is no increase upon injection of derCD23 over aεFab-bound IgE-Fc it
would indicate that none of CD23 binding sites are available. Again, aεFab may
elicit this effect through either steric or allosteric means: the aεFab may bind
to the CD23 binding sites of IgE-Fc or it may sterically occlude CD23 binding,
alternatively it may bind to IgE-Fc and cause a conformational switch to IgE-Fc
conformers that cannot bind derCD23, respectively. It is possible that the number
of CD23 binding sites in the aεFab-bound IgE-Fc population may be reduced rather
than completely depleted, and this would be manifested as a reduction in Bmax. In
2:1 aεFab:IgE-Fc SPR experiments, we assume 100 % of IgE-Fc present is bound
by two aεFabs via specific Fab binding sites, and therefore a reduction in Bmax
must indicate that the aεFab is an allosteric inhibitor: it causes a shift towards,
but not completely to, conformations of IgE-Fc that cannot bind derCD23, thereby
reducing the available derCD23 binding sites in the IgE-Fc population.
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2.7 Flow cytometry
2.7.1 An introduction to flow cytometry
Flow cytometry is a widely used method for the analysis of cell surface and intracel-
lular molecules and works by measuring cell-associated fluorescence intensities. In
the context of this project it was used to analyse the binding of fluorescently-labeled
rIgE to membrane CD23 expressed on the surface of RPMI 8866 cells (Sigma) in
the presence of different aεFabs. In flow cytometry experiments single-cell sus-
pensions are incubated with fluorophore-labeled proteins specific for a particular
cellular target, and the single-cell suspensions are subsequently run through the
cytometer that consists of three main systems: the fluidics, the optics, and the
electronics (Figure 2.3). The fluidics system moves the cells in a stream past the
lasers, which are part of the optics system. The lasers illuminate the cells and the
resulting fluorescence is directed towards the appropriate detectors using optical
filters. The electronics system then converts the light signals into electronic signals










































Figure 2.3: A schematic representation of a flow cytometry experiment.
Sheath fluid focuses the single-cell suspension such that the cells pass through the
beam of the laser one cell at a time. As the beam interrogates the cell the light
is scattered in forward and side directions and fluorescence is emitted from the
stained cells. A series of mirrors focus the fluorescent light onto filters so that each
photomultiplying tube (1-3) detects a specific wavelength. The photomultiplying
tubes then convert the photon energy into an electronic signal (a voltage) that is
amplified and stored on a computer.
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Initially in a flow cytometry experiment, the single-cell suspension is taken up
and injected into a sheath fluid within a flow chamber. This forces the cells into
a single-file stream and the cells pass by the laser light one at a time (Figure 2.3).
When a cell intersects the light from the laser, some of the light is scattered (Figure
2.4.a). The extent of light scattering depends upon the physical properties of the
cell, including its size, shape and granularity. Forward-scattered light (FSC) is
proportional to the size of the cell and is measured by detectors just in front of the
light beam. Whereas side-scattered light (SSC) correlates well with cell granularity
and internal complexity, and is measured by detectors to the side of the incident
beam. FSC and SSC measurement can therefore be used to differentiate cells from
debris, single cells from doublets, and in some cases different cells types from one
another. Additionally, because cells condense during apoptosis, FSC from dead
cells is typically lower and populations of dead cells can usually be differentiated











apoptotic nuclei a) b) 
Figure 2.4: Cells scatter light in forward and side directions. (a) When the
laser interrogates the cell, light scatters in forward (FSC) and side (SSC) directions
and is measured by detectors in front of, or to the side of, the laser beam, respec-
tively. The amount of forward scatter is dependent on the size of the cell, whereas
the level of side scatter depends on its internal complexity. (b) A dot plot of the
degree of forward and side scatter of each cell can be and used to characterize the
cells which pass through the flow cells and differentiate dead and live cells. (Figure
adapted from [157]).
If a fluorescently-labeled protein is bound to the cell, when the cell enters the
laser beam, electrons in the fluorophore are excited to higher energy levels and
quickly decay to the ground state, emitting the excess energy as photons of light.
Different fluorophores have characteristic absorption and emission spectra. The
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optics of the BD FACSCantoTM II system, used for the purposes of this project,
consists of an excitation source with blue, red and violet lasers. The fluorescent
dyes, FITC and Alexa Fluor647, were used in this project and are excited by the
blue and red lasers of the BC FACSCantoTM II system, respectively. The fluorescent
signals are diverted to photomultiplier tubes (PMTs) via a system of mirrors and
optical filters (Figure 2.3). Placing a particular filter in front of the PMT restricts
the range of wavelengths that reach the detector and optimises detection of a
specific fluorescent dye [158].
When the photons hit the PMT they are converted into a proportional, but
greater, number of electrons. The electrical current then travels to an amplifier
and is converted into a proportional voltage pulse, which is at a maximum when
centre of the cell is at the centre of the laser beam. The measured voltage pulse
area is directly proportional to the fluorescence intensity of that ‘event’. The mean
fluorescence intensity (MFI) is the mean fluorescence intensity recorded for all
selected ‘events’ [159]. The FSC, SSC and fluorescence data collected for every
‘event’ is stored on a computer. All flow cytometry data collected during this
project were stored according to the flow cytometry standard (FCS) format [160]
using FACSDiVaTM (BD Biosciences) and data analysis, was performed in FlowJo
(FlowJo LLC).
2.7.2 Experimental details of cell-based assays using flow
cytometry
The RPMI 8866 cell line (Sigma) is a human B cell line that was established from
the peripheral blood of a chronic myelogenous leukaemia patient, and expresses
membrane CD23 [161]. RPMI 8866 cells were grown in RPMI 1640 media, sup-
plemented with 10 % FBS, 2 mM L-glutamine, 50 µg/ml penicillin, 50 µg/ml
streptomycin and 1 mM sodium pyruvate (Gibco R©), Thermo Fisher Scientific).
The cells were maintained under log phase growth at a cell density of 3-9 x 105
cells/ml in a humidified incubator at 37 ◦C with 5 % CO2.
To remove soluble CD23 in the supernatant RPMI 8866 cells were washed twice
by centrifugation at 1,000 g in cold supplemented RPMI 1640, and resuspended in
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cold HBS supplemented with 0.1 % BSA and 2 mM CaCl2 at a cell density of 2
x 107 cells/ml. Throughout the experiment the cells were kept on ice to prevent
CD23 shedding.
The Fabs were serially diluted in HBS supplemented with CaCl2 to ten times
their working concentrations. rIgE-A647 was diluted in HBS supplemented with 2
mM CaCl2 to 15 nM. 40 µl was rIgE-A647 was plated into a 96 well plate (Costar)
with 5 µl Fab, or for the unstained cell samples, 5 µl HBS supplemented with 0.1
% BSA and 2 mM CaCl2. 5 µl Fab was also plated with 20 µl A647-labeled control
antibody and 20 µl HBS supplemented with 0.1 % BSA and 2 mM CaCl2. The
plate was incubated at 37 ◦C in the dark for one hour. The plate was then placed
on ice, and 5 µl cells were added to each well. The samples were gently mixed
and left to incubate on ice in the dark for one hour. Following incubation the cells
were washed twice with 200 µl/well of HBS supplemented with 0.1 % BSA and 2
mM CaCl2 and then resuspended in 200 µl/well of the same buffer. The samples
were then analysed in 14 ml FACS tubes (BD Bioscience) on a FACSCanto II (BD
Biosciences) cytometer, with gating on live cells as determined by forward and side
scatter. For each sample, measurements were collected from at least 5,000 single
live cells.
2.8 Intramolecular fluorescence resonance energy
transfer (FRET)
2.8.1 An introduction to FRET
Fluorescence
Fluorophores are chemical compounds that re-emit light upon their excitation to
a higher energy level. Both the ground state and the excited state of a fluorophore
have several vibrational energy levels. When a photon of energy (hvex) is supplied
to the fluorophore, for example by a laser, the fluorophore absorbs the energy and
is excited from the ground state (S0) to the excited single state (S1). i.e. one of
its electrons from the occupied orbital is excited to an unoccupied orbital. After a
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finite time (∼10-15 s) the fluorophore relaxes to the lowest energy vibration level of
the excited state (S1’) by vibrational relaxation. Eventually the fluorophore returns
to a ground state and the energy upon relaxation is dissipated either via radiative
or non-radiative processes. The dissipation of energy through radiative processes
results in fluorescent emission of a photon (hvem) (Figure 2.5) [162].
fluorescence 











Figure 2.5: A simplified Jablonski diagram illustrating the basic principles
of FRET. Electrons of a donor fluorophore that have been excited from the lowest
vibrational level of the ground state (S0) to an excited state (S1) relax to the
lowest vibrational level of the excited state by vibrational relaxation (VR). When
the electron returns to the ground state, the energy can be dissipated as donor
fluorescence, or the the energy can be transferred non-radiatively from the excited
state of the donor fluorophore to the excited state of the acceptor fluorophore. The
acceptor fluorophore can then dissipate its energy, returning to the ground state
to yield fluorescence emission of the acceptor.
FRET
Fluorescence resonance energy transfer is the process through which the energy
from the relaxation of an excited donor fluorophore is transferred non-radiatively to
an acceptor molecule, which may or may not be fluorescent (Figure 2.5) [163]. As a
result of FRET, the fluorescence intensity of the donor is reduced. FRET occurring
between two chemically different molecules is called heterotransfer FRET, whereas
FRET occurring between two chemically identical molecules is called homotransfer
FRET. Homotransfer is only possible when the difference in the wavelength of the
emission and absorption maxima (the Stokes shift) is small [164]. In order for
FRET to occur the donor and acceptor pair must be close enough to one another
(typically 10 – 100 Å), the dipole-dipole angles must not be at 90 degrees and the
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emission spectrum of the donor must overlap with the excitation spectrum of the








Figure 2.6: A schematic illustration of the Förster principle. For FRET to
occur, the emission spectrum of the donor must overlap (grey) with the excitation
spectrum of the acceptor.
The rate at which FRET occurs is calculated according to Equation 2.18 [164].
Because FRET is strongly dependent on the distance between the donor and accep-
tor pair, it is possible to use FRET to study the average distances between them.
However, the FRET efficiency is dependent upon the Förster radius (R0), which
is in turn dependent on the relative orientation of the donor-acceptor dipoles. Be-
cause the orientations of the dipoles cannot be measured exactly there is always
some degree of error associated with distances determined by FRET (a maximum








Where kT is the rate of energy transfer, τD is the decay time of the donor in
absence of the acceptor, and r is the distance between the donor and the acceptor.
In FRET experiments the emission of a (donor/acceptor) fluorophore can be
measured using two main methods: steady-state and time-resolved (TR) measure-
ments. During steady-state experiments, the donor fluorophore is excited by a
continuous beam of light, whereas in TR experiments, the donor is exposed to
pulses of excitation light that are shorter than the time it takes for the excited
donor to decay. There is a short wait after the excitation pulse and before mea-
suring the emission, during which time possible background fluorescence of the
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sample and auto-fluorescence of surrounding materials decreases. Accordingly, TR
measurements of fluorophore emission are more specific than steady-state measure-
ments [164]. All intramolecular FRET experiments performed in this project were
performed using TR-FRET measurements of the emission of both the donor and
acceptor upon donor excitation only. The TR-FRET value was determined as the
ratio of the emission of the acceptor to the emission of the donor, with the donor
emission acting as an internal standard.
TR-FRET measurements require that the lifetime of the fluorophore emission
is sufficiently long to allow for the wait between donor excitation and emission
measurement. Lanthanides are fluorescent metals that have very slow emission
rates and decay times in aqueous solutions (0.5 – 3 ms) and consequently are very
useful for TR-FRET experiments. In addition to their long decay times, the Stokes’
shift of lanthanide chelates are large (>250 nm), which reduces interferences from
excitation when measuring emission. Terbium chelate is a lanthanide and was used
for the purposes of the intramolecular TR-FRET experiments performed during
this project, and Alexa Fluor 488 was used as the acceptor fluorophore (Figure
2.7) [164].










Figure 2.7: An illustration of the terbium chelate and Alexa Fluor 488
emission and excitation spectra. Terbium chelate (Tb) is maximally excited
at around 340 nm, and it emission spectrum has four sharp peaks (blue and grey
dotted line), with silent regions between each peak. The emission spectrum of Tb
has multiple peaks because it has multiple ground state.
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2.8.2 Experimental details of intramolecular
FRET experiments
Intramolecular FRET experiments were used to determine the degree of ‘bendid-
ness’ of IgE-Fc when bound to various aεFabs. IgE-Fc(E289C)-biotinylated was
fluorescently-labeled with the terbium-Alexa Fluor 488 donor-acceptor pair.
Fluorophore labeling
Thiol-reactive terbium chelate was used to label the N-terminus IgE-Fc(E289C)-
biotinylated via the introduced E298C mutation in the Cε2 domains according to
the manufactures instructions (LanthaScreen R©, Thermo Fisher Scientific). The
terbium to protein ratio was calculated using Equation 2.19 and Equation 2.20,




× dilution factor (2.19)
Where [Tb chelate] is the concentration of terbium chelate, A343 is absorbance of
the sample at 343 nm, and 12,570 is the extinction coefficient of the terbium
chelate at 343 nm, in M-1cm-1.
[IgE-Fc](M) =
A280 − (0.75× A343)
48, 830
× dilution factor (2.20)
Where [IgE-Fc] is the concentration of IgE-Fc, A280 is sample absorbance at 280
nm, 0.75 is the correction factor because when conjugated to a thiol the
extinction coefficient of Tb chelate is 75 % of its value at 343 nm. A343 is sample
absorbance at 343 nm and 48,830 is the extinction coefficient of IgE-Fc at 280
nm, in M-1cm-1.
The C-terminus of the terbium labeled IgE-Fc(E289C)-biotinylated was la-
beled with Alexa Fluor 488-streptavidin according to manufacturers instructions
(Thermo Fisher Scientific). The Alexa Fluor 488 to protein ratio was calculated
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Where [A488 ] is the concentration of Alexa Fluor 488, A494 is absorbance of the
sample at 494 nm, and 71,000 is the extinction coefficient of the Alexa Fluor 488
at 494 nm, in M-1cm-1.
[IgE-Fc](M) =
A280 – (0.11× A494)
48, 830
× dilutionfactor (2.22)
Where [IgE-Fc] is the concentration of IgE-Fc, A280 is sample absorbance at 280
nm, 0.11 is the correction factor to account for the absorption of the Alexa Fluor
488 dye at 280 nm. A494 is sample absorbance at 494 nm and 48,830 is the
extinction coefficient of IgE-Fc at 280 nm, in M-1cm-1.
As a control for minimum FRET, the C-terminus of terbium-labeled IgE-Fc(E289C)-
biotinylated was incubated with un-labeled streptavidin.
Assay design
IgE-Fc is a homodimer and consequently contains two sites for each fluorophore.
The intramoleclar FRET signal could therefore arise from FRET occurring between
an acceptor/donor pair on the same IgE-Fc chain or between an acceptor/donor
pair on a different IgE-Fc chain [75]. In addition, there may be some homotransfer
between two Alexa Fluor 488 labels on the two different chains of IgE-Fc since
there is some overlap in their excitation/emission spectra [75]. Because of these
inherent complexities, the intramolecular FRET data were not used to determine
changes in intramolecular distances upon binding different aεFabs, but rather the
FRET signals were compared in relative terms to those for IgE-Fc alone (bent)
and IgE-Fc bound to aεFab1 (extended).
The doubly-labeled IgE-Fc was mixed with each aεFab titrated to a final con-
centration of 1 µM in 20 mM Tris, 150 mM NaCl, 0.002 % Tween 20, pH 7.2 in low
volume black, non-binding 384-well plates (Corning). Terbium-only labeled IgE-
Fc was also mixed with each of the aεFabs titrated to 1 µM in the same buffer.
The final volume in each well was 25 µl and the final concentration of IgE-Fc
was 10 nM. The mixtures were left to incubate at room temperature in the dark
with shaking for 120 minutes. The plates were read in time-resolved FRET mode
on the EnVision Multilabel plate reader (PerkinElmer) with excitation at 330 nm
97
Chapter 2. Materials and methods
and emission read at 485 nm and 520 nm. The effect was expressed as % inhibi-
tion of the maximum signal generated in the assay (doubly-labeled IgE-Fc without
aεFab) after subtracting the minimum signal (terbium-labeled IgE-Fc with 1µM
unlabelled streptavidin) from both. The FRET ratio ((E520/E485) x10
4) was plot-






Where x 0 is the centre of the sigmoidal curve, p is the power, A1 is the initial y
value, A2 is the final y value, and the y value at x 0 is halfway between the two
limiting values A1 and A2
Statistical analysis
All statistical analysis was done using the nonparametric, unpaired Wilcoxon rank-
sum test (or Mann-Whitney U test) [166]. The Wilcoxon rank-sum test, tests the
null hypothesis - that it is equally likely that a randomly selected value from one
sample will be less than or greater than a randomly selected value from a second
sample. The tests were performed as such:
• All observations were ranked in increasing order of magnitude, ignoring the
sample they are from. Observations with the same magnitude were given an
average ranking.
• The ranks were summed in the smaller of the two samples, or either of the
samples if they were matched in size.
• The two individual samples sizes were used to identify the appropriate critical
values expressed in terms of a range in a predetermined table. If the sum
of the ranks of the smaller sample lay inside the critical range then the null
hypothesis was accepted, if the sum of the ranks of the smaller samples lay
outside of the critical range then then null hypothesis was rejected.
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The interactions between immunoglobulin E (IgE) and its receptors (FcεRI and
CD23) can be allosterically modulated (Section 1.3) [18, 89, 81, 108]. Previous
studies have described two main types of rigid-body domain motions associated
with the allosteric modulation of IgE-Fc-receptor interactions; an opening and
closing of the Cε3 domains [18, 81] and the extension of Cε2 domains from a bent
conformation [81]. Allosteric modulation through opening and closing of the Cε3
domains was first described in terms of the mutual inhibition of IgE-receptor bind-
ing [18, 89] and it has since been associated with the inhibition of the interaction
between FcεRI and aεFab1-bound IgE-Fc [81].
aεFab1, a fragment antigen binding (Fab) molecule, binds to IgE-Fc with a
2:1 stochiometry (KD1 ∼ 80 nM, KD2 ∼ 1.5 µM) and inhibits the IgE-Fc/FcεRI
interaction (Section 1.3.3) [81]. The extension of the Cε2 domain pair in the
aεFab1:IgE-Fc complex is striking, however, the Cε3 domains of the structure are
also in a very ‘open’ conformation [81]. Both of these features contribute to the
allosteric inhibition of FcεRI by aεFab1, but the latter may also affect the binding
of CD23 to IgE-Fc.
CD23 binds to ‘closed’ IgE-Fc with a 2:1 stochiometry [18]; a single CD23 head
domain binds to a single Cε3 domain. The affinity of a single CD23 head domain
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for IgE-Fc is relatively low (KD ∼ 1 x 10-6 M), however on cell surfaces CD23 exists
as trimer and the affinity of the interaction is increased through the avidity effect
[88, 39, 167, 90].
Both aεFab1 and CD23 bind the Cε3 domain of IgE-Fc, but whether aεFab1
inhibits CD23 binding in addition to FcεRI binding has not been established.
On the basis of evidence suggesting that CD23 binds a ‘closed’ conformation of
IgE-Fc, and that aεFab1 stabilises an ‘open’ conformation, it was hypothesised
that aεFab1 could inhibit CD23 binding. The following study was performed to
test this hypothesis; it aimed to establish whether aεFab1 inhibits CD23 binding
and whether this is a result of allosteric communication between the two sites,
potentially involving the ‘opening’ and ‘closing’ of Cε3 domains.
3.2 Results
3.2.1 Production and purification of derCD23
derCD23 is a construct of CD23 composed of single CD23 lectin head domain
(Section 2.4.1) [20]. derCD23 was produced recombinantly and purified in order to
investigate the effect of aεFab1 on the CD23/IgE-Fc interaction.
Expression of derCD23
BL21 (DE3) E. coli were transformed with a pET5a vector containing an insert
for derCD23. derCD23 expression was induced by addition of IPTG to the cell
cultures (Section 2.4.2) (Figure 3.1).
derCD23 was intra-cellularly over-expressed into insoluble inclusion bodies (Fig-
ure 3.2). The inclusion bodies were separated from soluble cellular proteins and
were washed, solubilised and denatured to yield relatively pure but unfolded derCD23.
Approximately 20 mg of derCD23 was extracted from inclusion bodies produced
from 1 L Luria broth (LB) cultures (Sections 2.4.3 and 2.4.4).
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Figure 3.1: Induced expression of derCD23 in E. coli BL21 (DE3) cells.
A 15 % SDS-PAGE analysis of solubilised cell pellets before (L2) and four hours
after (L3) IPTG induction. A significant increase in derCD23 (16 kDa) expression
was observed post IPTG induction. Protein makers (L1) are labelled with their
respective molecular weights (kDa).
Purification of derCD23
The solubilised and denatured derCD23 was refolded by drop-wise addition to
refolding buffer. Refolded derCD23 was purified using a two-step purification pro-
tocol (Section 2.4.5).
Cation-exchange chromatography with a heparin column was used to purify
correctly folded derCD23 from misfolded derCD23 (Section 2.4.6). After loading
the column, an increasing salt gradient was applied to elute derCD23. Misfolded
derCD23 eluted at a lower salt concentration, and hence a lower elution volume,
than folded derCD23 owing to its lower affinity for the negatively charged matrix
(Figure 3.3). The peak fractions of correctly folded derCD23 were pooled and
SDS-PAGE analysis revealed the presence of contaminants with higher molecular
weights than derCD23 (Figure 3.2). These contaminants were most likely small
multimers of correctly folded derCD23 and were probably responsible for the small
tail in the cation exchange elution peak (Figure 3.3).
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Figure 3.2: derCD23 over-expression into insoluble inclusion bodies
and purification. 15 % SDS-PAGE gel analysis of culture fractions from
derCD23 expression in E. coli and derCD23 samples post chromatographic pu-
rification. derCD23 (16 kDa) was expressed intracellularly post IPTG-induction
(L2). derCD23 was not over-expressed in the soluble fraction (L3) but was over-
expressed in the insoluble fraction (L4). Purification of monomeric derCD23 was
improved through heparin chromatography (L5) and further still by size exclu-
sion chromatography (L6). Protein makers (L1) are labelled with their respective
molecular weights (kDa).
Figure 3.3: Chromatogram of derCD23 purified by heparin-sepharose
chromatography. Folded derCD23 eluted during a gradient from 25 mM Tris,
pH 7.5 to 40 % 25 mM Tris, 1 M NaCl, pH 7.5. Folded derCD23 (green) eluted at
higher salt concentrations than misfolded derCD23 (grey).
The pooled fractions were subjected to size exclusion chromatography (SEC) in
order to isolate the desired monomeric derCD23 from the multimeric forms (Section
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2.4.7) (Figure 3.4).
Figure 3.4: Chromatogram of derCD23 purified by size exclusion.
Monomeric derCD23 was separated from aggregates based upon differences in hy-
drodynamic volume using a Superdex 75 column (GE Healthcare). The larger
molecular weight aggregates eluted first (grey), followed by monomeric derCD23
(green).
The multimers were eluted at lower volumes during SEC, and appeared as
‘shoulders’ to the left of the main monomeric derCD23 elution peak. SEC fractions
were pooled to avoid contamination with the multimeric forms and contained pure
derCD23 (Figure 3.2).
Mass spectrometry of derCD23
Positive ion electrospray mass spectrometry was used to corroborate the exact
molecular weight of the purified derCD23 protein sample (Section 2.4.8). The
mass spectrum consisted of a single peak at 16,137 Da, which corresponds to the
mass of derCD23 with four disulphide bonds (Figure 3.5).
1D 1H NMR spectroscopy of derCD23
1D 1H NMR spectroscopy was used to determine if the purified derCD23 was folded
(Section 2.4.9). Several features of the 1H NMR spectra indicate that the purified
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Figure 3.5: Positive ion electrospray mass spectrometry of purified
derCD23. A single peak at 16,139 Da was observed, corresponding to the molec-
ular mass of folded derCD23.
derCD23 was folded (Figure 3.6). The presence of signal dispersion at chemical
shifts between 8.5-11 parts per million (ppm) demonstrate that the protein amides
of the sample were in different chemical environments, which is indicative of a
well-folded protein [168]. The signal dispersion in the aliphatic region of the 1D
1H NMR spectrum of the spectrum (between -1 and 1 ppm) also suggests that
the sample was folded [168]. In addition to these general characteristics for folded
proteins, the spectrum also displays four characteristic methyl peaks up-field of 0
ppm from residues 221, 223 and 227, which indicate that derCD23 is well folded
[39].
3.2.2 Production of His-tagged IgE-Fc
His-tagged IgE-Fc was required as a control for surface plasmon resonance (SPR)
investigations into the effect of aεFab1 on the interaction between IgE-Fc and
derCD23.
Cloning and expression of His-tagged IgE-Fc
DNA of IgE-Fc(N265Q,N371Q) with a 6x N-terminal His-tag was synthesised
and cloned into UCB’s pNAFH vector by The GeneArtTM Gene Synthesis ser-
vice (Thermo Fisher Scientific). The pNAFH vector is a mammalian expression
vector under the control of the human cytomegalovirus promoter, it also has a
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Figure 3.6: 1D 1H NMR spectroscopy of purified derCD23. A 1D 1H NMR
spectrum for purified derCD23 was recorded at 500 MHz at 35 ◦C. Signal dispersion
from -1 to 1 and from 8.5 to 11 ppm, and four characteristic up-field shifted methyl
peaks (in black dotted box) indicate that the protein was well-folded.
pUC origin of replication and encodes kanamycin resistance. BL21 E. coli were
transformed with the pNAFH vector containing the His-tagged IgE-Fc construct,
and the expanded plasmid DNA was isolated from LB cultures.
Human Embryonic Kidney 293 (HEK293) cells were transiently transfected with
the pNAFH vector containing the His-tagged IgE-Fc insert using the 293fectin
TM
reagent (Thermo Fisher Scientific). The supernatant was harvested by centrifuga-
tion after six days of incubation.
Verification of His-tagged IgE-Fc expression using SPR
SPR was used to determine if His-tagged IgE-Fc had been expressed into the su-
pernatants and if it had native-like function. SPR is a label-free technique used
to follow biomolecular interactions in real-time (Section 2.6). Changes in response
can provide a measure of the change in the amount of binding of analyte in so-
lution to a ligand immobilised on a sensor surface. Alpha-gamma [88] (the alpha
subunit of FcεRI fused to IgG4 constant domains) was immobilised on the surface
of a sensor chip using amine-coupling (Section 2.6.2) at a moderate density (∼ 500
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RUs). IgE-Fc was injected for 180 s over the surface at various concentrations as a
control. The His-tagged IgE-Fc supernatant was injected for 180 s over the surface
at various dilutions. A 350 s dissociation phase followed each sample injection and
the surface was regenerated by two 60 s pulses of 10 mM glycine-HCl pH 2.2. The
SPR sensorgrams for the binding of IgE-Fc and His-tagged IgE-Fc to the alpha-
gamma surface were comparable, indicating that His-tagged IgE-Fc was present in
the supernatant and was functional (Figure 3.7).
Figure 3.7: The SPR sensorgrams profiles for the binding of un-purified
His-tagged IgE-Fc to immobilised alpha-gamma (an FcεRIα construct)
are very similar to the binding of non-His-tagged IgE-Fc to the same
surface.
3.2.3 SPR studies of the effect of aεFab1 on the interaction
between IgE-Fc and CD23
SPR was used to study the effect of aεFab1 on the interaction between IgE-Fc
and derCD23. Steady-state analysis of SPR data can be used to determine the
equilibrium constant (KD) and binding capacity (Bmax) of an interaction from a
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plot of the steady-state response versus the analyte concentration (Section 2.6.4)
[151]. Steady-state analysis is only appropriate if the interaction reaches steady-
state during the course of analyte injection. The interaction between IgE-Fc and
derCD23 reaches steady-state relatively fast, largely as a result of its rapid off-
rate [39] and is therefore suitable for steady-state analysis. SPR experiments were
performed to determine how aεFab1 affects the interaction between IgE-Fc and
derCD23 and steady-state analysis was employed to quantify these effects in terms
of KD and Bmax.
An anti-His-tag antibody (THETM His-Tag Antibody, mAb, Mouse, Genscript)
CM5 sensor surface and an aεFab1 CM5 sensor surface were prepared using amine-
coupling techniques (Section 2.6.2). A mock amine-coupled surface was used as a
reference-subtraction surface. A 1 in 4 dilution of supernatant containing His-
tagged IgE-Fc was injected over the surface for 180 s and was captured by the
anti-His-tag antibody. Various concentrations of derCD23 were then injected for
120 s over the captured His-IgE-Fc in order to characterise the interaction between
IgE-Fc and derCD23 in the absence of aεFab1 (Figure 3.8.a). Separately, IgE-
Fc was injected for 180 s over the aεFab1 surface to generate an immobilised
aεFab1:IgE-Fc (1:1) complex. IgE-Fc was captured at a higher density on the
aεFab1 surface than on the anti-His antibody surface because the later surface had a
lower immobilisation density. Nevertheless, the capture levels of IgE-Fc in each case
were low enough to ensure that binding between IgE-Fc and immobilised antibody
was monomeric and would not give density dependent phenomena (Section 2.6.2).
derCD23 was then injected for 120 s over the aεFab1:IgE-Fc (1:1) complex using
the same range of concentrations (Figure 3.8.b). 8 µM derCD23 was also injected
for 120 s over both the anti-His-tag surface and the aεFab1 surface directly and no
binding was observed (data not shown). A dissociation phase lasting 180 s followed
all sample injections and the surfaces were fully regenerated by applying two 60 s
pulses of 10 mM glycine-HCl pH 2.2. All experiments were run in duplicate and
gave highly replicable results.
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Comparisons of IgE-Fc/derCD23 binding profiles in the presence and
absence of aεFab1
The double reference-subtracted sensorgram of derCD23 binding to the His-tag cap-
tured IgE-Fc (Figure 3.8.a) was very similar to previously reported IgE-Fc/derCD23
SPR binding profiles; association and dissociation were rapid and the interaction
reached steady-state within seconds of the derCD23 injection [39, 89]. The binding
profile for derCD23 to aεFab1-bound IgE-Fc (1:1) was markedly different. The as-
sociation was still rapid, however a steady-state was only achieved at lower derCD23
concentrations. The affinity of the higher-affinity site of derCD23 has been esti-
mated to be around 1 µM [88], at concentrations above 1 µM the response fell
during the derCD23 injection (Figure 3.8.b). The drop indicates a loss of mass at
the sensor surface, which can be explained by derCD23-mediated accelerated dis-
sociation of IgE-Fc from aεFab1. The result is indicative of negative cooperativity:
that binding of a second derCD23 molecule to the tertiary IgE-Fc complex (one
aεFab1 molecule and one derCD23 molecule) weakens the aεFab1/IgE-Fc interac-
tion.
There are many published examples of ligand-induced accelerated dissociation
[169, 170, 171, 172, 109], in which the binding of increasing concentrations of a
ligand to a complex, increases the rate of complex dissociation. Ligand-induced
accelerated dissociation of IgE-Fc complexes is possible (Section1.3.5); a ligand
(DARPin E2 79) was found to increase the rate of an IgE-Fc-receptor complex
(IgE-Fc:FcεRIα) [109]. DARPin E2 79-induced accelerated dissociation of IgE-
Fc:FcεRIα was attributed to competition for subsite attachment points within a
ligand-binding site [109]. It is possible, however, that ligand-induced accelerated
dissociation can occur as a result of allosteric communication (Section 1.3.5).
Steady-state analysis of IgE-Fc/derCD23 binding profiles in the presence
and absence of aεFab1
The steady-state responses of derCD23 binding to anti-His-tag-bound IgE-Fc and
to aεFab1-bound IgE-Fc were plotted against derCD23 concentration. The data
were fit using a one-to-one binding model (Section 2.6.4, Equation 2.17) (Figure
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Figure 3.8: SPR sensorgrams of derCD23 binding to (a) His-tagged IgE-
Fc and (b) aεFab1-bound IgE-Fc derCD23 bound to both the His-tagged and
aεFab1-bound IgE-Fc. A steady-state of binding CD23 to His-tagged IgE-Fc and
aεFab1-bound IgE-Fc at low derCD23 concentrations was achieved. At higher
derCD23 concentrations derCD23 caused accelerated dissociation of IgE-Fc from
aεFab1. The boxes show double reference-subtracted data for derCD23 binding
in each case. The green indicates the 5 s interval at which steady-state response
values were averaged in the equilibrium analysis.
3.9).
Steady-state analysis of the anti-His-bound-IgE-Fc/derCD23 interaction gave
an estimated KD of 4.5 ± 0.5 µM. At derCD23 concentrations below 1-2 µM the
occupancy of the lower-affinity binding site is low and therefore its overall contri-
butions to the KD are less significant. Consequently, it was more appropriate to
apply a one-to-one fit to the data from 0-2 µM. The fit to the data was improved
(Figure 3.9.b) and the resultant KD was 0.88 ± 0.1 µM, and provided an estimation
of the binding of derCD23 to the higher affinity site on IgE-Fc.
In addition to the above considerations, it was also appropriate to perform
steady-state analysis on the data collected from the binding of derCD23 to aεFab1-
bound IgE-Fc at lower derCD23 concentrations because at these concentrations
there was little or no accelerated dissociation. The data fitted well to a one-to-
one binding model, indicating only one derCD23-binding site was occupied (Figure
3.9.b). There was a notable reduction in the steady-state response for the inter-
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Figure 3.9: IgE-Fc bound to aεFab1 has a lower capacity and affinity for
derCD23. Steady-state analysis was performed on derCD23/IgE-Fc steady-state
binding responses from SPR experiments where IgE-Fc was either pre-bound to an
anti-His-tag antibody surface or an aεFab1 surface. A one-site binding model was
used to fit data over a range of (a) 0 - 8 µM derCD23 and (b) 0 - 2 µM derCD23.
Each fit has been normalised according to the IgE-Fc-capture response.
action between IgE-Fc and derCD23 when IgE-Fc was pre-bound to aεFab1 and
when it was not; the normalised Bmax values were 36.9 ± 2.1 RUs and 75.7 ± 4.1
RUs respectively. The reduction in Bmax indicates that pre-formed aεFab1:IgE-Fc
has fewer available derCD23 binding sites. The KD of the IgE-Fc/derCD23 inter-
action was higher when IgE-Fc was bound to aεFab1 compared to when it was not;
the KD values were 2.0 ± 0.2 µM and 0.88 ± 0.1 µM respectively. These results
suggest that the the interaction between one aεFab1 molecule and IgE-Fc reduces
both the capacity and affinity of IgE-Fc’s higher-affinity CD23 binding site.
3.2.4 Inhibition studies on the surface of B cells
Cell-based assays were performed in order to investigate how the IgE/CD23 in-
teraction is affected by aεFab1 under homogeneous equilibrium conditions. The
cell-based assays that were performed were homogeneous, essentially at equilib-
rium, and looked at the effect of aεFab1 on the binding of a full length IgE an-
tibody (rIgE, [173]) to the more biologically relevant membrane-bound trimeric
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CD23 (mCD23) expressed on the surface of RPMI 8866 cells.
Flow cytometry is a technique that can be used to measure the fluorescence
intensity of a single-cell suspension when a fluorescently-labeled antibody binds a
specific cell-associated molecule, or a ligand that detects a specific cell-associated
molecule (Section 2.7.1). A readout of mean fluorescence intensity (MFI) at 660 nm
by flow cytometry was used to investigate the effect of increasing concentrations of
aεFab1 on the amount of binding of an Alexa Fluor 647-labeled rIgE (rIgE-A647)
to mCD23. Prior to all biological replicates, mCD23 expression on the surface of
the cells was confirmed using a FITC-labelled anti-human CD23 (MHM6-FITC,
clone F7062, Dako) (data not shown).
Dose-dependent inhibition studies
Preliminary experiments were performed in which a constant number of RPMI 8866
cells were incubated with increasing concentrations of rIgE-A647. Dose-dependent
curves, a plot of the mean A647 fluorescence intensity as a function of rIgE-A647
concentration, estimated the KD of the interaction between rIgE-A647 and mCD23
to be ∼ 10-20 nM. The inhibition experiments were performed with 12 nM rIgE-
A647, because at this concentration the rIgE-A47/mCD23 interaction will be sen-
sitive to the effects of addition of the aεFabs.
12 nM of rIgE-A647 was incubated with a constant number of RPMI 8866 cells
in the presence of increasing concentrations of anti-IgE-Fc control Fabs (Xolair Fab
mutant 3 and aεFab3) or aεFab1 (Section 2.7.2). The MFI readings of the single-
cell suspensions were measured at 660 nm using flow cytometry. 0 % inhibition
was defined as the MFI when neither control Fab nor aεFab1 were present. 100
% inhibition was defined as the mean fluorescence intensity when rIgE-A647 was
replaced with an A647-labelled antibody with no mCD23 binding activity. The
experiments were performed in duplicate and gave good agreement (Figure 3.10).
aεFab3 is a monoclonal Fab that binds to IgE-Fc and has no dose-dependent
effect on the rIgE/mCD23 interaction in cell-binding assays. Xolair Fab mutant 3
(aεFabXol3) also binds to IgE-Fc but it is known to inhibit the IgE/CD23 inter-
action in a dose-dependent manner (Section 1.3.4) [82]. For both biological repli-
cates, aεFab3 had no dose-dependent effect on the rIgE/mCD23 interaction and
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Figure 3.10: aεFab1 caused dose-dependent inhibition of the IgE/CD23
interaction on the surface of B cells. RPMI 8866 cells, constitutively express-
ing CD23 on their surface were incubated with fluorescently-labeled rIgE (rIgE-
A647) and increasing concentrations of (a) control Fabs or (b) aεFab1. The mean
fluorescent intensity (MFI) of the single-cell suspensions was measured by flow cy-
tometry. Inhibition of the IgE/CD23 interaction was assumed to be equivalent to
the reduction in MFI. The experiments were run in duplicate on different days.
aεFabXol3 inhibited the interaction in a dose-dependent manner (Figure 3.10.a).
In both biological replicates, aεFab1 inhibited the rIgE/mCD23 interaction in
a dose-dependent manner (Figure 3.10.b). The Xolair Fab mutant 3 data and the
aεFab1 data fitted well to sigmoidal models and indicate a maximal level of inhi-
bition of around 98 % and 95 % by Xolair Fab mutant 3 and aεFab1, respectively.
The concentration of aεFab1 that was required to reach maximum inhibition is
above the KD of both the higher and lower affinity aεFab1 binding sites on IgE
(KD1 = 95 ± 6 nM KD2 = 1,400 ± 100 nM). Since aεFab1 is in molar excess of
rIgE-A647 at both 95 and 1,400 nM, the data indicate that both aεFab1 sites must
be occupied for maximal inhibition of the rIgE/mCD23 interaction, assuming that
the IgE-Fc/aεFab1 KD values are not significantly altered in this system.
Multiple replicates were performed for the lowest and the highest tested con-
centrations of aεFabXol3 and aεFab1. The lowest concentrations of aεFabXol3 and
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aεFab1 were 0.125 nM and 0.02 µM, respectively, and both resulted in approxi-
mately 0 % inhibition of the rIgE/mCD23 interaction. The highest concentrations
for Xolair Fab mutant 3 and aεFab1 were 80 nM and 3 µM, respectively, and re-
sulted in around 95 % and 85 % inhibition, respectively. The mean values of the
replicated data agreed with the previous data, and Wilcoxon sum-rank tests [166]
suggested that that the 85 % increase in inhibition of the rIgE/mCD23 interaction
observed by the addition of 3 µM compared to 0.02 µM is statistically significant (p
<0.025) (Figure 3.11). Similarly, Wilcoxon sum rank tests confirmed that the ob-
served 95 % increase in inhibition of the rIgE/mCD23 interaction was statistically
significant (p <0.01).
Figure 3.11: The aεFab1 dose-dependent inhibition of the IgE/CD23 in-
teraction on the surface of (RPMI 8866) B cells is statistically signifi-
cant. Wilcoxon sum-rank tests on replicate MFI readings indicate that the ∼ 85
% inhibition of the rIgE-A647/mCD23 interaction observed upon incubation with
3 µM of aεFab1 statistically different from the ∼ 0 % inhibition of MFI signal
observed when only 0.02 µM aεFab1 is incubated with CD23-expressing cells and
rIgE-A647. The crosses indicate the individual measurements for each of the repli-
cates, the green bars show the mean averages of the readings, and the error bars
show the standard error of the mean.
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3.2.5 Structural comparisons of derCD23-bound IgE-Fc and
aεFab1-bound IgE-Fc
The crystal structures of aεFab1-bound IgE-Fc [81] and derCD23-bound IgE-
Fc [18] were compared to try and understand the basis for aεFab1 inhibition of
derCD23 and derCD23-induced accelerated dissociation of the aεFab1:IgE-Fc com-
plex. In these comparisons, the structures, or different regions of the structures,
were superposed on one another in Pymol using the ‘align’ function. This function
performs a sequence alignment of the two structures, or regions of the structures,







Where dii is the distance between the ith atom of structure 1 and the ith atom of
structure 2 and N is the number of atoms matched in each structure.
Superpositions may show conformational differences between two states of macro-
molecule, such as between two ligand-bound states of a protein. However proteins
are dynamic and care must be taken to not over interpret these static image com-
parisons.
Binding-site analysis
Both derCD23 and aεFab1 bind the Cε3 domain of IgE-Fc [39]. Superposition of
the derCD23:IgE-Fc(3-4) complex [18] and the aεFab1:IgE-Fc complex [81] upon
the Cε4 domain pairs (Section A.1) revealed that the derCD23 and aεFab1 binding
sites are non-overlapping (Figure 3.12). Additionally, the derCD23 and aεFab1
molecules occupy distinct space, which suggests that aεFab1 inhibition of derCD23-
binding to IgE-Fc, and derCD23-mediated accelerated dissociation of aεFab1 from
IgE-Fc are allosterically driven.
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Figure 3.12: Superposition of derCD23-bound IgE-Fc onto aεFab1-bound
IgE-Fc upon the Cε4 domains suggests that the CD23 and aεFab1 bind-
ing sites are spatially distinct and non-overlapping. Superposition was
performed in Pymol using the ‘align’ function. aεFab1-bound IgE-Fc structure
PDB ID: 4J4P, derCD23-bound IgE-Fc (3-4) structure PDB ID: 4EZM
Inter-domain angle comparison
The movement of Cε3 domains upon the Cε4 domain pair is thought to contribute
to the reciprocal allosteric inhibition of CD23 and FcεRI-binding to IgE-Fc (Sec-
tion 1.3.1) [18, 89]. The crystal structure of IgE-Fc (3-4) bound to two derCD23
molecules represents the most ‘closed’ conformation of IgE-Fc (3-4) described [18],
in which both Cε3-Cε4 inter-domain angles are acute. The crystal structure of
IgE-Fc bound to two aεFab1 molecules, however, is the most ‘open’ IgE-Fc con-
formation that has been published to date (Figure 3.13) [81].
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Figure 3.13: Superposition of the derCD23 bound IgE-Fc (3-4) and
aεFab1-bound IgE-Fc (3-4) shows that the Cε3 domains differ in the
extent of their openness. IgE-Fc (3-4) of the derCD23-bound crystal structure
(green) was superposed onto the IgE-Fc (3-4) of the aεFab1-bound crystal struc-
ture (blue) upon the Cε4 domain pair. One Cε3 domain from each symmetrical
complex is depicted in cartoon representation. IgE-Fc is shown in surface repre-
sentation. aεFab1-bound IgE-Fc structure PDB ID: 4J4P, derCD23-bound IgE-Fc
(3-4) structure PDB ID: 4EZM.
Superpostions of the ‘closed’ derCD23-bound IgE-Fc (3-4) crystal structure and
the ‘open’ aεFab1-bound IgE-Fc crystal structure upon one or the other Cε3 do-
mains were performed i.e. each chain of aεFab1-bound IgE-Fc was superposed onto
the derCD23-bound IgE-Fc structure by alignment of each Cε3 domain (Section
A.1) and visa versa. The comparisons show that steric clashes could potentially
prevent optimal binding of both ligands at the same time. The ‘Show Bumps’
Pymol script [174] was used to determine the steric clashes (default settings). The
superposition shows both derCD23 molecules clash with the open Cε3 domains and
the Cε4 domains of the IgE-Fc chain to which they would bind (Figure 3.14.a).
Similarly, in the closed derCD23-bound conformation, the images indicate each
aεFab1 molecule could clash with the Cε3 domain of the opposite chain to which
it is bound (Figure 3.14.b).
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Figure 3.14: Superposition images of the derCD23 (green) and aεFab1
(blue) complexes with IgE-Fc(3-4) show mutual incompatibility of op-
timal binding. The complexes were superposed on their Cε4 domain pairs. (a)
Steric clashes between derCD23 and Cε3-4 of the aεFab1:IgE-Fc (3-4) complex are
shown in red. (b) Steric clashes between aεFab1 and Cε3-4 of the derCD23:IgE-
Fc (3-4) complex are shown in red. The steric clashes were determined using the
pymol script ‘show bumps’ [174]. aεFab1-bound IgE-Fc structure PDB ID: 4J4P,
derCD23-bound IgE-Fc (3-4) structure PDB ID: 4EZM. There is a 90 degree rota-
tion of IgE-Fc between (a) and (b).
Cε3 domain comparison
The Cε3 domain, to which both aεFab1 and CD23 bind, is highly dynamic [78].
Different ligands may bind to/induce different Cε3 conformations, which could
have an impact on the degree of Cε3 opening and closing, as well as on the coor-
dination of residues at various ligand binding sites within the domain. The Cε3
domains (Section A.1) of the derCD23/IgE-Fc(3-4) complex and the aεFab1/IgE-
Fc complex were superposed with a RMSD of matched atoms of 0.7 Å (Figure
3.15). Cε3 has two cysteine residues that form an intra-domain disulphide bond,
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in the superposition the difference in the distance between the two Cα atoms of
these cysteine residues for the aεFab1-bound Cε3 and the derCD23-bound Cε3
was 0.2 Å. The difference in the distance between Cα atoms of E412 and R440,
two residues important in CD23 binding [18], was 1.6 Å; greater than the RMSD.
A large change in coordination of derCD23-binding residues, as described in the
superposed aεFab1-bound structure, could negatively affect CD23 binding. The
superposition also showed shifts of 1.3-2.2 Å in the Cα atoms of residues involved
in aεFab1 binding in the derCD23-bound structure. The observed change in po-
sition of the aεFab1-binding residues in the CD23-bound structure may disrupt
aεFab1 binding.
Figure 3.15: Superposition images of the Cε3 of derCD23-bound IgE-Fc
(3-4) (green) and aεFab1-bound (blue) IgE-Fc shows mutual incompati-
bility of optimally coordinated binding sites. The Cε3 domains were super-
posed upon one another in Pymol with an RMSD of 0.7 Å. Shifts in key residues of
the aεFab1 binding site and the derCD23 binding site were greater than the overall
RMSD. These shifts could prevent optimal coordination of both molecules simulta-
neously. The Cε3 domains used in this superposition were from the aεFab1-bound
IgE-Fc structure, PDB ID: 4J4P, and the derCD23-bound IgE-Fc (3-4) structure,
PDB ID: 4EZM.
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3.2.6 The effect of Cε3 rigidification on allosteric commu-
nication between aεFab1 and CD23 binding sites
In the SPR experiments described in Section 3.2.3, derCD23 was found to cause
accelerated dissociation of IgE-Fc from immobilised aεFab1. Further SPR experi-
ments were performed by Dr Seema Mayank to determine if reducing the confor-
mational flexibility of the Cε3 domain has an effect on the accelerated dissociation.
Disulphide-stabilised IgE-Fc (dssIgE-Fc) is a mutant form of IgE-Fc in which each
Cε3 domain has been rigidified through the introduction of an additional intra-
domain disulphide bond. L340 and R341 of the Cε3 domain of IgE-Fc were mutated
to cysteine residues and their close proximity allowed for disulphide bond formation
(Figure 3.16). Isolated Cε3 exists as a molten globule [78], 1-anilino-8-naphthalene
sulphonate (ANS) binding studies showed the disulphide-stabilised Cε3 domain to
be less molten globule-like than wildtype Cε3. Moreover, {1H},15N-heteronuclear
nuclear Overhauser effect studies indicated that the extra disulphide bond reduced
Cε3 backbone dynamics (unpublished data).
Figure 3.16: Model of the Cε3 disulphide-stabilised IgE-Fc (dssIgE-Fc). In
native IgE-Fc a disulphide forms between C358 and C418 of Cε3 (aqua). dssIgE-Fc
was engineered, by Dr Seema Mayank, to contain an additional disulphide bond in
the Cε3 domain (yellow), through the introduction of L340C and R431C mutations.
The Cε3 domain was taken from the IgE-Fc structure 1O0V, and the mutations
were made in Pymol. The image shows the dssCε3 model from two perspectives
that are rotated 90 degrees from one another.
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IgE-Fc or dssIgE-Fc were captured by aεFab1 immobilised on the surface of
a sensor chip and His-tagged IgE-Fc was captured by an anti-His-tag surface to
be used as a control for unperturbed derCD23 binding. derCD23 was injected at
various concentrations over the two surfaces. As previously observed, the signal de-
creased when derCD23 bound aεFab1-captured IgE-Fc but not when it bound anti-
His-captured His-IgE-Fc (Figure 3.17). The signal also decreased when derCD23
bound aεFab1-captured dssIgE-Fc, but at a slower rate to aεFab1-captured IgE-
Fc. A decrease in signal may result from loss of mass at the surface but also
from performing a reference subtraction with the sensorgram from a surface that
non-specifically bound higher amounts of analyte than the experimental surface. If
IgE-Fc and dssIgE-Fc bound non-specifically and variably to the reference surface,
this may have given rise to the difference in the rate of signal decrease on derCD23
injection. Inspection of the reference surface sensorgrams showed neither IgE-Fc or
dssIgE-Fc bound to the reference surface non-specifically, and therefore the effect
is not a result of differential non-specific binding. Instead, we suggest that the
difference in the rate of signal decrease may be due to a differential rate of loss of
IgE-Fc/dssIgE-Fc from aεFab1 and that derCD23-induced accelerated dissociation
of aεFab1 from IgE-Fc is dependent on the flexibility of the Cε3 domain (Figure
3.18).
The sensorgrams for the binding of 5 µM derCD23 to aεFab1-captured IgE-Fc
and dssIgE-Fc both show an apparent increase in response during the dissociation
phase following the derCD23 injection, once the respective control sensorgrams (0
µM derCD23) have been subtracted (Figure 3.18). However, this phenomenon is
not due to molecules associating to the aεFab1/IgE-Fc complex during the disso-
ciation phase, it is due to the subtractions of the control surface (routinely used in
SPR to control for bulk refractive indices from injected buffers). The upward trend
in the dissociation phase is a result of slower dissociation of IgE-Fc from aεFab1
occurring after derCD23-mediated accelerated dissociation compared to the disso-
ciation of IgE-Fc from aεFab1 in the absence of accelerated dissociation; this is
clearly seen in Figure 3.17.b. The upward trend in the dissociation phase is an
inevitable consequence of an accelerated dissociation event. The most extreme ver-
sion of this phenomenon would be seen if accelerated dissociation stripped away all
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of the bound IgE-Fc; in that case the amount of apparent association occurring in
the dissociation phase would be equal to the amount of dissociating material from
the control surface.
In the case of derCD23-mediated acceleration of the aεFab1/IgE-Fc complex,
the observed effects during the dissociation phase are somewhat more complicated
due to the heterogeneity of the system. The population of IgE-Fc molecules that
remain bound to aεFab1 after accelerated dissociation is more stably bound than
the overall (unperturbed) population of IgE-Fc molecules bound to aεFab1. This
indicates that IgE-Fc/aεFab1 complexes cannot be structurally homogeneous. The
simplest explanation for this heterogeneity would be the two different aεFab1 bind-
ing sites present on the IgE-Fc homodimer, each with distinct affinities [81] If
derCD23-mediated accelerated dissociation was more effective at dissociating IgE-
Fc from the weaker aεFab1 binding site than the stronger aεFab1 binding site, then
the remaining population of bound IgE-Fc after accelerated dissociation would be
expected to show slower dissociation than the overall heterogeneous population.
The conformational heterogeneity of IgE-Fc and its implications on receptor bind-
ing are discussed further in Chapter 6.
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Figure 3.17: SPR sensorgrams showing derCD23-mediated accelerated
dissociation of wildtype IgE-Fc from aεFab1. (a) IgE-Fc was injected over
the aεFab1 surface (phase 1) and then buffer was injected over the surface during
a short dissociation phase (phase 2). 5 µM derCD23 or 0 µM derCD23 was then
injected over the aεFab1:IgE-Fc (1:1) complex (phase 3), followed by a dissociation
phase (phase 3) in which only buffer was injected over the surface. The derCD23
injection and dissociation phases are enlarged in (b) and show that when 0 µM
derCD23 was injected over the aεFab1-captured IgE-Fc there was no change in-
crease in response. Subtracting the 0 µM derCD23 sensorgram from the 5 µM
derCD23 sensorgram removes changes in response that occurred as a result of the
inherent dissociation of IgE-Fc from the aεFab1 surface (c). When 5 µM derCD23
was injected over the aεFab1-captured IgE-Fc there was an initial increase in re-
sponse that was quickly followed by a decrease in response, indicating binding
followed by the accelerated dissociation of IgE-Fc from aεFab1.
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Figure 3.18: Rigidifying the Cε3 domain of IgE-Fc reduces the effect of
derCD23-mediated accelerated dissociation from aεFab1. SPR sensor-
grams of the effect of binding 5 µM derCD23 to aεFab1-bound IgE-Fc, with a
wildtype or rigidified (dssIgE-Fc) Cε3 domain. derCD23 does not induce acceler-
ated dissociation of IgE-Fc from an anti-His-tag antibody.
3.3 Discussion
The mutual inhibition of receptor binding to IgE-Fc is associated with the move-
ment of the Cε3 domains upon the Cε4 domain pair [18]. Crystal structure com-
parisons suggest that derCD23 binds a closed form of IgE-Fc that cannot bind
FcεRI, and FcεRI binds an open form of IgE-Fc that cannot bind CD23 (Section
1.3.1) [18]. This study provides another example in which opening and closing of
the Cε3 domain could act as a means of allosteric communication between two sites
within IgE. Furthermore, the study alludes to an additional or alternative mech-
anism of allosteric communication in IgE-Fc that involves rearrangements within
the intrinsically flexible Cε3 domains, and which affect the positioning of key CD23
and aεFab1 binding residues.
The results of the SPR and cell-based binding studies show that aεFab1:IgE-
Fc (1:1) complexes have a reduced affinity (negative cooperatively with respect to
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CD23) and capacity for CD23 binding, and increasing concentrations of aεFab1
inhibit the interaction of IgE and CD23 on the surface of cells, respectively. The
data indicate that saturation of the first aεFab1 binding site on IgE-Fc has an in-
hibitory effect on the interaction between IgE-Fc and CD23, but that the binding
of two aεFabs to IgE-Fc is required for maximal inhibition. To have greater confi-
dence in the effect of aεFab1 stochiometry on CD23 inhibition one could perform
the cell-binding assays with IgE in molar excess of aεFab1, ensuring only a one-to-
one aεFab1:IgE-Fc stochiometry. However, this is hard to do in practice since this
would require working at µM concentrations of IgE, and therefore at IgE/mCD23
saturating conditions.
Comparisons of the aεFab1:IgE-Fc X-ray structure [81] and the derCD23:IgE-
Fc (3-4) X-ray structure [18] show that derCD23 and aεFab1 binding sites are
non-overlapping and that their binding is spatially distinct, thereby supporting the
hypothesis that aεFab1 works allosterically to inhibit the CD23/IgE interaction.
Cε3 domain opening and closing could be involved in allosterically inhibiting the
interaction. Potential steric clashes with IgE-Fc(3-4) would prevent CD23 binding
optimally to an open aεFab1:IgE-Fc complex, or aεFab1 binding optimally to a
closed CD23:IgE-Fc complex (Section 3.2.5). Molecular dynamic simulations that
take thermal fluctuations into account would help to validate the clashes [175].
Additional data are required to test the hypothesis that allosteric-communication
between the aεFab1 and CD23 binding sites in IgE is mediated by Cε3 domain
opening and closing. SPR binding studies of aεFab1 and derCD23 to mutant IgE
constructs that are locked in either ‘open’ or ‘closed’ states could help interrogate
the hypothesis. However, ‘open’ and ‘closed’ states of IgE-Fc can be subtly differ-
ent [77] and molecular dynamics indicate the energy landscape of IgE-Fc is complex
[81]. There is a danger in thinking of ‘open’ and ‘closed’ states as being binary;
for example IgE-Fc ‘closed’ and ‘open’ mutants may not be representative of the
‘closed’ derCD23-bound IgE-Fc state or the aεFab1-bound state, in terms of exact
conformation or thermodynamic profile, both of which could affect their ability to
bind ligands. NMR spectroscopy could be used to compare differences in IgE-Fc
dynamics upon titration of aεFab1 and derCD23. Such titration experiments would
provide a wealth of knowledge about the conformational and dynamic changes as-
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sociated with allosteric communication between the aεFab1 and derCD23 binding
sites. However, IgE-Fc is a challenging NMR target and as of yet no NMR studies
of IgE-Fc have been published.
Additional structural comparisons investigating Cε3 domain conformations in
isolation indicate that allosteric communication between the CD23- and aεFab1-
binding sites may additionally, or alternatively, involve intra-domain rearrange-
ments (Section 3.2.5). Cε3 superposition reveals significant conformational shifts
in key residues involved in the either aεFab1 or CD23 binding sites, when one or the
other site is occupied. The Cε3 domain exhibits a high degree of conformational
flexibility that would facilitate such intra-domain motions [78]. The fact that it is
possible to limit CD23-mediated accelerated dissociation of aεFab1 from IgE-Fc by
rigidifying the Cε3 domain supports the notion that conformational changes within
the Cε3 domain itself could contribute to this mechanism of allosteric communica-
tion (Section 3.2.6). The current literature largely explains allostery in IgE-Fc in
terms of rigid-body motions and this study highlights that intra-domain movements
may also contribute to allostery in IgE and should be explored in the future.
The SPR studies showed that not only can aεFab1 inhibit the interaction be-
tween IgE-Fc and derCD23, but derCD23 can negatively affect the kinetics of the
IgE-Fc/aεFab1 interaction (Section 3.2.3). The IgE receptors themselves recipro-
cally inhibit the binding of the other to IgE-Fc allosterically [18, 89], which prevents
soluble CD23 from cross-linking FcεRI-bound IgE-Fc on the surface of mast cells
and basophils, which would otherwise result in anaphylaxis (Section 1.1.1). Here,
however, we describe a form of mutual inhibition in IgE-Fc in which simultaneous
binding of inhibitors can occur. The SPR experiments performed in this study
showed that derCD23 bound the aεFab1:IgE-Fc complex and induced accelerated
IgE-Fc dissociation from aεFab1 (Section 3.2.3). Both allostery and facilitated
dissociation can describe ligand-induced accelerated dissociation (Section 1.3.5)
[172, 109]. Facilitated dissociation, in which the ligand competes for a subset of
ligand attachment points that become exposed during partial complex dissociation,
was used to describe how the protein DARPin E2 79 accelerates the dissociation
of IgE-Fc from its FcεRI receptor [109]. Here we show that ligand-induced ac-
celerated dissociation of IgE-Fc complexes can occur via an allosteric mechanism.
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Therapeutics with the ability to destabilise pre-formed IgE-Fc:receptor complexes
could potentially have increased efficacy (Section 1.3.5) and so the fact that it is






By gaining a comprehensive understanding of allostery in IgE-Fc it may be pos-
sible to start to harness it therapeutically in the design of drugs for allergy and
asthma. Characterising antibodies that modulate IgE-Fc structure and function
has been validated as a method to identify mechanisms of allostery in IgE-Fc [81]
(Section 1.3.3). Generating allosteric modulators with varied effects on IgE-Fc
structure and function will provide a deeper comprehension of its allosteric nature.
Projects to screen for antibodies that affect the IgE-Fc/FcεRI interaction were
already in progress in an ongoing collaboration between KCL and UCB. Finding
and characterising antibodies that affect the IgE-Fc/CD23 interaction could poten-
tially contribute to our understanding of allostery in IgE-Fc (Section 1.5). Using
UCB’s Core Antibody Discovery Process, a number of antibodies were generated
that bind IgE-Fc and modulate the interaction between IgE-Fc and CD23. The
panel of antibodies were again tested for their ability to bind IgE-Fc and mod-
ulate the IgE-Fc/CD23 interaction using surface plasmon resonance (SPR). The
aim was to identify antibodies that bind IgE-Fc with a high affinity and have a
range of effects on the IgE-Fc/CD23 interaction. 15 anti-IgE antibodies (aεAbs)
were selected for their expression as aεFabs and for further selection on the basis
of biophysical analysis.
Antibodies are composed of a constant Fc region that binds to receptors and a
Fab region that is responsible for antigen binding activity (Figure 4.1). The Fab
region is composed of heavy and light chains (which can be of two types, kappa or
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lambda), each chain has a single constant and a single variable domain. The vari-
able domains contain the antigen binding site, and are comprised of a set of three
complementary determining regions (CDRs) which have highly variable sequences
and are critical for antigen specificity. The immense repertoire of antigen binding
sites is largely generated by the combinatorial assembly of germline-encoded vari-
able domain gene segments. This process, known as V(D)J recombination, occurs
in developing B cells and generates a diverse set of naive B cells that can then
express functioning antibodies on their surface. The third complementarity region
(CDR3) is composed of V, (D) and J sections and is the most diverse of the three
CDRs. Specific binding of antigen to antibodies expressed on the surface of naive
B cells triggers somatic hypermutation in the V region genes, and mutations that
increase the affinity of the antibody for the antigen are selected for [1].
Figure 4.1: Schematic representation of a full-length IgG antibody and an
IgG Fab. IgG antibodies and IgG Fabs are composed of heavy and light chains.
IgG antibodies have three regions, an Fc region and two Fab regions. The Fc region
is composed of two constant domains from two heavy chains. The Fab region is
composed of heavy chain domains and a light chain. There are two types of light
chain; kappa and lambda light chains. The heavy chain of a Fab is composed of
a constant domain (CH1) and a variable domain (VH). The light chain, which is
a kappa light chain in this example, is also composed of a constant domain (Cκ)
and a variable domain (Vκ). Antigen binds to the variable domains, whose high
sequence diversity is crucial for antigen affinity and specificity.
Because of their incredible diversity and high specificity monoclonal antibodies
are powerful tools in research and the diagnosis and treatment of diseases [176].
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Hybridoma technology has traditionally been instrumental in the discovery of mAbs
with desired specificities [177, 178]. Antibody-producing B cells, generally from
subjects exposed to the antigen of interest, are fused with myeloma cells to generate
hybridomas, which can still produce antibodies but have an extended lifetime and
greater reproductive ability than B cells in culture. The hybridomas are then
screened for the production of antibodies with the desired characteristics [177].
Hybridoma technology, however, is restricted by the poor efficiency of the fusion
process [179], which in turn narrows the B cell repertoire that can be screened.
Phage display technology is an alternative to hybridoma technology, in which
recombinant libraries of antibodies or antibody fragments are displayed on the
surface of bacteriophage. This technique allows rapid antibody selection through
methods such as enzyme-linked immunosorbent assays (ELISAs) and provides a
direct link between phenotype and genotype [180]. The libraries can be made from
a range of different sources and do not require immunisation. The libraries can be
displayed on a range of platforms other than phage, including; yeast, mammalian
cells and ribosomes [181]. Phage display technologies can screen vast numbers of
antibody genes and circumnavigate the hybridoma process, however the natural
cognate heavy and light chain pairings are usually lost, which can result in the
generation of lower affinity antibodies and antibodies with undesirable physical
properties [180, 147].
To navigate the issues associated with hybridoma and display technologies a
number of single B cell approaches have been developed [176]. Single B cell ap-
proaches involve screening B cells for the production of antibodies of interest, iso-
lation of B cells expressing the antibodies of interest, isolating the complementary
DNA (cDNA) for those antibodies, then cloning and expressing the antibodies in
vitro. UCB’s Core Antibody Discovery Process achieves this by linking a B cell
culture method to homogeneous assay screening [146], positive B cell picking and a
sensitive PCR process [147], to ultimately isolate cognate antibody variable regions
of interest [146] (Figure 4.2).
UCB’s Core Antibody Discovery Process is highly automated and allows screen-
ing in excess of 1 billion different immune B cells for the production of antibodies
with desired binding specificities. The high-throughput nature of the process per-
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mits a very wide, and highly efficient, screen of the immune B cell repertoire, in
which only a very small percentage of relevant and suitable heavy and light chain
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Figure 4.2: Schematic representation of the workflow for UCB’s Core
Antibody Discovery Process. Lymphocytes from three New Zealand White
rabbits, immunised against IgE-Fc, were seeded into 150 96-well culture plates (50
per animal) at a density of ∼5,000 cells per well (∼7.2 x107 lymphocytes in total).
4.2 Results
4.2.1 Primary fluorescence-based homogeneous screening
Three New Zealand White rabbits (Oryctolagus cuniculus) were immunised subcu-
taneously with IgE-Fc in order to elicit an immune response against IgE-Fc (Section
2.5.1). Using UCB’s Core Antibody Discovery Process, the peripheral blood from
these animals was used to set up B cell cultures in 96-well culture plates (Section
2.5.2) [148]. The B cells were cultured for one week to allow enough time for clonal
expansion, antibody expression and secretion (Section 2.5.3) [147]. The immunisa-
tions and sample preparation were performed by Victoria O’ Dowd of UCB. Using
a fluorescence-based homogeneous assay, the B cell supernatants were screened for
containing antibodies that bind IgE-Fc (Section 2.5.4).
The primary homogeneous assay consisted of three components: biotinylated
IgE-Fc bound to superavidin-coated beads, B cell supernatant (containing ex-
pressed antibodies), and a fluorescently-labeled antibody that binds rabbit IgG-Fc
(Goat Anti-Rabbit IgG, Fc fragment specific F(ab’)2, Alexa Fluor 488-conjugated,
Jackson ImmunoResearch, 111-546-046). The components were incubated for an
hour in the dark and the fluorescence intensity around the beads was measured
using the TTP Labtech Mirrorball R© fluorescence cytometer. The Mirrorball R© flu-
orescence cytometer detects beads and measures the fluorescence intensity around
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those beads. Bead-localised fluorescence was used as an indication of the presence
of an anti-IgE-Fc antibody in the supernatant (Figure 4.3).
Figure 4.3: Schematic representation of the primary fluorescence-based
homogeneous assay. Beads were coated with IgE-Fc and incubated with super-
natants from the rabbit B cell cultures as well as a AlexaFluor488-labeled rab-
bit IgG-Fc specific F(ab’)2 (Jackson ImmunoResearch, 111-546-046) (AlexaFluor
488-anti-rabbit Fc). Localised fluorescence around the bead, measured by a TTP
Labtech Mirrorball R© fluorescence cytometer, indicated the presence of an anti-IgE
antibody in the supernatant, and the supernatant was listed as a ‘hit’.
The primary screening data were analysed in Spotfire DecisionSite R© (TIBCO),
which rapidly produces visual reports of data. 14,400 supernatants were screened
and 1,702 ‘hit’ supernatants were identified, which gave a fluorescence reading
over the background level (100 AFUs), suggesting they contained an antibody that
bound to IgE-Fc. The Spotfire software then generated a top ‘hit list’ of 796 ‘hit’
B cell culture wells (Section 2.5.5). The supernatants that produced the highest
bead-localised mean fluorescence intensity came from these wells. The supernatants
from these ‘hit’ wells were then plated into 96-well masterplates and taken on for
further screening for IgE-Fc/CD23 modulating activity. The B cell cultures were
frozen and stored at -80 ◦C.
4.2.2 Secondary fluorescence-based homogeneous
screening
A secondary fluorescence-based homogeneous assay was developed to screen the
800 top IgE-Fc binding supernatants for antibodies that modify the interaction
between IgE-Fc and CD23 (Section 2.5.6). The secondary assay was based upon
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the same homogeneous fluorescence-based method as the primary screen, however
fluorescently-labeled derCD23 (derCD23-A488) was added instead of the fluorescently-
labeled anti-rabbit-Fc antibody. The intensity of bead-localised fluorescence was
used as a measure of derCD23-A488 binding to biotinylated IgE-Fc on the surface
of the bead (Figure 4.4).
Figure 4.4: Schematic representation of the secondary fluorescence-based
homogeneous assay. Beads were coated with IgE-Fc and incubated with ‘hit’ B
cell supernatants identified from the primary screen, as well as fluorescently-labeled
derCD23 (derCD23-A488). Localised fluorescence around the bead, measured by
a Mirrorball R© fluorescence cytometer, was used as a measure of the binding of
derCD23-A488 to IgE-Fc on the surface of the beads.
Development of the secondary screen
Prior to the secondary screen, preliminary experiments were performed to find the
optimal conditions for screening. Different concentrations of biotinylated IgE-Fc
were tested for coating the superavidin beads, alongside a titration of fluorescently-
labeled derCD23 in order to establish the best fluorescent signal-to-noise ratio.
Initially optimisations were performed in HEPES buffer with 4 mM calcium in
place of what would be ‘hit’ B cell supernatant. An increase in fluorescence intensity
was observed upon addition of increasing concentrations of derCD23-A488 when
the beads were coated with 1 and 0.75 µg/plate of biotinylated IgE-Fc (Figure
4.5.a).
When the beads were coated with biotinylated IgE-Fc at concentrations lower
than 0.75 µg/plate the fluorescent signal was relatively low and there was no
obvious dose-dependent response (Figure 4.5.a). A linear dependence between
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derCD23-A488 concentration and bead fluorescence intensity was observed be-
tween 0.3 - 1 µg/ml derCD23-A488 in the dose-response curve for 1.0 µg IgE-
Fc/plate (Figure 4.5.b). At 3.2 µg/ml derCD23-A488 the bead fluorescence inten-
sity dropped and at 10 µg/ml the signal fell to around 0 AFUs, which could be the
result of high background levels of fluorescence.
When binding experiments are performed with both reactants at concentra-
tions above the KD of the interaction, binding becomes limited by the ratio of
the reactants - all of the analyte will bind the ligand, up until the point where
the ligand becomes saturated, and past that point excess analyte will exist in so-
lution. In this assay , bead-based fluorescence was the result of crosslinking of
immobilised IgE-Fc molecules by trimeric derCD23-A48 (KD ∼1-10 nM). At con-
centrations above 1µg/ml derCD23-A488 (∼20 nM trimeric derCD23-A488) the
drop in fluorescence may have occurred because both reactants were at concen-
trations above the KD of the interaction, and IgE-Fc was saturated. Any excess
derCD23-A488 would have resulted in an increase in Alexa Fluor 488 background
fluorescence. Any bead-localised fluorescence within two standard deviations of
the background fluorescence of the well was not acquired by the cytometer, and
therefore an increase in background fluorescence would have increased the thresh-
old for acquisition of bead-localised measurements [182]. Accordingly, the drop in
average bead-localised fluorescence to 0 AU at 10 µg/ml derCD23-A488 could be
because the excess derCD23-A488 resulted in a level of background fluorescence so
great that even when IgE-Fc was saturated, none of the beads had localised fluores-
cence two-standard deviations above the background level. Similar ‘hook effects’
are commonly observed in other Mirroroball assays and alternative ‘mix and read’
immunoassays when excessive primary antibody saturates the assay, preventing the
true readout of bound fluorescence from the detection antibody [183].
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Figure 4.5: Secondary screen development in HEPES buffer. (a) Beads
coated with varying concentrations of biotinylated IgE-Fc were incubated with in-
creasing concentrations of derCD23-A488 in HEPES buffer with 4 mM calcium.
Bead-localised fluorescence was used as a measure for binding of derCD23-A488 to
IgE-Fc on the surface of the beads. Readings for experiments performed with 1
and 0.75 µg IgE-Fc/plate showed a general dose-dependent response to increasing
derCD23-A488 until 3.16 µg/ml derCD23-A488. (b) The bead-localised fluores-
cence recorded when increasing concentrations of derCD23-A488 was incubated
with superavidin beads coated in 1 µg/plate biotinylated IgE-Fc. A linear depen-
dence between derCD23-A488 concentration and bead fluorescence intensity was
observed between 0.3 - 1 µg/ml derCD23-A488.
When the same development assays were performed in a non ‘hit’ B cell culture
(from a different rabbit immunisation and B cell culture) there was no fluorescent
signal, suggesting that something in the culture-media quenched the fluorescence.
UCB has also observed this effect in other systems (data not shown). It was
therefore necessary to establish an appropriate level of supernatant dilution in order
to optimise the fluorescent signal. Using 1 µg of biotinylated IgE-Fc per plate gave
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the most robust fluorescent signal in the initial development screen (Figure 4.5.a)
and accordingly this concentration of IgE-Fc was used to coat the beads that were
then incubated with increasing concentrations of derCD23-A488 and at different
negative B cell supernatant dilutions. It was decided that for the secondary screens
the supernatant should be diluted to 20 % in HEPES buffer with 4 mM calcium
chloride, as this still gave a robust signal in the linear range of the binding curve
(Figure 4.6).
Figure 4.6: Secondary screen development in non-‘hit’ B cell super-
natant. The bead-localised fluorescence recorded when increasing concentrations
of derCD23-A488 were incubated with 20 % non-‘hit’ supernatant and superavidin
beads coated in 1 µg/plate biotinylated IgE-Fc. A linear dependence between
derCD23-A488 concentration and bead fluorescence intensity was observed between
0.5 - 1 µg/ml derCD23-A488.
The secondary screen
Each of the supernatants was diluted to 20 % and the supernatant solution was in-
cubated for an hour in the dark with IgE-Fc-coated beads (constant density, coated
at 1 µg/plate) and derCD23-A488 (1 µg/ml). The bead-localised fluorescence was
read in 384-well plates. Supernatant from another B cell culture, without IgE-Fc
binding activity, was also sampled in order to determine a baseline level of fluo-
rescence indicative of an ‘average’ interaction between IgE-Fc and derCD23 under
this system (Section 2.5.6).
The average bead-localised fluorescence reading for the ‘baseline’ supernatants
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was higher than the average for the ‘hit’ supernatants (Figure 4.7). A majority
of the supernatants gave fluorescent readings below the ‘baseline’ suggesting that
a majority of the antibodies had a negative effect on the interaction. This inter-
pretation, however must be treated with caution since the ‘baseline’ supernatants
originated from a rabbit immunisation and B cell culture set-up different to the
origin of the ‘hit’ supernatants. In the absence of a robust control baseline level
of fluorescence intensity, selection of ‘secondary hit’ supernatants was based on an
internal comparison.
Figure 4.7: Secondary homogeneous fluorescence-based assay results.
Bead-localised fluorescence intensity was used as a guide to how the ‘hit’ super-
natants, containing IgE-Fc-specific antibodies, affected the interaction between
IgE-Fc and derCD23-A488. Each green circle represents the result from a sin-
gle B cell supernatant. An average of the results from the ‘baseline’ supernatant
(no IgE-Fc-specific antibody) suggests a ‘baseline’ level of fluorescence and hence a
‘baseline’ level of interaction between derCD23-A488 and IgE-Fc on the surface of
the beads. Two standard deviations from the mean of the plate ‘hit’ results were
used as a guide to select a range of supernatants to take on for further analysis.
Several ‘hit’ supernatants gave readings above or below two standard deviations
from the mean. The internal comparison unfortunately could not indicate whether
the effects of the supernatants on the IgE-Fc/derCD23 interaction were actually
positive or negative, respectively. Even if a robust baseline had been established
it would have been difficult to determine this since the concentration of the anti-
bodies in the supernatant was unknown. A strong inhibitor present at very low
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concentrations could appear to be neutral in its effect on the interaction.
IgE-Fc - free screens were performed in parallel to the actual secondary screens.
These ‘negative’ screens were the same in all respects except that that the super-
avidin beads had not been coated with biotinylated IgE-Fc. The results from the
negative screens showed no bead-localised fluorescence, indicating that in each case
the fluorescently-labeled derCD23 did not stick to the beads and any localised fluo-
rescence in the actual screens was the result of the interaction between IgE-Fc and
derCD23. Those supernatants above and below two standard deviations from the
mean were selected as ‘secondary hits’, as were random supernatants within two
standard deviations from the mean.
4.2.3 Cloning of variable region genes and DNA sequencing
UCB’s proprietary fluorescent foci picking method was used to isolate 6-12 in-
dividual IgE-Fc-specific B cells from the selected ‘secondary hit’ B cell cultures
(Section 2.5.6) [147]. The ‘secondary hit’ B cell cultures containing the ‘secondary
hit’ B cells were incubated with superavidin beads coated in biotinylated IgE-Fc
in addition to a fluorescently-labeled (AlexaFluor 488) anti-rabbit IgG-Fc F(ab’)2
(Jackson ImmunoResearch, 111-546-046), used for detection. A fluorescent micro-
scope was used to visualise the B cells of interest, which were surrounded by a
‘halo’ of fluorescence due to localised binding of their secreted antibodies to prox-
imal IgE-Fc-coated beads. A micromanipulator was used to pick these individual
‘hit’ B cells, alternatively named fluorescent foci. 44 different B cell cultures were
selected based on the results of the secondary homogeneous fluorescence-based as-
say (named F89-132) and foci were successfully isolated from 43 of these (Table
4.1).
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F118 4515 40.2 A Z LOW CAP  
F102 4963 78 B Y LOW FC  
F128 2226 88.3 B X 65 17 
F127 2528 89 B X 68 15 
F123 4686 90.8 N/A N/A LOW CAP  
F119 4634 100 B X 42 13 
F90 4288 101 B Z 56 2 
F111 3914 134 B Z 53  
F103 4337 138 B Z 49  
F89 5803 214 C Z 34 19 
F115 1629 224 B Y 45  
F130 6558 232 C Z 48 18 
F93 1430 279 A Y 54  
F91 2162 285 B Y 44 3 
F117 2165 306 A Y 48  
F107 2293 314 B X 71  
F109 3215 325 B Y LOW FC  
F94 2400 332 B X 47 5 
F101 2038 335 B X 69 9 
F114 2010 337  N/A Z LOW CAP  
F92 3369 342 A X 53 4 
F112 4594 342 C N/A 28 10 
F116 4386 343 C X 87 12 
F125 4633 344 B N/A LOW FC  
F131 6939 344 C Y LOW CAP  
F132 6250 344 N/A Y LOW CAP  
F105 4407 352 N/A X LOW CAP  
F108 2787 352 C X LOW FC  
F100 1408 353 B Z 83 7 
F122 5075 355 B Z 53 14 
F120 1564 357 A Y LOW CAP  
F95 1790 361 B Z 52  
F121 3460 378 B Z LOW CAP  
F126 4996 380 B Z 50  
F106 2051 382 A Z LOW CAP  
F99 4596 387 B Z 60  
F98 2920 400 C Y 52 6 
F96 2056 477 B X 56  
F110 3145 495 B Z LOW CAP  
F104 4328 596 N/A Y LOW CAP  
 
Table 4.1: An overview of the screening and sequencing data from the
different ‘secondary hit’ antibodies that were successfully cloned and
transiently expressed. The antibodies are named according to the foci number
from which they were derived, and are listed in terms of their secondary screen
result, from lowest to highest arbitrary units AFUs. The primary screen identi-
fied IgE-Fc binding activity of B cell supernatants, with higher values indicative
of greater binding. The secondary screen measured the effect on the interaction
between derCD23 and IgE-Fc, with higher values indicative of greater binding
between IgE-Fc and CD23. The SPR screen investigated the effect on derCD23
binding to IgE-Fc pre-bound to antibody. The occupancy of derCD23 binding sites
on IgE-Fc during the steady-state was expressed as a percentage of the theoretical
steady-state occupancy (thBeq). LOW CAP indicates the antibody capture level
was too low for analysis. LOW FC indicates the antibody did not bind IgE-Fc.
The families were based on nodal analysis of the pyhlogenetic trees outputted from
the CDR3 sequence alignments. For antibodies assumed to be clones, only the data
for one clone is shown. 15 antibodies were selected to be expressed as Fabs based
on this screening.
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Single B cell reverse transcription PCR (RT-PCR) was performed on three of the
6-12 foci picked in each of the 43 cultures (Section 2.5.8). The RT-PCR produced
cDNA for the antibody produced by that particular B cell clone. The cDNA for
each antibody was used to amplify the heavy and the light variable domain genes
and clone them into transcriptionally active DNA fragments [184] using several
rounds of transcriptionally active PCR (TAP) (Section 2.5.9) (Figure 4.8) [147].
Figure 4.8: Workflow for transcriptionally active PCR (TAP) of variable
region genes. Three rounds of PCR were used to amplify cognate pairs of vari-
able region genes and to anneal them into transcriptionally active DNA fragments.
Primary PCRs were performed using the cDNA from isolated B cells to amplify
the variable region genes. The secondary PCRs added small sequences at each
end of the variable regions that overlap with the human cytomegalovirus (HCMV)
promoter (grey) and the heavy or kappa chain constant regions (teal) containing
a polyadenylation sequence (light green). In the tertiary PCRs the HCMV, vari-
able regions and constant regions were annealed to give a transcriptionally active
product.
The heavy and light variable domain DNAs from the secondary TAP reactions
were gel purified. At least one of the three isolated B cells from each of the 43
B cell cultures gave secondary TAP products that ran at the expected size on a
1% agarose gel (Figure 4.9). Following purification, the DNA encoding the heavy
and light variable domains were cloned into UCB in-house ‘rabbit-Fab vectors’
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containing the DNA encoding for the heavy CH1 and Cκ domains, respectively.
The plasmid also contained an HMCV promoter, a polyadenylation sequence, a
pUC origin of replication and encoding kanamycin resistance. The secondary TAP
reactions introduced restrictions sites at the 5’ and 3’ ends of the variable domain
sequences, so that the variable domains could be cloned into the plasmid using
restriction enzymes (Section 2.5.10) (Figure 4.10).
Figure 4.9: 1 % agarose gel of secondary TAP products. (a) kappa chain
variable regions (b) heavy chain variable regions. The first and last lane of both
gels contained 2 log DNA ladder (New England Biolabs). The intermediate lanes
contained the PCR products from the secondary PCRs from three different foci
for 16 of the 43 different ‘secondary hit’ B cells cultures (F89-F104). The variable
region DNA runs at 0.5 kb.
The plasmid DNA was used to transform XL1-Blue E. coli (Stratagene) using
heat shock (Section 2.2.3). The expanded plasmid DNA was purified from overnight
cultures and sequenced in both forward and reverse directions. A sequence com-
parison of the third complementary determining region (CDR3) (Section 4.1) of the
heavy and the kappa chains was performed using the MUSCLE multiple sequence
alignment tool [185] (Figure 4.11). Some of the antibodies were found to have the
same heavy and kappa CDR3 sequences, which for the purpose of selection were
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assumed to be clones. It was promising to see that the supernatants containing the
presumed clones had similar secondary screening results (Table 4.2).
Figure 4.10: Heavy and light chain variable domains were cloned into UCB
in-house plasmids using restriction enzymes. The variable domains were
excised from the secondary TAP products using restriction enzymes and introduced
into a UCB in-house plasmid cut with the same enzymes. The heavy variable
domain was cloned into a ‘heavy chain Fab vector’ containing a downstream CH1
domain and the light chain variable domain was cloned into a ‘light chain Fab



















Table 4.2: There is good agreement between the secondary screen mea-
surements of the supernatants of presumed clones. Sequence alignment of
heavy and kappa CDR3s indicated that some antibodies were clones, shown here
as A, B, C and D. The secondary screen results were in relatively close agreement
for the different supernatants from which these clones were identified.
The phylogenetic trees that were output from the alignments of the heavy and
kappa chain CDR3s were used to assign the antibodies to families based on their
sequence similarities (Figure 4.12). The phylogenetic trees show the inferred evolu-
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tionary relationship between the CDR3 sequences. The lengths of the branches in-
dicate the closeness of the evolutionary relationships between the different CDR3s.
The branches split off from nodes, which suggest a common ‘ancestor’. The first
set of nodes in both phylogenetic trees were used to class heavy CDR3s into A,
B and C families, and kappa CDR3s into X, Y and Z families. There appears to
be no obvious or immediate correlation between the different CDR3 families and
effect on the derCD23/IgE-Fc interaction as determined by the secondary screens.
The two antibodies with C and Z heavy and kappa CDR3s, respectively, were both
associated with lower derCD23/IgE-Fc binding, but due to the small numbers of
sequences it is inappropriate to assign any significance to this.
4.2.4 Investigating the effect of the full-length antibodies
on the interaction between IgE-Fc and derCD23
using SPR
ExpiF293TM HEK cells (Thermo Fisher Scientific) were transfected with cognate
tertiary TAP products and cultured for transient expression of full-length rabbit
IgG antibodies (Section 2.5.11). The 43 supernatants were harvested and subjected
to SPR analysis to ascertain the effect of the antibody/IgE-Fc interaction on the
binding of derCD23 to IgE-Fc.
An IgG-Fc-specific goat anti-rabbit F(ab’)2 fragment (Jackson ImmunoResearch,
111-006-046) was immobilised on the surface of the sensor chip using amine-coupling
techniques (Section 2.6.2) at a density of ∼1,200 RUs. A mock amine-coupled sur-
face was used as a reference-subtraction surface (Section 2.6.2). The supernatants
were diluted 1 in 4 in SPR running buffer and were injected over the surfaces for
120 s. The antibodies in the supernatants were separately captured on the sensor
chip surface by the anti-rabbit-Fc surface at low density (<200 RUs). IgE-Fc was
injected for 120 s over the captured rabbit antibodies and the reference surface.
IgE-Fc/antibody binding was measured in response units (RUs). Following the
IgE-Fc injection, derCD23 was injected over the surfaces for 120 s at 10 µM and
the derCD23/IgE-Fc response on binding was measured (Figure 4.13). A 100 s dis-
sociation phase followed each derCD23 injection, and the surface was regenerated
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each time by two 60 s pulses of 10 mM glycine-HCl pH 1.7, and one 30 s pulse of
5 mM NaOH.
b. Kappa chains a. Heavy chains 
Figure 4.11: Protein sequence alignment of the (a) heavy and (b) kappa
CDR3s of ‘secondary hit’ antibodies. The sequence alignment was performed
using the online MUSCLE sequence alignment tool [185]. Identical amino acids are
coloured dark blue, similar amino acids are coloured light blue. For shading, 50 %
of the sequences must agree with the identity or similarity.
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a. Heavy chains 
b. Kappa chains 
Figure 4.12: Protein sequence alignment and phylogenetic analysis of the
CDR3s of ‘secondary hit’ antibodies using the online MUSCLE tool. (a)
Heavy CDR3 phylogenetic tree with the main families and assigned from the first
three nodes. (b) Kappa CDR3 phylogenetic tree with the main families assigned
from the first three nodes.
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Figure 4.13: A schematic representation of SPR experiments performed to
ascertain the effect of the antibody/IgE-Fc interaction on the binding of
derCD23 to IgE-Fc. Antibody, in supernatant, was captured by an immobilised
anti-rabbit-IgG F(ab’)2 fragment (Jackson ImmunoResearch, 111-006-046). IgE-
Fc bound to the captured rabbit antibody, and derCD23 binding to the complex
was measured as an increase in SPR response. Two molecules of derCD23 bind to
native IgE-Fc.
Unfortunately, at this time there was no antibody available that was known to
have no effect on the interaction between IgE-Fc and CD23 and therefore there was
no control for IgE-Fc/CD23 binding. As such, the recorded values were expressed as
a percentage of a theoretical steady-state response. The SPR response is directly
related to mass (Section 2.6.4) and IgE-Fc (75 kDa) can potentially bind two
molecules of derCD23 (2 x 16 kDa, 32 kDa). Theoretically if all the derCD23 sites
on the captured IgE-Fc were saturated, the binding response of derCD23 to IgE-Fc
during the steady-state (Beq) would be 0.43 (32/75) times the response recorded
during IgE-Fc binding. The percentage of the theoretical steady-state response
gives an approximation of the derCD23 occupancy of IgE-Fc, which was used for
comparisons between different antibodies (Table 4.1).
Eleven of the supernatants did not cause an increase in response when injected
over the anti-rabbit-Fc surface indicating that no antibody bound to the surface.
This may be a result of very low expression levels or incorrectly folded protein. As a
result, analysis of how these antibodies affected the interaction between IgE-Fc and
derCD23 was not possible using this method. Four of the antibodies bound to the
anti-rabbit-Fc surface but did not bind IgE-Fc. It is possible that these antibodies
were classified as ‘hits’ in the primary screens because they bound non-specifically
to the bead or they recognised superavidin/ biotin rather than IgE-Fc.
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The remaining aεAbs captured IgE-Fc capable of binding derCD23. The es-
timated occupation of derCD23 binding sites on IgE-Fc ranged from 28 % to 87
% depending on the aεAb used to capture IgE-Fc on the SPR surface. 100 %
occupancy of derCD23 binding sites on IgE-Fc was not achieved when IgE-Fc was
pre-bound to any of the aεAbs, which could suggest that all of the antibodies had
some inhibitory effect on the interaction between IgE-Fc and derCD23. In the ab-
sence of a rigorous control, however, we cannot be certain of such an interpretation.
It is also possible that under these experimental conditions theoretical saturation
of the derCD23 binding sites was not possible.
4.3 Discussion
Using UCB’s Core Antibody Discovery Process, 25 different monoclonal IgG rabbit
antibodies, which bound specifically to IgE-Fc and appeared to differentially mod-
ulate the IgE-Fc/CD23 interaction, were successfully isolated and recombinantly
expressed. The secondary homogeneous fluorescence-based assay was designed to
screen supernatants for their effect on the IgE-Fc/CD23 interaction. The secondary
screen could be performed in high-throughput; it required small volumes of super-
natant and could be performed in 384-well formats. Unfortunately, the presence
of something in the cell-culture media that quenched the derCD23-A488 fluores-
cence meant that it was necessary to test diluted supernatant, thereby reducing
the signal-to-noise ratio. Performing the screens repeatedly would have provided
greater confidence in the observed values, especially in the absence of a robust con-
trol for a ‘baseline’ level of IgE-Fc/derCD23-A488 binding. To avoid the problem
of fluorescence quenching one could look at the effect of the supernatants on the
IgE-Fc/CD23 interaction using a label-free technique, such as SPR or BioLayer
Interferometry (BLI) [186].
Sequence comparisons of the heavy and light chain CDR3s suggested that the
selected antibodies were relatively diverse and consequently more likely to bind and
affect IgE-Fc in different ways. A by-eye analysis suggested there were no obvious
correlations between the CDR3 sequence and effect on IgE-Fc/CD23 binding as
ascertained by the secondary screen. Regions other than the CDR3 contribute
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towards antibody specificity including CDR1 and CDR2. These regions were not
sequenced, and a sequence alignment of the whole variable domain would provide a
better basis for drawing correlations between genealogical lineage and modulation
of the IgE-Fc/CD23 interaction. A computational comparison may also reveal
subtle links missed in this analysis. Although potentially interesting, investigating
the evolution of the immune response to IgE-Fc was tangential to the antibody
discovery process and so it was not pursued further.
SPR was successfully used to eliminate poorly expressing and non-IgE-Fc-
specific antibodies from further selection. It was also employed as a means of
further probing the effect of the antibodies on the interaction between IgE-Fc and
derCD23. The experiment investigated how much derCD23 could bind IgE-Fc pre-
bound to one aεAb. Unfortunately, without an experimental control it was only
possible to compare the relative effects of pre-binding IgE-Fc with aεAbs.
In some cases there was agreement between the results of the effect of aεAbs on
the IgE-Fc/CD23 interaction from the SPR and secondary screening assays. For
example F119 was identified in both assays as having had a particularly negative
effect on the IgE-Fc/derCD23 interaction relative to the other aεAbs. Similarly,
F116 was identified in both assays as having had a particularly positive effect on
the IgE-Fc/derCD23 interaction relative to the other aεAbs. In other cases the
results from the two assays were quite contrasting; the secondary screen reading
for F98 suggested it had a positive effect on IgE-Fc/CD23 binding but in the SPR
experiments gave a slightly below average CD23 occupancy measurement (Table
4.1). These differences in results are perhaps to be expected given that the two
assays are fundamentally different in their approach to investigating the effect
of aεAbs on the IgE-Fc/CD23 interaction. The secondary assay is performed at
equilibrium with unknown concentrations of aεAbs, whereas the SPR experiments
are non-homogeneous and not at equilibrium. By pre-forming aεFab complexes the
SPR experiments bias the interpretation of the effect of aεAbs on the IgE-Fc/CD23
interaction in favour of the aεAbs. The SPR experiments, however, do allow for
the normalisation of signal with respect to antibody concentration.
Despite its imperfections the SPR analysis provided a basis for the selection of
antibodies to take on to the next stage of the process. The eleven supernatants
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that did not elicit a response when injected onto the anti-rabbit-Fc surface were not
selected to be expressed as Fabs. Similarly, four other antibodies that bound IgE-
Fc poorly in the SPR assay were also not selected, since antibodies with low affinity
for IgE-Fc may make some biophysical characterisations more difficult. Positive
selections were made to try to cover the range of results from the SPR analysis,
with a preference for those antibodies that gave most robust responses. We are
more likely to be interested in the aεAbs at either end of the occupancy spectrum,
irrespective of the nature of the effect, since we hope to select antibodies that have
different effects on the IgE-Fc/CD23 interaction. More aεAbs were selected that
gave the highest or lowest derCD23 occupancy levels (Table 4.1). In the next stage
of the process, the chosen heavy and light chains pairings will be expressed as
aεFabs and further scrutinised for their effect on receptor binding with the hope of
ultimately identifying and characterising novel allosteric IgE-Fc/CD23 modulators.
148
Chapter 5
Anti-IgE Fab selection and
generation
5.1 Introduction
The previous chapter described how we used UCB’s Core Antibody Discovery Pro-
cess [148, 147] to find monoclonal rabbit antibodies that bind IgE-Fc and modulate
its binding to the IgE-receptor, CD23. The screening resulted in the selection of
15 anti-epsilon antibodies (aεAbs) to take on to the next stage of the process, in
which the cognate heavy and light variable regions of each antibody are expressed
as a fragment antigen-binding (Fab) protein (Table 4.1). Due to its lower mass
and monovalent antigen-binding capacity, the Fab format is often favoured over
full-length antibodies for biophysical and structural studies.
In this chapter we describe how surface plasmon resonance (SPR) was used to
investigate the binding properties of 13 of the 15 cognate pairs of heavy and light
variable regions, each expressed as Fabs. We characterise how well the 13 aεFabs
bind IgE-Fc, how differently they affect receptor binding (CD23 and FcεRI) and
how they affect the binding of one another to IgE-Fc. The aim was to identify
five or six aεFabs that bind IgE-Fc with high affinity and have a diverse range
of allosterically mediated effects on IgE-Fc receptor. These selected aεFabs were
expressed on a larger scale and purified. The next chapters will describe how
further biophysical examination of the purified aεFabs has expanded our knowledge
of allosteric processes in IgE.
Here we used SPR to investigate the binding characteristics of the 13 aεFabs.
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This versatile technique can be used to determine the dissociation constant (KD)
and binding capacity (Bmax) of an interaction using steady-state binding responses
(Section 2.6.4). Steady-state analysis of SPR data is particularly useful for charac-
terising interactions with fast-on and fast-off rates, whose kinetics cannot be easily
analysed. Providing the kinetics of an interaction are not too fast, or too slow,
to accurately fit the association and dissociation rates, SPR can be used to anal-
yse the binding kinetics and thermodynamic properties of an interaction (Section
2.6.3). By fitting the association and dissociation phases of an SPR sensorgram
it is possible to determine the association and dissociation rate constants (Section
2.6.3). The rate constants can be used not only to characterise the kinetics of an
interaction but also to derive the KD of an interaction (Equation 2.4). We used
both kinetic and steady-state analysis of SPR data to describe how the different
aεFabs interact with IgE-Fc, and to compare the different ways they affect receptor
binding using derCD23 and sFcεRIα constructs.
5.2 Results
5.2.1 Investigating binding of IgE-Fc to aεFabs using SPR
A laboratory clean-out unfortunately resulted in the misplacement of the plasmid
DNA for aεFab10 and aεFab15. It would have been possible to perform the ter-
tiary TAP experiments again, but since there were 13 other aεFabs to select from
it was decided, in the interest of time, to proceed without making aεFab10 and
aεFab15. Plasmids for the cognate pairs of rabbit IgG heavy and kappa chain Fab
fragments were used to transiently co-transfect HEK293 cells using 293fectin
TM
(Thermo Fisher Scientific) (Section 2.5.11) [187]. The Fabs, in transient transfec-
tion supernatant, were tested for their ability to bind IgE-Fc using SPR.
A Fab-specific goat anti-rabbit F(ab’)2 fragment (Jackson ImmunoResearch,
111-046-047) was immobilised on the surface of a sensor chip using amine-coupling
techniques (Section 2.6.2). A mock amine-coupled surface was used as a reference-
subtraction surface (Section 2.6.2). The supernatants were diluted 1 in 4 in SPR
running buffer and were injected over the sensor surfaces for 240 s. The aεFabs
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were captured on the goat anti-rabbit-Fab surface at low densities (<200 RUs).
IgE-Fc was injected for 210 s over the surface at various concentrations and the
binding between the aεFab and IgE-Fc was measured as a change in SPR response
(Figure 5.1 and Appendix A.2). A dissociation phase lasting 700 s followed each
aεFab injection and the surfaces were completely regenerated with two 60 s pulses
of 10 mM glycine-HCl pH 1.7 and one pulse of 5 mM NaOH. Experiments were
performed in duplicate and gave highly replicable results.
There was no increase in response when aεFab19 was injected over the anti-
rabbit surface. aεFab6 and aεFab14 bound to the anti-rabbit surface but bound
IgE-Fc very weakly (Figure 2). The remaining aεFabs were successfully captured
by the anti-rabbit Fab surface and bound IgE-Fc.
The interactions between IgE-Fc and the different aεFabs showed varied kinetic
profiles. The interaction between IgE-Fc and aεFab2, for example, had a very
slow off-rate, whereas the off-rate between the same concentration of IgE-Fc and
aεFab3 was comparatively fast (Figure 5.2.a). The interaction between IgE-Fc
and aεFab9, and the interaction between IgE-Fc and aεFab17, had very similar
off-rates, however there were clear differences in their association rates at the same
IgE-Fc concentration (Figure 5.2.b).
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Figure 5.1: Example sensorgrams from SPR experiments to investigate
the binding of IgE-Fc to aεFabs in transient transfection supernatant. (a)
Transient supernatants containing aεFab (aεFab2 here) were injected over a Fab-
specific goat anti-rabbit F(ab’)2. IgE-Fc was injected over the captured aεFab, and
binding was observed as change in SPR response. (b) The response when 0 nM
IgE-Fc was injected over the captured aεFab and was subtracted from the response
measured when IgE-Fc was injected over the aεFab at increasing concentrations in
order to eliminate changes in response as a result of dissociation of aεFab from the
anti-rabbit-Fab surface.
Figure 5.2: The binding of IgE-Fc to the different aεFabs show varied
kinetics as determined by SPR. A comparison of the binding kinetics of IgE-Fc
binding to captured (a) aεFab2 and aεFab3, (b) aεFab9 and aεFab17. The aεFabs
were captured by Fab-specific goat-anti-rabbit F(ab’)2 (Jackson ImmunoResearch)
immobilised on a sensor surface. For clarity, binding of only a single concentration
of IgE-Fc is shown (100 nM). Each sensorgram has been normalised to give a
maximal response of 200 RUs.
The dissociation and association rates for the interactions between each of the
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aεFabs and IgE-Fc were fit in order to determine the dissociation and association
rate constants (koff and kon, respectively) for each of the aεFab-IgE-Fc interac-
tions. The data were fit using single koff and kon models (Section 2.6.3) (Figure
5.3 and Appendix A.2) and were used to determine the KD of each aεFab/IgE-Fc
interaction using Equation 2.4. Some binding curves, particularly at higher IgE-Fc
concentrations, were obviously biphasic, for example the curve for binding of 100
nM IgE-Fc to aεFab17 (Figure 5.2). The simplest interpretation of this biphasicity
is that there are two aεFab binding sites on IgE-Fc that have different affinities.
Single koff and kon models do not accurately fit biphasic data but may still provide
a simplified understanding of the kinetic data. The data from the 6 nM IgE-Fc
injections were fit because at these concentrations of IgE-Fc the binding was mostly
monophasic. Although fitting the data in this way did not provide a full account
of the kinetics of the interactions, it did allow for an estimation of the overall
affinity of the interaction. The aεFabs (excluding 6, 14 and 19, which did not
bind the anti-rabbit surface/IgE-Fc) bound IgE-Fc with sub-nanomolar binding
affinities (Table 5.1). Only these aεFabs were used in further SPR experiments to
determine which aεFabs to express on a large-scale and purify for a more in-depth
biophysical characterisation.
5.2.2 Investigating the effect of one aεFab molecule on the
IgE-Fc/derCD23 interaction using SPR.
aεFabs 2, 3, 4, 5, 7, 9, 12, 13, 17 and 18 were shown to bind IgE-Fc in SPR
experiments (Section 5.2.1). SPR experiments with the supernatants containing
these aεFabs were performed to determine which of the aεFabs have the most
diverse effects on IgE-Fc’s apparent affinity and binding capacity for derCD23. A
Fab-specific goat anti-rabbit F(ab’)2 fragment (Jackson ImmunoResearch, 111-046-
047) was immobilised on the surface of a CM5 sensor chip using amine coupling
techniques (Section 2.6.2). A mock amine-coupled surface was used as a reference-
subtraction surface (Section 2.6.2). The Fabs, in supernatant, were diluted 1 in 4
in SPR running buffer and were injected for 240 s over the sensor surfaces. The
Fabs were captured on the goat anti-rabbit-Fab surface at a low density (<200
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Figure 5.3: Example of fitting kinetic data for the aεFab/IgE-Fc interac-
tion as determined by SPR. Single koff and kon models were used to fit SPR
data for IgE-Fc binding to captured aεFab. This example shows the kinetic fits
(light green and light blue) of the data (dark blue) for the interaction between
aεFab9 and 6 nM IgE-Fc.
RUs). 100 nM IgE-Fc was injected over the sensor surface for 210 s and bound the
captured aεFab, forming an aεFab:IgE-Fc (1:1) complex. derCD23 was injected
for 120 s over the captured complex at various concentrations, and binding to the
aεFab:IgE-Fc (1:1) complex was measured as a change in the SPR response (Figure
5.4). A dissociation phase of 300 s followed each derCD23 injection and the surface
was regenerated by two 60 s pulses of 10 mM glycine-HCl pH 1.7 and one 30 s
pulse of 5 mM NaOH.
The aεFab:IgE-Fc (1:1) complexes bound derCD23, and reached a steady-state
during the time-course of the injection (Section 2.6). Steady-state analysis of the
steady-state response was performed and the binding curves were fit using a one-to-
one binding model (Section 2.6.4, Equation 2.17) (Figure 5.5 and Appendix A.3).
The KD values of the different aεFab1:IgE-Fc (1:1)/derCD23 interactions ranged
from 0.6 x 10-6 M - 4.9 x 10-6 M (Table 5.2). The interaction between IgE-Fc and
derCD23 is reported to have a KD of 1 x 10
-6 M [89, 88]. There is an 8-fold difference
between the highest and lowest KD values, which suggests that the aεFab:IgE-Fc
complexes have a range of cooperative effects on the IgE-Fc/derCD23 interaction.
At these working concentrations of derCD23 only the higher-affinity CD23-
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 2.7 x 106 	
 2.4 x 10-4 	
 0.9 x 10-10 	

aεFab2	
 6.9 x 105 	
 7.0 x 10-5 	
 1.0 x 10-10 	

aεFab12	
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 1.0 x 10-10 	

aεFab7	
 2.0 x 106	
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aεFab4	
 1.1 x 106	
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 3.6 x 10-10 	

aεFab3	
 1.4 x 106	
 9.9 x 10-4	
 7.1 x 10-10 	

aεFab13	
 8.4 x 105 	
 6.4 x 10-4	

















Table 5.1: Summary of the association and dissociation rate constants,
and the dissociation constants for IgE-Fc binding to aεFabs as deter-
mined by SPR and using transiently transfected aεFab supernatants.
The data for the binding of 6 nM IgE-Fc to the aεFabs were fit using single koff
and kon models (Section 2.6.3). aεFab was captured by injection of transient trans-
fected supernatant, containing aεFab, over an immobilised surface of Fab-specific
goat-anti-rabbit F(ab’)2 (Jackson ImmunoResearch).
binding site on native IgE-Fc (KD ∼1 µM) would be significantly occupied (Section
1.2.3). The normalised Bmax values were therefore reported in terms of a theoretical
Bmax (thBmax) for the binding of one molecule of derCD23 to IgE-Fc (Section 2.6.2).
Except for aεFab17, the Bmax values were all in excess of 100 %, which indicated
that the lower-affinity derCD23 binding site was partially occupied. The binding
of two derCD23 molecules to aεFab-bound IgE-Fc indicates that the aεFabs did
not sterically occlude binding of derCD23. It is therefore likely, but not certain,
that any inhibitory effects the aεFabs (excluding aεFab17 and potentiall aεFab12,
which had a Bmax value that was 105 % of the theoretical Bmax) had on the IgE-
Fc/derCD23 interaction were allosteric in nature. This will be discussed further in
Chapter 7. The Bmax values, given as a percentage of the theoretical Bmax, ranged
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Figure 5.4: Example sensorgrams from SPR experiments to investigate
the binding of derCD23 to aεFab-bound IgE-Fc in transient transfec-
tion supernatant. (a) Transient transfection supernatant, containing aεFab
(aεFab2 here), was injected over a Fab-specific goat anti-rabbit F(ab’)2. IgE-Fc
bound the captured aεFab and derCD23 was injected over the aεFab:IgE-Fc (1:1)
complex. Binding was observed as change in SPR response. (b) The response
when 0 nM derCD23 was injected over the captured aεFab:IgE-Fc (1:1) complex
was subtracted from the response measured when derCD23 was injected over the
aεFab:IgE-Fc (1:1) complex, at increasing concentrations, in order to eliminate
changes in response as a result of dissociation of aεFab from the anti-rabbit-Fab
surface and IgE-Fc from the aεFab. The crosses indicate the 5 s interval during the
steady-state response for which the response was averaged for steady-state analysis.
from 90 - 163 %, which implies that the different aεFab:IgE-Fc complexes have
differing binding capacities for derCD23.
The binding of derCD23 to aεFab13-bound IgE-Fc was distinct in that it ap-
pears to have accelerated the dissociation of IgE-Fc from aεFab13 (Figure 5.6).
There was an increase in response upon the injection of derCD23 to aεFab13-bound
IgE-Fc, which indicated that derCD23 bound the aεFab13:IgE-Fc (1:1) complex
and formed a tertiary (aεFab13:IgE-Fc:derCD23) complex, but instead of reaching
a steady-state, the SPR signal began to decrease during the association phase. This
decrease in response indicates negative cooperativity: that the binding of derCD23
increased the rate of IgE-Fc dissociation from aεFab13. Accelerated dissociation
of the IgE-Fc/sFcεRIα complex by DARPin E2 79 has been proposed to be due
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derCD23 concentration (nM) 
KD = 4.9 x10-6 M  
Bmax = 100 RUs 
Figure 5.5: The binding curve for the interaction between derCD23 and
aεFab2-bound IgE-Fc. The data were generated from SPR experiments in which
derCD23 binding to a captured aεFab2:IgE-Fc (1:1) complex was measured as a
change in response. The steady-state response was averaged from 5 s of steady-
state binding data (blue circles) and was fit (black line) using a one-to-one binding
model (Section 2.6.4).
to the partial overlap of ligand binding [109], however in Chapter 3 we proposed
that it is possible that the binding of a ligand to a pre-bound IgE-Fc complex can
affect the rate of dissociation of that complex via allosteric means (Section 3.2.3).




Fab-bound IgE-Fc/derCD23 interaction 
  KD (µM) Bmax (% of 
thBmax) 
  KD (µM) Bmax (% of 
thBmax) 
a!Fab12 0.6 105  a!Fab9 1.9 163 
a!Fab17 1.0 135  a!Fab7 1.9 133 
a!Fab4 1.1 138  a!Fab13* 1.9 133 
a!Fab3 1.4 130  a!Fab18 2.4 156 
a!Fab5 1.5 118  a!Fab2 4.9 156 
97	

Table 5.2: Summary of the dissociation constants and Bmax values for
derCD23 binding to aεFab-bound IgE-Fc as determined by SPR using
transiently transfected aεFab supernatants. The steady-state response of
derCD23 binding to aεFab-bound IgE-Fc was plotted as a function of derCD23
concentration. The data were fit using a one-to-one binding model (Section 2.6.4).
The Bmax values are expressed as a percentage of the theoretical Bmax (Section
2.6.2). The asterisk indicates derCD23-mediated aεFab:IgE-Fc accelerated disso-
ciation.
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Figure 5.6: derCD23 accelerates the dissociation of IgE-Fc from aεFab13
as shown by SPR experiments using aεFab transient transfected super-
natants. A double-reference subtracted SPR sensorgram of derCD23 binding to
captured aεFab13:IgE-Fc.
5.2.3 Investigating the effect of one aεFab molecule on the
IgE-Fc/sFcεRIα interaction using SPR.
SPR experiments with supernatants containing the aεFabs were performed to de-
termine what effects the aεFabs have on the binding of sFcεRIα to IgE-Fc. A Fab-
specific goat anti-rabbit F(ab’)2 fragment (Jackson ImmunoResearch, 111-046-047)
was immobilised on the surface of the sensor chip using amine-coupling techniques
(Section 2.6.2). A mock amine-coupled surface was used as a reference-subtraction
surface (Section 2.6.2). The supernatants, containing the aεFab, were diluted 1 in
4 in SPR running buffer and injected for 210 s over the sensor surfaces. The Fabs
were captured on the goat anti-rabbit-Fab surface at low densities (<200 RUs).
100 nM IgE-Fc was then injected for 150 s over the sensor surfaces and bound
the captured aεFab to form an aεFab:IgE-Fc (1:1) complex. sFcεRIα was injected
for 120 s over the captured complex at various concentrations and binding to the
aεFab:IgE-Fc (1:1) complex was measured as a change in the SPR response (Figure
5.7). A dissociation phase of 300 s followed each sFcεRIα injection and the goat
158
Chapter 5. Anti-IgE Fab selection and generation
anti-rabbit-Fab surface was regenerated by two 60 s pulses of 10 mM glycine pH
1.7 and one 30 s pulse of 5 mM NaOH.
Figure 5.7: Example sensorgrams from SPR experiments to investigate
the binding of sFcεR1α to aεFab-bound IgE-Fc in transient transfection
supernatant. (a) transient supernatant containing aεFab (aεFab2 here) was in-
jected over a Fab-specific goat anti-rabbit F(ab’)2. IgE-Fc bound the captured
aεFab, sFcεR1α was injected over the aεFab:IgE-Fc (1:1) complex. Binding was
observed as change in SPR response. (b) The response when 0 nM sFcεR1α was
injected over the captured aεFab:IgE-Fc (1:1) complex was subtracted from the
response measured when sFcεR1α was injected over the aεFab:IgE-Fc (1:1) com-
plex at increasing concentrations, in order to eliminate changes in response as a
result of dissociation of aεFab from the anti-rabbit-Fab surface and IgE-Fc from
the aεFab.
There was an increase in SPR response upon injection of sFcεRIα onto all of the
aεFab-IgE-Fc complexes indicating that the different aεFab-IgE-Fc complexes were
all capable of binding sFcεRIα (Appendix A.4). From looking at the sensorgrams,
the binding of FcεRIα to IgE-Fc bound to the different aεFabs broadly fell into
three classes: those with slower off-rates (aεFab2, 12 and 17), those with faster
off-rates (aεFab3, 7, 13 and 18) and those more difficult to interpret because the
signal was significantly limited by the capture level (aεFab4, 5 and 9). The data for
the first two groups were fit using single koff and kon models (Section 2.6.3) (Figure
5.8) and were used to determine the KD of each aεFab-IgE-Fc interaction using
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Equation 2.4. Because of the low signal, the data for aε4, aε5 and aεFab9 were
not suitable for fitting. The rest of the aεFab:IgE-Fc complexes bound sFcεRIα
with nanomolar binding affinities (Table 5.3).
Figure 5.8: Different aεFab:IgE-Fc (1:1) complexes bind sFcεR1α with
different kinetics. A comparison of the kinetics of binding by SPR of (a)
aεFab2:IgE-Fc (1:1) and (b) aεFab3:IgE-Fc (1:1) to 50 nM sFcεRIα. The data
has been normalised to give a maximal response of 12 RUs. The data were fit in
the Biacore Evaluation software (GE Healthcare) using their single koff and kon
model.
The KD values were around one order of magnitude greater than the published
values for the interaction between sFcεRIα [83]. The published kon and koff values
for the IgE-Fc/sFcεRIα interaction are about 3 x 105M-1 s-1 and 1.9 x 10-4 s-1
respectively [83]. The kon values determined from the aεFab experiments were also
in the 105M-1 s-1 range. The koff values were generally in the range of 10
-4 s-1. This
relatively small discrepancy could be accounted for by differences in experimental
set-up and does not necessarily mean that the presence of the aεFabs had a negative
effect on the IgE-Fc/sFcεRIα in each case.
These experiments were performed in the absence of a control for the sFcεRIα:IgE-
Fc interaction as we did not have a previously characterised aεFab that was known
not to effect the interaction, therefore the comparisons were made in relation to
the published values [83]. Assuming kon values closer to 10
5 M-1 s-1 and koff closer
to 10-4 s-1 represent more ‘native-like’ IgE-Fc/sFcεRIα binding, the binding of
sFcεRIα to IgE-Fc clearly appears to have been affected by pre-complexing IgE-Fc
with aεFab3. Both the association and dissociation rate constants of the interac-
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tion are different from the most ‘native-like’ values, for example those of aεFab2
(Figure 5.8). The dissociation rate constant is nearly 14 times faster than that of
the aεFab2:IgE-Fc/sFcεRIα interaction. Although less marked, aεFab7, aεFab13
and aεFab18-IgE-Fc complexes also exhibited more rapid sFcεRIα dissociation.
The observed increase in IgE-Fc/sFcεRIα off-rate suggests that these aεFabs do




Fab-bound IgE-Fc interaction/Fc!RI" interaction 
 kon M-1 s-1 koff s-1 KD (x 10 -9 M) 
a!Fab12 5.9 x 105 6.9 x 10-4 1.2 
a!Fab2 4.7 x 105 7.1 x 10-4 1.5 
a!Fab17 5.4 x 105 9.9 x 10-4 1.8 
a!Fab4 2.6 x 105 5.2 x 10-4 2.0 
a!Fab5 2.2 x 105 6.3 x 10-4 2.9 
a!Fab7 1.5 x 105 5.6 x 10-4 3.7 
a!Fab9 7.6 x 105 4.0 x 10-3 5.3 
a!Fab18 7.4 x 105 4.8 x 10-3 6.5 
a!Fab13 8.3 x 105 5.7 x 10-3 6.9 
a!Fab3 1.2 x 106 9.8 x 10-3 8.2 




Fab-bound IgE-Fc interaction/Fc!RI" interaction 
 kon M-1 s-1 koff s-1 KD (x 10 -9 M) 
a!Fab12 5.9 x 105 6.9 x 10-4 1.2 
a!Fab2 4.7 x 105 7.1 x 10-4 1.5 
7 4  9 - 8
4 2 6 5 2 - 2 0
5 2 2 6 3 - 2 9
7 1 5 6 - 3 7
9 7 6 4 0 -3 5 3
18 7 4 4 8 -3 6 5
13 8 3 5 7 - 6 9
3 1 2 6 9 - 8 2 
 
Fab-bound IgE-Fc interaction/Fc!RI" interaction 
 kon M-1 s-1 koff s-1 KD (x 10 -9 M) 
a!Fab12 5.9 x 105 6.9 x 10-4 1.2 
a! ab2 4.7 x 105 7.1 x 10-4 1.5 
a! ab17 5.4 x 105 9.9 x 10-4 1.8 
a!Fab4 2.6 x 105 5.2 x 10-4 2.0 
a!Fab5 2.2 x 105 6.3 x 10-4 2.9 
a!Fab7 1.5 x 105 5.6 x 10-4 3.7 
a!Fab9 7.6 x 105 4.0 x 10-3 5.3 
a!Fab18 7.4 x 105 4.8 x 10-3 6.5 
a!Fab13 8.3 x 105 5.7 x 10-3 6.9 
a!Fab3 1.2 x 106 9.8 x 10-3 8.2 
6 8 5	
 3 5 3	
 2	

Table 5.3: Summary of the association and dissociation rate constants and
the dissociation constants for sFcεRIα binding to aεFab-bound IgE-Fc
as determined by SPR. The data for binding 50 nM (or 25 nM for aεFab18) of
sFcεR1α were fit in the Biacore Evaluation software (GE Healthcare) using their
single koff and kon model.
5.2.4 aεFab competition experiments using SPR.
Surface plasmon resonance experiments were performed in an effort to determine
if the different aεFabs share overlapping binding epitopes on IgE-Fc. To do this
we investigated the binding of each of the aεFabs to different captured aεAb:IgE-
Fc:aεFab complexes. The complexes were made by sequential injections of aεAb,
IgE-Fc and then the respective aεFab. In these experiments full length aεAbs
(Section 4.2.4) were captured by an anti-IgG-Fc surface rather than aεFabs by an
anti-Fab surface in order to prevent the binding of aεFabs to the SPR surface in
subsequent injections.
An SPR sensor surface was generated onto which a goat anti-rabbit IgG-Fc-
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specific F(ab’)2 fragment (Jackson ImmunoResearch) was immobilised using amine-
coupling techniques (Section 2.6.2). A mock amine-coupled surface was used as a
reference-subtraction surface (Section 2.6.2). The aεAbs, in supernatant, were
diluted 1 in 4 in SPR running buffer and were injected over the sensor surfaces for
150 s. The aεAbs were captured on the IgG-Fc-specific goat-anti-rabbit surface at a
low density (<250 RUs). 100 nM IgE-Fc was injected for 150 s over the surfaces and
bound to form aεAb:IgE-Fc (1:1) complexes. The equivalent aεFab in supernatant
(diluted 1 in 4 in SPR running buffer) was then injected over the surfaces for 150
s to determine if the aεFabs/Abs bind IgE-Fc with a 2:1 stochiometry, and if so,
to ensure that a majority of the sites were occupied. Finally, each of the other
aεFabs, in supernatant (diluted 1 in 4 in SPR running buffer) were injected over
the surfaces for 150 s, and any binding was observed as an increase in SPR response
(Figure 5.9 and Appendix A.5). A dissociation phase of 300 s was followed by two
60 s injections of 10 mM glycine-HCl pH 1.7 and one 30 s injection of 5 mM NaOH
to regenerate the surface for the next cycle.
All of the aεFabs bound to their corresponding aεAb:IgE-Fc complexes, indicat-
ing that they all bind IgE-Fc with a 2:1 stochiometry (aεFab:IgE-Fc). There were
several instances where the injection of an aεFab did not result in an increase in
response when injected over a different aεAb:IgE-Fc:aεFab complex and visa versa
(Figure 5.10). For example, aεFab4 did not bind to the aεAb5:IgE-Fc:aεFab5
complex and aεFab5 did not bind to the aεAb4:IgE-Fc:aεFab4 complex. Pairs of
aεFabs that mutually inhibited one another may share overlapping binding epi-
topes on IgE-Fc or sterically occlude one another’s binding, however the observed
inhibition could also be allosteric in nature. Interestingly, aεFab2 and aεFab3 mu-
tually inhibited one another as did aεFab2 and aεFab18, however aεFab3 bound
aεAb18:IgE-Fc:aεFab18 complex and aεFab18 bound aεAb3:IgE-Fc:aεFab3. Per-
haps aεFab18 and aεFab3 IgE-Fc binding sites do not overlap but the aεFab2
binding site partially overlaps both. Alternatively, aεFab2 may communicate al-
losterically with either or both aεFab3 and aεFab18. The aεAb12:IgE-Fc:aεFab12
complex did not prevent binding of any of the other aεFabs, which suggests that
it binds distinct sites on IgE-Fc.
In some cases aεFab inhibition was not reciprocal. For example, aεFab9 did not
162
Chapter 5. Anti-IgE Fab selection and generation
Figure 5.9: An example sensorgram from SPR experiments to investi-
gate aεFab competition. This is the data for the binding of aεFabs in tran-
siently transfected supernatant to a captured aεAb2:IgE-Fc:aεFab2 (1:1:1) com-
plex. aεAb (aεAb2, here), in transiently transfected supernatant, was captured by
immobilised IgG-Fc-specific goat-anti-rabbit F(ab’)2 (Jackson ImmunoResearch).
IgE-Fc was injected over the captured aεAb to generate an aεAb:IgE-Fc complex.
The corresponding aεFab (aεFab2, here), in transiently transfected supernatant,
was injected in over the surface and bound to give an aεAb:IgE-Fc:aεFab (1:1:1)
complex. Other aεFabs, in transiently transfected supernatant, were then injected
over the complex and binding was measured as a change in SPR response.
bind the aεAb:IgE-Fc:aεFab 3, 7, 13 and 18 complexes, but aεFabs 3, 7, 13 and 18
did bind the aεAb13:IgE-Fc:aεFab9 complex. This observation could be explained
by a situation in which the binding of aεFab9 to IgE-Fc does not significantly affect
the conformational ensemble of IgE-Fc, and therefore the binding of other aεFabs
is still viable. Whereas the other aεFabs may bind and stabilise conformations of
IgE-Fc where aεFab9 binding is not permissible.
Another interesting observation was that aεFab18 caused accelerated dissocia-
tion of the aεAb13:IgE-Fc:aεFab13 complex (Figure 5.6). With this experimental
setup, it is not possible to deduce whether aεFab18 caused accelerated dissociation
of aεFab13 from IgE-Fc or aεFab13:IgE-Fc from aεAb13. Although accelerated dis-
sociation is not necessarily an allosteric phenomenon, in Chapter 3 we showed that
accelerated dissociation can occur as a result of allosteric communication (Section
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3.3).
Initially the aim of these experiments was to try to identify aεFabs that may
bind to very similar sites, and thereby prevent the selection of similar aεFabs.
The results, however, also provided insights into possible allosteric communication
between different aεFab binding sites, which together with the results from the
receptor-binding assays, helped in the selection of which aεFabs to express on a
larger-scale. It should be noted that these experiments were performed with a single
unknown concentration of aεFab, which limits the certainty of the observed results.
Once the selected aεFabs have been purified and their concentration ascertained, we
plan to perform these experiments again at a range of different aεFab concentrations
in order to determine the extent of competition between the different antibodies.
5.2.5 Selection of six aεFabs
The ultimate aim of the project is to find, express and characterise Fabs that bind
to IgE-Fc and allosterically modulate binding of IgE to its ‘low affinity receptor’,
CD23. The previous chapter described how the immune repertoires of rabbits,
immunised against IgE-Fc, were screened to discover antibodies that bind IgE-Fc
and have an effect on derCD23 binding. This chapter describes how those anti-
bodies were expressed as Fabs and characterised in greater detail for their ability
to bind IgE-Fc and modulate derCD23 binding using SPR. We wanted to select
about six antibodies that have diverse effects on derCD23 binding, therefore we
also analysed their effect on the interactions between IgE-Fc and the ‘high-affinity
receptor’, FcεRI, and IgE-Fc and the other Fabs. Two Fabs, for example, may ap-
pear to have the same effect on CD23 binding as each other, but by investigating
these additional binding characteristics we can perhaps see if the way they interact
with IgE-Fc is actually distinct. Importantly, we also wanted to select for those
aεFabs that appear to modulate receptor binding by allosteric processes. Of the
13 Fabs tested in this chapter, six were selected for large-scale expression: aεFab2,
aεFab3, aεFab9, aεFab12, aεFab13 and aεFab18.
aεFab2 and aεFab12 were selected because of their apparent effects on derCD23
binding: the aεFab2:IgE-Fc complex had the lowest apparent affinity for derCD23
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(KD = 4.9 x 10
-6 M), whereas aεFab12:IgE-Fc had the highest apparent affinity
for derCD23 (KD = 0.6 x 10
-6 M). In the absence of a control for derCD23 bind-
ing to captured IgE-Fc we are unable, at this point, to describe the aεFabs as
‘inhibitors’ or ‘enhancers’, however given the difference in KD values of the var-
ious aεFab:IgE-Fc/derCD23 interactions, it is probable that at least one of the
aεFab:IgE-Fc complexes has a significant cooperative effect on derCD23 binding.
The Bmax value for derCD23 binding to the aεFab2:IgE-Fc complex was 156 %
of the theoretical Bmax value calculated for the binding of one derCD23 molecule to
IgE-Fc, indicating partial occupancy of the second, lower-affinity, derCD23 bind-
ing site. This suggests that saturation of the first aεFab2 binding site does not
completely prevent binding of derCD23 to either of the two CD23 binding sites on
IgE-Fc and instead its effect on the CD23/IgE-Fc interaction may be allosteric.
The Bmax value for the aεFab12:IgE-Fc complex was estimated to be around 100
% of the theoretical Bmax value calculated for the binding of a single derCD23
molecule to IgE-Fc. aεFab12 may have blocked the lower-affinity derCD23 binding
site so that IgE-Fc could only bind derCD23 with a 1:1 stochiometry.
The relatively high KD of the interaction between aεFab2:IgE-Fc and derCD23
could suggest that aεFab2 reduces the affinity of the IgE-Fc/derCD23 interaction.
Whereas the relatively low KD of the interaction between aεFab12:IgE-Fc and
derCD23 may suggest that aεFab12 increases the affinity of the IgE-Fc/derCD23
interaction. However, as described, the Bmax values of the two interactions (ex-
pressed as a percentage of the theoretical Bmax of IgE-Fc binding one molecule of
derCD23) are also markedly different and suggest that the the KD values for the
aεFab2:IgE-Fc/derCD23 interaction and the aεFab12:IgE-Fc/derCD23 interaction
may reflect contributions from both, and just one, of CD23 binding sites, respec-
tively. Because the two CD23 binding sites have two different affinities and because
these appear differentially occupied in the the aεFab2 and aεFab12 experiments,
the KD values cannot be directly used to compare the effects of these two aεFabs
on the affinity of the IgE/CD23 interaction. Nevertheless, the marked differences
in both the KD and Bmax values for these two aεFab:IgE-Fc complexes indicates
the effects that they have on the IgE-Fc/derCD23 interaction are probably very
different.
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Figure 5.10: An overview of the results from the aεFab SPR competition
experiments. Tertiary IgE-Fc complexes were formed in which IgE-Fc was bound
to an aεAb and its corresponding aεFab. Other aεFabs, in transiently transfected
supernatant, were injected over the captured tertiary complex to determine if bind-
ing could occur - i.e. to see if a quaternary complex could form. Blue indicates that
the quaternary complex did not form, white indicates a quaternary complex did
form, and AD indicates that binding of the aεFab triggered accelerated dissociation
of the tertiary complex.
Like the aεFab2:IgE-Fc/derCD23 interaction, the aεFab13:IgE-Fc/derCD23 in-
teraction had a Bmax value in excess of 100 % of the theoretical Bmax for the binding
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of a single molecule of derCD23 (133 % of the theoretical Bmax). The aεFab13:IgE-
Fc complexes therefore appears to be able to bind two molecules of derCD23, indi-
cating that the aεFab13 binding sites do not overlap with the CD23 binding sites on
IgE-Fc. The interaction between derCD23 and the aεFab13:IgE-Fc complex had a
KD value about half the value of the KD for the aεFab2:IgE-Fc complex, indicating
aεFab2 and aεFab13 may affect the affinity of the IgE-Fc/CD23 interaction differ-
ently. aεFab13 is also interesting because the binding of derCD23 to aεFab13:IgE-
Fc induced accelerated dissociation of IgE-Fc from aεFab13. Similarly, aεFab18 in-
duced accelerated dissociation of the aεAb13:IgE-Fc:aεFab13 complex. We showed
in Chapter 3 that derCD23 can accelerate the dissociation of IgE-Fc complexes via
allosteric means. Accelerated dissociation is an interesting phenomenon, and an
understanding of its mechanisms could allow the design of drugs that can accelerate
the dissociation of pre-formed IgE:receptor complexes (Section 5.2.4).
The aεFab3:IgE-Fc complex appeared to have little effect on derCD23 binding
when compared to the other aεFab:IgE-Fc complexes and also appeared to be able
to bind two derCD23 molecules. However, aεFab3 appeared to have a cooperative
effect on the interaction between IgE-Fc and sFcεRIα. aεFab3-bound IgE-Fc had
both the largest association rate constant and the largest dissociation rate constant.
The off-rate for the interaction between sFcεRIα and aεFab3:IgE-Fc was seven
times faster than that of the slowest off-rate. The competition experiments showed
that aεAb2:IgE-Fc:aεFab2 could not bind aεFab3 and aεAb3:IgE-Fc:aεFab3 could
not bind aεFab2, indicating that these aεFabs are inhibitors of one another, but
further experiments using a range of known aεFab2 and aεFab3 concentrations are
necessary to confirm this. This result is particularly interesting as aεFab3 appears
to affect sFcεRIα binding but not derCD23 binding, and aεFab2 appears to affect
derCD23 binding but not sFcεRIα. aεFab2 and aεFab3 could be allosteric or or-
thosteric inhibitors of one another; either way it is interesting that they each appear
to affect the binding of only one of the IgE receptors, both of which allosterically
inhibit one another [18, 89].
The competition experiments revealed potential asymmetry in binding of the
different aεFabs to IgE-Fc. aεAb9:IgE-Fc:aεFab9 was able to bind all of the aεFabs
except 4 and 5, yet aεFab9 was unable to bind the aεAb:IgE-Fc:aεFab complexes
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except for aεFab2 and aεFab12. This suggests that the binding of aεFab9 may
cause a smaller shift in the IgE-Fc conformational ensemble than the other aεFabs,
however, repeating these experiments with known concentrations of aεFab would
be necessary to confirm this observation. Furthermore, the KD and Bmax values
determined for the SPR analysis of the binding of derCD23 to aεFab9-bound IgE-
Fc were not the highest or lowest compared to the other aεFab:IgE-Fc complexes
(Tables 5.2, perhaps suggesting that aεFab9 could act as a control aεFab in future
studies of the IgE-Fc/CD23 interaction. Low signal levels made determining the
effect of aεFab9 on the interaction between IgE-Fc and FcεRIα difficult, and we
plan to perform these experiments again in the future with purified material.
5.2.6 Expression of the selected aεFabs in CHOSXE cells
Previously, the DNA for the heavy and light variable domains of the aεFabs had
been separately cloned into UCB mammalian expression vectors (Section 2.5.10
and 5.2.1). Heavy variable domain DNA was inserted into a plasmid containing a
downstream rabbit IgG CH1 domain, whereas the kappa variable domain DNA was
inserted into a plasmid containing a downstream rabbit IgG Cκ domain. Both plas-
mids were under the control of a HMCV promoter, encoded kanamycin resistance,
and contained a pUC origin of replication in addition to a SV40 5’ polyadenylation
sequence.
Greater quantities of each of the plasmids were required for large-scale trans-
fections of a mammalian cell culture. Therefore, XL1-Blue chemically competent
E. coli (Stragene) were transformed, using heat shock, with the heavy and light
chain plasmid DNA for each of the selected aεFabs (Section 2.2.3). The trans-
formed XL1-Blue cells were grown in 1.5 L overnight cultures of LB and the ex-
panded plasmid DNA was purified using Qiagen’s GigaPrep Kit according to man-
ufacturer’s instructions. For each of the six selected aεFabs, the Fab heavy chain
plasmid DNA (encoding the VH1 and CH1 domains) and the Fab kappa chain plas-
mid DNA (encoding the Vκ1 and Cκ domains) were sequenced. The online tool,
ExPasy Translate [188], was used to translate the DNA sequences into protein
sequences (Figure 5.11). The CDR3 protein sequences were compared with the
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CDR3 sequences of the DNA used for transformation, which had been previously
sequenced (Section 4.2.3). For both the heavy and light chains of the six selected
aεFabs there was 100 % agreement between the CDR3 sequences of the DNA used
for transformation and the CDR3 sequences of the GigaPrep-derived DNA.
CHOSXE cells [150] were co-transfected with 1:1 ratios of heavy:kappa aεFab
plasmid, using electroporation (Section 2.5.12). The cells were cultured at 37 ◦C,
with shaking at 140 rpm and supplemented with 8 % CO2. After 14 days of
incubation, the cell cultures were centrifuged to harvest the supernatants. The
supernatants were sterile filtered and small aliquots were run on a protein G HPLC
column to determine the approximate aεFab concentration in the supernatants
(Section 2.5.12). Protein G is a bacterial cell wall protein from group B streptococci.
It binds to the Fc region of most mammalian antibodies, however protein G can also
bind the CH1 domain of heavy chains bound to Cκ light chains, albeit with a lower
affinity [189]. Protein G HPLC analysis of the supernatants indicated that five of
the six selected aεFabs had been expressed: Fab was not detected in the aεFab9
supernatant (Table 5.4). The transfections and the protein G HPLC analysis were
kindly performed by Hanna Hailu of UCB.
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The aεFabs were expressed in CHOS-XE cells and the final expression levels were 
det rmined by protein G-HPLC (Table 1). The protein G-HPLC data indicates that 
aεFab9 was the only Fab not to express. 
 
aεFab Protein G purification 
aεFabs 2, 3, 12, 13 and 18 were purified by Protein G chromatography. The aεFabs 
were acid eluted giving rise to a peak at 280nm (Figure 1[Fab2]). The apex of the 
peak at A280 nm was distorted when the detection limit was reached. The peak 
fractions were pooled and neutralized. 
Transfection 
supernatant 
Fab concentration  
(mg/L) 




aεFab2 539.4 0.9 485.5 
aεFab3 490.0 0.9 441.0 
aεFab9 1.0 0.9 0.9 
aεFab12 284.3 0.9 255.8 
aεFab13 325.7 0.9 293.2 
aεFab18 135.2 0.9 121.7 
Table 5.4: Protein G HPLC analysis of aεFab transfection supernatants.
CHOSXE cells [150] were transfected with a 1:1 ratio of heavy:kappa chain aεFab
plasmid DNA. The supernatants were harvested after a 14 day culture and 100 µl
was run on a 1 ml protein G HPLC column (GE Healthcare). The concentration
of aεFab in each supernatant was determined by comparing the area of the aεFab
elution peak to the elution peaks of a standard (Certolizumab Fab) at known
concentrations.
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Figure 5.11: Sequence alignment of the six aεFabs selected for large scale
expression and purification. The DNA encoding the (a) heavy and (b) kappa
chains of the aεFabs were in a UCB in-house mammalian expression vector contain-
ing containing an HMCV promoter, a polyadenylation sequence, a pUC origin of
replication and encoding kanamycin resistance. The DNA for the heavy and kappa
chains were sequenced using a forward primer complementary to the region of the
plasmid immediately upstream of the aεFab leader sequence (not shown) by the Eu-
rofins Genomics sequencing service. The sequence alignment was performed using
Tcoffee [190] version 11.00.d625267, which produces alignments based on analy-
sis of results from a variety of different methods. The default multiple sequence
alignment methods were analysed in this alignment.
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5.2.7 Purification of the aεFabs
Protein G affinity chromatography was used to purify the five aεFabs, but be-
cause of the relatively low affinity of the Protein G/Fab interaction, the aεFab
supernatants were first concentrated to at least 350 mg/L using a tangential flow
ultrafiltration system with a 10 kDa membrane (Section 2.5.13). The concen-
trated aεFab supernatants were run down a 100 ml column packed with protein
G sepharose (GE Healthcare) and the aεFabs were eluted from the column using
















Figure 5.12: aεFab12 purification using protein G affinity chromatogra-
phy. Supernatant, containing aεFab12, was run down a 100 ml column packed
with protein G-sepharose (GE Healthcare) in PBS pH 7.4. Bound aεFab12 was
eluted in 100 mM glycine-HCl, pH 2.7 and immediately neutralized.
The aεFab peak fractions were pooled, neutralised and concentrated using cen-
trifugal filter units (Millipore) and subsequently run on a size exclusion column
(HiLoad 26/600 Superdex 200 pg, GE Healthcare) to isolate monomeric aεFab (Sec-
tion 2.5.13) (Figure 5.13). The chromatograms consisted of a small peak, assumed
to be aεFab aggregates, followed by a major peak containing eluted monomeric
aεFab. The aggregated aεFab could account for the tailing seen in the Protein G
affinity purification chromatograms (Figure 5.12) as the aggregates may have had
a longer retention time than the monomers. The monomeric aεFab peak fractions
from the preparative SEC were pooled and concentrated using centrifugal filter
units (Millipore).
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Figure 5.13: Purification of aεFabs by size exclusion chromatrography
(SEC). Protein G-purified aεFab (aεFab12 here) was further purified using SEC.
Monomeric aεFab12 was separated from aεFab12 aggregates based upon differences
in hydrodynamic volume using a Superdex 26/60 S200 column (GE Healthcare).
The larger molecular weight aggregates eluted in a lower volume of PBS pH 7.4
than monomeric aεFab12. The blue shading indicates the pooled eluate.
30 µg of each of the purified aεFabs was run down a SEC HPLC column (G3000
SWXL, Tosoh) (Section 2.5.13). The analytical HPLC of the pooled fractions re-
solved aggregated and monomeric aεFab (Figure 5.14). The area under the re-
spective elution peak gave an estimation of the percentage of contamination from
aεFab aggregates; each aεFab sample contained less than 1.9 % aεFab aggregate
(Table 5.5).
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Figure 5.14: An HPLC SEC chromatogram for purified aεFab12. 30 µg
of purified aεFab12 was run down a G3000SWxl HPLC SEC (Tosoh) in in 0.05
M Na2HPO4, 0.05 M NaH2PO4, 0.15 M NaCl, pH 6.8 to assess the purity of the
sample. Aggregated and monomeric aεFab were resolved in separate elution peaks.
The areas under the elution peaks were calculated using the manual integration
function of the Clarity chromatography software (DataApex) and the proportional
peak areas were used to estimate the percentage of aggregated aεFab in each sam-
ple.






Table 5.5: The estimated level of aggregated aεFab contaminants in each
of the the purified aεFab samples as determined by HPLC SEC. 30 µg
of each purified aεFab sample was run down a G3000SWxl HPLC SEC (Tosoh)
in 0.05 M Na2HPO4, 0.05 M NaH2PO4, 0.15 M NaCl, pH 6.8. For each aεFab,
the chromatogram showed a minor peak preceding the major peak, in which it
was assumed aεFab aggregate and monomeric aεFab eluted, respectively. The area
under the peaks were calculated using the manual integration function of the Clarity
chromatography software (DataApex), and the proportional peak areas were used
to estimate the percentage of aεFab aggregate in each sample.
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5.2.8 aεFab mass determination mass spectrometry
Positive ion electrospray mass spectrometry (ES-MS) (Section 2.5.13) of the puri-
fied aεFabs was performed to determine the mass of the five different aεFabs, in
order to corroborate that they were composed of the correct cognate heavy and
light chains. The heavy and kappa chains of rabbit IgG Fabs each have two intra-
chain disulphide bonds and they also form an inter-chain disulphide bond. In order
to break the inter-chain disulphide bond and thereby separate the chains, each of
the aεFabs was incubated overnight at room temperature with a molar excess of
the reducing agent TCEP (Thermo Fisher Scientific). The samples were subse-
quently dialysed into 1 % acetic acid before being run on the mass spectrometer.
The mass spectra for aεFab2 (Figure 5.15.a), aεFab13 and aεFab18 showed two
distinct peaks corresponding to the masses of the heavy and light chains. The mass
spectra for aεFab3 and aεFab12 (Figure 5.15. b), however, were composed of two
distinct peaks corresponding to the masses of the heavy chains and the entire Fabs.
The presence of a peak corresponding to the mass of whole Fab indicates that
either the samples were not fully reduced and as such the chains did not completely
separate, or that upon dialysis, and hence removal of the reducing agent, an inter-
chain disulphide (re)formed. The masses of the single chain MS peaks were lower
than the values of the single chains estimated from the protein sequence using
the online tool ExPASy ProtPram [191]. The ProtPram program estimates the
molecular weight of a protein based upon the protein sequence and does not take
into account disulphide bond formation or post-translational modifications. The
differences can be accounted for by:
a) The presence of intra-chain disulphide bonds. The formation of a disulphide
bond is accompanied by the loss of two protons and therefore the loss of 2 Da.
b) The conversion of N-terminal glutamine residues (Gln) to pyroglutamate
(pGlu). Cyclization of N-terminal Gln to pGlu (Figure 5.16) is a common post-
translational modification of monoclonal antibodies [192, 193, 194] and is accom-
panied by the loss of NH3 (17.03 Da).
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Figure 5.15: The ES-MS mass spectra of (a) aεFab2 and (b) aεFab12. Prior
to molecular weight determination via ES-MS, purified aεFabs were incubated with
a molar excess of the reducing agent TCEP (Thermo Fisher Scientific) overnight
and dialyzed into 1 % acetic acid. The disulphide bond between the heavy and
kappa chain of aεFab2 was reduced, resulting in two distinct peaks for the two
chains. The mass spectrum of aεFab12 also shows two distinct peaks, however,
these correspond to the mass of the whole aεFab (45553.1 Da) and the single
heavy chain (22799.4 Da), suggesting that reduction was insufficient separate the
chains.
Figure 5.16: The mechanism of N-terminal glutamine conversion to N-
terminal pyroglutamate. Adapted from from Liu et al. [193].
The single-chain mass-spectra peaks were found to agree with the correct pre-
dicted masses having taken into account the formation of intra-chain disulphide
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bonds and N-terminal Gln to pyGlu conversion (Table 5.6).
The masses of the whole aεFab MS peaks were around 45 Da lower than the val-
ues estimated from the protein sequences using the online tool ExPASy ProtPram
[191]. Each aεFab has four intra-chain disulphide bonds and one inter-chain disul-
phide bond, which accounts for a difference of 10 Da. Moreover, both the heavy
and kappa chains of aεFab3 and aεFab12 have N-terminal Gln, and so N-terminal
Gln to pGlu conversion accounts for a difference of 34.06 Da (Table 5.7).
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Table 5.6: Reconciling the differences between the ES-MS-determined
aεFab single chain masses and the ProtPram-predicted aεFab single
chain masses. Prior to molecular weight determination via ES-MS, purified
aεFabs were incubated with the reducing agent, TCEP (Thermo Fisher Scientific)
overnight and dialyzed into 1 % acetic acid. ES-MS mass peaks for single chains
indicated that the inter-chain disulphide of the aεFabs had been reduced, however
the difference in the ES-MS-determined and ProtPram-predicted masses suggest
that presence of native and non-native intra-chain disulphide bonds. Additionally,
several of the aεFab chains have an N-terminal glutamine (N-Gln) that appear to
have undergone cyclization to pyroglutamate (pGlu). The N-Gln to pGlu transi-
tion results in the loss of ammonia (17 Da), whereas the formation of a disulphide
bond results in the loss of two protons (2 Da).
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MS peak mass (Da)  ProtPram mass (Da) ProtPram mass- MS 
peak mass (Da) 
aεFab3 44560.9 44605.9 45.0 
aεFab12 45553.1 45598.0 44.9 
Table 5.7: The differences between the ES-MS-determined whole aεFab
masses and the ProtPram-predicted whole aεFab masses. ProtPram [191]
estimates the molecular weights of proteins based upon their primary amino acid se-
quence, and does not account for post-translation modifications of disulphide bond
formation. The difference between the ES-MS-derived masses and the ProtPram-
predicted masses for aεFab3 and aεFab12 can be accounted for by the formation of
5 native disulphide bonds (5 x -2 Da), and the conversion of N-terminal glutamine
residues to pyroglutamate in both Fab chains (2 x -17 Da).
Together the formation of 5 disulphide bonds and the conversion of 2 Gln
residues to 2 pGlu residues per Fab accounts for a difference of 44.06 Da between
the MS-derived mass and the ProtPram-derived mass. In the case of both aεFabs,
this gives a final difference between the MS-derived mass and the theoretical mass
of less than 1 Da. After accounting for disulphide bond formation and N-terminal
Gln to pGlu conversion, the differences between the MS-determined and predicted
masses of the five purified aεFab and aεFab chains were less than 1.5 Da. This
indicated that the aεFabs were composed of the expected cognate heavy and light
chain pairings. Moreover, all the peaks in the spectra corresponded to the expected
masses of either the heavy and light aεFab chains or to the whole aεFab, which
confirmed the samples were pure from non-aεFab protein contaminants.
5.3 Discussion
Five aεFabs, selected for their high affinity for IgE-Fc and their apparent ability to
differentially modulate the binding of IgE-Fc receptors, were successfully expressed
and purified. SPR analysis of IgE-receptor binding provided a way to quantitatively
compare the effects of pre-binding IgE-Fc with the 13 different aεFabs. Although
aεFab selection was primarily based on their relative effects on the KD of the
interaction between IgE-Fc and derCD23, their effects on the KD and kinetics of
the interaction between IgE-Fc and sFcεRIα were also assessed, as well as how
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they modulate one-another’s binding to IgE-Fc. These additional selection criteria
provided information to help pick a diverse set aεFabs that appear to elicit their
effects on derCD23 binding in different ways (Table 5.8). The lack of a suitable
control for derCD23 binding to captured-IgE-Fc means we cannot unambiguously
describe any of the aεFabs as ‘inhibitors’ or ‘enhancers’, however the range of
different effects observed for the different aεFab:IgE-Fc complexes suggests that
the panel of antibodies does contain inhibitors and/or enhancers. Moreover, it
is important to note that whilst these experiments were performed in duplicate,
experimental repeats were not performed. In the future it will be necessary to
repeat these experiments and perform them in the presence of an experimental
control in order to have greater confidence in the observed effects.
Table 5.8: A summary of the binding characteristics of the selected
aεFabs as determined by SPR experiments of transient transfection su-
pernatants.
In addition to providing a route for quantitative analysis of receptor binding,
the SPR experiments also revealed all receptor binding sites were still accessible in
the aεFab:IgE-Fc complexes, indicating that the CD23 and aεFab binding sites do
not overlap, and the aεFabs may elicit their effects allosterically. The experiments
also indicated several cases of ligand-induced accelerated dissociation of aεFab:IgE-
Fc complexes (Section 5.2.2 and Section 5.2.4). Without knowledge of the different
aεFab binding sites we cannot be sure of the mechanism by which derCD23 induces
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accelerated dissociation of the aεFab13:IgE-Fc complex or the mechanism by which
aεFab18 induces the accelerated dissociation of the aεAb13:IgE-Fc:aεFab13 com-
plex. However, since it appears that an aεFab13:IgE-Fc:derCD23 (1:1:2) complex
can form (Section 5.2.2) it could be that derCD23 induces accelerated dissociation
of the aεFab13:IgE-Fc complex by allosteric means. In Chapter 3 it was posited
that derCD23 can allosterically induce accelerated dissociation of aεFab1 from
IgE-Fc through a mechanism involving a combination of intra- and inter-domain
motions. It would be interesting to determine the mechanisms of these newly ob-
served instances of accelerated dissociation, since understanding this process in
IgE could provide insights for the development of novel therapeutics that work by
disrupting IgE:receptor complexes.
The effect of aεFab on the IgE-Fc/CD23 interaction binding was examined
in the context of an aεFab:IgE-Fc complex, which meant that the aεFabs did
not have to be purified from their transient transfection supernatant. However,
the experimental set-up was inherently biased towards the interaction between
the aεFab:IgE-Fc complexes – we only observe binding events that were possible
between the receptor and conformations of IgE-Fc when it was pre-bound to an
aεFab. In the future, purified aεFabs could be used in homogeneous assays to
determine their effect on receptor binding at equilibrium, when the conformational
ensemble of IgE-Fc has not been biased by pre-binding to aεFab.
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Characterisation of the anti-IgE
Fab/IgE interactions
6.1 Introduction
IgE-Fc is a homodimer of two chemically identical chains each composed of three
domains: Cε2, Cε3 and Cε4 (Figure 6.1). FRET experiments [73, 74, 75], X-
ray solution scattering studies [76] and X-ray crystal structures of IgE-Fc [71, 72]
together suggest that IgE-Fc exists predominantly in a compact bent conformation,
in which the Cε2 domain pair folds back onto the Cε3 and Cε4 domains (Figure
6.1). Different X-ray crystallographic structures of the Cε3-Cε4 subfragment of
IgE-Fc (IgE-Fc(3-4)) suggest that the Cε3 domains can move upon the Cε3-4
hinge to adopt a range of ‘open’ and ‘closed’ conformations [77] (Section 1.2.1).
This conformational flexibility partly explains why receptor-binding to IgE-Fc is
mutually exclusive (Section 1.3.1) [18]. The FcεRI binding site is comprised of
two subsites that are composed of residues from the different Cε3 domains (Figure
6.1). To engage both subsites, both Cε3 domains must adopt ‘open’ conformations
[86, 72] (Figure 6.2). Two molecules of CD23 bind to IgE-Fc, one to each Cε3
domain, and they bind at the opposite end of the Cε3 domain to FcεRI (Figure
6.1). In contrast to FcεRI binding, CD23 binding requires both of the Cε3 domains
to adopt relatively ‘closed’ conformations (Figure 6.2), and this, in part, prevents
simultaneous receptor engagement. Additionally, X-ray crystal structures of IgE-Fc
bound to various engineered ligands (Figure 6.1) have provided evidence that IgE-
Fc can adopt conformations in which the Cε3 domains are even further apart than
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in the sFcεRIα-bound structure (Figure 6.2) and that their relative dispositions













Figure 6.1: X-ray crystal structures of IgE-Fc bound to the different anti-
IgE-Fc ligands. The crystal structures are shown in surface representations.
IgE-Fc is shown in white, except for the Cε3 domains in the first image. The
different anti-IgE receptors and ligands are coloured in accordance with the text.
The binding sites of the engineered ligands are located in the Cε3 domains of IgE-
Fc (coloured blue in the first image), to which the receptors (FcεRI and CD23)
also bind. The engineered anti-IgE-Fc ligands bind to IgE-Fc with 2:1 stochiome-
try. Apo IgE-Fc PDB: 2WQR [72], derCD23:IgE-Fc(3-4) (2:1) PDB: 2WQR [18],
sFcεRIα:IgE-Fc PDB: 2Y7Q [72], DARPin E2 79:IgE-Fc(3-4) (2:1) PDB: 4GRG
[109], aεFab1:IgE-Fc (2:1) PDB: 4J4P [81], Xolair Fab mutant 3:IgE-Fc (2:1) PDB:
in press.
The structures of aεFab1-bound and Xolair Fab mutant 3 bound-IgE-Fc also
illustrate a more extreme form of IgE-Fc conformational flexibility. The Cε2 do-
mains of the aεFab1:IgE-Fc (2:1) complex ‘unbend’ and IgE-Fc adopts an extended
and almost symmetrical structure that is irreconcilable with FcεRI binding [81]
(Figures 6.1 and 6.2). Similarly, the structure of IgE-Fc bound to two molecules
of Xolair Fab mutant 3 is partially extended [82] (Figures 6.1 and 6.2). Molecular
dynamic simulations suggest IgE-Fc has a complex energy landscape and when free
in solution IgE-Fc may be able to unbend and the Cε2 domains might even ‘flip’
from one side of IgE-Fc (3-4) to the other [81] (Figure 6.3).
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Figure 6.2: Different IgE-Fc complexes show that IgE-Fc is flexible and
can adopt a wide range of conformations. A schematic representation of
the different conformations that IgE-Fc adopts when bound to its receptors and
to anti-IgE-Fc Fabs. The Cε3 domains exist in a range of ‘open’ and ‘closed’
conformations: derCD23 binds the most closed conformation in which the Cε3
domains make the closest approach to one another, the most open conformation
known to date is that of the Xolair Fab mutant 3:IgE-Fc (2:1) complex [82], whereas
the most closed is the derCD23:IgE-Fc (1:1) complex [95]). The Cε2 domains of
IgE-Fc also undergo considerable conformational changes: sFcεRIα bound IgE-Fc
adopts the most compact structure [71, 72], whereas aεFab1-bound IgE-Fc is fully
extended [81].
The engineered anti-IgE-Fc ligands described in the literature (DARPin E2 79
[109], aεFab1 [81], Xolair [195]) elicit their effects on IgE-Fc conformation and
IgE-Fc-receptor interactions by binding to the Cε3 domains. Each anti-IgE ligand
completely, or principally, binds one Cε3 domain [106, 105, 109, 81, 108, 82] and
consequently they can bind IgE-Fc with a 2:1 stochiometry (Figure 6.1). Although
IgE-Fc is a homodimer, for each of the anti-IgE-ligands, the affinities of their two
binding sites are not identical [109, 81, 108, 82]. This is thought to be at least
in part because in solution, free IgE-Fc exits predominantly in a bent asymmetric
conformation.
The described engineered anti-IgE-Fc ligands were selected for their ability
to inhibit the interaction between IgE-Fc and FcεRI [195, 109, 81]. Structures
indicate that Xolair [108, 82] and DARPin E2 79 [109] also sterically inhibit the
CD23/IgE-Fc interaction (Figure 6.1) and in Chapter 3 we showed that aεFab1 is
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Figure 6.3: Molecular dynamic simulations of IgE-Fc extension. Figure
taken from Drinkwater et al. [81]. (a) The free-energy surface diagram generated
from a metadynamics simulation of IgE-Fc unbending suggests that IgE-Fc exists
predominantly in the bent conformation but that it can escape this conformation
and extend. A suggested pathway for IgE-Fc extension is shown by a dotted line
between energy minima. Models for the conformations of IgE-Fc that exist in the
minima are shown in (b) and a sketch of the suggested pathway is illustrated in
(c).
an allosteric inhibitor of CD23. In the previous chapter, five aεFabs were selected
for their ability to bind IgE-Fc with a high affinity, and for their different effects on
the IgE-Fc/CD23 interaction. The aεFab/IgE-Fc interactions had sub-nanomolar
binding affinities, as determined by SPR, and the binding curves appeared biphasic,
which suggested that the aεFabs may bind IgE-Fc with a 2:1 stochiometry (Section
5.2.1). The aεFabs were subsequently expressed on a larger scale and purified
(Section 5.2.6).
In this chapter we describe aεFab/IgE-Fc binding experiments that were per-
formed with the purified aεFabs, and examine the binding kinetics in greater detail.
In doing so, we determined the stochiometries and affinities of the interactions, and
provided further evidence of IgE-Fc heterogeneity. Intramolecular IgE-Fc FRET
assays indicated that the binding of aεFab2, aεFab12 and aεFab13 to IgE-Fc re-
sults in IgE-Fc unbending and suggests that at least these three aεFabs can cause
significant shifts in the conformational ensemble of IgE-Fc. Furthermore, we de-
scribe how SPR was used to investigate the interactions between the aεFabs and
different IgE-Fc subfragments. The results showed that these aεFabs, unlike any of
the previously engineered anti-IgE-Fc ligands, bind principally to the Cε2 domains
of IgE-Fc.
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6.2 Results
6.2.1 Determining the stochiometry of the aεFab/IgE-Fc
interactions using SEC
Size exclusion chromatography experiments were performed to determine the sto-
chiometry of the different aεFab/IgE-Fc interactions. Four samples were incubated
overnight at 4 ◦C for each of the aεFabs: 10 µM purified IgE-Fc, 17 µM purified
aεFab, 12 µM IgE-Fc with 5 µM aεFab, and 5 µM IgE-Fc with 12 µM aεFab. The
samples were then separately run down a Superdex S200 10x30 GL SEC column
(GE Healthcare) in PBS pH 7.4.
The chromatogram for IgE-Fc, aεFab2 and aεFab2:IgE-Fc complexes is shown
in Figure 6.4. Figure 6.4 is representative of the chromatograms for the other
aεFabs and aεFab:IgE-Fc complexes as they shared a similar profile (Appendix
A.6). Purified IgE-Fc eluted as a single peak on the chromatogram, as did purified
aεFab, but at a slightly later retention time owing to its smaller size (IgE-Fc MW
= 75 kDa, aεFab MWs ∼ 45-50 kDa). The sample with 12 µM aεFab and 5 µM
IgE-Fc eluted as three different peaks: two peaks appeared at lower retention times
than either IgE-Fc or aεFab, indicating the formation of two distinct aεFab:IgE-
Fc complexes, the third peak had the same retention time as IgE-Fc, indicating
that not all of the IgE-Fc was in complex (as expected since IgE-Fc was in molar
excess). The sample with 12 µM aεFab and 5 µM IgE-Fc eluted as two different
peaks: one major peak at the same retention time as the larger complex peak in
the previous sample, and one minor peak at the same retention time as purified
aεFab.
Given that the KD of the different aεFab/IgE-Fc interactions are thought to
be in the sub-nanomolar range (Section 5.2.1), at 5 µM or 12 µM IgE-Fc the
stochiometry of complex formation was dictated by the molar ratios of IgE-Fc and
aεFab. The presence of two complex peaks when the aεFab was in slight molar
excess of IgE-Fc suggests that the peaks correspond to a 1:1 aεFab:IgE-Fc complex
(later retention time) and a 2:1 aεFab:IgE-Fc complex (earlier retention time). This
is further supported by the fact that only one complex peak, corresponding to the
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Figure 6.4: A representative size exclusion chromatogram for aεFab, IgE-
Fc and aεFab:IgE-Fc complexes. Purified aεFab (aεFab2 here) was incubated
with purified IgE-Fc overnight at 4 ◦C at 1:2.4 (blue) and 2.4:1 molar ratios (green).
The mixture samples, aεFab alone (black), and purified IgE-Fc (purple), were run
down a Superdex S200 10x30 GL SEC column (GE Healthcare) in PBS, pH 7.4.
The results suggest the formation of 1:1 and 2:1 aεFab:IgE-Fc complexes.
2:1 complex was observed when aεFab was mixed with IgE-Fc at concentrations in
excess of a 2:1 molar ratio.
6.2.2 Determining the equilibrium dissociation constants
of the aεFab/IgE-Fc interactions using SPR
SEC indicated that a single IgE-Fc can bind two molecules of each of the selected
aεFabs. SPR was used to determine the KD values of the different aεFab binding
sites. Each aεFab was immobilised on to a different CM5 SPR sensor chip surface
(GE Healthcare) using amine-coupling (Section 2.6.2). aεFab was immobilised at
a low density (<400 RUs) that ensures that nearly all of the IgE-Fc that binds
is bound to only one aεFab molecule (Section 2.6.2). A titration of IgE-Fc was
injected for 180 s over the different aεFab surfaces as well as a mock amine-coupled
surface. The change in SPR response on the immobilised aεFab surfaces after
subtracting the response from the mock amine-coupled surface was used to measure
the specific binding of IgE-Fc to aεFab. Following each injection of IgE-Fc there
was a 780 s dissociation phase and the anti-rabbit-Fab surface was then regenerated
by two 60 s pulses of 10 mM glycine pH 1.7 and one pulse of 5 mM NaOH. The
experiments were performed in duplicate and the results were highly replicable.
The double reference-subtracted SPR sensorgrams indicated that the different
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aεFab/IgE-Fc interactions had varied binding kinetics (Figure 6.5), as was pre-
viously observed in Chapter 5 (Section 5.2.1). At low IgE-Fc concentrations the
binding of IgE-Fc to the aεFabs is monophasic: the data fit well to a monophasic
kinetic model as represented here by the fit of data for aεFab2 (Figure 6.6).
At higher IgE-Fc concentrations, binding had increasing biphasic character: the
binding curves did not fit well to a monophasic model (Figure 6.7.a) and were better
described by a biphasic model (Section 2.6.3), represented here by the example of
IgE-Fc binding to aεFab2 (Figure 6.7.b). Given that the aεFab:IgE-Fc complexes
can bind with a 2:1 stochiometry and that the experiments were performed at low
immobilisation densities to encourage monomeric binding, the biphasicity of the
binding curves is likely to be because the two aεFab binding sites on IgE-Fc have
non-identical intrinsic affinities, as also observed for both aεFab1 [81] and Xolair
Fab Mutant 3 [82]. Accordingly, monophasic binding, which was observed at low
IgE-Fc concentrations, was the result of the binding of IgE-Fc to captured aεFab
via its higher-affinity aεFab binding site, whereas the biphasic binding observed
at higher IgE-Fc concentrations describes the interactions that occurred between
aεFab and both the higher-affinity and the lower-affinity aεFab binding sites.
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aεFab2 aεFab3 
aεFab12  aεFab13 
aεFab18 
Figure 6.5: SPR sensorgrams for the binding of IgE-Fc to the different
immobilised aεFabs. IgE-Fc was injected over aεFabs immobilised to an SPR
sensor surface at a low density (< 400 RUs) using amine-coupling.
The association rate constant (kon) and dissociation rate constant (koff) were
determined from fitting the data using either monophasic or biphasic models where
appropriate (Section 2.6.3). The equilibrium dissociation constants (KD) were de-
termined from the dissociation and association phases using Equation 6.1. Fitting
both the monophasic (not shown) and the biphasic data indicated that the higher-
affinity aεFab/IgE-Fc interactions have KD values in the high picomolar range
(Table 6.1 and Appendix A.7). Fitting the biphasic data indicated that the lower-
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association dissociation 
koff = 7.0 x 10-5 M-1 s-1 
kon = 2.0 x 105 s-1 
data for 64 nM IgE-Fc binding to aεFab2 
data fitting (single kon and koff) 
Figure 6.6: The binding of 64 nM IgE-Fc to immobilised aεFab2 is well
described by single kon and koff kinetic models. 64 nM IgE-Fc was injected
over aεFab2 immobilised to an SPR sensor surface at a low density (< 400 RUs)
using amine-coupling. The association and dissociation phases were fit using single
kon and koff models kinetic models (Section 2.6.3) and were used to derive the disso-
ciation and association rate constants of the interaction (koff and kon, respectively).
affinity aεFab/IgE-Fc interactions have KD values in the high nanomolar range







Where KD is the equilibrium dissociation constant, koff is the dissociation rate
constant and kon is the association rate constant.
The association and dissociation curves for the binding of 0 - 2 µM IgE-Fc
to aεFab2, 3, and 18 could be fit using monophasic (at lower concentrations) or
biphasic (at higher concentrations) models. A biphasic model, however did not
accurately describe the interaction between IgE-Fc and aεFab12 or IgE-Fc and
aεFab13 at IgE-Fc concentrations above 8 nM (Figure 6.8.a). The dissociation
phase of the interaction between 2 µM IgE-Fc and aεFab12, and the dissociation
phase of the interaction between 2 µM IgE-Fc and aεFab13, fit to triphasic models
(Section 2.6.3) (Figure 6.8.b and Appendix A.7). Based on our previous experi-
ence of characterising IgE-Fc binding interactions, we think that it is likely that the
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association dissociation association dissociation 
kon1 = 7.6 x 104 s-1 
koff1 = 1.1 x 10-4 M-1s-1 
kon2 = 4.6 x 103 s-1 
koff2 = 6.5 x 10-3 M-1s-1 
a) b) 
data for 2 µM IgE-Fc binding to aεFab2 
data fitting (single kon and koff) 
data for 2 µM IgE-Fc binding to aεFab2 
data fitting (double kon and koff) 
Figure 6.7: The binding of 2 µM IgE-Fc to immobilised aεFab2 is well de-
scribed by biphasic kinetic models. 2 µM IgE-Fc was injected over a aεFab2
immobilised to an SPR sensor surface at a low density (<400 RUs) using amine-
coupling. The association and dissociation phases were not accurately described
using (a) monophasic kinetic models and were described better using (b) biphasic
kinetic models. The biphasic fits were used to derive the dissociation and associa-
tion rate constants of the interaction (koff and kon, respectively).
observed triphasic binding kinetics are a result of IgE-Fc conformational hetero-
geneity. In our laboratory we have observed similar complexities in the interaction
between IgE-Fc and sFcεRIα that are not the result of SPR artifacts and that we
propose are the due to IgE-Fc heterogeneity.
6.2.3 IgE-Fc heterogeneity
An introduction to IgE-Fc heterogeneity and the IgE/FcεRI interaction
As discussed in the chapter introduction (Section 6.1), X-ray structures and molec-
ular dynamic simulations suggest that IgE-Fc is highly dynamic and can exist in a
range of different conformations. The Cε3 domains of IgE-Fc can move upon the
Cε3-Cε4 hinges to adopt a range of ‘open’ and ‘closed’ states that have differential
receptor-binding capabilities [77, 18, 86, 72]. Moreover, IgE-Fc can exist in an
extended conformation and the Cε2 domains may even flip from one side of the
molecule to the other [81]. Our laboratory has demonstrated that conformational
heterogeneity is reflected in the binding kinetics of the interaction between IgE-Fc
and FcεRI.
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(x105 M-1 s-1) 
KD1
(x10-10 M)
aεFab2 0.80 0.88 9.0
aεFab3 3.7 4.8 7.7
aεFab12 1.5 6.9 2.2
aεFab13 2.8 22 1.3




(x104 M-1 s-1) 
KD2
(x10-7 M)
aεFab2 4.4 0.67 6.6
aεFab3 7.6 1.9 4.0
aεFab12 6.5 0.82 7.9
aεFab13 7.9 0.47 19
aεFab18 8.2 1.0 8.2
a) 
b) 
Table 6.1: The equilibrium dissociation constants of the (a) higher- and
(b) lower-affinity aεFab/IgE-Fc interactions as derived from kinetic bind-
ing experiments. The dissociation and association phases for the binding of IgE-
Fc to aεFabs immobilised to separate SPR sensor surfaces at a low density (< 400
RUs) using amine-coupling were fit using biphasic kinetic models (Section 2.6.3).
The resulting dissociation and association rate constants (koff and kon, respectively)
were used to derive the equilibrium dissociation constants (KD) of the interactions
using Equation 6.1. The fittings were performed on the data for the binding of
2 µM IgE-Fc to immobilised aεFab2, aεFab3 and aεFab18, and the data for the
binding of 8 nM IgE-Fc to immobilised aεFab12 and aεFab13. The fits were per-
formed in Origin (OriginLab). The fitting errors of kon1, koff1 and koff2 were all less
than 1 %. The fitting errors for kon2 were less than 10 %.
FcεRI is expressed on mast cells, basophils and a range of other immunological
cells as a tetrameric complex of αβγ2 chains. Cross-linking of IgE-bound FcεRI
on the surface of mast cells and basophils by allergen results in cell degranulation
and the release of a range of inflammatory-mediators that cause the immediate
hypersensitivity reactions associated with allergic disease [14]. The interaction
between IgE and FcεRI has a very high affinity (KD ≈ 1x10-10– 1x10-9 M) [4] owing
to a very slow off rate (koff ≈ 10-5s-1) [196, 197]. As a result of the slow off-rate
of the IgE/FcεRI interaction, the binding of IgE to FcεRI on the surface of mast
cells and basophils can cause long-term sensitization, allowing for an instantaneous
inflammatory response upon allergen encounter.
The IgE-Fc binding activity of FcεRI is located in the alpha chain of the protein.
Crystal structures of the soluble domains of FcεRI (sFcεRIα) bound to IgE-Fc
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association dissociation dissociation a) b) 
data for 2 µM IgE-Fc binding to aεFab12 
data fitting (double kon and koff) 
data for 2 µM IgE-Fc binding to aεFab12  
(dissociation phase) 
data fitting (triple koff) 
koff1 = 2.3 x 10-4 M-1s-1 
koff1 = 6.7 x 10-3 M-1s-1 
koff1 = 6.5 x 10-2 M-1s-1 
Figure 6.8: The aεFab12/IgE-Fc interaction has multiphasic binding ki-
netics at high IgE-Fc concentrations. (a) The binding kinetics of the interac-
tion between 2 µM IgE-Fc and aεFab12 captured on the surface of an SPR sensor
chip is not well described by a biphasic model. (b) The dissociation phase of the
interaction is better described by a triphasic model with three distinct koff values.
show that one molecule of sFcεRIα binds to one molecule of IgE-Fc [86, 72]. The
binding interface is extensive, largely hydrophobic and is composed of two non-
identical subsites located in the two different Cε3 domains of IgE-Fc (Figure 6.9).
The crystal structures indicate that two salt-bridges and three hydrogen bonds
in subsite 1, and packing interactions between a proline of IgE-Fc sandwiched
between two sFcεRIα tryptophan residues in subsite 2 are important in stabilising
the IgE-Fc:sFcεRIα complex [86, 72] (Figure 6.9).
The Cε2 domains of IgE-Fc are required to achieve the very slow off-rate be-
tween IgE-Fc and sFcεRIα [83], yet the crystal structure of the complex indicates
that no specific contacts form between sFcεRIα and the Cε2 domains [72]. Instead,
sFcεRIα binds to a more compact asymmetric IgE-Fc and the Cε2 domains make
more extensive contacts with the Cε3 domains than in the apo-state structure [72].
The Cε2-Cε3 interactions are thought to stabilise the Cε3 domains, reducing their
intrinsic flexibility and thereby reducing the entropic penalty that is incurred upon
FcεRI binding [83, 72].
Despite sFcεRIα binding IgE-Fc with a 1:1 stochiometry, the binding of IgE-Fc
to SPR senor chips with either sFcεRIα or IgG4-Fc-(sFcεRIα)2 immobilised on the
surface has biphasic binding kinetics and two distinct binding constants (KD1 ≈
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Figure 6.9: The extensive and largely hydrophobic sFcεRIα:IgE-Fc bind-
ing interface involves specific interactions at two subsites that involve
residues from the two different Cε3 domains of IgE-Fc. The crystal struc-
ture of the sFcεRIα:IgE-Fc complex [72]. sFcεRIα (purple) binds IgE-Fc (blue)
with a 1:1 stochiometry. Salt bridges and hydrogen bonds form between sFcεRIα
and Cε3 at subsite 1 of the binding interface. Stacking interactions between a
IgE-Fc proline residue sandwiched between two sFcεRIα tryptophan side chains
occurs at subsite 2.
0.1-1 nM, KD2 ≈ 100 nM) [196, 197]. The heterogeneity of the binding affinities is
attributed to two different binding phases, the nature of which have not been fully
resolved [196, 197].
Until recently, SPR experiments in our laboratory have largely focused on the
binding of IgE-Fc (or subfragments of IgE-Fc) to immobilised sFcεRIα or IgG4-Fc-
(sFcεRIα)2 because immobilising IgE or IgE-Fc on a sensor surface has historically
been problematic due to two established issues. Firstly, when immobilised through
amine-coupling, the immobilised IgE-Fc appears to be ∼90 % inactive, which is al-
most certainly because covalent coupling occurs within the Cε3 domain. Secondly,
even when the (∼10 %) immobilised material is active, regeneration conditions
that are sufficient to dissociate IgE-Fc from sFcεRIα rapidly deactivate IgE-Fc,
making repeating injections impossible. The most recent data from our laboratory
makes use of a new way of capturing IgE-Fc for SPR studies, and are supported by
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solution-based stopped-flow intrinsic fluorescence assays and stopped-flow FRET
studies.
Recent studies of IgE-Fc heterogeneity in relation to FcεRI binding
performed in our laboratory
IgE-Fc with a 6x histidine tag at C-terminus was expressed in Expi293TM HEK cells
(Thermo Fisher Scientific) (Section 3.2.2). Immobilisation of an anti-His-antibody
(THETM his-tag monoclonal antibody, mouse, Genscript) to an SPR sensor surface,
via amine-coupling, allowed the capture of His-IgE-Fc. Capturing IgE-Fc via a His-
tag eliminated the problems associated with covalent immobilisation of IgE-Fc and
provided a system for the straightforward deconvolution of binding rates/affinities







Figure 6.10: Capturing His-IgE-Fc via its His-tag provides a straightfor-
ward way of deconvoluting the KD and Bmax of IgE-Fc/analyte inter-
actions. THETM anti-His mouse monoclonal antibody (Genscript) is immobilised
to a CM5 SPR sensor chip surface using amine-coupling. His-tagged IgE-Fc, in
transient transfection supernatant is injected over the surface and is captured by
the anti-His antibody. Analyte is then injected over the anti-His:His-IgE-Fc com-
plex and specific binding of analyte to IgE-Fc is observed as an increase in SPR
response once reference subtractions have been performed.
Professor James McDonnell performed SPR experiments to determine the Bmax
and KD of the interaction between sFcεRIα and captured His-IgE-Fc using pico-
molar to low nanomolar concentrations of sFcεRIα. The expected steady-state
response was estimated from fitting the association and dissociation phases. The
estimated steady-state response was then plot as a function of sFcεRIα concen-
tration and the data were fit using a one-to-one binding model (Section 2.6.4).
The KD of the His-IgE-Fc/sFcεRIα interaction was estimated to be ∼ 100 pM.
The Bmax, however was estimated to be one-third the value of the theoretical Bmax
value, which suggests that only about one-third of the IgE-Fc binds sFcεRIα with
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the sub-nanomolar affinity that is often reported for the interaction. In contrast,
the Bmax values for the interaction between derCD23 and the captured His-IgE-Fc
indicated that ∼100 % of the IgE-Fc molecules bound derCD23 with affinities of





















KD = 0.1 nM 
Figure 6.11: Binding curves for (a) sFcεRIα (b) derCD23 binding to His-
tagged IgE-Fc. Beq is the steady-state response. The Bmax of the sub-nanomolar
affinity interaction between His-IgE-Fc and sFcεRIα is one third of the theoretical
Bmax value, indicating that only one-third of IgE-Fc can bind FcεRI with a sub-
nanomolar binding affinity.
A wide concentration range of sFcεRIα was injected over the captured His-
IgE-Fc in subsequent experiments. The resultant sensorgrams show a change in
the character when only the high affinity sites are occupied (at 4 nM for example)
compared to when the low affinity sites are also occupied (at 4 µM for example)
(Figure 6.12). At low concentrations, the binding kinetics for the interaction be-
tween sFcεRIα and His-IgE-Fc fit a monovalent model. However, at very high
sFcεRIα concentrations three populations of binding affinities were observable, in-
dicating a greater level of binding heterogeneity than suggested by previous SPR
experiments of the IgE-Fc/sFcεRIα interaction [196, 197]. These three binding
affinities were estimated to be ∼100 pM, ∼20 nM and ∼1 µM.
The multiphasic nature of the IgE-Fc/sFcεRIα interaction does not appear
to be an artifact of SPR and further evidence supporting multiphasic binding
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Figure 6.12: SPR sensorgrams for the binding of sFcεRIα to His-tagged
IgE-Fc. Fitting the association and dissociation rate constants from this data
suggested that IgE-Fc binds FcεRI with three different binding affinities: ∼100
pM, ∼20 nM and ∼1 µM.
was provided in solution-state studies performed by Dr Anthony Keeble (Figure
6.13). Stopped-flow intrinsic fluorescence studies of the IgE-Fc/sFcεRIα inter-
action showed an immediate change in fluorescence as a result of the initial bi-
molecular interaction event. The stopped-flow derived KD for this interaction was
estimated to be ∼1 µM, and thereby ∼1000 times weaker than the previously de-
termined KD values of the interaction. Following the initial binding event there
was a further change in fluorescence, hypothesised to be the result of isomerisa-
tion events required for the formation of a sub-nanomolar affinity complex (Figure
6.13.a).
Similarly, a stopped-flow FRET dissociation experiment indicated the presence
of multiple populations of IgE-Fc:sFcεRIα complexes. 1 µM of a Alexa488-IgE-
Fc:sFcεRIα-Alexa594 complex, equilibrated for 24 hours, was chased with 10 µM
of unlabeled sFcεRIα. The displacement of the labeled sFcεRIα by unlabeled
sFcεRIα resulted in a decrease in FRET signal. Three dissociation rates were
observed, consistent with the existence of at least three different populations of
bound complexes with different affinities (∼1 µM,∼20 nM,∼100 pM as determined
by SPR, Figure 6.13.b). Unlike for IgE-Fc, the literature does not suggest that
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Figure 6.13: Solution-based stopped-flow experiments show the IgE-
Fc/sFcεRIα has multiphasic binding characteristics. (a) Stopped-flow in-
trinsic fluorescence experiments of IgE-Fc and sFcεRIα showed an initial change
in fluorescence as a result of the bimolecular collision, and a subsequent change in
fluorescence as a result of isomerisation towards a higher affinity state. (b) Stopped-
flow FRET experiments, in which 1 µM Alexa488-IgE-Fc:sFcεRIα-Alexa594 was
chased with 10 µM unlabeled sFcεRIα, resulted in multiphasic changes in FRET,
indicating the dissociation of three distinct populations of IgE-Fc:sFcεRIα com-
plexes with different affinities. The low affinity complexes seem to be overpop-
ulated. Experiments performed by Dr Anthony Keeble, figures courtesy of Dr
Anthony Keeble.
sFcεRIα is conformationally diverse or particularly dynamic. The stopped-flow
FRET data therefore indicate that even when IgE-Fc is bound to sFcεRIα it can
still exist in multiple conformations with different receptor-binding affinities.
The SPR and the stopped flow data demonstrate the heterogeneous nature of
IgE-Fc and indicate that there are at least three different populations of sFcεRIα-
bound IgE-Fc with affinities of around 1 µM, 20 nM, and 100 pM. The data also
indicate that the weakly-bound IgE-Fc:sFcεRIα complexes are highly populated.
The Boltzmann equation (Equation 6.2) can be used to describe the frequency
distribution of particles in the different states of a system at equilibrium. Using
the experimentally determined KD values of the highest and lowest affinity IgE-
Fc/sFcεRIα complexes to derive their Gibb’s free energy (∆G) (Equation 6.3), the
Boltzmann equation (Equation 6.2) can be applied to determine the expected pop-
ulation distribution of the weakly-bound and strongly-bound complexes (Figure
6.14). A Boltzmann distribution suggests the ratio of the strongly-bound complex
(the 100 pM complex) to the weakly-bound complex (the 1 µM complex) should
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be around 11,000:1. The experimental data indicate that the weakly-bound IgE-
Fc:sFcεRIα complexes are much more populated than the calculated Boltzmann
distribution: the lower-affinity IgE-Fc:sFcεRIα complexes are markedly overpopu-
lated.






Where ni: nj is the ratio of the number of molecules in state i compared to state
j. ∆E is the difference in the energy of states i and j. T is the temperature and
kB is the Boltzmann constant.
∆G = RTlnKD (6.3)
Where ∆G is the Gibb’s free energy of an interaction, R is the ideal gas constant,
T is the temperature and KD is the dissociation constant of the interaction.
Since the Boltzmann distribution only applies to systems at equilibrium, one
potential explanation for the observed the non-Boltzmann distribution is that the
data were derived from essentially non-equilibrium measurements. If the Gibb’s
free energy of the two different sFcεRIα-bound states is very large (∆∆G), the
energy barrier between the different states may be so high that the states essentially
never exchange and consequently experimental measurements cannot be recorded
at equilibrium. However, this is unlikely to be the case, as evidence from re-
binding SPR experiments showed that the species responsible for the multiphasic
nature of the IgE-Fc/sFcεRIα interaction must interconvert [196]. Accordingly,
an alternative explanation for the observed Boltzmann paradox is that the weaker
binding IgE-Fc:sFcεRIα state is overpopulated because in fact it is not a single
state, but instead represents many conformations (Figure 6.15).
Our current interpretation of the data suggests that there is heterogeneity
within the sFcεRIα-binding population of IgE: IgE-Fc exists in conformations that
can bind sFcεRIα with affinities of ∼100 pM, ∼20 nM and ∼1 µM. The lower affin-
ity IgE-Fc is not represented by a single state, but by a large number of different
low-affinity conformations. Upon sFcεRIα binding, the complexes undergo slow
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ΔG = RTlnKD 
R = 8.315 Jmol-1K-1  
T = 298.15 K  
ΔGB1 = RTln(1x10-6) 
ΔGB1 = ~ -34 kJmol-1 
ΔGB2 = RTln(1x10-10) 
ΔGB2 = ~ -57 kJmol-1 
ΔΔG = ΔGB2– ΔGB1 
ΔΔG = ~ -23 kJmol-1  
BOX1 
ni : nj = exp(-ΔE/kBT)  
kBT =  4.12 x10-21 J at 298.15 K 
ni : nj = nB2 : nB1 
ΔE = ΔΔG = ~ -23 kJmol-1 
nB2 : nB1 = exp(-ΔΔG/LkBT) 
L = 6.02 × 1023 mol-1 
nB2 : nB1 = 11,000:1 
BOX2 
Figure 6.14: The Boltzmann distribution suggests that for each weakly-
bound IgE-Fc:sFcεRIα complex, there should be 11,000 strongly-bound
Fc:sFcεRIα complexes. Results from the SPR and stopped-flow fluorescence
experiments suggest that at 298 K the IgE-Fc:sFcεRIα complexes can exist in either
weakly-bound states or strongly-bound states. The experimentally determined KD
values for these two complexes can be used to derive the Gibb’s free energy (∆G)
for each interaction using Equation 6.3, and thereby the energy difference between
the two states (∆∆G). By substituting ∆∆G for ∆E in the Boltzmann equation
(Equation 6.2), the Boltzmann distribution of the weakly-bound and the strongly-
bound states can be calculated.
isomerisation via induced-fit intermediates, resulting in an equilibrium mixture of
high-, low- and intermediate-strength IgE-Fc:sFcεRIα complexes (Figure 6.16).
IgE-Fc heterogeneity within the aεFab12 and aεFab13 binding popula-
tion
It is possible that the multiphasic nature of the kinetics observed for the binding
of IgE-Fc to aεFab12 and aεFab13 may also be a result of IgE-Fc conformational
heterogeneity. Perhaps within the conformational ensemble of IgE-Fc there exist
states that bind aεFab12 (or aεFab13) with higher- and lower-affinities. To ensure
that the multiphasic nature of the interaction was not an artifact of the SPR
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Many different low-affinity FcεRIα-bound 
states (~1 µM) 
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Figure 6.15: A schematic representation of the proposed IgE-Fc:sFcεRIα
energy landscape.
experiments performed and to see if different affinity states persist in the form
of the aεFab:IgE-Fc complexes, SPR and stopped-flow FRET experiments like
those described for the IgE-Fc/sFcεRIα interaction, could be performed but with
aεFab12 and aεFab13 instead of sFcεRIα.
6.2.4 Intramolecular FRET experiments
IgE-Fc’s conformational flexibility is central to both the heterogeneity of IgE-Fc
and its susceptibility to allosteric modulation. Cε2 domain extension in IgE-Fc
was predicted by molecular dynamic simulations [81] and is an extreme form of
conformational flexibility. Crystal structures the aεFab1:IgE-Fc [81] and Xolair
Fab mutant 3:IgE-Fc complexes [82], show IgE-Fc can exist in fully linearized
and partly extended conformations. Intramolecular FRET data indicate that Cε2
domain extension occurs in solution as a result of the interaction between IgE-Fc
and these Fabs: an acceptor/donor fluorophore were attached to the Cε2 and Cε4
domains of IgE-Fc (Figure 6.17) and a reduction in FRET between the fluorophores
was observed upon titration of aεFab1 or Xolair Fab mutant 3. The reduction in
FRET signal was attributed to IgE-Fc unbending, which increases the Cε2-Cε4
domain distance [81, 82]. Evidence suggests that the extension of the Cε2 domains
that is associated with the binding of aεFab1 is partly responsible for the inhibition
of the IgE-Fc/FcεRI interaction [81]. Intramolecular IgE-Fc FRET experiments
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IgE-Fc1 + sFcεRIα IgE-Fc1 : sFcεRIα* IgE-Fc1 : sFcεRIα 
IgE-Fc2 + sFcεRIα IgE-Fc2 : sFcεRIα* IgE-Fc2 : sFcεRIα 
IgE-Fc3 + sFcεRIα IgE-Fc3 : sFcεRIα* IgE-Fc3 : sFcεRIα 
Figure 6.16: Our current best description of the IgE-Fc/sFcεRIα binding
equation. We propose that IgE-Fc is heterogeneous: it can bind sFcεRIα with at
least three different affinities (IgE-Fc1, IgE-Fc2 and IgE-Fc3). When IgE-Fc binds
sFcεRIα it undergoes an induced-fit conformational change via an intermediate.
Three different final complex states exist at equilibrium, which have different affini-
ties (∼1 µM, ∼20 nM, ∼100 pM). The weakly-bound complexes are not represented
by a single conformation but by a large number of different conformations.
were performed to ascertain whether the binding of any of the five selected aεFabs
to IgE-Fc is associated with the linearization of IgE-Fc.
The experimental set up of the intramolecular FRET experiments
An IgE-Fc mutant (E289C), biotinylated at the C-terminus using a BirA tag, was
labeled with donor and acceptor fluorophores in the Cε2 domains and in the Cε4
domains, respectively. The donor fluorophore, a thiol-reactive terbium chelate
(Invitrogen), bound the C289 thiol in the Cε2 domains, and a monovalent amine-
reactive Alexa Fluor 488 (Invitrogen) labeled streptavidin bound the C-terminal
BirA tags (Figure 6.17). aεFab1 (positive control for IgE-Fc linearization) and the
different aεFabs were titrated into IgE-Fc in PBS to give a final concentration of
10 nM IgE-Fc and 1 µM aεFab, and then were incubated for 120 min at 25 ◦C.
FRET was measured on an Analyst HT microplate reader (LJL Biosystems) with
an excitation wavelength of 330 nm, and emission wavelengths of 485 and 520 nm.
The FRET signal (The FRET ratio ((E520/E485) x 10
4) in the absence of any aεFab
was defined as the maximum FRET signal (0 % inhibition). The FRET signal when
the experiments were performed with unlabeled streptavidin was defined as the
minimum FRET signal (100 % inhibition). The FRET measurements (in terms of
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Figure 6.17: A schematic representation of the experimental setup for
the IgE-Fc intramolecular FRET assays. IgE-Fc (E289C), with a C-terminal
BirA tag, was labeled with thiol-reactive terbium (Invitrogen) via an interaction
with C289 in the Cε2 domains, according to manufacturers instructions. Mono-
valent Alexa Fluor 488 (Thermo Fisher Scientific) labeled streptavidin also bound
to IgE-Fc(E289C) but via the C-terminal BirA tag. IgE-Fc in solution exists in
an asymetrically bent state. Excitation of the N-terminal terbium results in the
excitation of the C-terminal A488 via FRET. The resulting fluorescence signal of
the A488 fluorophore was measured and used to define the basal FRET efficiency
between the donor/acceptor pair. When aεFab1 binds IgE-Fc, IgE-Fc adopts an
extended conformation in which the distance between the Cε2 and Cε4 domains
is increased. Since FRET is a distance sensitive phenomenon, the FRET efficiency
between the donor/acceptor pair is reduced and accordingly so is excitement of
A488. Consequently the measured A488-fluorescence levels are lower.
percentage of FRET inhibition) were plotted as a function of aεFab concentration
and fit to a four parameter logistical equation (Equation 2.23) (Figure 6.18).
Intramolecular FRET results.
The binding of aεFab1 to IgE-Fc results in a nearly fully extended IgE-Fc structure
[81]; the aεFab1 titration here did not reach the concentrations required to saturate
the aεFab1 binding sites on IgE-Fc, but fitting predicts that the maximal FRET
inhibition achieved by aεFab1 would have been ∼ 60 % (Figure 6.18). aεFab3
and aεFab18 did not affect the FRET signal at saturating concentrations, whereas
aεFab2, aεFab12 and aεFab13 did inhibit the FRET signal (∼60 %, ∼20 %, ∼50
%, respectively) (Figure 6.18).
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These results suggest that the aεFab2:IgE-Fc complex is nearly fully extended,
the aεFab13:IgE-Fc complex is mostly extended, and the aεFab12:IgE-Fc complex
is only partially unbent. The KD values for the second (lower-affinity) aεFab bind-
ing sites on IgE-Fc were determined to be ∼640 nM, ∼800 nM and ∼170 nM for
aεFab2, aεFab12 and aεFab13, respectively. Since the maximum FRET inhibition
was achieved by the addition of ∼20-30 nM of these aεFabs, the binding of the
first aεFab was sufficient for maximal FRET inhibition, and hence the proposed
Cε2 domain extension. Neither aεFab3 nor aεFab18 markedly inhibited the in-
tramolecular IgE-Fc FRET signal, indicating aεFab3:IgE-Fc (1:1) complexes and
aεFab18:IgE-Fc (1:1) complexes are bent.
SPR studies described in the previous chapter indicated that aεFab2, aεFab12
and aεFab13 differentially affect receptor binding. The experiments were performed
in the absence of robust controls for unmodulated IgE-Fc/receptor interactions,
however aεFab2 and aεFab13 appeared to have an inhibitory effect on the IgE-
Fc/derCD23 interaction, whereas aεFab12 appeared to enhance the interaction
(Section 5.2.2). Furthermore, aεFab13 appeared to increase the off-rate of the IgE-
Fc:sFcεRIα interaction (Section 5.2.3). The results of the intramolecular FRET
experiments performed here suggest that aεFab2, aεFab12 and aεFab13 are capa-
ble of shifting the conformational landscape of IgE-Fc, which is a prerequisite of
allosteric modulation. However, whether the unbending of IgE-Fc by these aεFabs
plays a role in their apparent effects on receptor binding has yet to be established.
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Figure 6.18: IgE-Fc intramolecular FRET experiments suggest that bind-
ing of aεFab2, aεFab12 and aεFab13 to IgE-Fc is associated with a confor-
mational change in IgE-Fc. IgE-Fc was labeled with an N-terminal fluorophore
donor (terbium) and a C-terminal fluorophore acceptor (Alexa Fluor 488), and
incubated with increasing concentrations of each of the aεFabs. The terbium was
excitation by light at a wavelength of 330 nm and fluorescence emission was read
at wavelengths of 485 nm and 520 nm. The FRET signal (the FRET ratio ((E
520/E485) x 10
4) in the absence of any aεFab was defined as the maximum FRET
signal (0 % inhibition). The FRET signal when the experiments were performed
with unlabeled streptavidin was defined as the minimum FRET signal (100 % in-
hibition). The experiments were performed in duplicate and the data were fit to
a four-parameter logistic curve. aεFab1 is known to bind to an almost completely
extended IgE-Fc.
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6.2.5 The binding of different IgE-Fc subfragments to the
aεFabs
Having established the stochiometries and affinities for the aεFab/IgE-Fc inter-
actions, further SPR experiments were performed to try to determine to which
domains of IgE-Fc the different aεFabs bind. SPR experiments were performed in
which the binding between different IgE-Fc subfragments and each of the selected
aεFabs were measured. Each aεFab was immobilised at a low density (<400 RUs)
on a separate CM5 SPR sensor chip surface (GE Healthcare) using amine-coupling
(Section 2.6.2). Full length IgE-Fc, IgE-Fc(3-4), Cε2 dimer, and Cε2 monomer
protein constructs (Figure 6.19) were injected at different concentrations over the
aεFab surfaces and over a mock amine-coupled surface. IgE-Fc and IgE-Fc(3-4)
were injected at concentrations of 0 - 0.1 µM and the Cε2 dimer and monomer
were injected at concentrations of 0 - 5 µM. The changes in SPR response from the
immobilised aεFab surfaces, subtracting the changes in response from the mock
amine coupled surface upon the IgE-Fc subfragment injections, were used to mea-
sure the specific binding of IgE-Fc subfragments to the aεFabs. Scott Isherwood
and Virginia Casblancas Antras performed these experiments in duplicate and the



















Figure 6.19: Schematic representation IgE-Fc and different subfragments
of IgE-Fc. The binding of these different IgE-Fc subfragments to the five se-
lected aεFabs was measured using SPR. The light green patches illustrate the
approximate locations of the CD23 binding sites. IgE-Fc, IgE-Fc(3-4) and the
Cε2 monomer were recombinantly expressed and then purified. The Cε2 dimer
was a spontaneously proteolytically processed product of recombinantly expressed
IgE-Fc, which was purified by SEC and its mass confirmed by mass spectrometry.
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IgE-Fc vs. IgE-Fc(3-4) vs. Cε2 dimer
All of the aεFabs bound to IgE-Fc as expected (Figure 6.20). With the excep-
tion of aεFab12, none of the aεFabs bound IgE-Fc(3-4) (Figure 6.20). A further
SPR experiment was performed to confirm that aεFab12 does bind to IgE-Fc(3-4)
(Appendix A.8). The double-subtracted SPR sensorgrams, showed that all of the
aεFabs bound the Cε2 dimer (Figure 6.20), indicating that the binding of each of
the five selected aεFabs to IgE-Fc involves the Cε2 domains.
For aεFab2, aεFab3 and aεFab13 the sensorgrams for the binding of IgE-Fc (0
- 100 nM) and the sensorgrams for the binding of the Cε2 dimer (0 - 156 nM) have
very similar profiles (Figure 6.20). It should be noted that the IgE-Fc and Cε2
dimer have not been normalised for immobilisation density or for differences in the
masses of IgE-Fc and Cε2, and so RU values are not directly comparable). Fitting
the low concentration data to monophasic models where appropriate (not shown),
suggested that aεFab2, aεFab3 and aεFab13 bind the Cε2 dimer with around 10-
50 times lower affinity than IgE-Fc. Given that aεFab2, aεFab3 and aεFab13 did
not bind IgE-Fc(3-4), the results suggest that the binding sites for these Fabs are
primarily located in the Cε2 domains but that only in the context of the full IgE-Fc
molecule is native affinity binding achieved. The Cε3-Cε4 fragment may provide
additional stabilising contacts or may contribute entropically to the interaction.
The sensorgrams for the binding of Cε2 to aεFab18 are markedly different from
that of the binding of IgE-Fc (Figure 6.20). The off-rate of the interaction is signifi-
cantly faster for the binding of the Cε2 dimer, and it was estimated, by steady-state
analysis (data not shown), that the interaction had a micromolar binding affinity.
Since aεFab18 did not bind IgE-Fc(3-4) and bound the Cε2 dimer very weakly, we
propose that the aεFab18 binding sites are located at the Cε2-Cε3 domain inter-
face. Cε2 domain residues probably provide the major surface contacts, but Cε3
residues are also likely to have significant roles in stabilising the aεFab18/IgE-Fc
interaction. The results of these experiments also suggest that aεFab12 binds to
the Cε2-Cε3 interface. Unlike aεFab18, both the Cε2 dimer and the IgE-Fc(3-
4) bound at significant levels to aεFab12 (Figure 6.20). The interaction between
aεFab12 and the Cε2 dimer, and the interaction between aεFab12 and IgE-Fc(3-4)
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had about 100 and 10 times lower affinities than the interaction between aεFab12
and IgE-Fc, respectively. This suggests that although aεFab12 is capable of bind-
ing both domains (further SPR experiments confirming this finding are shown in
Appendix A.8 and Appendix A.9), both domains are required to achieve native-
binding affinity. Furthermore, the Cε3 domains appear to have a more significant
role in binding of aεFab12 than in the binding of any of the other five selected
aεFabs.
Cε2 dimer vs. Cε2 monomer
Comparisons of sensorgrams for the interaction of each aεFab with the Cε2 dimer
and the Cε2 monomer constructs (Figure 6.21) developed our understanding of
the nature of the interactions between the aεFabs and the Cε2 domains of IgE-Fc.
Having accounted for the difference in molecular mass of the Cε2 monomer and
dimer, the sensorgrams for the interactions between aεFab2 and the Cε2 monomer
and Cε2 dimer were very similar (Figure 6.21); the response for the binding of the
monomer was half that of the response for the binding of the dimer, because the
Cε2 monomer has half the molecular mass. This suggests that one molecule of
aεFab2 binds a single Cε2 domain. Likewise, the sensorgram for the binding of the
Cε2 dimer to aεFab18 and the sensorgram for the binding of the Cε2 monomer to
aεFab18 (Figure 6.21) suggests that that one molecule of aεFab18 binds a single
Cε2 domain.
Despite being half the molecular mass, the binding of the Cε2 monomer to
aεFab3, and the binding of the Cε2 monomer to aεFab13, gave the same SPR
responses as the binding of the Cε2 dimer to aεFab3 and aεFab13, respectively
(Figure 6.21). This suggests that either a single molecule of aεFab3 (or aεFab13)
can bind two molecules of Cε2, perhaps by binding the Cε2 dimer interface, and/or
aεFab3 (or aεFab13) induces Cε2 dimerisation.
aεFab12 was the only aεFab that did not bind to the Cε2 monomer, despite
binding the Cε2 dimer (Figure 6.21). This suggests that when binding to the Cε2
domains, one molecule of aεFab12 engages both Cε2 domains of IgE-Fc. The most
plausible explanation is that aεFab12 binds at the Cε2 dimerisation interface.
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IgE-Fc (2-4) IgE-Fc (3-4) Cε2 dimer 
5000 nM Cε2 
2500 nM Cε2 
1250 nM Cε2 
625 nM Cε2 
313 nM Cε2 
156 nM Cε2 
78 nM Cε2 
Figure 6.20: The five selected aεFabs bind to the Cε2 domains of IgE-
Fc. SPR sensorgrams for the binding of different fragments of IgE-Fc to the five
selected aεFab surfaces. IgE-Fc, IgE-Fc(3-4) and Cε2 dimer was injected over
aεFab immobilised on individual SPR sensor surfaces at low densities (< 400 RUs)
using amine coupling. Whilst all aεFabs bound the Cε2 dimer, as shown by an
increase in SPR response upon injection of the dimer, only aεFab12 bound IgE-
Fc(3-4). It should be noted that the sensorgrams have not been normalised for
immobilisation density (which differ between the IgE-Fc/IgE-Fc (3-4) and Cε2
experiments), or for differences in the masses of the analytes, and so RU values are
not directly comparable.
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625 nM Cε2 
313 nM Cε2 
156 nM Cε2 
78 nM Cε2 
5000 nM Cε2 
2500 nM Cε2 
1250 nM Cε2 
Figure 6.21: SPR sensorgrams for the binding of Cε2 dimer and Cε2
monomer to the five selected aεFab surfaces. Cε2 dimer and Cε2 monomer
were injected over aεFab immobilised on individual SPR sensor surfaces at low
densities (< 400 RUs) using amine-coupling. The Cε2 dimer data is replicated
from Figure 6.20.
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6.3 Discussion
Size exclusion chromatography and SPR binding experiments indicate that the five
selected aεFabs bind to IgE-Fc with a 2:1 stochiometry. IgE-Fc is a homodimer
and ligands specific for IgE-Fc may bind to two symmetrically related epitopes,
as has been observed for other IgE-Fc binding proteins (Figure 6.1) [18, 109, 81,
108, 82]. The SPR binding data further suggests that the aεFab binding sites have
different binding affinities: in each case the higher-affinity binding site has a very
low nanomolar, or even sub-nanomolar, binding affinity and the second binding
site has a high nanomolar binding affinity. Data for the binding of other anti-IgE
Fabs to IgE-Fc have also suggested that the symmetrically-related binding sites on
IgE-Fc are non-equivalent (derCD23 [88, 18, 89], aεFab1 [81] and Xolair [108, 82]),
and it is proposed that this is at least partly because IgE-Fc exists predominantly
in an asymmetric bent conformation in solution (Section 6.1) [71, 72]. In these
respects, the five selected aεFabs are similar to anti-IgE-ligands already described
in the literature, however, the aεFabs that have been generated in this project are
set-apart by the location of their binding sites on IgE-Fc.
SPR experiments showed that all of the five selected aεFabs bind exclusively,
or principally, to the Cε2 domains of IgE-Fc, whereas other previously described
engineered anti-IgE-Fc ligands bind exclusively, or primarily, to the Cε3 domains
[109, 81, 108, 82] (Figure 6.1). Like these anti-IgE-Fc ligands, the selected aεFabs
affect the binding of IgE-Fc receptors, but unlike the other anti-IgE-ligands, the
aεFabs appear to exert their effects via a different domain of IgE-Fc.
aεFab2, aεFab3 and aεFab13 bind the Cε2 domains with almost the same affin-
ity as they bind IgE-Fc, suggesting that IgE-Fc(3-4) has only a peripheral role in
the binding of these aεFabs. The data suggest that aεFab12 and aεFab18, however,
bind to the Cε2-Cε3 interface. The five aεFabs were primarily selected for their
apparently different effects on the IgE-Fc/CD23 interaction (Section 5.2.2). CD23
binds to the Cε3 domain very close to the Cε3-Cε4 interface, consequently, these
aεFabs do not elicit their effects on the IgE-Fc/CD23 interaction by binding at, or
adjacent to, the CD23 binding sites. Although the aεFabs do not bind at the CD23
binding sites, steric inhibition of one CD23 binding site is still possible since IgE-Fc
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exists predominantly in a bent asymmetric structure in solution and consequently
the Cε2 domains come into close proximity with the Cε3 domain of one chain.
IgE-Fc, however can exist in extended, or partly extended conformations: aεFab1
binds to IgE-Fc and stabilises a conformation of IgE-Fc in which the Cε2 domains
are unbent [81] (Figure 6.1). If an aεFab stabilises an extended conformation of
IgE-Fc in which the Cε2 domains are no longer bent against the Cε3 domain of
one chain, IgE-Fc/CD23 inhibition would likely be allosteric in nature.
FRET assays, in which acceptor and donor fluorophores are attached to the
Cε2 and Cε4 domains, have previously been used to determine the extent of
IgE-Fc extension in solution [73, 74, 75, 81, 82]. Intramolecular FRET stud-
ies performed in this chapter indicated that the aεFab2:IgE-Fc complex is ex-
tended, the aεFab13:IgE-Fc complex is partially extended and aεFab12:IgE-Fc
complex is partly unbent (Figure 6.22). If, as the data suggests, aεFab2:IgE-
Fc and aεFab13:IgE-Fc complexes are mostly extended, it is unlikely that they
could sterically interfere with CD23 binding (Figure 6.22). SPR experiments per-
formed in Chapter 4 suggested that aεFab2 and aεFab13 are inhibitors of the
IgE-Fc/CD23 interaction (Section 5.2.2). In light of the experiments performed
in this chapter we suggest that the apparent inhibition is mediated by allosteric
processes. However, further inhibition assays with appropriate controls for unmod-
ulated IgE/CD23 binding are required to confirm that these aεFabs inhibit the
IgE/CD23 interaction.
The intramolecular FRET data suggest that the binding of aεFab2, aεFab12
and aεFab13 are associated with a shift in the conformational equilibrium of IgE-
Fc. Cε2 domain extension is a large conformational change and could potentially
affect IgE-Fc/receptor interactions in a variety of ways. At present it is unknown
if and how the changes in Cε2 domain extension, associated with the binding of
these three aεFabs, affect IgE-Fc/receptor interactions. Changes in the Cε2-Cε3
interdomain angle could affect the Cε3-Cε4 interdomain angle, which is known to
be important in the binding of both receptors to IgE-Fc [71, 72, 18]. Furthermore,
the unbending of IgE-Fc induced by the aεFab1/IgE-Fc interaction prevents the
binding of sFcεRIα, as the newly adopted position of the Cε2 domain pair blocks
the receptor binding site. If, as the data suggest, aεFab13:IgE-Fc is partially un-
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Cε2s FcεRI binding site 
IgE-Fc:derCD23 
Figure 6.22: Intramolecular FRET studies suggested that the binding of
some of the aεFabs results in IgE-Fc unbending. IgE-Fc exists primarily in
an asymmetrically bent conformation [73, 74, 71, 75]. IgE-Fc retains an asymmet-
rically bent conformation when bound to derCD23 [75, 95]. Intramolecular FRET
studies indicated that IgE-Fc also retains an asymmetric bent conformation when
bound to aεFab3 and aεFab18. The intramolecular FRET data suggested that
aεFab2 binds the Cε2 domains IgE-Fc and aεFab2:IgE-Fc is almost fully extended
IgE-Fc, consequently there is a significant distance between the aεFab2 and CD23
binding sites. The intramolecular FRET data also suggested aεFab13:IgE-Fc is
partially extended and aεFab12:IgE-Fc is partially unbent. The schematic mod-
els are not meant as accurate reflections of the exact degree of Cε2 unbending
and instead are non-quantitative representations of the relative degree of IgE-Fc
extension as suggested by the intramolecular FRET data.
bent, the position of the Cε2 domains could be partly responsible for the increase in
off-rate of the IgE-Fc/sFcεRIα interaction that was observed in Chapter 5 (Section
5.2.3).
In addition to Cε2 domain extension, the Cε3 domains of IgE-Fc can undergo
significant conformational changes. The Cε3 domains can move upon the Cε3-
Cε4 hinge so that they are either further from, or closer to, one another, thereby
adopting a range of ‘open’ and ‘closed’ conformations [77, 71, 72, 18, 81, 82] (Figure
6.2). FcεRI binds a specific ‘open’ conformation and CD23 binds a specific ‘closed’
conformation of IgE-Fc, consequently simultaneous receptor binding is not possible,
and partly explains how aεFab1 [81] and Xolair Fab mutant 3 [82], which bind very
open forms of IgE-Fc, inhibit receptor binding (Figure 6.2). Furthermore, the Cε3
domain itself has a high level of intrinsic flexibility [78], which is believed to play a
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role in the mutual allosteric inhibition of receptors [18] and the allosteric inhibition
of derCD23 binding by aεFab1 (Section 3.2.5).
IgE-Fc’s unusually high degree of conformational flexibility results in a com-
plex energy landscape [81], which we suggest is reflected in the binding kinetics of
the sFcεRIα/IgE-Fc interaction. sFcεRIα binds IgE-Fc with a 1:1 stochiometry
but data from SPR, stopped-flow intrinsic fluorescence studies and stopped-flow
FRET are best described by triphasic models. The sFcεRIα/IgE-Fc interaction is
described in the literature as having sub-nanomolar affinity but the data presented
here suggest that only around 30 % of the complexes exist in this strongly-bound
state, and that the conformational heterogeneity of IgE-Fc results in the formation
weakly-bound complexes. Consequently, the results suggest that at any one time
in the human body, only 30 % of circulating IgE binds FcεRI on the surface of
mast cells and basophils with the characteristic sub-nanomolar affinity. Defining
healthy persons as having serum IgE at a concentration of 0.8 nM [198], if 100 %
of serum IgE bound to FcεRI on the surface of effector cells with 100 pM affinity,
the fractional saturation of FcεRI would be 89 %, as opposed to 70 % if only 30 %
of the serum IgE bound with this affinity (assuming FcεRI concentrations are not
mass limiting). Defining atopic persons as having serum IgE at a concentration of
2.5 nM [199], if 100 % of IgE bound to FcεRI on the surface of effector cells with
100 pM affinity, the occupancy of FcεRI would be 96 %, as opposed to 88 % if
only 30 % of serum IgE bound with this affinity (assuming FcεRI concentrations
are not mass limiting).
The kinetics for the interactions between IgE-Fc and aεFab12 and IgE-Fc and
aεFab13, as determined by SPR, were also well described by a triphasic model.
Both aεFab12 and aεFab13 bind IgE-Fc with 2:1 stochiometries and we therefore
propose that the observed multiphasic binding kinetics could be the result of IgE-
Fc heterogeneity: in IgE-Fc’s complex conformational landscape there are states
that can bind aεFab12 (or aεFab13) weakly, and states that can bind aεFab12
(or aεFab13) strongly. Stopped-flow experiments, like those performed for the
sFcεRIα/IgE-Fc interaction, could establish whether multiphasic kinetics of the
aεFab12/IgE-Fc and aεFab13/IgE-Fc interactions occur without potential artifacts
of solid phase immobilisation.
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Modulation of the IgE/CD23
interaction by anti-IgE Fabs
7.1 Introduction
CD23 is expressed on the surface of B cells, various inflammatory cells and epithe-
lial cells [16]. It is expressed as a trimer: three lectin domain heads are tethered
to the cell surface by an α-helical coiled-coil stalk (Figure 7.1.a) [17]. The stalk is
susceptible to proteolysis by various endogenous and exogenous proteases, which
results in the release of different soluble CD23 (sCD23) fragments that have dif-
ferent activities dependent on their oligomeric state [4]. The protease der p1 is
found in the feces of the house dust mite Dermatophagoides pterronysinus and
cleaves membrane CD23 (mCD23) resulting in the release of monomeric sCD23
head domains (derCD23) (Figure 7.1) [20].
IgE-Fc binds sCD23 and mCD23 through interactions with the CD23 head
domain. A single CD23 head domain binds a single Cε3 domain of IgE-Fc and
consequently a single molecule of IgE-Fc can bind two CD23 head domains [88]
(Figure 7.1.b). Geometric and physical constraints mean that two CD23 heads
from the same mCD23 molecule cannot bind the same IgE-Fc molecule, however
one molecule of IgE could cross-link two molecules of mCD23, and one molecule
of trimeric CD23 could bind two or even three molecules of IgE. The high avidity
of the IgE/mCD23 interaction enhances the strength of the interaction and the
binding of IgE to mCD23 has a KD in the range of 1-10 nM [39].
Despite their symmetry, the affinities of the two different CD23 binding sites on
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Figure 7.1: Each Cε3 domain of IgE-Fc can bind one CD23 head domain.
(a) A schematic representation of CD23. CD23 is expressed on the surface of
various cells, including B cells, as a trimer (mCD23). Three soluble lectin head
domains are tethered to the surface by an α-helical coiled-coil stalk. Cleavage of
the stalk by the der p1 protease results in the release of single soluble CD23 head
domains called derCD23. (b) derCD23 (green) binds IgE-Fc(3-4) (white) with a
2:1 stochiometry (PDB: 4EZM) [18]. (c) The crystal structure of IgE-Fc bound
to a single molecule of derCD23 shows that IgE-Fc remains in an asymmetrically
bent conformation when bound to derCD23 [95].
IgE-Fc are not equal: one has a KD of around 0.1 – 1 µM and the other has a KD
of around 10 – 20 µM [88]. The variance is likely to be at least in part the result
of IgE-Fc’s conformational asymmetry [71, 72]. The structure of IgE-Fc bound
to a single molecule of derCD23 has been solved and shows that IgE-Fc retains
an asymmetrically bent conformation when bound to derCD23 (Figure 7.1.c) [18],
which is also supported by intramolecular FRET data [75]. The derCD23 molecule
is bound to the site closest to the Cε2 domain pair and the Cε3 domain to which it
is bound is in the ‘closed’ conformation that is thought to be required for optimal
CD23 binding [18]. The other CD23 binding site is unoccupied and this unbound
Cε3 domain is slightly more ‘open’. One could suggest that the CD23 binding site
furthest from the Cε2 domains has the lower affinity, however this is speculation,
and as of yet there is not enough evidence to convincingly assign the higher- and
lower-affinity binding activities to particular CD23 binding sites of the structure.
The primary aim of this project is to generate aεFabs that bind IgE-Fc and
modulate the IgE-Fc/CD23 interaction allosterically. The binding of an allosteric
modulator to one site of a macromolecule affects the functionality of another, often
distal, site through changes in structure/dynamics. In the past a number of mod-
els have been employed to explain allosteric processes (Section 1.4). The ensemble
view of allostery is comprehensive and been used to model a wide range observed
allosteric phenomenon [111]. It is widely accepted that a protein exists as fluctua-
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tion of structures around an average conformation, and that the different states of
a protein exist in a conformational equilibrium [119, 120, 121]. The ensemble view
of allostery suggests that the binding of an allosteric modulator causes a shift in
the conformational ensemble of a protein that results in a change in the function-
ality of that protein (Section 1.4) [129]. An allosteric modulator that binds IgE-Fc
may cause a shift in the conformational ensemble of IgE such that binding between
CD23 is inhibited or enhanced.
Both orthosteric and allosteric modulators can mediate their effects on interac-
tions in a number of ways (Figure 7.2). Enhancers shift the conformational equi-
librium of the protein to which it binds towards the increased population of states
that bind ligand with higher affinity. Allosteric inhibitors can either shift the con-
formational equilibrium of the protein to which it binds towards an the increased
population of states that cannot bind ligand (Figure 7.2.a), or towards states that
have a reduced affinity for ligand (Figure 7.2.b). Orthosteric inhibitors could in-
hibit interactions by binding at, or partially to, the ligand binding site, thereby
spatially occluding simultaneous binding (Figure 7.2.c), or by binding close to the
ligand binding site in such a way that results in non-optimal ligand binding (Figure
7.2.d).
FcεRI and Xolair R© (Novartis) are known inhibitors of the IgE/CD23 interaction
(Figure 7.3). FcεRI allosterically inhibits CD23, partly by stabilising a conforma-
tion of IgE-Fc with ‘open’ Cε3 domains, which CD23 cannot bind [18]. Conversely,
Xolair is an orthosteric inhibitor of the IgE/CD23 interaction: crystal structures of
Xolair Fab and Xolair Fab mutant 3 bound to IgE-Fc show that CD23 and Xolair
binding sites overlap (Figure 7.3). In Chapter 3 we demonstrated that aεFab1 also
inhibits the binding of CD23 to IgE-Fc and suggested that it does so allosterically,
by holding IgE-Fc in an ‘open’ conformation and by shifting key residues within
the Cε3 domains. There are, however, no reports of proteins that bind to IgE-Fc
and enhance the interaction between IgE-Fc and CD23.
Previous chapters have described how five aεFabs, with seemingly different
effects on IgE/receptor binding, were discovered, selected and purified. Unlike the
other known IgE/CD23 modulators, which bind the Cε3 domain of IgE-Fc, these
aεFabs primarily bind the Cε2 domains. In this chapter we show that the aεFabs
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Figure 7.2: A schematic representation of the different types of IgE/CD23
inhibition that are theoretically possible by aεFabs. If increasing concen-
trations of aεFab cause a decrease in CD23 binding the aεFab is an inhibitor.
Inhibition can be allosteric or orthosteric. An allosteric inhibitor could bind at a
site distal to the CD23 binding site and inhibit the interaction by shifting IgE-Fc’s
conformational ensemble such that CD23-binding is less favourable. An allosteric
inhibitor could shift the conformational ensemble of IgE such that states that can
bind IgE-Fc are less populated (a) Alternatively, an allosteric inhibitor could cause
a shift that stabilises transiently populated conformations that bind CD23 with
a lower affinity (b). Orthosteric inhibitors could bind IgE at, or close to, the
CD23 binding sites and prevent CD23 binding (c), or they may bind close to the
CD23 binding site resulting in non-optimal binding of CD23 to its binding site and
thereby reduce the affinity of the interaction (d).
have different enhancing and inhibitory effects on the interaction between IgE and
CD23, and provide evidence that suggests they elicit some of these effects through
allosteric mechanisms.
Using concentration-dependent binding assays, we show how each of the aεFabs
affects the binding of IgE to mCD23 on the surface of B cells under equilibrium
conditions. We then describe how we used SPR to investigate how the different
aεFab:IgE-Fc complexes bind derCD23 compared to a control for unmodulated
IgE-Fc/derCD23 binding. We determined the KD, an indicator of the apparent
affinity of an interaction, and the Bmax, an indicator of the binding capacity, for
the interactions between each of the five aεFab:IgE-Fc complexes and derCD23,
and used these values to understand how the different aεFabs elicit their effects on
the IgE-Fc/CD23 interaction (Section 2.6.5).
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Figure 7.3: FcεRI, aεFab1 and Xolair R© bind IgE-Fc and inhibit the
IgE-Fc/CD23 interaction. The crystal structures of sFcεRIα:IgE-Fc [72],
aεFab1:IgE-Fc (2:1) [81] and Xolair Fab mutant 3: IgE-Fc (2:1) [82]. IgE-Fc is
shown as a white surface representation, and the CD23 inhibitors are shown as
coloured surface representations.
7.2 Results
7.2.1 Modulation of the IgE/CD23 interaction on the
surface of cells by aεFabs
Flow cytometry was used to measure the binding of a fluorescently-labeled IgE
molecule (rIgE-A647) to CD23 expressed on the surface of RPMI 8866 cells in
the presence of increasing concentrations of each of the aεFabs. The RPMI 8866
cell-line is a human B lymphocyte cell-line that expresses CD23 on its surface
[161]. rIgE is a patient-derived full-length IgE antibody specific for the grass-pollen
allergen Phl p7 [173]. For the purposes of this experiment rIgE was labeled with
the Alexa Fluor 647 (A647) fluorophore (Thermo Fisher Scientific) using amine-
coupling according to manufacturers instructions.
Experimental design
Preliminary experiments were performed to establish an appropriate working con-
centration of rIgE-A647. RPMI 8866 cells (1 x 105 cells per test) were incubated for
one hour on ice with a titration of rIgE-A647 concentrations. The cell suspensions
were subsequently washed to remove unbound rIgE-A647 and the fluorescence in-
tensity of at least 5 x 103 single live cells per test was measured using flow cytometry
(Figure 7.4.a).
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Figure 7.4: rIgE-A647 binds to mCD23 with nanomolar binding affin-
ity. Preliminary experiments were performed to determine the appropriate work-
ing concentration of a fluorescently-labeled (A647) full length IgE (rIgE) for the
concentration-dependent aεFab studies. RPMI 8866 cells expressing mCD23 were
incubated at 4 ◦C for one hour with varying concentrations of rIgE-A647. The cells
were washed twice with wash buffer (Section 2.7.2) and the A647 fluorescence of
single live cells was read using flow cytometry (a). The mean A647 fluorescence
intensity (MFI) of each test sample was plotted as a function of rIgE-A647 con-
centration, and the data were fit using a one-to-one model (Section 2.6.4) (b). The
KD was estimated to be about 18 nM. At 12 nM rIgE-A647 the binding was in the
linear range of the dose-response curve (c).
The mean A647 fluorescence intensity A647-MFI per cell was used as a measure
of binding of rIgE-A647 to membrane CD23 (mCD23): higher A647-MFI values
indicated a greater level of binding. The A647-MFI of a single cell suspension
incubated with an A647-labeled antibody lacking specific CD23-binding activity
was used to determine the non-specific background A647 fluorescence level. The
A647-MFI values were plotted as a function of rIgE-A647 concentration to establish
a saturation curve for the binding of rIgE-A647 to mCD23 (Figure 7.4.b). The data
were fit to a one-to-one binding model (Section 2.6.4) and the KD of the interaction
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was approximated as 18 nM. 12 nM rIgE-A647 was chosen as a suitable working
concentration of rIgE-A647 as it is close to the determined KD of the interaction and
the A647-MFI of RPMI 8866 cells incubated with rIgE-A647 at this concentration
was in the linear range of the dose-response (Figure 7.4.b). Positive and negative
modulation would therefore be observable under these conditions.
IgE-Fc has two CD23 binding sites, one with a KD around 1 µM and the other
with a KD around 10-20 µM [88] (Section 6.2.3). CD23 exists as a trimer on the
surface of cells and through the avidity effect the IgE/mCD23 interaction can reach
low nanomolar binding affinity. The concentration of mCD23 in each test was esti-
mated to be <0.3 nM, and therefore 12 nM rIgE-A647 the only observable binding
was the binding between one molecule of rIgE-Fc and two molecules of CD23 (Fig-
ure 7.5.a). Accordingly, any effect on the A647-MFI as a result of increasing aεFab
concentration could be a consequence of an impact on one or both of the CD23
binding sites. For example, an orthosteric or allosteric inhibitor that eliminated
only one of the two CD23 binding sites could still, in theory, achieve 100 % inhi-
bition of the rIgE-A647 binding signal at saturating concentrations, because at 12
nM rIgE-A647 will not show appreciable binding to a single CD23 molecule (KD ∼
1 µM).
The aεFabs were incubated with rIgE-A647 and RPMI 8866 cells on ice for
one hour at final concentrations of 0 – 80 nM, using a two fold-dilution series
(Section 2.7.2). Given the KD values of the two different aεFab binding sites (high
picomolar and low nanomolar) and the working concentration of rIgE-A647 (12
nM), it was assumed that only the higher-affinity site reached saturation in these
experiments and that the lower-affinity aεFab site remained mostly unoccupied. In
the previous chapter the KD values of the lower affinity aεFab sites were determined
to range from 170 nM to 800 nM. The fractional saturation of an interaction can
be estimated using Equation 7.1. The fractional saturation of the second aεFab
















































Figure 7.5: Schematic representation of the rIgE-A647/mCD23 binding
assays. (a) A full-length IgE antibody (rIgE) was fluorescently-labeled with A647
(Thermo Fisher Scientific). rIgE-A647 was incubated with RPMI 8866 cells ex-
pressing mCD23 for one hour on ice. The cell suspensions were washed with wash
buffer twice to remove unbound material. The A647 fluorescence of single live
cells was measured using flow cytometry on a BD FACSCanto II (BD Biosciences).
Binding of one rIgE molecule to one mCD23 molecule has a micromolar bind-
ing affinity, whereas the binding of one rIgE molecule to two mCD23 molecules
has a nanomolar binding affinity. Accordingly, only the binding of one rIgE-A647
molecule to two mCD23 molecules occurs at 12 nM rIgE-A647. The A647 fluores-
cence intensity observed for this interaction was defined as 0 % inhibition. (b) The
A647 fluorescence intensities of single RPMI 8866 cells incubated with an A647-
labeled negative control and 80 nM of the different aεFabs, and was used to define
100 % inhibition. (c) The different aεFabs were incubated with rIgE-A647 and
RPMI 8866 cells at various concentrations (80 - 0 nM) and their effect on the A647
fluorescence intensity of single live cells was measured using flow cytometry.
The experiments were performed to identify both positive and negative effects
of the aεFabs on the IgE/CD23 interaction. Despite this, experimental results are
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expressed in terms of percentage inhibition. 0 % inhibition, or more accurately 0
% modulation of the rIgE-A647/mCD23 interaction was established as the A647-
MFI when the aεFab concentration was 0 nM (Figure 7.5.a). 100 % inhibition was
defined as the A647-MFI when 80 nM of aεFab was incubated with RPMI 8866 cells
in the absence of rIgE-A647, but in the presence of an A647-labeled antibody with
no specific CD23-binding activity (Figure 7.5.b). An inhibiting effect is presented
as a reduction in A647-MFI, and the difference in this MFI from the A647-MFI at
0 % is expressed a percentage of the difference between MFIs defined as 0 and 100
% inhibition. No enhancing effects were observed, but an enhancing effect would
have manifested itself as an A647-MFI value greater than that observed for the 0
% data points.
Control experiments
Two controls were performed for each experiment. The first control was performed
to check that RPMI 8866 mCD23 expression levels were similar for each biological
replicate. MHM6-FITC (Dako) is a fluorescently-labeled (FITC) antibody that
binds specifically to CD23. MHM6-FITC was incubated on ice for one hour with
RPMI 8866 cells, the cells were subsequently washed and the FITC fluorescence of
single live cells was measured using flow cytometry. The MFI for background FITC
fluorescence was determined by incubating RPMI 8866 cells with a FITC-labeled
antibody lacking specific CD23-binding activity (Figure 7.6).
A positive control was also performed, in which Xolair Fab mutant 3 was in-
cubated with rIgE-A647 and RPMI 8866 cells at the same concentrations as the
aεFabs. Xolair Fab mutant 3 binds to IgE with nanomolar binding affinity and or-
thosterically inhibits the IgE/CD23 interaction [82]. The plot of A647-fluorescence
inhibition as a function of Xolair Fab mutant 3 concentration showed a dose-
dependent inhibition of the IgE/mCD23 interaction. The data were fit in Origin
(OriginLab) to a dose-response sigmoidal equation and indicated that at saturating
conditions Xolair Fab mutant 3 completely inhibited the IgE/mCD23 interaction
(Figure 7.7). Although Xolair Fab mutant 3, a known orthosteric inhibitor of
the IgE/CD23 interaction, achieved 100 % inhibition at saturating concentrations,
there are circumstances in which inhibitors that elicit their effect by completely
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Figure 7.6: The FITC-labeled MHM6-monoclonal antibody (Dako) indi-
cated the levels of mCD23 expression on RPMI 8866 cells. RPMI 8866
cells incubated with only buffer did not show fluoresence in the A647 or FITC
channels. RPMI 8866 cells incubated with FITC-MHM6, an anti-CD23 antibody,
showed fluorescence in the FITC channel, indicating the binding of the antibody to
the surface of the cells. RPMI 8866 cells incubated with a FITC-labeled antibody
lacking specific CD23 binding activity did not give fluorescence in the FITC chan-
nel, indicating that FITC-MHM6 bound to mCD23 on the cell surface specifically,
and the FITC fluorescence intensity therefore gave an indication of the level of
CD23 expression on the surface of the RPMI 8866 cells.
eliminating a binding site may not achieve 100 % inhibition at saturating condi-
tions. For example, if a molecule exists in a range of conformations, some of which
cannot bind inhibitor, the inhibitor cannot ever bind 100 % of the molecules and
therefore cannot achieve 100 % inhibition.
Concentration-dependent effects of the different aεFabs
Each aεFab titration experiment was performed on three separate days. Satura-
tion of the first aεFab3 and aεFab18 binding sites did not have any concentration-
dependent inhibitory effects on the A647-MFI, suggesting that the binding of these
aεFabs to IgE had no effect on the amount of rIgE-A647/mCD23 binding at equi-
librium (Figure 7.8.a). This experiment, however, could not differentiate between
whether the binding of aεFab3 (or aεFab18) to IgE had no effect on either CD23
binding site or if, for example, one binding site was enhanced and one was inhibited.
Repeated experiments were performed for the highest and lowest concentrations of
aεFab3 and the Wilcoxon Sum Rank tests 2.8.2 [166] indicated there was no sig-
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Figure 7.7: Xolair Fab mutant 3, a Fab that binds to IgE and orthosteri-
cally inhibits CD23 binding, showed concentration-dependent inhibition
of the rIgE-A647/CD23 interaction on the surface of RPMI 8866 cells.
RPMI cells, expressing mCD23, were incubated on ice for one hour with 12 nM
rIgE-A647 and with increasing concentrations of Xolair Fab mutant 3. The cells
were washed twice with buffer and the fluorescence of single live cells was read by
flow cytometry. Reduction in MFI of the single cell suspensions was assumed to
result from inhibition of the rIgE-A647/mCD23 interaction. 0 % inhibition was
defined as the MFI in the absence of Xolair Fab mutant 3. 100 % inhibition was
defined as the MFI in the absence of rIgE-A647, but in the presence of 80 nM
Xolair Fab mutant 3 and an A647-labeled antibody with no specific CD23 binding
activity.
nificant difference in the level of inhibition when 0.125 nM and 80 nM aεFab3 were
added to the incubations (Figure 7.8.b).
The results of the titration experiments showed that aεFab2, aεFab12 and
aεFab13 had concentration-dependent inhibitory effects on the A647-MFI, suggest-
ing that they inhibited the interaction between IgE-A647 and mCD23 at equilib-
rium. Although aεFab12 inhibited IgE/mCD23 binding in these cell-based assays,
in Chapter 5 we observed that aεFab12 appeared to enhance the affinity of the inter-
action between IgE-Fc and the high-affinity CD23 binding site in SPR experiments
(Section 5.2.2). This apparent contrast in results will be discussed in greater depth
later in the chapter. Plots of percentage inhibition of the IgE/mCD23 interaction
versus aεFab concentration were fit to a sigmoidal model in Origin (OriginLab) and
suggested that the aεFabs could achieve maximal inhibition of between 30-50 %
(Figure 7.9, Table 7.1 and Appendix A.10). Repeated experiments were performed
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Figure 7.8: aεFab3 showed no dose-dependent inhibition of the rIgE-
A647/CD23 interaction on the surface of RPMI 8866 cells. RPMI 8866
cells expressing mCD23 were incubated for one hour on ice with rIgE-A647 at a
final concentration of 12 nM and increasing concentrations of aεFab3 The cells
were washed twice with buffer and then the A647 fluorescence of single live cells
was measured using flow cytometry. (a) The A647-MFI was compared to the MFI
of RPMI 8866 cells incubated with 12 nM rIgE-A647 in the absence of any aεFab
(0 % inhibition) and the MFI of of RPMI 8866 cells incubated in the presence of
80 nM aεFab3 in the presence of an A647-labeled antibody with no CD23-specific
binding activity (100 % inhibition). The difference in the MFI in relation to these
two MFI values indicated the percentage of rIgE-A647/mCD23 perturbation. (b)
Five different measurements were taken of the RPMI 8866 cells incubated with 12
nM rIgE-Fc and aεFab3 at either 1.25 nM and or 80 nM. Wilcoxon sum rank tests
[166] indicated there is no significant difference between the mean average level of
inhibition of the two populations. The bars represent the means and the standard
error of the means.
for the highest and lowest concentrations of aεFab2 and aεFab13, and the Wilcoxon
sum rank tests [166] indicated the level of inhibition of the IgE/mCD23 achieved
upon the addition of 80 nM aεFab was statistically significant (Figure 7.10).
As briefly discussed, there are certain conditions in which inhibitors that elim-
inate binding sites cannot achieve 100 % inhibition. IgE-Fc exists as a complex
conformational ensemble and it is conceivable that each of the aεFabs can only
bind a percentage of the available IgE-Fc and therefore cannot achieve 100 % inhi-
bition at saturating conditions. Moreover, the binding of an allosteric inhibitor to
IgE may result in a shift in IgE’s conformational ensemble towards, but not com-
pletely to, conformations of IgE that cannot bind CD23. Alternatively, fractional
maximal inhibition could occur through negative cooperativity (Section 1.4): if the
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Figure 7.9: aεFab2 showed concentration-dependent inhibition of the
rIgE-A647/CD23 interaction on the surface of RPMI 8866 cells. RPMI
cells, expressing mCD23, were incubated on ice for one hour with 12 nM rIgE-A647
and increasing concentrations of aεFab2. The cells were washed twice with buffer
and the fluorescence of single live cells was read by flow cytometry. Reduction in
MFI of the single cell suspensions was assumed to result from inhibition of the
rIgE-A647/mCD23 interaction. 0 % inhibition was defined as the MFI in the ab-
sence of Xolair Fab mutant 3. 100 % inhibition was defined as the MFI in the
absence of rIgE-A647, but in the presence of 80 nM Xolair Fab mutant 3 and an
A647-labeled antibody with no specific CD23 binding activity.
aεFab-bound IgE was still capable of binding CD23, but at a low affinity, such that
the equilibrium levels of mCD23-engaged IgE were reduced. Such an effect can be
mediated both allosterically and orthosterically (Figure 7.2. b and d).
In cases where both CD23 and aεFab can simultaneously bind IgE, CD23 may
also affect the affinity of the aεFab:IgE interaction. In Chapter 5 we saw that
derCD23 binding induced the accelerated dissociation of the aεFab13:IgE-Fc (1:1)
complex (Section 5.2.2).
Based upon the estimated affinities of the two aεFab binding sites on IgE-Fc,
the concentrations of aεFab used in these experiments were sufficient to saturate
only the higher-affinity aεFab binding site. Since the observed inhibition of the
IgE/mCD23 interaction by aεFab2, aεFab12 and aεFab13 reaches a maximum
upon addition of ∼ 30 nM aεFab, it appears that occupation of only one aεFab
binding site on IgE-Fc is necessary for the observed inhibition.
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Maximum inhibition of IgE/mCD23 interaction (%) 
mean (± standard deviation) 
aεFab2 36 ± 1 
aεFab3 - 
aεFab12 33 ± 1 
aεFab13 49 ± 1 
aεFab18 - 
Xolair Fab mutant 3 106 ± 6 
Table 7.1: Maximum inhibition of the IgE/CD23 interaction on the sur-
face of RPMI 8866 cells under saturating conditions of different aεFabs.
RPMI cells, expressing mCD23, were incubated on ice for one hour with 12 nM
rIgE-A647 and increasing concentrations of different aεFabs. The cells were washed
twice with buffer and the fluorescence of single live cells was read by flow cytom-
etry. Reduction in MFI of the single cell suspensions was assumed to result from
inhibition of the rIgE-A647/mCD23 interaction. 0 % inhibition was defined as the
MFI in the absence of Xolair Fab mutant 3. 100 % inhibition was defined as the
MFI in the absence of rIgE-A647, but in the presence of 80 nM aεFab and an
A647-labeled antibody with no specific CD23 binding activity. The percentage in-
hibition was plot as a function of the log of aεFab concentration and the data were
fit to a sigmoidal binding model. The maximal inhibition was indicated by the
upper plateau of each curve, when the lower plateau asymptoted to 0 % inhibition.
The mean average of the maximum inhibition was determined from three biological
repeats. aεFab3 and aεFab18 showed no concentration-dependent inhibition.
7.2.2 SPR investigations into the binding of derCD23 to
different aεFab:IgE-Fc complexes
The cell-based binding assays described the effect of a single aεFab molecule on
the binding of IgE to two molecules of CD23 under equilibrium conditions. These
assays, however, could not resolve the observed effects in terms of the two different
CD23 binding sites (Figure 7.11), nor could they be used to differentiate between
inhibition as a result of change in the affinity of the interaction or inhibition as
a result of elimination of binding sites (Figure 7.2). Understanding both of these
details would help to uncover how the aεFabs elicit their modulating effects, and
the latter may indicate whether any allosteric processes are involved.
Two sets of experiments were performed to ascertain the effect of binding of each
of the aεFabs to IgE-Fc on the binding of derCD23 to IgE-Fc in terms of apparent
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Figure 7.10: The concentration-dependent inhibition of the rIgE-
A647/CD23 interaction on the surface of RPMI 8866 cells by aεFab2
and aεFab13 is statistically significant. Five different tests were performed
to determine fluorescence of RPMI 8866 cells incubated with 12 nM rIgE-Fc and
different aεFabs at either 1.25 nM and or 80 nM. (a) Wilcoxon ranked sum tests
[166] indicated there is no significant difference between the mean average inhibi-
tion for cells incubated with 1.25 nM aεFab2, aεFab13 or Xolair Fab mutant 3,
and 1.25 nM aεFab3, which is known to have no inhibiting effect. However, (b)
Wilcoxon ranked sum tests [166] indicated the difference between the mean average
inhibition for cells incubated with 80 nM aεFab2, aεFab13 or Xolair Fab mutant 3,
and 80 nM aεFab3 is significant. The bars represent the means and the standard
errors of the means.
affinity (KD) and occupancy (Bmax). The first set of experiments looked at the
binding of a single molecule of derCD23 to an aεFab:IgE-Fc (1:1) complex, and
the second looked at the binding of single molecule of derCD23 to an aεFab:IgE-Fc
(2:1) complex. Both types of complex were captured on the surface of a SPR sensor
chip via the interaction between aεFab and a Fab-specific goat-anti-rabbit F(ab’)2
(Jackson ImmunoResearch) (Figure 7.12.a and b). The goat-anti-rabbit surface was
immobilised at a relatively low density (∼400 RUs), using amine-coupling (Section
2.6.2), to ensure the aεFab/IgE-Fc interactions in the first set of experiments, and
the IgE-Fc/derCD23 interactions in both sets of experiments, were monovalent.
There were two main reasons for investigating the effect on the aεFabs on the higher
(∼1 µM) derCD23 binding activity rather than the the higher and the lower (∼10
µM) derCD23 binding activities. Firstly, the difference in affinity between the two
sites is relatively small and it could therefore be difficult to attribute the two sets
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Figure 7.11: The equilibrium effect of the aεFabs on the interaction be-
tween 12 nM rIgE-A647 and CD23 on the surface of RPMI 8866 cells is a
combination of the effects of each of the sites. In these assays an aεFab may
have an inhibitory effect on the interaction, an enhancing effect of the interaction
or no effect at all at equilibrium. However, the observed effects can be achieved in
multiple ways by modulating the two CD23 binding sites differently.
of experimentally determined KD and Bmax values to the two different binding sites
if the aεFabs alters these values. Secondly, determining the effect of the aεFabs on
the KD and Bmax values of the 10 µM binding site would require titrating derCD23
from high concentrations (∼ 100 µM), which would require significant quantities
of derCD23.
his-tag 
c) un-modulated binding 
Key 
SPR surface 
anti-his antibody his-tagged IgE-Fc 
derCD23 
aεFab 
anti-Fab F(ab’)2 IgE-Fc 
a) binding to 1:1 
complex  
b) binding to 2:1 
complex  
Figure 7.12: A schematic representation of the SPR experiments per-
formed to assess the binding of derCD23 to the the higher-affinity bind-
ing site of different aεFab:IgE-Fc complexes.
A mock amine-coupled surface was used as a reference-subtraction surface in all
SPR cycles. derCD23 was injected over the different aεFab:IgE-Fc complexes at
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concentrations ≤ 2 µM, at which only the higher-affinity derCD23 binding site is
significantly occupied in an unmodulated IgE-Fc/derCD23 interaction. The SPR
response during the steady-state of derCD23 binding to the different aεFab:IgE-Fc
complexes was plot as a function of derCD23 concentration and fit using a one-to-
one binding model (Section 2.6.4). The fits were used to determine the KD and
Bmax values for the binding of a single molecule of derCD23 to an aεFab:IgE-Fc
complex. These values were compared to the values derived for a control for the
binding of derCD23 to IgE-Fc in the absence of aεFab (Figure 7.12.c).
Experiments similar to the first set of experiments were performed on the aεFabs
in Chapter 5 except that the aεFabs had not been purified and they were performed
in the absence of a control for unmodulated binding of a single molecule of derCD23
to IgE-Fc (Section 5.2.2). The production of anti-His-tagged IgE-Fc (Section 3.2.2)
enabled these experiments to be performed alongside a control for an unmodulated
derCD23/IgE-Fc interaction, and consequently the effects of the aεFabs could be
defined as inhibitory or enhancing. An anti-histidine antibody (THETM His tag
mouse mAb, Genscript) was immobilised at a low density on an SPR surface using
amine-coupling. His-tagged IgE-Fc was captured by the anti-His antibody and the
same concentrations of derCD23 as injected over the aεFab:IgE-Fc surface were
also injected over the anti-His:His-IgE-Fc complex as a control for unmodulated
binding of derCD23 to IgE-Fc (Figure 7.12.c).
This experimental set-up can indicate different modes of modulation (inhibition
versus enhancement) as well as different types of inhibition (Section 2.6.5) (Figure
7.2). If an aεFab sterically precludes the binding of derCD23 to its higher-affinity
site (Figure 7.2.c) then there would be no increase in SPR response upon injection
of derCD23, as derCD23 would be unable to bind to the aεFab:IgE-Fc complex.
However, if the Bmax of the derCD23/IgE-Fc interaction is reduced by the binding
of an aεFab to IgE-Fc, it indicates that there are fewer derCD23 binding sites
available as a result of allosteric modulation (Figure 7.2.a). Accordingly, these
assays can differentiate between modulators that eliminate derCD23 binding sites
allosterically and those that eliminate derCD23 binding sites orthosterically.
derCD23, however, may bind to an aεFab:IgE-Fc complex with the native ca-
pacity but with lower affinity (negative cooperativity (Section 1.4)). In which case,
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the Bmax would be 100 % of the theoretical Bmax value, but the KD of the inter-
action would be reduced. This assay is unable to distinguish whether an aεFab
with this effect on derCD23 binding to IgE-Fc mediates the effect allosterically or
orthosterically (Figure 7.2.b vs d).
derCD23 binding to aεFab:IgE-Fc (1:1) complexes
Firstly, to control for any nonspecific binding between the different aεFabs and
derCD23, 100 nM of each of the purified aεFabs was injected for 180 s over the
anti-rabbit-fab surface, followed by a 120 s injection of 2 µM derCD23. There was
no increase in SPR response upon injection of 2 µM derCD23 over the different
captured aεFabs (data not shown), indicating derCD23 does not bind appreciably
to any of the aεFabs.
20 nM of each of the purified aεFabs were separately injected for 180 s over the
anti-rabbit-Fab surface and 75 nM IgE-Fc was injected for 180 s over the captured
aεFab resulting in the formation of captured aεFab:IgE-Fc (1:1) complexes. A
two-fold dilution series of derCD23, starting at 2 µM, was injected for 120 s over
the aεFab:IgE-Fc (1:1) complex (Figure 7.13.a). The binding of derCD23 to each
of the aεFab:IgE-Fc complexes reached steady-state during the time-course of each
derCD23 injection (Figure 7.13.b and Appendix A.11). The KD and Bmax values for
the binding of a single molecule of derCD23 to His-tagged IgE-Fc were established
by the binding of the same derCD23 titration to captured histidine-tagged IgE-Fc
(Figure 7.14). The anti-rabbit-Fab surface was regenerated by two 60 s pulses of
10 mM glycine pH 1.7 and one 30 s pulse of 5 mM NaOH.
The Bmax of the control interaction was around 100 % of the theoretical Bmax
for the binding of one molecule of derCD23 to IgE-Fc, indicating the experiment
had been correctly set up to interrogate the binding of derCD23 to just one site on
to IgE-Fc. The KD of the interaction was ∼0.7 µM.
Two of the aεFab:IgE-Fc (1:1) complexes, aεFab3:IgE-Fc (1:1) and aεFab13:IgE-
Fc (1:1) also had Bmax values around 100 % of the theoretical Bmax value and had
KD values close to the control. This suggested that the binding of a single molecule
of aεFab3, or a single molecule of aεFab13, to IgE-Fc did not affect the binding
of derCD23 to the 1 µM derCD23 binding site (Figure 7.15.a). The binding of
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aεFab2, aεFab12 and aεFab18 to IgE-Fc, however, did modulate the binding of
one molecule of derCD23 to IgE-Fc (Figure 7.15.a). aεFab2 appeared to inhibit
the interaction (via negative cooperativity), aεFab12 and appeared to enhance it
(positive cooperativity), and aεFab18 appeared to have a mixed effect.
We plan to perform additional experimental repeats to verify the sometimes
subtle effects of the various aεFabs that were observed. Experimental repeats
are particularly important in assays where materials are highly variable, such as
in cellular experiments. The number of variables that contribute to protein-only
assays, like this, are comparatively very low. The variables in biophysical assays
using purified proteins include protein concentration and the harder-to-quantitate
protein quality. Variations in protein concentration, through errors in absorbance
measurements or pipetting, for example, would affect the KD and Bmax values
calculated from this set of experiments, and therefore statistical analysis of repeated
measurements is necessary for a greater level of confidence in the results. Whilst
the values themselves may be affected by concentration errors, the general trends
in these observables, and the relation of the observables to the control, would
not be effected by such variations since the injections were from the same closed
vials of purified IgE-Fc and derCD23 for all SPR cycles. Indeed, we observe the
same general trends in KD and Bmax in the same type of experiments performed in
Chapter 5 with unpurified aεFabs.
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Figure 7.13: Example sensorgrams from SPR experiments performed to
investigate the binding of derCD23 to aεFab-bound IgE-Fc (1:1) com-
plexes. (a) Purified aεFab (aεFab2 here) was injected over a Fab-specific goat-
anti-rabbit F(ab’)2 sensor surface. IgE-Fc bound the captured aεFab and derCD23
was injected over the aεFab2:IgE-Fc (1:1) complex. Binding was observed as an
increase in SPR response. (b) The response when 0 nM derCD23 was injected over
the aεFab2:IgE-Fc complex was subtracted from the response when derCD23 was
injected over the complex at increasing concentrations. This subtraction eliminated
changes in response that occurred as a result of dissociation of aεFab2:IgE-Fc from
the anti-rabbit surface, as well as changes as a result of IgE-Fc dissociation from
aεFab2.
























Bmax = 102 RUs 
KD     =  0.7 µM   
Bmax = 105 RUs 
KD     =  2.9 µM   
Figure 7.14: Binding plots for the interaction between derCD23 and
His-IgE-Fc (green) and derCD23 and the aεFab2:IgE-Fc (1:1) complex
(blue). The binding of derCD23 was measured as an increase in SPR response.
The steady-state response values (circles) were determine from an average of 5 s
of the steady-state response. The data were fit (lines) using a single binding site
model. The steady-state response was normalized such that the maximum response
for the binding of IgE-Fc to aεFab was 360 RUs. aεFab2-bound IgE-Fc shows a
reduced affinity for the binding of derCD23 compared to His-IgE-Fc.
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derCD23 binding to aεFab:IgE-Fc (2:1) complexes
In order to investigate the binding of one molecule of derCD23 to IgE-Fc pre-
complexed with two identical aεFabs it was first necessary to generate the aεFab:IgE-
Fc (2:1) complexes. Protein G purified aεFabs were incubated at 4◦C overnight
with IgE-Fc at a 2:1 molar ratio. An additional 10 % molar excess of each aεFab
was also added to ensure the full occupation of all aεFab binding sites on the IgE-Fc
molecules.
After incubation, each of the aεFab:IgE-Fc (2:1) complex solutions were run
down a Superdex 200 preparative SEC column (GE Healthcare) to purify the
aεFab:IgE-Fc (2:1) complex from potential contaminants such as unbound aεFab,
unbound IgE-Fc or 1:1 complexes. The aεFab:IgE-Fc (2:1) complexes were eluted
in 25 mM Tris-HCl, 125 mM NaCl pH 7.4, and appeared as the main peak in
the chromatograms (data not shown). Aliquots of the main peak fractions were
run down a G3000SWxl analytical HPLC SEC column (Tosoh) in 20 mM sodium
phosphate, 50 mM sodium chloride buffer, pH 7.4 to determine their purity. HPLC
analysis indicated that each of the aεFab:IgE-Fc (2:1) complexes contained a very
small percentage of contaminant in the form of un-complexed aεFab (Figure 7.16
and Appendix A.12).
The purified aεFab:IgE-Fc (2:1) complexes were injected for 180 s over the Fab-
specific goat-anti-rabbit F(ab’)2 sensor chip surface at a concentration equating to
100 nM IgE-Fc, and increasing concentrations of derCD23 were injected for 120
s over the captured 2:1 complex (Figure 7.17 and Appendix A.13). Due to the
intrinsic dissociation of the aεFab:IgE-Fc (2:1) complexes, a small percentage of
the derCD23 may actually have bound IgE-Fc that was bound to only a single
molecule of aεFab. The binding of derCD23 to each aεFab:IgE-Fc (2:1) complex
reached a steady-state during the time-course of each derCD23 injection (Figure
7.17.b). The KD and Bmax values for the unmodulated binding of one molecule of
derCD23 to His-tagged IgE-Fc were established by injecting of the same derCD23
titration over captured histidine-tagged IgE-Fc (Figure 7.18).
235

















Figure 7.15: Histograms shown the dissociation constants (KD) and Bmax
values for the binding of derCD23 to aεFab:IgE-Fc complexes as de-
termined by SPR. The steady-state binding responses for the binding of 0-2
µM of derCD23 to (a) captured aεFab:IgE-Fc (1:1) complexes and (b) captured
aεFab:IgE-Fc (2:1) complexes, were plotted as a function of derCD23 concentra-
tion. The data were fit using a one-to-one binding model to determine the KD and
Bmax values. The Bmax values are expressed as a percentage of the theoretical Bmax
values for the binding of one molecule of derCD23 to one molecule of IgE-Fc. The
same experiments and analysis was performed the binding of derCD23 to captured-
His-IgE-Fc as a control for unmodulated derCD23 binding to IgE-Fc. The error
bars indicate the errors associated with the fit of the data.
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Figure 7.16: Analytical HPLC SEC analysis of aεFab2:IgE-Fc (2:1) com-
plex preparative SEC fractions. aεFab2, IgE-Fc and peak fractions from SEC
of the aεFab2:IgE-Fc (2:1) complex were run down a G3000SWxl analytical HPLC
SEC column (Tosoh) in 20 mM sodium phosphate 50 mM sodium chloride buffer
pH 7.4. The results suggest that the SEC fractions contain aεFab2:IgE-Fc (2:1)
complex with a very small proportion of unbound aεFab2.
The experiments were performed with concentrations of derCD23 expected to
result in significant occupation of the higher-affinity derCD23 site of the control
His-tagged IgE-Fc only. However, the Bmax for the binding of derCD23 to His-
tagged IgE-Fc was calculated to be around 125 % of the theoretical Bmax value,
suggesting that under these experimental conditions the second derCD23 site was
partially occupied. The KD of the interaction was determined to be 1 µM, which
is the expected KD for the binding of derCD23 to the higher-affinity site of IgE-Fc
(Figure 7.15.b). It is immediately obvious from the binding curves (Figure 7.18)
that none of the aεFab:IgE-Fc (2:1) complexes had the same binding profile as the
control, indicating that in each case the binding of two aεFabs to IgE-Fc modu-
lated the IgE-Fc/derCD23 interaction. As with the previous set of experiments
that investigated the binding of derCD23 to 1:1 aεFab:IgE-Fc complexes, we plan
to perform additional experimental repeats to verify and statistically analyse the
results.
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Figure 7.17: Example sensorgrams from SPR experiments performed to
investigate the binding of derCD23 to aεFab:IgE-Fc (2:1) complexes
(here the aεFab2:IgE-Fc (2:1) complex). (a) The purified aεFab2:IgE-Fc (2:1)
complex was captured on the surface of a sensor chip by a Fab-specific goat-anti-
rabbit F(ab’)2. derCD23 was injected over the complex and binding was observed
as an increase in SPR response. (b) The response when 0 µM derCD23 was injected
over the complex at increasing concentrations. This subtraction eliminated changes
in response that occurred as a result of aεFab2:IgE-Fc (2:1) complex dissociation,
and the dissociation of the complex from the surface.
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Figure 7.18: Binding curves for the interactions between derCD23 and
His-IgE-Fc and between derCD23 and aεFab:IgE-Fc (2:1) complexes.
The binding of derCD23 to either His-IgE-Fc captured on an anti-his tag antibody
(Genscript) surface, or aεFab:IgE-Fc (2:1) captured on an a Fab-specific goat-anti-
rabbit F(ab’)2 (Jackson ImmunoResearch) surface, was measured as an increase in
SPR response. The steady-state binding values (circles) were determined from an
average of 5 s of response recorded during the steady-state binding of derCD23 to
IgE-Fc. The data were fit (lines) using a single-site binding model. The steady-
state response normalised so that the maximum binding of complex to the anti-Fab
surface was equivalent of 400 RUs of IgE-Fc binding.
7.2.3 Models for how each aεFab modulates the interaction
between IgE and CD23
The results of the SPR experiments were examined in conjunction with the cell-
based binding assays to build models for how each of the aεFabs modulate the
interaction between IgE and CD23 (Figure 7.19). The cell-based assays investigated
the effect that saturation of the first aεFab binding site had on the binding of IgE
to membrane CD23 and was sensitive to effects on either CD23 binding sites.
The SPR experiments, however, investigated how saturation of one or both aεFab
binding sites affected the binding of derCD23 to the higher-affinity site of IgE-
Fc only. Because one assay looked at the effect of the aεFabs on just one CD23
binding site and the other investigated the effects on either CD23 binding site,
comparing the results allowed us to speculate how the second CD23 binding site
was affected by the binding of each of the aεFabs. In some cases the results of the
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two assays were in good agreement and the effect of aεFab binding on the IgE/CD23
interaction could be described by a simple model. In other cases the effect of an
aεFab in the SPR experiments was not matched by the effect observed in the cell-
binding experiments. In such cases it was necessary to invoke a more complicated
mechanism to rationalise both results. In these latter cases, the models are more
speculative, and it is possible that in fact the differences that were observed between
the two results of the two assays are not simply a consequence of their differential
sensitivities to effects of the two CD23 binding sites on IgE. These differences may
also be the result of variations in the two assays such as the use of IgE versus
IgE-Fc or mCD23 versus derCD23.
1 x aεFab2 2 x aεFab2 1 x aεFab12 2 x aεFab12 1 x aεFab3 2 x aεFab3 
1 x aεFab13 2 x aεFab13 1 x aεFab18 2 x aεFab18 
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allosteric 
modulation A 
Figure 7.19: Schematic representations of the proposed models for the
affect of each aεFab on the IgE/CD23 interaction. The left-hand side CD23
binding site represents the higher-affinity binding site, whereas the right-hand side
CD23 binding site represents the lower-affinity binding site.
The aεFab2 model
The binding of 0 - 2 µM derCD23 to aεFab2:IgE-Fc had an increased KD compared
to the control interaction, which did not increase further upon binding of a second
aεFab2 molecule to IgE-Fc (Figure 7.15). It is possible that the higher-affinity
CD23 site was blocked and the lower affinity activity that was observed was the
result of derCD23 binding to an enhanced lower-affinity site (positive cooperativity
with respect to the lower-affinity CD23 site). Two molecules of derCD23, however,
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appeared able to bind to the aεFab2:IgE-Fc (2:1) complex, indicating that even
when IgE-Fc is bound to two molecules of aεFab2, the two CD23 binding sites are
both still available. We therefore attribute the increase in KD to a reduction in
the affinity of the higher-affinity site (negative cooperativity with respect to the
higher-affinity CD23 site), rather than the abolition of the higher-affinity site and
the enhancement of the lower-affinity site. The cell-based assay data also indicate
that aεFab2 inhibits the interaction between IgE and CD23. The assay showed
around a 30 % reduction in the binding of IgE to CD23 expressed on the surface
of RPMI 8866 cells when incubated with aεFab2 under equilibrium conditions
(Figures 7.9, 7.10 and Table 7.1), and this inhibition reached a maximum under
conditions required to saturate the first aεFab2 binding site of IgE. It is therefore
proposed that one molecule of aεFab2 inhibits the interaction between IgE-Fc and
CD23 by reducing the affinity of the higher-affinity CD23 binding site. Evidence
suggests that aεFab2 binds to the Cε2 domains of IgE-Fc and that the aεFab2:IgE-
Fc complex is extended (Section 6.2.5 and Section 6.2.4). Consequently we propose
that aεFab2 acts as an allosteric inhibitor of the IgE/CD23 interaction, as aεFab2-
bound to IgE-Fc would be unlikely to sterically interfere with the binding of CD23
(Figure 6.22).
The aεFab3 model
The binding of 0 - 2 µM derCD23 to the aεFab3:IgE-Fc (1:1) complex had a bind-
ing profile comparable to the control interaction (Figure 7.15.a) indicating that
the binding of the first aεFab3 molecule to IgE-Fc does not perturb the binding of
derCD23 to the higher-affinity CD23 binding site on IgE-Fc. Similarly, saturation
of the first aεFab3 binding site on IgE did not result in any change in the level of
binding of IgE to CD23 on the surface of RPMI 8866 cells at equilibrium (Figure
7.8). The binding of 0 - 1.7 µM derCD23 to the aεFab3:IgE-Fc (2:1) complex did,
however, have a Bmax value around 75 % the value of the theoretical Bmax for the
binding of one derCD23 molecule to IgE-Fc (Figure 7.15.a). The reduction in Bmax
suggests that when IgE-Fc is bound to two molecules of aεFab3, the higher-affinity
CD23 binding site is still available, but over the entire population the number
of binding sites has been reduced. We therefore suggest that the binding of one
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molecule of aεFab3 to IgE-Fc does not modulate the interaction between IgE and
CD23, however the binding of a second aεFab3 molecule inhibits the binding of
derCD23 to the higher-affinity binding site by shifting the conformational equilib-
rium of IgE-Fc such that states that cannot bind aεFab3 become more populated.
The aεFab12 model
The KD for the binding of 0 - 2 µM derCD23 to the aεFab12:IgE-Fc (1:1) complex
was reduced compared to the control interaction, and it was further reduced by
the binding of a second aεFab12 molecule to IgE-Fc (Figure 7.15). These results
indicate positive cooperativity: that the binding of aεFab12 to IgE-Fc enhances
the affinity of the higher-affinity derCD23 binding site. In the second set of SPR
interactions, which investigated the effect of two molecules of aεFab on the binding
of derCD23 to the higher-affinity binding site, the control interaction had a Bmax
in excess of 100 % of the theoretical Bmax for the binding of a single derCD23 to
IgE-Fc. This suggests that the concentrations of derCD23 that were used in these
experiments was sufficient to give partial, but observable, binding to the lower-
affinity binding site. Nevertheless, the Bmax of the interaction between derCD23
and the aεFab12:IgE-Fc (2:1) complex was around 100 % of the theoretical Bmax
value, indicating that the binding of the second derCD23 site was inhibited by the
presence of aεFab12 (Figure 7.15.b).
In the cell-based binding assays, increasing concentrations of aεFab12 resulted
in about a 30 % reduction of binding between IgE and CD23 expressed on the
surface of RPMI 8866 cells (Table 7.1), which may be attributed to the inhibition
of the second CD23 binding site that was observed in the SPR experiments. It is
proposed, therefore, that aεFab12 binds to IgE-Fc and acts as a positive allosteric
modulator of the higher-affinity CD23 binding site, but that it inhibits the binding
to the lower-affinity CD23 site. It is not possible to ascertain exactly how the second
site is inhibited from this data: it could be allosterically or sterically inhibited.
aεFab12 is thought to bind to the Cε2-Cε3 domain interface and evidence suggests
that aεFab12:IgE-Fc is partially unbent. Depending on the degree of Cε2 extension,
overlap between a single aεFab12 molecule and a single CD23 head domain is
possible, and therefore aεFab12 may potentially inhibit the lower-affinity binding
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site orthosterically. X-ray crystallographic data will help to clarify if the lower-
affinity derCD23 binding site is sterically inhibited by the the binding of aεFab12.
The aεFab13 model
Similar to aεFab3, the binding of 0 - 2 µM derCD23 to the aεFab3:IgE-Fc (1:1)
had a binding profile comparable to the control interaction (Figure 7.15.a) and
the binding of 0 - 1.7 µM derCD23 to the aεFab13:IgE-Fc (2:1) complex had a
Bmax around 70 % of the theoretical Bmax for the binding of one derCD23 molecule
to IgE-Fc (Figure 7.15.b). Saturation of the first aεFab13 binding site on IgE,
however, resulted in a decrease of ∼50 % in the binding of IgE to CD23 on the
surface of RPMI 8866 cells under equilibrium conditions (Figure 7.10 and Table
7.1). Since the cell-binding assay is sensitive to effects on either CD23 binding site,
it is possible that the inhibition that was observed upon saturation of only the
first aεFab13 binding site was the consequence of inhibition of the second CD23
binding site only. Accordingly, it is proposed that the binding of one molecule
of aεFab13 to IgE-Fc does not modulate the higher-affinity CD23 binding site on
IgE, but that it does inhibit the lower-affinity CD23 binding site. The binding of a
second molecule of aεFab13 to IgE-Fc, however, allosterically reduces the number
of available derCD23 binding sites. Evidence suggests that aεFab13 binds the
Cε2 domains of IgE-Fc and aεFab13:IgE-Fc is partly extended (Section 6.2.5 and
Section 6.2.4). Consequently, aεFab13 would be unlikely to sterically interfere with
the binding of CD23 to the Cε3 domain near the Cε3-Cε4 interface (Figure 6.22).
Accordingly, inhibition of the lower-affinity CD23 binding site is also likely to be
allosteric.
The aεFab18 model
The binding of 0 - 2 µM of derCD23 to the aεFab18:IgE-Fc (1:1) complex had a
Bmax that was ∼130 % of the theoretical Bmax for the binding of derCD23 to IgE-
Fc with a 1:1 stochiometry (Figure 7.15.a), which suggests that the lower-affinity
CD23 binding site was partially occupied. The contribution from the binding of a
second derCD23 molecule to IgE-Fc made it difficult to establish the effects that the
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binding of a single molecule of aεFab18 had on the higher-affinity derCD23 binding
site, it did, however, indicate that aεFab18 enhanced the affinity of the lower-
affinity derCD23 binding site (positivity cooperativity with respect to the lower-
affinity derCD23 binding site). The cell-based binding studies showed that the
binding of one molecule of aεFab18 to IgE had no effect on the levels of IgE binding
to CD23 on the surface of RPMI 8866 cells under equilibrium conditions. This
suggests that aεFab18 probably had an inhibitory effect on the higher-affinity CD23
binding site, which counteracted the enhancement of the lower-affinity site. The
binding of 0 - 1.7 µM derCD23 to the aεFab18:IgE-Fc (2:1) had an increased KD
compared to the control interaction (Figure 7.15.b), suggesting it had an inhibiting
effect on the binding of derCD23 to the higher-affinity binding site. It is proposed,
therefore, that the binding of one molecule of aεFab18 to IgE reduces the affinity
of the higher-affinity CD23 binding site, but acts as a positive allosteric modulator
of the lower-affinity CD23 binding site. The mechanism by which the binding of a
second aεFab18 molecule to IgE-Fc elicits its inhibitory effect is unknown.
derCD23-induced accelerated dissociation of aεFab13 from IgE-Fc.
The negative cooperative phenomenon of derCD23-induced accelerated dissocia-
tion of an aεFab13:IgE-Fc (1:1) complex was previously described in Chapter 5.
Accelerated dissociation of other IgE-Fc complexes have previously been described
(Section 1.3.5). DARPin E2 79 has been shown to induce the accelerated dissoci-
ation of IgE-Fc from FcεRI [109] and in Chapter 3 it was described how derCD23
induced the accelerated dissociation of aεFab1 from IgE-Fc. DARPin E2 79 has
been proposed to induce accelerated dissociation via a facilitated dissociation mech-
anism, in which DARPin E2 79 binds several attachment points at the FcεRI bind-
ing site that become available during the normal dissociation process, and thereby
increases the intrinsic rate of dissociation. It has also been proposed, by the same
laboratory, that Xolair acts to accelerate dissociation of IgE:FcεRI complexes by
facilitated dissociation [108]. However, these conclusions were based upon crystal
structures of DARPin E2 79 and Xolair Fab bound to a constrained IgE-Fc(3-4)
construct held in a ‘closed’ conformation [109]. Davies et al. have suggested that
accelerated dissociation of Xolair actually occurs via an allosteric mechanism [82],
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and in Chapter 3 we suggested that derCD23 induces the accelerated dissociation of
the aεFab1:IgE-Fc (1:1) complex via allosteric processes involving conformational
changes within the Cε3 domains of IgE.
125 nM derCD23 
500 nM derCD23 
250 nM derCD23 
aεFab13:IgE-Fc (2:1) 
1000 nM derCD23 
2000 nM derCD23 
aεFab13:IgE-Fc (1:1) 
200 nM derCD23 
500 nM derCD23 
800 nM derCD23 
1100 nM derCD23 
1400 nM derCD23 
1700 nM derCD23 
a) b) 
Figure 7.20: derCD23-induced accelerated dissociation of aεFab13 from
IgE-Fc occurs when aεFab13 is in a 1:1 complex with IgE-Fc but not a 2:1
complex. The double-reference subtracted SPR sensorgrams of derCD23 binding
to (a) captured aεFab13:IgE-Fc (1:1) complex and (b) captured aεFab13:IgE-Fc
(2:1) complex. derCD23 binds to the aεFab13:IgE-Fc (1:1) complex resulting in an
increase in signal, but during the derCD23 injection, the response falls, indicating
a drop in mass at the surface from the accelerated dissociation of the aεFab13:IgE-
Fc (1:1) complex. derCD23-induced accelerated dissociation of the aεFab13:IgE-Fc
(2:1) complex does not occur.
The SPR experiments that were performed with purified aεFab13 described
in this chapter also show that derCD23 induced the accelerated dissociation of
aεFab13 from IgE-Fc, but only when aεFab13 was present in a 1:1 complex (Fig-
ure 7.20). When derCD23 bound to the aεFab:IgE-Fc (2:1) complex it did not
induce accelerated dissociation. At present we do not know the exact binding site
of aεFab13, but evidence suggests that aεFab13 binds to the Cε2 domains of IgE-
Fc and aεFab13:IgE-Fc is partly extended (Section 6.2.5 and Section 6.2.4). Given
that the derCD23 binding sites are located in the Cε3 domains close to the the Cε3-
Cε4 interface, it is unlikely that the aεFab13 and derCD23 binding sites share any
partial overlap required to induced accelerated dissociation by a facilitated dissoci-
ation mechanism. We therefore propose that derCD23 induced dissociation of the
aεFab:IgE-Fc (1:1) is allosterically driven. The fact that derCD23 does not induce
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accelerated dissociation of the 2:1 complex further suggests that the phenomenon
described here is not mediated by facilitated dissociation. The same attachment
points would presumably become available to derCD23 during the dissociation of
both the 1:1 and 2:1 complexes, and so one would expect accelerated dissociation
of both complexes could occur. Whereas it is plausible that the binding of two
aεFab13 molecules to IgE-Fc, as opposed to one, prevents the dynamic processes
required for allosterically-mediated accelerated dissociation of the complex upon
binding derCD23.
7.3 Discussion
The ultimate aim of this project is to identify allosteric modulators of the IgE/CD23
interaction, and through their characterisation gain insights into the mechanisms of
allostery in IgE. Five aεFabs were selected for their ability to bind IgE-Fc and their
apparent ability to modulate IgE-receptor interactions in different ways. The aim of
the work presented in this chapter was to determine the effects of the aεFabs on the
IgE/CD23 interaction compared to suitable controls for unmodulated interaction,
and to ascertain whether the aεFabs mediated any enhancing or inhibitory effects
through allosteric processes.
Determining the exact effect of the aεFabs on the IgE/CD23 interaction is
complicated by the fact that IgE-Fc has two CD23 binding sites of different affinities
(Section 1.2.3). The SPR experiments that were performed were designed to try to
understand how each of the aεFabs affects the higher-affinity CD23 binding site.
In some instances the combination of SPR and cell-based experiments provided
insights into how the aεFabs may modulate the lower-affinity site.
The cell-based binding assays investigated the effect of saturation of a single
aεFab binding site on IgE-Fc on the interaction between IgE and CD23 expressed on
the surface of a B lymphocyte cell-line under equilibrium conditions. Three aεFabs
inhibited the interaction, with a maximal level of inhibition around 30-50 %. None
of the aεFabs enhanced the binding between IgE and mCD23 under equilibrium
conditions at the concentrations tested. These experiments explored the effect
of aεFab on IgE bound to mCD23 with a 1:2 stochiometry. To deconvolute the
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effects of the two different CD23 binding sites, SPR experiments were performed
to investigate the binding of derCD23 to the higher-affinity binding site of IgE-Fc
in complex with one and two molecules of aεFab. By determining the KD and
Bmax values of the interaction between derCD23 and the different aεFab:IgE-Fc
complexes it was possible to determine the effect of the aεFabs on the higher-
affinity derCD23 site. Using the SPR data in combination with the cell-based
assay data, intramolecular FRET data and Cε2 binding data, models for how each
of the aεFabs affects the IgE/CD23 interaction were generated
The cell-based assays indicated that aεFab2, aεFab12 and aεFab13 inhibit the
interaction between IgE and CD23, and the SPR studies suggest that the aεFabs
achieve inhibition differently by affecting the two CD23 binding sites differentially.
aεFab2, for example, appears to reduce the affinity of the higher-affinity binding
site, whereas aεFab12 appears to simultaneously enhance the higher-affinity CD23
binding site and inhibit the lower-affinity site.
The results suggest that the aεFabs mediate at least some of their effects
through allosteric mechanisms (Figure 7.19). Additionally, the SPR studies in-
dicate that derCD23-induced accelerated dissociation of aεFab13 from IgE-Fc is
allosterically driven. These examples of allosteric modulation are unique com-
pared to any other instances of allosteric modulation of IgE-Fc reported in the
literature. Firstly, no other engineered modulators that have been reported in the
literature bind IgE and allosterically modulate CD23 binding. Furthermore, all
of the published work on allosteric modulation of IgE-Fc to date, describes al-
losteric communication between two sites within a single Cε3 domain [18, 81]. The
aεFabs described here bind to the Cε2 domains of IgE-Fc (Section 6.2.5) and in
some cases allosterically communicate with the CD23 binding sites located near
to the Cε3-Cε4 interface of the Cε3 domains. This suggests that receptor binding
can be allosterically modulated over relatively long distances and between different
domains of IgE-Fc.
It is important to note that the models that have been proposed were based
upon the assumption that the effect of one aεFab on the binding of a single CD23
head to the higher-affinity site of full-length IgE in the context of the cellular assays
is the same as the effect of binding of derCD23 to the higher-affinity site of IgE-Fc
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in the SPR assays. Because the SPR experiments were only sensitive to changes
in the higher-affinity site, whereas the cell-binding assays were sensitive to changes
in either CD23 binding site, the assumption was made in some cases in order to
infer the effect that an aεFab had on the second binding site, so as to reconcile
the observations from the two different experiments. For example, saturation of
the first aεFab13 site reduced the level of mCD23-bound IgE at equilibrium by
∼50 % in the cell assays. Whereas results from SPR experiments suggest that the
saturation of the first aεFab13 binding site had no effect on the binding of CD23
to its higher-affinity site. These two results could be explained if the inhibition
observed in the cell-based assay was the result of negatively affecting the lower-
affinity CD23 binding site as opposed to higher-affinity CD23 binding site.
Differences in IgE-Fc’s environments in the SPR and cell-based experiments
may, however, affect the functional outcome of a perturbation in each experiment.
The exact effect a modulator has when it binds to its target depends upon the
position of the ensemble equilibrium of the target at that time, and this can be
altered by numerous factors (Section 1.4). For example, even if all other experi-
mental conditions were identical, the position of the equilibrium of the ensemble of
aεFab-bound IgE-Fc in the context of full length IgE (as used in the cell-binding
experiments), may be different from the position of the equilibrium ensemble of
aεFab-bound IgE-Fc. Consequently, the most populated of aεFab-bound IgE-Fc
under the two distinct conditions may be different, and therefore the weighted
functional outcome of the ensemble may not be the same in the two different con-
ditions. In this way, an allosteric modulator could have opposing effects under
different conditions (Section 1.4).
Understanding exactly how the aεFabs modulate the binding of the lower-
affinity CD23 site may help to validate the models. The effects of the lower-affinity
site may be better understood by performing the SPR experiments at higher con-
centrations of derCD23 that saturate both the higher-affinity and lower-affinity
binding sites. However, this requires working at high micromolar concentrations of
derCD23, and therefore requires significant quantities of derCD23. Furthermore,
unambiguously attributing the two sets of KD and Bmax values to the two different
binding sites may not be possible if these values are perturbed by the presence of
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aεFab.
Comparisons of X-ray crystallographic structures of the various aεFab:IgE-Fc
complexes with those of derCD23-bound IgE-Fc could also help validate the models
and may help to understand the mechanisms by which some of these aεFabs appear
to allosterically modulate the IgE/CD23 interaction. Similar comparisons of the
aεFab1:IgE-Fc (2:1) structure and derCD23:IgE-Fc (2:1) structure performed in
Chapter 3 suggested an allosteric mechanism by which aεFab1 inhibits derCD23
binding.
X-ray crystallographic data, however, may not definitively reveal the mecha-
nisms by which the aεFabs modulate CD23 binding. X-ray crystallographic struc-
tures are generally an average static structure of the protein or complex ensemble
[200]. Allosteric modulators may shift the conformational ensembles of molecules
towards states to different extents. The modulator-favoured state would only be
well represented by the average crystal structure if the shift resulted in the majority
of molecules existing in this state. aεFab3 and aεFab13 appear to act to alloster-
ically reduce the number of available derCD23 binding sites by around 25-30 %.
If this represents a scenario in which the binding of aεFab13 or aεFab3 to IgE-Fc
shifts the conformational ensemble of IgE so that only 25-30 % of the molecules
in the ensemble have non-viable higher-affinity binding sites, the average crystal
structure may not represent these states. Additionally, structural averaging itself
can result artifacts that do not represent reality and therefore may be misleading
when trying to determine the mechanism by which a modulator works [200].
Whereas X-ray crystallography is often unable to directly probe the dynamic
ensembles of proteins, NMR spectroscopy can. NMR can be used to determine the
ensemble model for a protein structure, although generally these are not believed to
be fully representative of the true solution-based equilibrium because the software
used to derive the models biases the structures towards homogeneity [201]. NMR
spectroscopy can however be used look at changes in dynamic processes in a protein
on a wide range of timescales upon addition of increasing amounts of modulator.
Such studies would help to understand dynamic changes that occur in IgE-Fc
upon addition of the different aεFabs, and in this way could help to understand
their allosteric mechanisms. Unfortunately, even IgE-Fc alone is a very challenging
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NMR target: it has a relatively high molecular mass (72 kDa) and because of its
complicated disulphide chemistry it is expressed in mammalian and insect cell-
lines. Accordingly, no NMR data on full-length IgE-Fc has been published to date,
however the McDonnell laboratory has recently produced isotopically-labeled IgE-





The interactions between IgE and its receptors, FcεRI and CD23, are central to
many immunological mechanisms that initiate and propagate allergic disease (Sec-
tion 1.1.1). Consequently, numerous studies have been performed in order to un-
derstand the biophysical and structural basis of IgE/receptor interactions (Section
1.2). It has emerged that the Fc region of IgE, which binds to the receptors, is
highly dynamic and that its conformational versatility is central to the specificity
and affinity of IgE/receptor interactions (Section 1.2). In the last few years it has
been demonstrated through X-ray crystallographic structures of IgE-Fc complexes
combined with kinetic and thermodynamic data, that receptor binding to IgE-Fc
can be modulated from distal sites through conformational changes (Section 1.3).
A rigid-body motion of the Cε3 domains of IgE-Fc upon the Cε4 domain pair has
been implicated in the mutual allosteric inhibition of CD23 and FcεRI binding [18],
as well as the allosteric inhibition of FcεRI binding by the therapeutic monoclonal
antibody Xolair [82], and an engineered Fab (aεFab1) [81]. An even more dramatic
rigid-body movement in which the the Cε2 domains extend from a bent conforma-
tion, has been suggested to occur in solution, and the crystal structure of IgE-Fc
bound to aεFab1 shows IgE-Fc in an almost fully and symmetric conformation,
which is incapable of binding FcεRI [81].
The ensemble model of allostery posits that allosteric perturbations redistribute
the population of species within the conformational ensemble of a protein [129]
(Section 1.4.1). Accordingly, by learning more about the conformational ensemble
of IgE-Fc, and the receptor-binding capabilities of the different IgE-Fc conformers,
we may uncover more about the range of conformational changes that can occur
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in IgE-Fc and that are involved in allosteric modulation of receptor-binding. Ulti-
mately this may provide insights that prove to be useful in the development of novel
therapeutics for allergy and asthma. This study set out to discover more about
the allosteric processes of IgE that modulate binding to one of its two principal
receptors, CD23, through either positive or negative cooperativity. We hypothe-
sised that by investigating the impact of anti-IgE Fabs/IgE interactions on CD23
binding, we may learn more about the conformational ensemble of IgE-Fc and how
it can be perturbed to alter the functionality of IgE.
Initially the study investigated the allosteric modulation of the IgE/CD23 in-
teraction by phage display-derived aεFab1, and the results from binding assays
and structural comparisons described novel IgE/receptor interaction behaviours.
Through a similar approach with different antibodies it was thought that more
could be learnt about the dynamic properties of IgE and how this relates to recep-
tor binding. Using UCB’s Core Antibody Discovery Process, we aimed to identify
new antibodies that bind to IgE-Fc and modulate the IgE/CD23 interaction pref-
erentially through allosteric processes.
UCB’s Core Antibody Discovery Process [148] is a single B cell technology (Sec-
tion 4.1). Single B cell technologies involve the direct amplification, from individual
B cells, of heavy and light variable region DNAs [176]. These technologies therefore
circumnavigate the problems associated with the loss of original light and heavy
chain pairings that are often encountered in display technologies (Section 4.1). For
the first time, UCB’s Core Antibody Discovery Process was used to screen the
immune repertoire of three IgE-Fc immunised rabbits for antibodies that bind to
IgE-Fc and modulate the IgE/CD23 interaction.
The process successfully generated antibodies that interact with IgE-Fc with
high affinities (Section 5.2.1), are sequentially diverse (Section 4.2.3) and have
a range of effects on the IgE/CD23 interaction (Section 5.2.2). Five antibodies
were eventually chosen for further biophysical characterisation after initial selection
using a homogeneous fluorescence-based assay (Section 4.2.1) and further selection
using SPR (Section 4.2.4 and Chapter 5). When expressed as Fabs, the five selected
antibodies bound to IgE-Fc with sub-nanomolar to nanomolar affinities; stronger
than the IgE-Fc/aεFab1 interaction [81]. In addition, the SPR sensorgrams of IgE-
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Fc binding to the aεFabs had different kinetic profiles (Section 6.2.2), indicating
that the discovery process had successfully selected for diverse high-affinity IgE-Fc
binders.
The second round of antibody screening involved another homogeneous-based
assay that was used to identify antibodies that increase or decrease IgE-Fc/derCD23
binding, by analysing changes in associated fluorescence (Section 4.2.2). The sec-
ondary screen had several limitations, in particular there was a problem with flu-
orescence quenching: a component of the cell culture supernatant quenched the
fluorescence from the labeled derCD23, which necessitated significant dilution of
the supernatants (Section 4.2.2). The reduction in antibody concentration con-
sequently reduced the signal-to-noise ratio and therefore made meaningful inter-
pretation of single data points difficult. It is possible that the quenching was
fluorophore-specific and consequently may be avoided using a different fluorescent
label. Alternatively, the problem may be circumnavigated using a label-free screen-
ing technique.
Despite the lack of a stringent control for unperturbed binding, and problems
with fluorescence quenching during the secondary screening process (Section 4.2.2),
SPR studies of derCD23 binding to aεFab:IgE-Fc complexes, indicated that the an-
tibody discovery process had successfully identified five aεFabs that have different
effects on the IgE-Fc/CD23 interaction (Section 7.2.2). aεFab12, for example, was
shown to enhance the interaction between IgE-Fc and derCD23, whereas aεFab3
was shown to inhibit it. Moreover, the impact of aεFab binding on the affinity and
availability of the CD23 binding sites was different for each of the aεFabs, which
was reflected in the SPR-determined KD and Bmax values, respectively.
It should be noted, however, that despite picking some of the antibodies that
scored the lowest in the secondary screen, none of the 25 antibodies that were
initially tested for their effect on the IgE/CD23 interaction using SPR, completely
inhibited the interaction (Section 4.2.4). Competitive inhibitors may have existed
in the screening population but did not give significantly lower signals because of
the described limitations and insensitivity of the secondary screen, and through
chance were not selected. There does also seem to have been some intrinsic bias
in the discovery process, since all five of the final selected antibodies bind to the
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Cε2 domains of IgE-Fc rather than the Cε3 domains to which CD23 binds (Section
6.2.5). The reasons for this bias remain unclear, but the differences between rabbit
IgE-Fc and human IgE-Fc (N265Q, N371Q), with which the immunisations were
performed, is likely to shape the antibody repertoire and may be a contributing
factor. Sequence alignments of rabbit IgE-Fc and human IgE-Fc (N265Q, N371Q)
domains indicated that the Cε2 domains share the least homology, which may
render them more immunogenic (Appendix A.14).
SPR experiments investigating the binding of sub-fragments of IgE-Fc to each
of the aεFabs suggested that the binding sites of the five selected aεFabs are com-
pletely, or at least predominately, located in the Cε2 domains of IgE-Fc (Section
6.2.5). Subsequent SPR and cell-based binding assays went on to identify the ef-
fects of the aεFabs on the IgE/CD23 interaction (Section 7.2.2), and combining
these data and the results from intramolecular FRET experiments (Section 6.2.4),
indicated that the aεFabs can allosterically modulate receptor binding by binding
to the Cε2 domains, and do so in a variety of ways. Saturation of the first aεFab2
binding site appears to result in the extension of IgE-Fc and a shift towards con-
formations with reduced affinity for CD23. Saturation of both aεFab3 binding
sites, however, is not associated with IgE-Fc extension and reduces the number of
available CD23 binding sites.
Differences in the data collected from the other aεFabs in the SPR and cell-based
binding assays, were likely to be, at least in part, because the SPR experiments
were only sensitive to effects on the higher-affinity CD23 binding site, whereas the
cell-based assays were sensitive to effects on either of the two CD23 binding sites
(Chapter 7). This difference in the experiments allowed us to infer the effect of
aεFab on the lower-affinity CD23 binding site. In some cases complicated models
were invoked to rationalise the results from the two experiments. The interpretation
of the data may, however, be complicated by other differences in the two types of
experiment, for example the distinct environments of IgE-Fc. Such differences
may affect the position of IgE-Fc’s conformational equilibrium differentially and
therefore the models require verification. Nevertheless, to the best of our knowledge
the results indicate that this project is the first study to successfully select for
allosteric modulators of the CD23/IgE interaction.
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It is hoped that these newly generated aεFabs will reveal more about how
changes in IgE-Fc dynamics affect the interactions between IgE and its receptors,
which play pivotal roles in allergic disease (Section 1.1.1). Even in the early stages
of their characterisation, these aεFabs and aεFab1, have provided new insights into
IgE-Fc’s dynamic behaviour and the allosteric regulation of receptor binding, as
summarised below.
Intra-domain motions may contribute towards allosteric mechanisms of
IgE/CD23 inhibition
SPR and cell-based assays performed under equilibrium conditions showed that
aεFab1 is a potent inhibitor of the IgE/CD23 interaction. A comparison of the
structures of IgE-Fc(3-4) bound to derCD23 (PDB: 4EZM [18]), and IgE-Fc bound
to aεFab1 (PDB: 4J4P [81]), showed that the CD23 and aεFab1 binding sites are
non-overlapping and that their binding sites are spatially distinct (Section 3.2.5).
To our knowledge, this is the first demonstration of allosteric inhibition of the
IgE/CD23 interaction by an engineered protein. The naturally occurring IgE re-
ceptor, FcεRI, is known to allosterically prevent the binding of IgE to CD23, at least
in part, by stabilising an ‘open’ IgE conformation in which the Cε3 domains are
further apart from one another than in the ‘closed’ IgE-Fc conformation, thought
to be necessary for CD23 binding (Section 1.3.1) [18]. aεFab1 stabilises an even
more ‘open’ conformation of IgE-Fc [81], and the results from comparisons of the
derCD23:IgE-Fc(3-4) complex and aεFab1:IgE-Fc complex similarly indicated that
the rigid-body motion of the Cε3 domains upon the Cε4 domain pair may also in
part be responsible for preventing the interaction between IgE-Fc and CD23.
Whereas it has previously been suggested that conformational changes within
the intrinsically flexible Cε3 domains of IgE-Fc may play a role in the allosteric
inhibition of IgE/CD23 interactions by FcεRI [18], the results from the compari-
son of aεFab1-bound IgE-Fc and derCD23-bound IgE-Fc structures explicitly show
significant conformational differences within the Cε3 domains that may affect the
coordination of the CD23 binding sites (Section 3.2.5). Additionally, negative coop-
erativity between the CD23 and aεFab1 binding sites was reduced in IgE-Fc with
internally rigidified Cε3 domains (Section 3.2.6), further supporting the role of
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intra-domain Cε3 conformational changes in the allosteric inhibition of IgE/CD23
interactions by aεFab1. Whereas conformational changes associated with allostery
in IgE-Fc have largely been realised in terms of large-scale motions, this finding
reinforces that smaller dynamic changes may play significant roles, and their po-
tential contributions to allostery in IgE should not be ignored.
Unfortunately, the comparison of static structures does not reveal even smaller-
scale dynamic processes that may also play an important role in the allosteric
inhibition of the CD23/IgE interaction by aεFab1 (Section 1.4.1). The binding of
aεFab1 may change the amplitude and frequency of thermal fluctuations in IgE-Fc
that disfavour the binding of CD23 (Section 1.4). Thermodynamic binding studies
using isothermal calorimetry, for example, may indicate if entropic changes are
involved in the allosteric inhibition of IgE/CD23 interactions by aεFab1. Molecular
dynamic simulations may also prove to be useful in pinpointing the residues and
regions of IgE-Fc that are most susceptible to dynamic changes upon the binding
of aεFab1, and that may affect CD23 binding [175, 137].
Free IgE-Fc is heterogeneous in solution
X-ray crystallographic structures of various IgE-ligand complexes show IgE-Fc can
adopt a range of conformations (Section 1.2.1). Intramolecular FRET studies, in
which a donor and acceptor pair were attached to the N and C termini of IgE-
Fc, also indicate that bent IgE-Fc can extend partially or fully when incubated
with Xolair Fab mutant 3 [82] and aεFab1 [81], respectively. Although IgE-Fc
can adopt these various conformations in the presence of ligand, relatively little
is known about what conformations free IgE-Fc experiences. Structures of IgE-
Fc(3-4) determined from different crystal forms indicate that IgE-Fc(3-4) does not
require a stabilising ligand to populate a range of ‘open’ and ‘closed’ conformations
[77]. However, the Cε2 domain pair is thought to limit this rigid-body motion [72],
and consequently the results of these experiments do not report on whether IgE-Fc
spends significant time in a range of ‘open’ and ‘closed’ conformations. Molecular
dynamic simulations suggest that IgE-Fc can transiently populate extended con-
formations, and the Cε2 domains may even ‘flip’ from one side of the molecule to
the other, but that it exists predominantly in a bent asymmetric conformation,
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as supported by intramolecular FRET data [81]. Work from our laboratory, in
conjunction with work undertaken in this this project, provides further evidence
to suggest that free IgE-Fc populates various conformations and that this has im-
portant implications for receptor binding.
As part of this project, a His-tagged IgE-Fc construct was generated (Section
3.2.2). This construct was captured on an anti-His-tag sensor chip surface to allow
the straightforward deconvolution of Bmax and KD values for IgE-Fc in SPR binding
studies. Using this approach, it was found that only ∼ 30 % of IgE-Fc in solution is
capable of binding sFcεRIα with the sub-nanomolar affinity that is often reported
in the literature, and the remaining IgE-Fc binds sFcεRIα with ∼ 20 nM or low
micromolar affinities, accounting for the multiphasic kinetics of IgE-Fc/sFcεRIα
interaction. Multiphasic kinetics of the IgE-Fc/sFcεRIα interaction were also ev-
ident in stopped-flow intrinsic fluorescence experiments and suggested an induced
fit conformational change occurred after the initial binding event. Stopped-flow
FRET studies of the IgE-Fc/sFcεRIα also indicated that IgE-Fc could experi-
ence these different conformations even when in complex with FcεRI. Two of the
aεFabs generated during this project, aεFab12 and aεFab13, bind IgE-Fc with a
2:1 stochiometry, yet they interact with IgE-Fc with triphasic binding kinetics,
which may also be indicative of IgE-Fc’s heterogeneous conformational character
(Section 6.2.3).
In collaboration with Dr Simon Ameer-Beg (KCL), our group is in the early
stages of trying to understand more about the heterogeneity of IgE-Fc using single
molecule FRET. Conventional FRET methods look at the statistical distribution of
observables over a large number of molecules in a sample, whereas single molecule
FRET observes individual molecules. Consequently, single molecule FRET can
avoid ensemble averaging and can allow for the study of specific homogeneous pop-
ulations within a heterogeneous sample [202]. Single molecule FRET experiments
of IgE-Fc may be able to determine the distributions of various intermolecular dis-
tances and the relative populations of different IgE-Fc states. Initially the group
aims to perform single molecule FRET experiments to determine Cε2-Cε4 dis-
tances in single IgE-Fc molecules and thereby ascertain the distribution of various
extended states within the IgE-Fc population.
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The link between IgE-Fc extension and FcεRI inhibition is not binary
FcεRI binds to the most bent and compact conformation of IgE-Fc so far observed
[87, 75] (Section 1.2.2). The striking extension of IgE-Fc’s Cε2 domain pair, which
occurs upon the binding of aεFab1, prevents FcεRI from binding (Section 1.3.3)
[81]. Using intramolecular FRET, the binding of aεFab2, aεFab12 and aεFab13 to
IgE-Fc were shown to be associated with various degrees of Cε2 domain extension
(Section 6.2.4). The binding of aεFab2 to IgE-Fc resulted in comparable levels of
FRET inhibition to aεFab1, indicating that aεFab2 stabilises a conformation of
IgE-Fc that is nearly fully extended. In Chapter 5, SPR experiments indicated
that aεFab2 does not inhibit the IgE-Fc/FcεRI interaction (Section 5.2.3). To-
gether, these results demonstrate that extension of the Cε2 domains of IgE-Fc
does not necessarily result in the inhibition of FcεRI binding. IgE-Fc may adopt
a variety of extended conformations that differ in the arrangement of the Cε2-Cε3
linker region and the rotation of the Cε2 domains, both of which may affect FcεRI
binding (Section 1.3.3). The structure of the aεFab2:IgE-Fc complex may reveal
a new extended conformation of IgE-Fc and elucidate why it does not prevent
FcεRI binding. These findings highlight that although ‘open’, ‘closed’, ‘bent’ and
‘extended’ can be useful descriptors of IgE-Fc structure, each term encompasses a
whole range of conformations and receptor-binding behaviours.
Long-range allostery can occur in IgE
To date, the handful of modulators known to affect IgE/receptor interactions al-
losterically have all been shown to bind to the Cε3 domains, to which the receptors
also bind. In this study, however, we have generated Fabs that bind to the Cε2 do-
mains of IgE-Fc and allosterically modulate CD23 binding, which occurs near the
Cε3-Cε4 domains interfaces. This allosteric regulation is occurring over the longest
distance observed in IgE-Fc to date, and indicates that allosteric communication




derCD23 can allosterically accelerate the dissociation of IgE-Fc
complexes
A Designed Ankarin Repeat Protein, DARPin E2 79, and Xolair have both been
shown to accelerate the dissociation of IgE/FcεRI complexes [109, 110, 108] (Sec-
tion 1.3.5). Xolair only mediates accelerated dissociation at concentrations far in
excess of prescribed dosages and therefore it is not part of the mechanism through
which it operates therapeutically. Instead, Xolair, the only anti-IgE-therapeutic
antibody currently licenced for the treatment of allergic disease, primarily works
by binding free IgE-Fc in the serum and by consequently affecting the levels of
IgE-Fc bound to FcεRI on the surface of mast cells, basophils and dendritic cells
(Section 1.1.2). Because of the very slow dissociation rate of the IgE/FcεRI inter-
action, IgE-Fc:FcεRI complexes can persist on the surface of these effector cells for
weeks, resulting in long-term sensitisation (Section 1.1.1 and Section 1.2.2). While
the levels of free IgE and IgE on the surface of basophils drops within days of Xolair
treatment, the levels of IgE on mast cells remain higher for longer [108]. Accord-
ingly, a drug that could bind to IgE-Fc in complex with FcεRI and destabilise the
IgE-Fc/FcεRI complex could rapidly reduce the level of mast cell sensitisation and
may have a more immediate therapeutic effect.
Evidence suggests that the benefit of Xolair may be limited by IgE-dependent
homeostatic mechanisms that respond to the decline in receptor-bound IgE upon
treatment [35, 55, 58, 37, 203, 204]. Pennington et al. have proposed that a drug
capable of disrupting the IgE-receptor interactions may be used in combination
with drug-resistant IgE variants to effectively replace the native IgE on effector
cells [108]. One possibility is to engineer a variant of Xolair with an enhanced
disruptive capability such that it could rapidly remove native IgE from effector
cells at therapeutic concentrations, providing that, like Xolair, the variant did not
have the propensity to form large immune complexes [205, 206, 207]. Accordingly,
understanding what drives accelerated dissociation of IgE-Fc-ligand complexes may
be beneficial in the design of novel drugs that harness this phenomenon.
The negative cooperative phenomenon of accelerated dissociation can be steric
or allosteric. Facilitated dissociation is a process in which a competitor increases the
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native rate of complex dissociation by engaging ligand attachment points during the
dissociation process, thereby invoking atomic overlap. DARPin E2 79- and Xolair-
mediated accelerated dissociation of IgE-Fc/FcεRI complexes have been suggested
to operate via facilitated dissociation [109, 108]. The conclusions were, however,
based in part upon structural data from constrained IgE-Fc(3-4) complexes, in
which IgE-Fc was held in a ‘closed’ conformation. The crystal structure of IgE-Fc
bound to Xolair Fab mutant 3, in conjunction with SPR data, suggests that the
Xolair Fab allosterically mediates accelerated dissociation of IgE/FcεRI complexes
(Section 1.3.5).
In this study we discovered two new examples of accelerated dissociation of
IgE-Fc complexes, and reported, for the first time, receptor-mediated accelerated
dissociation of IgE-Fc complexes. SPR experiments showed that derCD23 bound
to aεFab1:IgE-Fc (1:1) and aεFab13:IgE-Fc (1:1) complexes, and accelerated their
dissociation (Section 3.2.3 and Section 7.2.3).
Crystal structures of the aεFab1:IgE-Fc (2:1) and derCD23:IgE-Fc(3-4) (2:1)
complexes clearly show that the aεFab1 and CD23 binding sites are distinct and
the binding of the two ligands to IgE-Fc is spatially separated, which suggests that
derCD23 mediated accelerated dissociation of aεFab1:IgE-Fc is an allosteric pro-
cess (Section 3.2.5). At present there is no crystal structure available for IgE-Fc
bound to aεFab13, but the results of SPR experiments investigating the binding
of different IgE-Fc sub-fragments to aεFab13 indicate that aεFab13 binding sites
are located in the Cε2 domains of IgE-Fc, far from the CD23 binding sites at the
Cε3-Cε4 domain interface (Section 6.2.5). Consequently derCD23-mediated ac-
celerated dissociation of aεFab13:IgE-Fc (1:1) complexes cannot occur through a
facilitated dissociation mechanism. It is possible that derCD23-mediated acceler-
ated dissociation of aεFab13:IgE-Fc (1:1) complexes is the result of atomic overlap
between aεFab13 and derCD23 bound to IgE-Fc, however, intramolecular FRET
data suggests that aεFab13 binds partially extended Cε2 domains (Section 6.2.4).
A partially extended conformation of IgE-Fc would have an increased distance
between the Cε2 and Cε3 domains and therefore atomic overlap of aεFab13 and
CD23 is unlikely. Furthermore, derCD23 was able to bind the aεFab13:IgE-Fc
(2:1) complex but was unable to accelerate its dissociation at the tested concen-
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trations (Section 7.2.3); if the phenomenon was sterically driven then it is unlikely
that the stochiometry of the complex should be influential. Structural data may
help to determine if derCD23 does actually act to accelerate the dissociation of
aεFab13:IgE-Fc via an allosteric mechanism.
Regardless of the mechanism of derCD23-mediated accelerated dissociation of
aεFab13:IgE-Fc complexes, the studies of aεFab1 demonstrate that accelerated
dissociation of IgE-Fc complexes can be mediated allosterically (Section 3.2.5).
Although not directly comparable, understanding more about the way derCD23
allosterically induces the accelerated dissociation of aεFab1:IgE-Fc may indicate
ways of destabilising IgE:FcεRI complexes allosterically. derCD23-mediated accel-
erated dissociation of aεFab1:IgE-Fc was reduced by stabilising the Cε3 domains of
IgE-Fc (Section 3.2.6), indicating that changes within the Cε3 domains themselves
contribute to destabilisation of the aεFab1:IgE-Fc complex. Perhaps, intra-domain
changes may also play a role in the accelerated dissociation of IgE:FcεRI complexes.
General implications
Because the IgE/FcεRI interaction occurs over an extended and largely flat inter-
face, and because the interaction has such a high affinity, it was suggested that
it was unlikely that the interactions could be inhibited by a small molecule drug
and IgE was deemed ‘undruggable’ [208]. The findings from this research pro-
vide new insights into the highly dynamic nature of IgE and sheds light on novel
mechanisms and properties that can affect its allosteric behaviour. Accordingly, we
propose that IgE is in fact druggable; that instead of targeting the receptor-binding
sites of IgE-Fc directly, small molecule drugs binding distal to them could inhibit
receptor interactions through changes in IgE conformation and/or dynamics.
An understanding of how antibodies allosterically modulate IgE-receptor in-
teractions may allow the design of small molecules with similar related effects.
Antibodies that stabilise IgE in biologically relevant conformations could be used
to hold IgE in transiently populated conformations during fragment screening and
crystallography [209]. Such approaches may identify novel, perhaps normally in-
accessible, binding sites on IgE that could be used in the development of small
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molecules drugs for allergy and asthma.
IgE-Fc’s conformational plasticity could be key in the design of novel allosteric
therapeutics for allergy and asthma, but how does the immune system itself benefit
from the evolution of such a highly dynamic structure? Allosteric regulation of IgE-
Fc is already known to be crucial in preventing simultaneous engagement of both
FcεRI and CD23, which would result in systemic analphylaxis [18]. Additionally, it
has been suggested that the the bent conformation of IgE-Fc bound to FcεRI aids
allergen cross-linking on the surface of mast cells, basophils and antigen presenting
cells, whereas Cε2 domain extension may facilitate the capture of allergen in the
context of the B cell receptor [81]. It could also be that IgE-Fc’s conformational
diversity may play a role in tuning IgE-mediated immune responses.
Any conformationally-dependent functionality of IgE, such as the binding of
IgE to FcεRI or CD23, is dependent on the position of IgE’s conformational equi-
librium and can be perturbed by changes in conditions. For example, shifting the
equilibrium towards conformations that can bind FcεRI, or bind FcεRI with a
higher affinity, will result in increased binding of IgE to FcεRI on the surface of
effector cells. Whereas shifting the equilibrium towards conformations that cannot
bind FcεRI, or those with lower affinities for the receptor, will result in less binding
of IgE to FcεRI on the surface of effector cells. By existing in a range of different
conformations with different FcεRI binding affinities, perturbing the equilibrium
can ‘tune’ the amount of FcεRI-bound IgE on the surface of the effector cells at
any one time. Tuneability allows a system to adapt to change and being able to
adapt to change is crucial in the immune system, where a lack of response or an
over-response to change can be fatal. The high-affinity IgE/FcεRI interaction on
the surface of mast cells and basophils results in long-term sensitisation of these
potent effector cells. Whilst this may be beneficial for a rapid response to a par-
asitic infection, it is the rapid release of inflammatory mediators by mast cells in
response to otherwise innocuous antigens that triggers allergic reactions and can
cause anaphylaxis. It is possible that IgE-Fc heterogeneity provides IgE with the
tools to adapt to its environment, in order to prevent under- or over-reaction. For
example, a shift towards conformations with high affinity for FcεRI may increase
the local concentration of mast cells coated with antigen-specific IgE during a par-
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asitic infection. Or to avoid anaphylaxis, a shift towards weakly-bound IgE:FcεRI
complexes may accelerate the dissociation of IgE from FcεRI on the surface of mast
cells.
This logic may apply to any conformationally-dependent function of IgE in-
cluding binding to CD23. IgE/CD23 interactions have been implicated in various
immunological roles including IgE-homoeostasis, although the exact mechanisms
through which CD23 can prompt both up- and down-regulation of IgE are dis-
puted, perhaps conformational dynamism of IgE-Fc may be involved in fine-tuning
these processes.
Additionally, the role of allostery in IgE-Fc may extend beyond the scope of
IgE/receptor interactions. IgE-Fc is joined to two Fab regions via links with the
two Cε2 domains. Traditionally antigen-binding and receptor-binding/signalling
have been treated as strictly distinct functionalities of the Fab and Fc regions of
antibodies, respectively. There is now growing evidence that suggests the whole
immunoglobulin should be considered in regards to both of these activities [210].
Antigen binding at the variable domains must somehow be communicated to the
rest of the molecule to initiate signalling events. For example, antigen cross-linking
of IgE on the surface of a mast cell is in some way relayed to the Fc region,
which through its interaction with FcεRI triggers intracellular signalling cascades
required for mast cell activation and degranulation. Similarly, binding of allergen
to the Fab regions of IgE-B cell receptors must in some way be transmitted to
the intracellular signalling machinery in order to initiate the signalling required for
B cell proliferation or antigen internalisation. Furthermore, various studies have
shown that the constant region of an immunoglobulin can affect the affinity and
specificity of the variable regions [210].
Exactly how the antigen binding events are transduced to intracellular signalling
domains and constant regions, and the mechanisms through which the constant re-
gions affect antigen binding, remain obscure. It is certainly possible, however, that
conformational changes provide a method of bidirectional communication. The
binding of antigen to antibody is thought to require a degree of structural flexi-
bility at the variable domains, and perhaps the conformational changes associated
with the binding event are transmitted via allosteric processes to the necessary
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signalling domains [210]. For example, it has been proposed that the binding of
antigen leads to conformational changes in the constant region of the B cell receptor
that then promotes oligomerisation, clustering and consequently signalling [211].
In this present study we show that perturbations can indeed be allosterically com-
municated across different domains of IgE. Perhaps the conformational flexibility
of IgE-Fc does not simply provide IgE with the tools to fine-tune the outcomes of
IgE-receptor interactions, but it may also provide a vital means of communicating
the antigen binding and signalling events that fuel the allergic response.
Further studies
The data presented in this thesis suggest that the aεFabs that have been generated
elicit their effects on CD23 binding, at least in part, through allosteric processes.
X-ray crystallographic structures of IgE-Fc bound to the different aεFabs would
establish whether their binding sites are indeed within the Cε2 domains and there-
fore distal from the CD23 binding sites. By overlaying the crystal structures of
the aεFab:IgE-Fc complexes with structures of IgE-Fc bound to derCD23, we may
also determine if the binding of each of the aεFabs and derCD23 is in fact spatially
distinct.
X-ray structures will not only map the aεFab binding sites, but will reveal
conformational changes associated with the binding of the different aεFabs. Crys-
tallisation trials of aεFab:IgE-Fc complexes with 1:1 and 2:1 stochiometries have
been set up. We have grown crystals for the 2:1 complex of aεFab2:IgE-Fc and
we have collected some diffraction data from these crystals at the Diamond Light
Source (Harwell, UK). The data were scaled to 4.4 Å resolution and some progress
has been made in structural determination. We have obtained a partial solution
comprised of two aεFab2 molecules and the Cε2 domain pair using molecular re-
placement (Figure 8.1). At present, the model does not contain the Cε3 and Cε4
domains. In addition to solving the complete structure, we are currently trying to
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Figure 8.1: A partially-solved crystal structure of the aεFab2:IgE-Fc (2:1)
complex. (a) The partially-solved crystal structure of the aεFab2:IgE-Fc (2:1)
complex. The data were collected at the Diamond Light Source (Harwell, UK)
and were scaled to 4.4 Å. The partial solution, comprising two aεFab2 molecules
and the Cε2 domain pair, shows that each aεFab2 binds a single Cε2 domain.
(b) The partial solution does not contain the Cε3 and Cε4 domains, but there is
sufficient space in the crystal lattice to accommodate the remainder of the IgE-Fc
molecule. Superposition of an extended IgE-Fc (4J4P) on the Cε2 domain pair
of the partial solution, demonstrates how the lattice could accommodate the Cε3
and Cε4 domains of an extended IgE-Fc molecule. (c) Superposition of the bent
IgE-Fc structure (2WQR) on the Cε2 domain pair of the partial solution shows
that a bent IgE-Fc molecule would significantly clash with a symmetry-related
aεFab2 molecule. (d) Superposition of an extended IgE-Fc structure (4J4P) on
the Ceε2 domain pair of the partial solution shows that this particular extended
conformation of IgE-Fc would clash with a symmetry-related aaεFab2 molecule.
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Although the structure of the aεFab2:IgE-Fc (2:1) complex has not been fully
solved, the data validate the findings reported in this thesis that relate to the
binding of aεFab2 to IgE-Fc. The partial solution shows two molecules of aεFab2
bound to the Cε2 domain pair of IgE-Fc (Figure 8.1.a). From the crystal packing,
we can see sufficient space in the lattice for the Cε3 and Cε4 domains of IgE-Fc
(Figure 8.1.b). Bent IgE-Fc (PDB: 2WQR) superposed on the Cε2 domain pair
of the partial solution is incompatible with the crystal lattice as there is extensive
atomic overlap between one Cε3 domain and a symmetry-related aεFab2 molecule
(Figure 8.1.c). Extended IgE-Fc (IgE-Fc bound to aεFab1, PDB: 4J4P) superposed
on the Cε2 domain pair of the partial solution fits better into the space of the crystal
lattice, but still clashes with a symmetry-related aεFab2 molecule (Figure 8.1.d).
It is therefore likely that the aεFab2:IgE-Fc (2:1) complex is extended, but that
it adopts a distinct conformation from the extended aεFab1-bound structure. An
extended and twisted conformation would fit into the space in the crystal lattice
and the flexibility of the Cε2-Cε3 linker-region could accommodate this.
It is necessary to solve the rest of the aεFab2:IgE-Fc (2:1) crystal structure to
determine how extended the conformation is and if it is indeed twisted. Solving
and refining the complete structure will also reveal any conformational differences
between apo and aεFab2-bound IgE-Fc that may contribute towards the allosteric
inhibition of CD23 binding. We hope to obtain diffraction data for all of the other
aεFab complexes and that the structures of these complexes will describe conforma-
tions of IgE-Fc distinct from any that have already been observed. Consequently,
we will reveal dynamic processes that occur within IgE-Fc that have not yet been
described.
Whilst X-ray crystallography may reveal rigid-body domain movements and
residue shifts involved in allosteric communication, it generally does not report
changes in dynamics that may also contribute towards allosteric mechanisms. NMR
spectroscopy provides information about protein structure, dynamics and thermo-
dynamics and has been fundamental in the understanding of the allosteric regula-
tion of many proteins [111]. NMR spectroscopy can report on dynamic processes
that occur in proteins on a range of different timescales, and fast internal motions
can be used as proxy for conformational entropy [212]. In collaboration with UCB,
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the McDonnell laboratory has produced sufficient amounts of isotopically-labeled
IgE-Fc for NMR spectroscopy experiments, but before the dynamics of IgE-Fc can
be studied, the difficult task of protein assignment must be completed. Until then
we hope to use isothermal calorimetry to characterise the thermodynamics of the
interactions between IgE-Fc and its receptors in the presence and absence of each
of the aεFabs. In this way we intend to establish if binding of aεFab to IgE-Fc is
associated with changes in entropy that affect how it binds to its receptors, CD23
and FcεRI.
Further binding studies may help to verify the effects that the different aεFabs
have on the IgE/CD23 interaction. Upon generation of sufficient quantities of
derCD23, we plan to perform SPR studies investigating the effect of each of the
aεFabs on the binding of two molecules of derCD23 to IgE-Fc. As described in
Chapter 7’s discussion, this experiment has potential limitations but it may pro-
vide insights into how each of the aεFabs affects the IgE/CD23 interaction. To
verify the results of the cell-binding assays we also plan to look at the effect of
each of the aεFabs on the IgE/CD23 interaction in a different homogeneous as-
say, for example using time-resolved FRET (TR-FRET) experiments. In addition
to looking at the effect of the aεFabs on the interaction between IgE and CD23,
we are planning on performing SPR experiments to investigate modulation of the
IgE/FcεRI interaction more closely.
Although the findings of this study show that derCD23 can accelerate the disso-
ciation of IgE-Fc from aεFab1 and aεFab13, we have not investigated the ability of
the aεFabs to accelerate the dissociation of IgE:receptor complexes. To determine
if any of the aεFabs can mediate accelerated dissociation of IgE:CD23 complexes
we will perform flow cytometry to detect any decrease in cell-associated fluores-
cence upon addition of each aεFab to RPMI 8866 cells that have been pre-incubated
with fluorescently-labeled IgE. Performing similar experiments using a rat basophil
cell-line that expresses human sFcεRIα will also indicate whether the aεFabs can
accelerate the dissociation of IgE from FcεRI. If any of the aεFabs do mediate
the accelerated dissociation of IgE/receptor interactions, crystal structures of the




Furthermore, we hope to establish whether the effects of the aεFabs that we
have observed in SPR and cell-based assays actually translate to the modulation
of IgE-receptor functions. IgE-allergen complexes bind to CD23 on the surface
of B cells and are internalised, processed and presented to TH2 cells in a process
known as facilitated antigen presentation. This process results in the activation and
propagation of a TH2 allergic response (Section 1.1.1). We plan to use the facilitated
antigen binding (FAB) assay to obtain an indirect readout of the antigen presenting
capacity of B cells to T cells in the presence and absence of the different aεFabs.
The FAB assay uses flow cytometry to detect the amount of binding of allergen:IgE
complexes to CD23 on the surface of B cells, and although it does not directly
measure antigen presentation to T cells it has been shown to be representative of
this process [213].
The findings of this study also indicate that IgE-Fc:aεFab3 and IgE-Fc:aεFab13
complexes bind FcεRI with a lower affinity (Section 5.2.3). We would like to
determine what effect these aεFabs have on the level of mast cell degranulation.
Using a rat mast cell-line, transfected with alpha chain of human FcεRI, we intend
to investigate any potential differences in the amount of degranulation that occurs
upon incubation with allergen-specific IgE (rIgE) and subsequent allergen (Phl p7)
challenge, in the presence and absence of the aεFabs [214, 215].
IgE/CD23 and IgE/FcεRI interactions are also thought to be important in
initiated cell-mediated killing of infected and foreign cells during parasitic infec-
tions (Section 1.1.1). We intend to perform experiments using flow cytometry
to ascertain any potential effect that each of the aεFabs may have on antibody-
dependent tumour cell killing by cytotoxicity and phagocytosis. Tumour target
cells are fluorescently-labeled and mixed with effector cells and a tumour antigen-
specific IgE. Following incubation, the effector cells are stained with a different
fluoresenctly-conjugated antibody and dead cells are labeled with propidium io-
dide. The three different fluorescent stains can be differentiated by flow cytometry




IgE and its receptors, FcεRI and CD23, are central molecules in the mechanisms of
allergic disease. Using UCB’s Core Antibody Discovery Process we have success-
fully generated a small panel of aεFabs that bind IgE-Fc with high affinities and
that allosterically modulate the interaction between IgE and CD23. We have char-
acterised how each of the aεFabs binds IgE-Fc, and using SPR and cell-based assays
we have also characterised how each aεFab affects the IgE/CD23 interaction. Our
findings provide further evidence that IgE-Fc is conformationally heterogeneous
and that IgE/receptor interactions can be perturbed by the manipulation of IgE-
Fc’s conformational ensemble. We emphasise that IgE-Fc is highly amenable to
allosteric regulation as a result of its conformational plasticity, and consequently
understanding allostery in IgE-Fc is fundamental to understanding how IgE medi-
ates allergic disease.
We propose that small-scale intra-domain movements, as well as larger-scale
rigid-body motions, contribute towards allosteric mechanisms in IgE. For the first
time, we provide evidence that allosteric communication can occur between differ-
ent domains of IgE-Fc, which raises the question of the biological role of long-range
allostery in IgE. In addition we show that accelerated dissociation of IgE-Fc com-
plexes can be allosterically driven. Understanding the mechanisms of accelerated
dissociation of IgE-Fc complexes may provide insights into how to disrupt pre-
existing IgE/receptor interactions, which may be a novel way of targeting IgE in
the design of therapeutics for asthma and allergy.
Using X-ray crystallography we hope to determine the structural basis of the
allosterically-mediated accelerated dissociation of aεFab13:IgE-Fc complexes by
CD23, as well as the structural basis of the allosteric modulation of IgE/CD23
interaction by the aεFabs. Crystallisation trials of the aεFab:IgE-Fc complexes
were recently set up and are already looking promising: we have collected data
for an aεFab2:IgE-Fc complex and they appear to describe a new conformation of
IgE-Fc.
Allosteric perturbations may involve conformational changes anywhere on the
dynamic continuum and may even be manifested as changes in the frequency and
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amplitude of very fast thermal fluctuations. Whilst X-ray crystallography can be
used to describe rigid-body movements and intra-domain motions in atomic de-
tail, NMR spectroscopy can study dynamic processes that occur on a wide range
of timescales. Producing isotopically-labeled IgE-Fc for NMR studies has been
difficult because it is usually expressed in mammalian or insect cell-lines as a con-
sequence of its complicated glycosylation and disulphide chemistry. The McDon-
nell laboratory, however, has recently produced sufficient amounts of isotopically-
labeled IgE-Fc for NMR spectroscopy experiments. Using a combination of X-ray
crystallography and NMR we will reveal the allosteric mechanisms by which the
aεFabs modulate IgE/CD23 binding, and in doing so discover the range of dynamic
















Figure 1: The protein sequence of a single IgE-Fc chain (N265Q, N371Q
background). The Cε2 domain is in green (residues 232-239), the Cε3 domain is
in black (residues 333-437) and the Cε4 domain is in blue (residues 443-542).
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A.2 SPR analysis of the interaction between IgE-
Fc and unpurified aεFabs
a) b) c) 
d) f) e) 
g) h) i) 
j) k) 
Figure 2: Reference-subtracted sensorgrams from SPR experiments in-
vestigating the binding of IgE-Fc to aεFabs in transient transfection
supernatant. Transient supernatants containing aεFabs were injected over a Fab-
specific goat anti-rabbit F(ab’)2. IgE-Fc was injected over the captured aεFab at
various concentrations, and binding was observed as a change in SPR response.
In each case the response for the binding of 0 nM IgE-Fc to the respective aεFab
was subtracted to eliminate changes changes in response as a result of dissociation
of aεFab from the anti-rabbit-Fab surface. The sensorgrams have not been nor-
malised for aεFab capture levels. (a) aεFab3, (b) aεFab4, (c) aεFab5, (d) aεFab6,




a) b) c) 
d) e) f) 
g) h) i) 
Figure 3: Fitting the kinetic data for the interaction between IgE-Fc and
aεFabs in transient transfection supernatant. A Single koff and kon model
was used to fit SPR data for the binding of 6 nM IgE-Fc to captured aεFab. The
data is shown in blue and the fits are shown in red. (a) aεFab3, kon = 1.4 x10
6
M-1s-1, koff = 9.9 x10
-4 s-1, (b) aεFab4, kon = 1.1 x10
6 M-1s-1, koff = 1.7 x10
-4 s-1,
(c) aεFab5, kon = 1.6 x10
6 M-1s-1, koff = 4.9 x10
-4 s-1, (d) aεFab7, kon = 2.0 x10
6
M-1s-1, koff = 2.7 x10
-4 s-1, (e) aεFab9, kon = 1.1 x10
6 M-1s-1, koff = 2.4 x10
-4 s-1,
(f) aεFab12, kon = 2.3 x10
6 M-1s-1, koff = 2.4 x10
-4 s-1, (g) aεFab13, kon = 8.4 x10
5
M-1s-1, koff = 6.4 x10
-4 s-1, (h) aεFab17, kon = 2.7 x10
6 M-1s-1, koff = 2.4 x10
-4 s-1,
(i) aεFab18, kon = 1.7 x10




A.3 SPR analysis of the interactions between
derCD23 and IgE-Fc bound to unpurified
aεFabs
a) b) c) 
d) e) f) 
g) h) i) 
Figure 4: Reference-subtracted sensorgrams from SPR experiments in-
vestigating the binding of derCD23 to aεFab-bound IgE-Fc. Transient
supernatants containing aεFabs were injected over a Fab-specific goat anti-rabbit
F(ab’)2. IgE-Fc was injected over the captured aεFab. derCD23 was then injected
over the aεFab:IgE-Fc (1:1) complex at various concentrations (grey - 0.78 nM,
light blue - 156 nM, purple - 312 nM, navy - 625 nM, green - 1250 nM, cyan -
2500 nM, black - 5000 nM) and binding was observed as a change in SPR response.
IgE-Fc was injected over the captured aεFab at various concentrations, and bind-
ing was observed as a change in SPR response. In each case the response for the
binding of 0 nM derCD23 to the respective aεFab:IgE-Fc complex was subtracted
to eliminate changes changes in response as a result of dissociation of aεFab from
the anti-rabbit-Fab surface and IgE-Fc from the aεFab.The sensorgrams for the
binding of derCD23 have been normalised such that the maximum response for the
binding of IgE-Fc to aεFab was 450 RU. (a) aεFab3, (b) aεFab4, (c) aεFab5, (d)
aεFab7, (e) aεFab9, (f) aεFab12, (g) aεFab13, (h) aεFab17, (i) aεFab18.
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a) b) c) 
d) e) f) 
g) h) i) 
Figure 5: Binding curves for the interactions between derCD23 and
aεFab-bound IgE-Fc. The data were generated from SPR experiments in which
derCD23 binding to captured aεFab:IgE-Fc (1:1) complexes was measured as a
change in response. The steady-state response was averaged from 5 s of the steady-
state binding data (circle) and fit (lines) using a one-to-one binding model. The
steady-state binding data had been normalised such that the maximum response
for binding of IgE-Fc to aεFab was 450 RU. (a) aεFab3, KD = 1.4 µM, Bmax = 130
RU. (b) aεFab4, KD = 1.1 µM, Bmax = 138RU. (c) aεFab5, KD = 1.4 µM, Bmax
= 118 RU. (d) aεFab7, KD = 1.9 µM, Bmax = 133 RU. (e) aεFab9, KD = 1.4 µM,
Bmax = 130 RU. (f) aεFab12, KD = 0.6 µM, Bmax = 105 RU. (g) aεFab13, KD =
1.9 µM, Bmax = 133 RU. (h) aεFab17, KD = 1.0 µM, Bmax = 97 RU. (i) aεFab18,
KD = 2.4 µM, Bmax = 156 RU.
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A.4 SPR analysis of the interactions between










Figure 6: Reference-subtracted sensorgrams from SPR experiments in-
vestigating the binding of sFcεRIα to aεFab-bound IgE-Fc. Transient
supernatants containing aεFabs were injected over a Fab-specific goat anti-rabbit
F(ab’)2. IgE-Fc was injected over the captured aεFab. derCD23 was then injected
over the aεFab:IgE-Fc (1:1) complex at various concentrations (green - 3.13 nM,
cyan - 6.25 nM, navy - 12.5 nM, purple - 25 nM, black - 50 nM) and binding was
observed as a change in SPR response. In each case the response for the bind-
ing of 0 nM sFcεRIα to the respective aεFab:IgE-Fc complex was subtracted to
eliminate changes changes in response as a result of dissociation of aεFab from
the anti-rabbit-Fab surface and IgE-Fc from the aεFab. The data have been nor-
malised to give a maximal response for the binding of 50 nM sFcεRIα of 10 RU. (a)
aεFab3, (b) aεFab4, (c) aεFab5, (d) aεFab7, (e) aεFab9, (f) aεFab12, (g) aεFab13,
(h) aεFab17, (i) aεFab18. Single koff and kon kinetic fits of the data for the binding
of 50 nM sFcεRIα (or 25 nM in the case of aεFab18) are shown in red where ap-
plicable (Section 5.2.3). aεFab7 koff = 3.5 x10
-3 s-1 kon = 6.8 x10
5 s-1M-1, aεFab12
koff = 6.9 x10
-4 s-1 kon = 5.9 x10
5 s-1M-1, aεFab13 koff = 5.7 x10
-3 s-1 kon = 8.3 x10
5
s-1M-1, aεFab17 koff = 9.9 x10
-4 s-1 kon = 5.4 x10
5 s-1M-1, aεFab18 koff = 4.8 x10
-3



















































































Figure 7: SPR analysis to investigate aεFab competition. aεAb, in tran-
siently transfected supernatant, was captured by immobilised IgG-Fc-specific goat-
anti-rabbit F(ab’)2 (Jackson ImmunoResearch). IgE-Fc was injected over the cap-
tured aεAb to generate an aεAb:IgE-Fc:aεFab (1:1:1) complex. Other aεFabs,
in transiently transfected supernatant were then injected over the complex and
the binding was measured as a change in SPR response. (a) aεAb3:IgE-Fc:aεFab3,
(b) aεAb4:IgE-Fc:aεFab4, (c) aεAb5:IgE-Fc:aεFab5, (d) aεAb7:IgE-Fc:aεFab7, (e)












10 15 20 25 




10 15 20 25 




10 15 20 25 





10 15 20 25 








Figure 8: Size exclusion chromatograms for each aεFab, IgE-Fc and
aεFab:IgE-Fc complexes. Purified aεFab was incubated with purified IgE-Fc
overnight at 4 ◦C at 1:2.4 (blue) and 2.4:1 molar ratios (green). The mixture sam-
ples, aεFab alone (black), and purified IgE-Fc (purple), were run down a Superdex
S200 10x30 GL SEC column (GE Healthcare) in PBS, pH 7.4. The results sug-
gest the formation of 1:1 (filled triangle) and 2:1 aεFab:IgE-Fc complexes (empty
triangle) for each aεFab. (a) aεFab3, (b) aεFab12, (c) aεFab13, (d) aεFab18.
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A.7 SPR analysis of the interaction between IgE-




Figure 9: Fitting the kinetic data for the interaction between IgE-Fc and
purified aεFabs. Purified aεFabs were injected over a Fab-specific goat anti-rabbit
F(ab’)2. IgE-Fc was injected over the captured aεFab at various concentrations,
and binding was observed as a change in SPR response (shown here). The data
(blue) were fit using double koff and double kon models (red) (a-d) and the disso-
ciation of 2 µM IgE-Fc from aεFab13 was fit to a triple koff model (e). (a) 2 µM
IgE-Fc to aεFab3, koff1 = 3.7 x 10
-4s-1, koff2 = 7.6 x 10
-3 s-1,kon1 = 4.8 x 10
5 M-1
s-1, kon2 = 1.9 x 10
4 M-1 s-1. (b) 8 nM IgE-Fc aεFab12, koff1 = 1.5 x 10
-4 s-1, koff2
= 6.5 x 10-3 s-1,kon1 = 6.9 x 10
5 M-1s-1, kon2 = 8.2 x 10
3 M-1s-1. (c) 8 nM IgE-Fc
to aεFab13, koff1 = 2.8 x 10
-4 s-1, koff2 = 7.9 x 10
-3 s-1, kon1 = 2.2 x 10
6 M-1s-1, kon2
= 4.7 x 103 M-1s-1. (d) 2 µM IgE-Fc to aεFab18, koff1 = 3.0 x 10
-4 s-1, koff2 = 8.2
x 10-3 s-1,kon1 = 4.6 x 10
5 M-1s-1, kon2 = 1.0 x 10
4 M-1s-1. (e) The dissociation of 2
µM IgE-Fc from aεFab13 is well described by a triphasic model for dissociation.
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A.8 Repeat SPR experiment for the binding of
IgE-Fc (3-4) to aεFab12
a) IgE-Fc (2-4) to aεFabXol3 b) IgE-Fc (3-4) to aεFabXol3 
c) IgE-Fc (2-4) to aεFab12 d) IgE-Fc (3-4) to aεFab12 
Figure 10: IgE-Fc (3-4) binds aεFab12 in a repeated SPR binding ex-
periment. Double reference-subtracted sensorgrams for the binding of full length
IgE-Fc to Xolair Fab Mutant 3 (aεFabXol3) and aεFab12 are shown in (a) and
(c), respectively. IgE-Fc was injected over the surfaces at concentrations of 200
nM (black), 50 nM (purple), 12.5 nM (blue), 3.1 nM (green). Double reference-
subtracted sensorgrams for the binding of IgE-Fc (3-4) to Xolair Fab Mutant 3
and aεFab12 are shown in (b) and (d), respectively. IgE-Fc (3-4) was injected over
the surfaces at concentrations of 200 nM (black), 50 nM (purple), 12.5 nM (blue),
3.1 nM (green). The sensorgrams have not been normalised for the difference in
mass between IgE-Fc and IgE-Fc (3-4). Here, Xolair Fab Mutant 3 is a positive
control for binding to IgE-Fc (3-4): X-ray crystallography shows the symmetrical
Xolair Fab Mutant 3 binding sites are centred on the Cε3 domains of IgE-Fc [82].
Xolair Fab mutant 3 was immobilised onto the sensor surface using amine coupling.
aεFab12 was captured by a goat anti-rabbit-Fab surface. Both aεFab12 and Xolair
Fab Mutant 3 were present at densities of approximately 400 RU.
280
Appendix .
A.9 Repeat SPR experiment for the binding of
the Cε2 dimer to aεFab12
a) IgE-Fc (2-4) to aεFab3 b) Cε2 dimer to aεFab3 
c) IgE-Fc (2-4) to aεFab12 d) Cε2 dimer to aεFab12 
Figure 11: The Cε2 dimer binds aεFab12 in a repeated SPR binding ex-
periment. aεFab3 and aεFab12 were immobilised on separate sensor surfaces
using amine coupling at densities below 400 RU. Double-reference subtracted sen-
sorgrams for the binding of full length IgE-Fc to aεFab3 and aεFab12 surfaces are
shown in (a) and (c), respectively. Full length IgE-Fc was injected over the sur-
faces at concentrations of 100 nM (black), 50 nM (purple), 25 nM (blue), 12.5 nM
(green), 6.25 nM (olive), 3.13 nM (orange), 1.56 nM (red) and 0.78 nM (brown).
Double-reference subtracted sensorgrams for the binding of the Cε2 domain pair of
IgE-Fc to aεFab3 and aεFab12 surfaces are shown in (b) and (d), respectively. The
Cε2 dimer was injected over the surfaces at concentrations of 4,000 nM (black),
2,000 nM (purple), 1,000 nM (blue), 500 nM (green), 250 nM (orange) and 125
nM (red). The sensorgrams have not been normalised for the difference in mass
between IgE-Fc and the Cε2 dimer.
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A.10 IgE/mCD23 inhibition assays
a) b) 
c) 
Figure 12: IgE/mCD23 inhibition assays. RPMI cells, expressing mCD23, were
incubated on ice for one hour with 12 nM rIgE-A647 and increasing concentrations
of each aεFab. The cells were washed twice with buffer and the fluorescence of
single live cells was read by flow cytometry. Reduction in MFI was assumed to
be the result of inhibition of the rIgE-A647/mCD23 interaction. The experiments
were performed two or three times for each aεFab, and the results of these repeats
are given in different colours. The data were fit to four parametric logistic curves
where applicable. Concentration-dependent inhibition was observed for aεFab12
and aεFab13, but not for aεFab18.
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A.11 SPR experiments investigating the bind-




Figure 13: SPR experiments investigating the binding of derCD23 to
aεFab:IgE-Fc (1:1) complexes. Purified aεFabs were injected over a Fab-
specific goat anti-rabbit F(ab’)2. IgE-Fc was injected over the captured aεFab.
derCD23 was then injected over the aεFab:IgE-Fc (1:1) complex at various con-
centrations (green - 125 nM, cyan- 250 nM, navy - 500 nM, purple 1000 nM, black
- 2000 nM) and binding was observed as a change in SPR response. The double-
subtracted sensorgrams for the binding of derCD23 (a-c) have been normalised
such that the maximum response for the binding of IgE-Fc to aεFab was 360 RU.
(a) aεFab3, (b) aεFab12, (c) aεFab18. (d) The various steady-state responses
for the binding of derCD23 to the different aεFab1:IgE-Fc (1:1) complexes (dots)
were fit (lines) using a single binding site model, as was the steady-state binding
responses for the same derCD23 concentrations binding to anti-histidine captured
His-IgE-Fc. The steady state binding responses in all cases were normalised for the
binding of 360 RU of IgE-Fc (or His-IgE-Fc). Black - anti-histidine bound His-IgE-
Fc, navy - aεFab2:IgE-Fc, cyan - aεFab3:IgE-Fc, purple - aεFab12:IgE-Fc, blue -
aεFab13:IgE-Fc, green - aεFab18:IgE-Fc.
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A.12 Analytical HPLC SEC analysis of aεFab:IgE-
Fc (2:1) complex preparative SEC fractions
a) b) 
c) d) 
Figure 14: Analytical HPLC SEC analysis of aεFab:IgE-Fc (2:1) complex
preparative SEC fractions. Each aεFab, IgE-Fc and peak fractions from each
SEC of the aεFab2:IgE-Fc (2:1) complex were run down a G3000SWxl analytical
HPLC SEC column (Tosoh) in 20 mM sodium phosphate 50 mM sodium chloride
buffer pH 7.4. The results suggest that the SEC fractions contain the aεFab:IgE-Fc
(2:1) complexes with a very small proportion of unbound aεFab
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A.13 SPR experiments investigating the bind-
ing of derCD23 to aεFab:IgE-Fc (2:1) com-
plexes
a) b) c) 
Figure 15: Double-subtracted SPR sensorgrams for the binding of
derCD23 to aεFab:IgE-Fc (2:1) complexes. Purified aεFab:IgE-Fc (2:1) com-
plexes were injected over a Fab-specific goat anti-rabbit F(ab’)2. derCD23 was then
injected over the aεFab:IgE-Fc (2:1) complexes at various concentrations (light blue
- 200 nM, green - 500 nM, cyan - 800 nM, navy - 1100 nM, purple 1400 nM, black -
1700 nM) and binding was observed as a change in SPR response. The sensorgrams
have been normalised such that the maximum response for the binding of IgE-Fc
to aεFab was 400 RU. (a) aεFab3, (b) aεFab12, (c) aεFab18.
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A.14 Protein sequence alignment of human and
rabbit IgE-Fc
Length  Identical residues Similar residues Gaps Score 
number  % number % number % 
Cε2 102 54 52.9 69 67.6 3 2.9 276.5 
Cε3 105 61 38.1 76 72.4 1 1.0 324.0 
Cε4 108 58 53.7 72 66.7 3 2.8 292.5 
b) 
Figure 16: Protein sequence alignment of human and rabbit (Oryctolagus
cuniculus) IgE-Fc. Protein sequence alignment was performed using the online
tool EMBOSS Needle [217] with default settings (BLOSUM 62 matrix). a) Align-
ment of rabbit IgE-Fc protein sequence with the sequence of the human IgE-Fc
(N265Q, N371Q) construct. A line between aligned residues indicates that they
are identical, two dots between aligned residues indicates that they are similar, one
dot indicates the residues are not similar and gaps are represented by white space.
b) The different IgE-Fc domains (defined in A.1) of human and rabbit IgE-Fc were
also aligned separately. The sequence alignment of the human and rabbit Cε2 do-
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